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Abstract 
 
Trypanosoma brucei evades host acquired immunity by antigenic variation, involving 
periodic switches in the variant surface glycoprotein (VSG) coat. DNA recombination 
is critical in this process and a key component of homologous recombination, RAD51, 
also plays a role in VSG switching. T. brucei encodes four proteins distantly related to 
RAD51; termed RAD51 paralogues, named RAD51-3, RAD51-4, RAD51-5 and 
RAD51-6. Two of these RAD51 paralogues, RAD51-3 and RAD51-5, have been 
shown to function in homologous recombination, DNA repair and RAD51 re-
localization into foci following DNA damage. Surprisingly, however, only RAD51-3 
appears to act in VSG switching. To examine the functions of all the RAD51 
paralogues in T. brucei, reverse genetics has been used to generate mutants of the two 
remaining unstudied paralogues, RAD51-4 and RAD51-6. Phenotypic analysis of 
both mutant cell lines indicates that these factors also play critical roles in RAD51-
directed recombination and repair, and both influence VSG switching in the parasite. 
As homozygous mutant cell lines of RAD51 and the RAD51 paralogues were 
available, it was possible to comprehensively compare the phenotypes of rad51 -/- 
with rad51-3 -/-, rad51-4 -/-, rad51-5 -/-, and rad51-6 -/-. From these results it was 
observed that the phenotypes of the rad51 paralogue mutants are broadly equivalent, 
with two exceptions. Firstly, as mentioned above, RAD51-5 does not function in VSG 
switching, and RAD51-4 and RAD51-6 may not have direct roles in VSG switching. 
Secondly, rad51-4 -/- mutants are less sensitive to the DNA damaging agent 
phleomycin and a higher percentage of rad51-4 -/- cells form DNA damage-induced 
RAD51 foci compared with the other homozygous mutant cell lines. These results 
may imply that RAD51-4 and RAD51-5 have a less central role in RAD51-directed 
DNA repair or that their functions can be performed by other factors. In addition, the 
physical interactions of all the RAD51 paralogues were examined. It was found by 
yeast two-hybrid and co-immunoprecipitation that they form at least two complexes, 
and probably function in sub-complexes in a similar manner to the Rad51 paralogues 
of higher eukaryotes. These analyses shed light on the evolution and role of 
eukaryotic RAD51 paralogues in DNA recombination and repair in general, as well as 
the contribution that recombination makes to antigenic variation in T. brucei. 
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1.1 General introduction to Trypanosoma brucei 
1.1.1 Phylogeny of the African trypanosome  
The genus Trypanosoma was first observed in 1841 by Gabriel Valentin; whilst examining 
blood from an infected brown trout, he detected the motile unicellular organism (Schmidt 
& Roberts, 1989). A century and a half of investigation of these microorganisms has 
defined Trypanosoma as members of the large and diverse protozoan kingdom. 
Trypanosoma are among the most ancient eukaryotic organisms known, diverging from 
Homo sapiens around 1.98 billion years ago (Hedges, 2002; McKean, 2003; Schmidt & 
Roberts, 1989). Taxonomically, they are ordered as Kinetoplastida, as their mitochondrial 
DNA is organised into a disc-like structure, the kinetoplast, located near the basal body 
(Maslov et al., 2001; McKean, 2003).  
 
Figure 1-1: Light microscope images of Trypanosoma brucei among red blood cells.  
A T. brucei cell in a blood smear, stained using the Giemsa method. The image on the left shows the cell 
surrounded by red blood cells and the image on the right shows the cell in more detail, clearly showing the 
undulating membrane. Reproduced with the permission of B. Neish. 
Within this order, the family Trypanosomatidae has nine genera (McGhee & Cosgrove, 
1980), which parasitise vertebrates, invertebrates and plants, of which the so-called 
“TriTryps” are members, Trypanosoma brucei, T. cruzi  and Leishmania major. 
Trypanosoma has two species which are human infective, the T. cruzi of South America, 
and T. brucei of Africa, while Leishmania species are endemic to South American and 
Asian countries (WHO, 2009). The majority of Trypanosoma species are heteroxenous, in 
that one stage of their life cycle is in the blood (see Figure 1-1) or tissue of a vertebrate and 
the other stage is in the intestine of a bloodsucking invertebrate (Schmidt & Roberts, 
1989). The genus Trypanosoma is also grouped into two broad categories: the Salivaria 
and the Stercoraria, based on the characteristics of its development in the invertebrate host 
(Schmidt & Roberts, 1989).  The three main Salivarian Trypanosoma species found in 
Rachel Dobson, 2009   Chapter 1, 3 
Africa are Trypanosoma brucei, Trypanosoma congolense and Trypanosoma vivax 
(Schmidt & Roberts, 1989; WHO, 2009). Of these three species, humans act as host to 
only one of them, T. brucei, whilst the others, T. congolense and T. vivax, are animal 
infective (Schmidt & Roberts, 1989).  
1.1.2 Epidemiology and Life cycle  
The species of T. brucei is pathogenically and geographically classified into three 
morphologically identical sub-species, T. brucei, T. b. gambiense and T. b. rhodesiense 
(Schmidt & Roberts, 1989). T. b. brucei is non-human infective, at least in part because it 
can be lysed by apolipoprotein L1, a trypanolytic factor in human serum (Pays et al., 
2006), whereas T. b. gambiense and T. b. rhodesiense have developed resistance to human 
trypanolysis (Turner et al., 2004). T. b. gambiense is found in the riverine areas of west 
and central Africa while T. b. rhodesiense is found in the savannah of the eastern part of 
the continent (Hide et al., 1990; Hide, 1999).  
T. brucei is a haemoflagellate and proliferates extracellularly in mammals (Schmidt & 
Roberts, 1989; see Figure 1-1).  It was realised, by David Bruce, that the parasite was 
insect-borne and infected members of the Glossina species, the so-called “Tsetse” fly 
(Cross, 2001; Steverding, 2008). Figure 1-2 shows the complex life cycle of the 
Trypanosoma brucei species (Barry & McCulloch, 2001). When an infective Tsetse fly has 
a blood meal from a vertebrate host, it deposits mature metacyclic cells in the connective 
tissue (Vickerman, 1985). In the mammalian host these parasitic cells undergo 
morphological changes while moving from the lymphatic system to the bloodstream and 
intracellular spaces (Matthews & Gull, 1994; Vickerman, 1985). From the non-dividing 
metacyclic form, the cells change into a long slender bloodstream form, which can 
proliferate by cell division (Matthews et al., 2004). The population in the bloodstream is 
pleomorphic, in that the long slender form differentiates into an intermediate form and then 
two types of short stumpy bloodstream: one type which can develop as a procyclic form in 
the vector and the other that is programmed to die and are not tsetse infective (Seed & 
Wenck, 2003). The parasitaemia fluctuates partly due to the antigenic variation 
mechanisms of the parasite (reviewed in: Barry & McCulloch, 2001; see Section 1.2  
below). Cells expressing a particular antigenic type form a part of the T. brucei population, 
called the homotype (Vickerman, 1985). An immune response mounted against this 
population results in death of this sub-set, while antigenic variant types survive. This 
causes waves of parasitaemia, where the majority of the cells are killed and the minority 
that switch live on (Morrison et al., 2005).  
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Once differentiated into the bloodstream short stumpy form, the cells can adapt to life in 
the alimentary canal of the Tsetse fly. When ingested by the fly, the parasites move by 
undulation along the flagellum and, once in the mid-gut, form established procyclic cells. 
These cells then differentiate into proventricular mesocyclic forms, which move from the 
mid-gut to the salivary glands (Roditi & Liniger, 2002). Once in salivary glands, 
epimastigotes and prometacyclics form and attach by flagellipodium to the gland wall 
(Fenn & Matthews, 2007). When the cells detach from the gland wall and differentiate into 
metacyclics, the life cycle is complete and the parasite can be transmitted to another 
mammalian host via a second blood meal; see Figure 1-2.  
 
Figure 1-2: Life Cycle of Trypanosoma species. 
T. brucei life cycle stages are shown as scanning electron micrographs (EM), shown to scale; an erythrocyte 
is shown next to the long slender bloodstream stage.  The host, Tsetse fly or mammal, and the name of the 
life cycle stage are labelled. Circular arrows represent replicative stages, whereas straight arrows represent 
differentiation and progression through the life cycle. Reproduced with permission of L. Tetley and D. Barry; 
adapted from Barry & McCulloch (2001). 
1.1.3 Trypanosomiasis: symptoms & treatment. 
Sleeping sickness, or Human African Trypanosomiasis (HAT), caused by T. b. gambiense 
and T. b. rhodesiense, is a fatal wasting disease if left untreated (Barrett et al., 2003). 
Together these species are estimated to be responsible for more than 300,000 human cases 
per year (Sternberg, 2004; Stich et al., 2002), with about 55 million at risk of infection 
(WHO, 2009). T. congolense, T. vivax and T. b. brucei are the cause of nagana in cattle, 
which has a great economic impact by destroying valuable livestock (WHO, 2009). T. b. 
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gambiense infection charts a chronically slow, but progressive course lasting anything up 
to several years. T. b. rhodesiense infection, in contrast, causes an acute form of the disease 
where progression to the later stages occurs within three months. Both infections have a 
similar clinical pathology and are fatal if left untreated. Once bitten by an infected Tsetse 
fly, the metacyclic parasites establish in the skin, differentiate in to the bloodstream stage 
and spread via the lymphatic system into the blood (Sternberg, 2004). The early 
haemolymphatic stage results in anaemia, weakness and weight-loss. In the late meningo-
encephalitic stage, the parasite passes through the blood-brain barrier and infects the 
central nervous system (Enanga et al., 2002), leading to  sensory, motor and psychiatric 
disturbance, along with sleep abnormality (Lundkvist et al., 2004). 
Treatment efficacy is limited as there are few effective safe drugs available. There are four 
main drugs available for the management of the infection. Suramin sodium and 
pentamidine isethionate are used for the early stages before CNS involvement, and treat T. 
b. rhodesiense and T. b. gambiense infections respectively (Kennedy, 2004).  In the 
advanced stages, the arsenical drug, melarsoprol is used for treatment of infections by both 
subspecies, while eflornithine (difluoromethylornithine; DFMO) is used for treatment of 
the disease caused by T. b. gambiense when the patients are unresponsive to melarsoprol 
(Kennedy, 2004). These drugs need to be administered intravenously or intramuscularly, 
and some cause a large group of side effects, including skin lesions, renal failure, cardiac 
abnormalities and fatal encephalopathy (Gull, 2002; Jannin & Cattand, 2004; Kennedy, 
2004). 
With these disadvantages and the fact that new drugs for treatment of trypanosomiasis are 
not being produced, the implementation of control strategies may be the best way of 
combating the disease in epidemic areas (Jannin & Cattand, 2004). The hope of 
development of an effective vaccine has somewhat been dismissed by the discovery of a 
complex antigenic variation system in trypanosomes. Nevertheless, understanding the 
mechanisms behind antigenic variation may lead to new drug targets as well as better 
knowledge of the recombination pathways of T. brucei and possibly of other eukaryotic 
cells. 
1.1.4 Use of T. brucei as a model organism? 
Scientists have used a small number of model organisms to attempt to simplify the study of 
complex molecular mechanisms (Hunter, 2008). A century of science has built-up on the 
belief that describing the sub-systems of a cell or organism will facilitate the understanding 
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of the whole system (this is reductionism). Another belief is that understanding the 
consequences of any two events will lead to a predictable result (this is causality). In the 
past decades, model organisms such as yeasts, rodents, E. coli, Drosophila and the 
nematode C. elegans have been used, representing only a small fraction of the biodiversity 
on the planet (Hedges, 2002). Extrapolation of findings from these experiments to all 
forms of life is potentially misleading or at least may not always be straightforward, yet a 
vast amount of useful data has been generated to describe the fundamental molecular 
mechanism supporting life such as replication, transcription, translation and DNA repair. 
Now, use of genome projects and development of molecular tools to examine other 
organisms, has allowed the metaphorical “research door” to open and more research 
opportunities to take place.  
Research on T. brucei was initially carried out to add to our clinical knowledge of the 
parasite. Now, with the complete genome sequenced and our ability to culture and 
genetically manipulate the parasite, T. brucei can be regarded as a candidate for use as a 
model organism. As well as this, T. brucei can be used, in combination with a few others 
such as Plasmodium falciparum, Toxoplasma gondii and Leishmania, as model parasites.  
Also, it has been shown by Hedges et al., 2004, that the sub-phylum of Euglenozoans 
(containing the TriTryps) diverged from other eukaryotes 1,840 +/-200 million years ago 
and are from an early branch of eukaryotes (Hedges et al., 2004; Hedges, 2002). This 
knowledge may lead to insights regarding phylogeny, and most importantly, for this 
project, insights into gene retention and function. 
1.1.5 Genome structure and gene expression by poly-
cistronic transcription 
The “TriTryps” are members of the order Kinetoplastida, as they possess a kinetoplast for 
the mitochondrial DNA. The nuclear chromosomes are present as linear DNA molecules, 
unlike the content of the kinetoplast, which is organised as an interconnected network of 
circular DNA comprising mini-circles and maxi-circles (reviewed in: Lukes et al., 2002). 
The nuclear genome of T. brucei contains 11 mega-base chromosomes that have a total 
size of ~ 26 Mb (0.9 to > 6 Mb individually) (Berriman et al., 2005; Hertz-Fowler et al., 
2007). There are also intermediate-chromosomes and mini-chromosomes found in the 
nucleus of T. brucei (Berriman et al., 2005). In most strains, there are 1-7 intermediate 
chromosomes of 200-700 kb and numerous (~100) mini-chromosomes of 30-150 kb 
(Alsford & Ersfeld, 2003; Melville et al., 2000; Wickstead et al., 2004). In 2005, the 
project to sequence the mega-chromosome DNA of T. brucei was completed (Berriman et 
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al., 2005) using the genome of the T. b. brucei strain TREU (Trypanosomiasis Research 
Edinburgh University) strain 927/4 that expresses a single variable antigen type (VAT), 
derivative GUTat 10.1. Systemic sequencing of the intermediate- and mini-chromosomes 
has not yet been reported. 
It has been shown that the T. brucei mega-base chromosomes contain the house-keeping 
genes structured in directional gene clusters (see below), including many tandemly 
repeated gene families such as tubulin, calmodulin and procyclic acidic repetitive proteins 
(PARP) (Berriman et al., 2005; Boothroyd & Konuniecki, 1995). Interestingly, the 
majority of the sub-telomeric genes found on the mega-chromosomes are members of the 
Variant Surface Glycoprotein (VSG) gene family which contains >1000 members, whilst 
the intermediate chromosomes house the expression sites for bloodstream VSGs and the 
mini-chromosomes contain a diverse array of silent VSGs (Berriman et al., 2005; Marcello 
& Barry, 2007a; Marcello & Barry, 2007b; Wickstead et al., 2004).  Approximately 9,068 
protein coding genes have been annotated on the sequenced mega-chromosomes of strain 
TREU 927/4, and of these predicted genes only 50.5 % have been assigned a function 
through sequence homology (Berriman et al., 2005). 
Most of the genes of T. brucei are transcribed by RNA polymerase II (RNA pol II), with 
the exception of the VSG, rRNA and PARP genes which are transcribed by RNA 
polymerase I (RNA pol I) (Boothroyd & Konuniecki, 1995; Navarro & Gull, 2001). Unlike 
higher eukaryotes, in which protein coding genes undergo mono-cistronic transcription, T. 
brucei, and the other TriTryps (as well as some other lower eukaryotes, such as nematodes 
and trematodes) undergo poly-cistronic transcription as inferred from the convergence of 
the genes as directional gene clusters (Blumenthal, 2005; Boothroyd & Konuniecki, 1995; 
Evans & Blumenthal, 2000; Johnson et al., 1987; Liang et al., 2003). Long poly-cistronic 
transcribed units (pre-mRNA) contain information for many proteins which are separated 
by short spacer regions. Post-transcriptional modification is required to process these long 
primary units into individual mature mRNAs and occurs by trans-splicing and 
polyadenylation (Clayton, 2002). Trans-splicing is a process where two separate transcripts 
(pre-mRNA) are joined together and occurs with addition of a 5’ cap called a spliced 
leader RNA at the 5’ end of the pre-mRNAs (Sather & Agabian, 1985; Ullu et al., 1993). 
The addition of a polyadenylated (poly(A)) tail at the 3’ end of the pre-mRNA also occurs 
(Matthews et al., 1994). These modified and mature mRNAs are then translated to amino 
acids.  
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1.2 Antigenic Variation 
The success of most pathogens can, in part, be attributed to the organism’s ability to 
overcome the protective immunity of the host. Scientists have uncovered a diverse 
collection of mechanisms used by bacteria, viruses and parasites to evade the onslaught of 
the host immune response. Some of these mechanisms include varying the antigens 
presented to the host immune system and/or modification of host immune responsiveness 
(Mims et al., 1995: Chapter 2). Some bacteria find a safe haven from the immune response 
by invading the host cells, such as members of the genera Listeria and Shigella that 
replicate within the cell cytosol, whereas some Legionella and Mycobacterium species 
replicate within vacuoles of the cell (reviewed in: Wilson et al., 2002). Parasites, such as 
Plasmodium, Leishmania and T. cruzi, also employ a similar tactic of evasion (Sibley, 
2004). Microorganisms that do not invade the host cell, such as the extracellular T. brucei, 
are constantly surrounded by host immune factors and initially may seem more vulnerable 
than their intracellular relatives. This is not the case, however, as many microorganisms 
use phase or antigenic variation to change the antigens exposed on their surface, thereby 
altering their appearance to the host immune system (Barbour & Restrepo, 2000; 
Zambrano-Villa et al., 2002). Phase variation refers to the reversible switch between two 
phenotypes, while antigenic variation refers to the irreversible, sequential expression of 
multiple different forms of the same antigen (van der Woude & Baumler, 2004).  
Antigenic variation is observed widely in viruses, bacteria, fungi and parasites, with 
divergent underlying mechanisms (Deitsch et al., 1997; Palmer & Brayton, 2007). Bacteria 
of the genus Borrelia use the mechanism of antigenic variation to change their exposed 
lipoprotein surface antigens termed variable large protein (vlp) and variable small protein 
(vsp) (Barbour et al., 2006). A pattern of waves of spirochete infection occurs in the 
infected host, where a relapsing fever is characterised by high temperature and high 
bacteraemia, followed by a period of clearance (Norris, 2006). This cyclical pattern occurs 
when the majority of the bacterial population expressing a particular serotype (vlp or vsp) 
is cleared by specific host antibodies to that particular serotype (Norris, 2006). A new 
wave of bacteraemia results when a minority of the spirochetes have switched to an 
immunologically distinct lipoprotein surface antigen. The main mechanism of lipoprotein 
switching in B. hermsii and B. burgdorferi has been shown to be gene conversion, 
involving homologous recombination (HR) (Dai et al., 2006; Zhang et al., 1997). It has 
been found that in B. hermsii some 60 silent pseudogenes are present episomally, and gene 
conversion can occur between these fragments of vlp and vsp genes (Dai et al., 2006). 
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T. brucei uses what appears to be a broadly related mechanism of antigenic variation to 
Borrelia (Palmer & Brayton, 2007). In T. brucei, the exposed antigen is a Variant Surface 
Glycoprotein (VSG) which covers the entire parasite surface and is switched to a different 
immunologically distinct antigen primarily by recombination, though transcriptional 
control mechanisms are also used, which is distinct from Borrelia (see Section 1.2.2; Barry 
& McCulloch, 2001). For T. brucei to evade the host’s acquired immunity, the parasite 
must replace its VSG coat rapidly and completely with a new VSG that contains epitopes 
unrecognised by existing antibodies (Miller & Turner, 1981; Morrison et al., 2005). When 
the antibodies eliminate a major part of the population, those parasites that have changed 
their VSG coat survive and proliferate. This pattern is repeated, resulting in fluctuating 
waves of chronic parasitaemia, with each wave containing T. brucei cells expressing 
distinct VSG coats (for reviews see Barry & McCulloch, 2001; Donelson, 2003; Pays, 
2006). This process of VSG gene activation or replacement is sometimes called VSG 
switching, and it is this mechanism that allows a small number of parasites expressing the 
new VSG to survive the hostile extracellular environment of the mammalian host (Schmidt 
& Roberts, 1989). The mechanisms and potential regulation of VSG switching holds the 
key to the parasite’s survival in the mammal, although the full picture of the factors 
involved seems to be elusive. 
1.2.1 The role of Variant Surface Glycoproteins (VSG) in 
antigenic variation 
The dense surface coat covering the plasma membrane of pathogenic African 
trypanosomes was first imaged by high resolution micrographs (Vickerman, 1969). In the 
mammalian host, the surface coat of T. brucei is composed of 5 x 106 dimers of Variant 
Surface Glycoprotein (VSG)  (Auffret & Turner, 1981; Cross, 1975) and is attached to the 
plasma membrane by a glycosyl-phosphatidyl-inositol (GPI) anchor (Ferguson et al., 
1988).  
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Figure 1-3: Variant Surface Glycoprotein (VSG) 
The diagram on the left shows the 3D structure of a VSG dimer attached to a model of the T. brucei plasma 
membrane by a glycosyl-phosphatidyl-inositol (GPI) anchor. The diagram on the right models the densely 
packed VSG coat of the cell and predicted binding of IgG and IgM host antibodies. Reprinted with 
permission from Elsevier: Engstler et al. (2007), Cell 131, pp 506. 
It is this VSG coat which prevents the host immune response from targeting underlying 
invariant antigens (Borst & Fairlamb, 1998; Overath et al., 1994). The VSG coat is 
immunogenic and is the point of attack for the host IgG and IgM responses (Engstler et al., 
2007; Turner et al., 1988). Each VSG polypeptide within the mature VSG homodimer is 
between 400 to 500 amino acid residues in length, and is composed of a single N-terminal 
domain of 350-400 residues and one or two smaller C-terminal domains, each consisting of 
40-80 residues (Carrington et al., 1991; Chattopadhyay et al., 2005; Pays, 2006; Pays et 
al., 2007). The antibody responses are raised against the exposed hypervariable N-terminal 
domain of the VSG (Borst & Fairlamb, 1998; Field & Boothroyd, 1996). Although there is 
limited sequence conservation of the N-terminal domain, its structure is conserved and 
consists of two long α helices, which interact with the neighbouring VSG in the 
homodimer (Blum et al., 1993); see Figure 1-3. It appears that the buried C-terminal 
domain is more conserved, where the VSG is anchored to the plasma membrane and is less 
accessible to immune attack (Ferguson et al., 1988).  
The T. brucei genome has a size of ~26 Mb (see Section 1.1.5) and contains a large archive 
of over 1000 silent VSG genes, which are present in the sub-telomeric arrays of the 
chromosomes (Barry et al., 2005). Some of these genes are also present in the VSG 
expression sites (ES) which are found in the megabase and intermediate chromosome 
telomeres (Berriman et al., 2005; Hertz-Fowler et al., 2007; Marcello & Barry, 2007a; 
Marcello & Barry, 2007b). Out of these silent VSG genes, 806 have been functional 
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annotated and only 7 % were found to encode fully functional VSGs, 9 % were atypical 
VSGs which are predicted not to be functional VSGs, 66 % were pseudogenes and 18 % 
were VSG gene fragments (Berriman et al., 2005). The functionality of the VSGs found at 
the telomeres of the some 100 mini-chromosomes has not been determined (Berriman et 
al., 2005; Pays et al., 2007). In the VSG bloodstream stage expression sites, VSG 
pseudogenes are found, but the VSG adjacent to the telomere appears always to be 
functional (Barry et al., 2005; Hertz-Fowler et al., 2008).  Although there is a large archive 
of silent VSG genes in the T. brucei genome, at any given time, only one single VSG gene 
is expressed from a VSG expression site (ES) (Barry & McCulloch, 2001). The ES is 
adjacent to the chromosomal telomere and the VSG gene is transcribed poly-cistronically 
with a series of other expression-site associated genes (ESAGs), which are normally 
separated from the VSG by a region of repeats each of 70 bp (Berriman et al., 2002; Borst 
et al., 1996) and are discussed below, in Section 1.2.2; Figure 1-4. 
7    6       5     3Ψ 4         8       3       2  11Ψ 1          70 bp repeats          VSG
 
Figure 1-4: Schematic representation of the structure of a bloodstream expression site (BES). 
The diagram shows an example of a T. brucei Lister 427 bloodstream expression site and indicates the 
variant surface glycoprotein (VSG; blue box) and expression-site associated gene (ESAG 1, 2, 3, 4, 5, 6, 7, 8, 
11; black boxes) separated by the  region of 70 bp repeats (orange boxes). Also shown are the promoter (red 
arrow), telomeric repeat region (vertical black line), and pseudo-ESAGs (Ψ). Adapted from Hertz-Fowler et 
al. (2008). 
1.2.2 Mechanisms of VSG switching 
The switching events that activate a previously non-expressed VSG gene occur 
independently of the host immune response (Doyle et al., 1980) suggesting this is a pre-
emptive survival strategy driven by the parasite. In the majority of cases, VSG switching 
occurs by gene replacement of the VSG in the ES with another VSG by DNA 
recombination (Hoeijmakers et al., 1980; Robinson et al., 1999). However, it has also been 
shown that there can be so-called in situ transcriptional switching events (Borst & Ulbert, 
2001; Myler et al., 1984), where one previously inactive ES is switched on to allow 
complete transcription of the VSG and ESAGs while the active ES is transcriptionally 
silenced (Figure 1-5).  
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Figure 1-5: in situ transcriptional VSG switching event 
An in situ VSG switching event occurs when an active expression site (ES) is transcriptionally switched off, 
called X and a previously inactive ES is switched on, called Y. This results in the green VSG not being 
actively transcribed while the blue VSG is transcribed and consequently expressed along with the expression 
site associated genes: black boxes and 70 bp repeat region: orange boxes. The promoters are indicated by the 
red or blue arrows.  
This can occur because there are multiple ESs within the T. brucei genome (Borst & 
Ulbert, 2001). Some of these are active for VSG expression in metacyclic cells (Rudenko 
et al., 1994), while the bloodstream VSG expression sites (BES) are specifically 
transcribed in the mammal (Chaves et al., 1999). A number of BES, from a few T. brucei 
isolates have now been sequenced, showing that their size, measured from the RNA pol I 
promoter to the telomere can span between 40-100 kb (Hertz-Fowler et al., 2008; Young et 
al., 2008). Within the BES there are at least eight expression site associated genes 
(ESAGs), only some of which have been assigned functions (Becker et al., 2004; Berriman 
et al., 2002). For example, two ESAGs (ESAG6 and ESAG7) encode the subunits for a 
transferrin receptor required for iron uptake (Schell et al., 1991; Steverding et al., 1995). 
Another ESAG, not found in all BES, encodes the serum resistance-associated (SRA) factor 
in T. b. rhodesiense (Van Xong et al., 1998). The mechanisms dictating how one particular 
BES is fully transcribed while the others remain largely silent are unknown. A distinct sub-
nuclear structure, named the expression site body (ESB), has been found to contain the 
actively transcribed VSG expression site along with RNA pol I, while the silent BESs are 
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found outside this ESB (McCulloch, 2004; Navarro & Gull, 2001). The discovery of the 
ESB may lead to an explanation for the controlling mechanisms for the expression of the 
active VSG. However, chromatin modification also appears to have a role, since mutation 
of the histone methyltransferase, DOT1B, causes de-repression of silenced BES and alters 
the dynamics of transcriptional switching (Figueiredo et al., 2008; Stockdale et al., 2008).  
The most common mechanism for VSG switching involves DNA recombination events 
(Robinson et al., 1999). There are three different recombination pathways of VSG 
switching, which are defined by the source of the donor DNA. All pathways rely on some 
sequence homology being present between the donor and recipient DNA. 
The first VSG switching mechanism involving DNA recombination is duplicative 
transposition, or gene conversion. Gene conversion involves creating a new copy of a 
silent VSG and moving it into the BES, where it replaces the previously expressed VSG. 
This is the most frequently observed pathway experimentally (Robinson et al., 1999). 
Silent VSGs in a number of genomic locations can act as gene donors (Figure 1-6; detailed 
below). The amount of VSG sequence copied during gene conversion is variable and 
normally extends beyond the boundaries of the VSG open reading frame. The upstream 
limit of gene conversion is often found to be 70 bp repeats (Liu et al., 1983), that flank >90 
% of VSGs (Marcello & Barry, 2007a) but can extend into the conserved ESAGs. The 
extent of the gene conversion event can vary downstream from the 3’ end of the VSG 
(Michiels et al., 1983), to the repeats of the telomere (De Lange & Borst, 1982).  
Gene conversion can occur by copying from the VSG sub-telomeric array of the mega-base 
chromosomes, where the 70 bp repeat region and 3’ end of the VSG are used most 
commonly as recombination homology (see Figure 1-6A) (Liu et al., 1983; Michiels et al., 
1983). Other gene donors for gene conversion include the telomeric VSG genes on either 
the mini-chromosomes or in the BES, either in the mega-base or intermediate 
chromosomes (see Figure 1-6B and 1-6C respectively). Though VSG gene conversion 
events have been shown to use the 70 bp repeat region upstream of the VSG gene as a 
substrate for the recombination event (the orange region in Figure 1-6) (De Lange et al., 
1983; Shah et al., 1987), deletion of this region within a BES does not compromise the 
antigenic variation mechanism (McCulloch et al., 1997) underlining the flexibility in 
substrate choice for this process.  
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Figure 1-6: VSG switching occurs by recombination of different VSG genes from different locations on 
the T. brucei chromosome. 
Gene conversion copies a silent VSG (blue box) into an active expression site (red box) replacing the resident 
VSG. The amount of the sequence copied is depicted by the brackets. The dashed lines show variation in the 
amount of sequence that may be copied. Expression site associated genes: black boxes; 70 bp repeats: orange 
boxes; BES promoter: red arrow; and telomeric repeats: vertical black line.  
The second mechanism of VSG switching is mosaic VSG gene formation. This is where 
segments of VSG pseudogenes are assembled most likely by segmental gene conversion 
reactions, to create a new functional VSG, that is subsequently expressed from the BES (as 
shown in Figure 1-7) (Roth et al., 1986). It appears that this reaction is dependent on VSG 
ORF sequence homology and does not rely on flanking homology, though it may be that 
the reactions are anchored by the 70 bp repeat upstream or by downstream homology. 
Mosaic formation occurs later in infection when the chronically-infected host generates 
comprehensive immunity against most intact VSGs (Kamper & Barbet, 1992; Marcello & 
Barry, 2007a). However, since most of the VSG archive consists of pseudogenes (66 % of 
analysed VSGs are pseudogenes) or VSG gene fragments (18 %) it is suggested that the 
mosaic formation is important for the parasite’s survival (Berriman et al., 2005; Kamper & 
Barbet, 1992; Marcello & Barry, 2007a). 
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Figure 1-7: Mosaic VSG formation by segmental gene conversion. 
Generating a new VSG from a number of silent VSG pseudogenes. The extent of the sequence copied is 
indicated by the brackets. Expression site associated genes: black boxes; 70 bp repeats: orange boxes; 
bloodstream expression site promoter: red arrow; and telomeric repeats: vertical black line. 
 
The third mechanism of VSG switching occurs by reciprocal exchange. This is a classical  
HR event where a crossover occurs (Pays et al., 1985; Shea et al., 1986), switching a 
telomeric VSG gene (either from a silent BES or a mini-chromosome) into the active BES 
and moving the previously active BES into the other telomere. There is no loss or gain of 
sequence, as the chromosome ends containing the active expression site and a silent VSG 
are simply exchanged (see Figure 1-8).  This mechanism is less common in VSG switching 
(Rudenko et al., 1996), as it cannot act on the majority of the archive (the silent array in 
the mega-base chromosomes) as it is presumably limited to the telomeric VSGs since 
exchange of a VSG array by this approach is likely to be lethal (Borst et al., 1996).  
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Figure 1-8: Reciprocal exchange of the VSG gene resulting in a VSG switching event. 
Reciprocal exchange occurs where HR of the VSG gene and/or surrounding sequences can occur (crossed 
lines). The previously silent VSG gene (blue box) recombines into the active expression site (called X). 
There is no loss of DNA during this cross-over event and both VSG genes are retained. Expression site 
associated genes indicated by: black boxes; 70 bp repeats: orange boxes; expression site promoter: red arrow; 
and telomeric repeats: vertical black line. 
These switching mechanisms enable the expression of new epitopes that have not been 
previously experienced by the host and allow the longevity of the parasite in the 
bloodstream. Significantly, accumulating evidence suggests that at least VSG gene 
conversion is driven by HR, as mutation of core factors such as RAD51, BRCA2 and 
RAD51-3, impair VSG switching (discussed below, Section 1.5). 
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1.3 DNA repair 
The genetic information encoded by genomes composed of nucleic acid molecules, DNA 
and RNA, allow information to be stored, transferred between generations and enable the 
production of RNA, proteins, and ultimately every cellular component (Lehninger et al., 
1993). As a result, the fidelity and preservation of the genome is extremely important. 
Endogenous and exogenous damaging agents, as well as the intrinsic instability of the 
DNA molecules themselves, result in a high level of damage to the DNA (Friedberg et al., 
1995). Endogenous damaging agents are mostly the by-products of metabolic pathways, 
such as oxidative metabolism, which results in hyperreactive oxygen molecules (hydrogen 
peroxide, peroxide and hydroxyl radicals), methylation and alkylation (Marnett & 
Plastaras, 2001; Pluskota-Karwatka, 2008). Exogenous damaging agents or environmental 
factors such as ionising radiation (X-rays and γ-rays), UV and chemical damaging agents 
can cause atypical bonding between the bases on the same strand, inter-strand crosslinks 
and breaks in the phosphodiester backbone. The intrinsic instability of the components of 
the DNA strand is also responsible for some DNA damage. Instability in the glycosyl-bond 
linking the pentose sugar ring to the base can cause the loss of that base and results in 
apurine or apyrimidine formation (Friedberg et al., 1995). DNA interactions with proteins 
can also cause damage and instability; for example, errors in the replication of the new 
DNA strand can result in mismatches, insertions or deletions of bases. Stalling of the 
replication fork can also cause DNA damage (Chang & Cimprich, 2009). Finally, some 
processes in the cell deliberately create DNA damage, such as immunoglobulin and T cell 
receptor gene arrangements in mammals, and meiosis in many eukaryotes (discussed in 
Section 1.5.4 below).   
Any DNA damage needs to be correctly repaired to maintain the fidelity of the genome. 
Repair of damaged DNA prevents chromosomal fragmentation or rearrangement, 
carcinogenesis in multicellular organisms and potentially cell death (Hakem, 2008). 
Consequently, all organisms have the ability to repair their DNA, which may be either 
error-free or error-prone. Given the diversity in the forms of DNA damage many different 
DNA repair pathways are used, which are conserved to a greater or lesser extent among all 
the phylogenetic groups (Eisen & Hanawalt, 1999). Broadly, these repair pathways can be 
divided into two groups; the first group uses excision mechanisms to repair the misplaced 
base(s) or distorted strand(s), and the second group repairs phosphodiester strand breaks, 
either single-stranded or double-stranded breaks.  
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Three main excision pathways of DNA repaired have been described; mismatch repair 
(MMR), base excision repair (BER), and nucleotide excision repair (NER) (review in: 
Christmann et al., 2003; Kunz et al., 2009; Robertson et al., 2009). All of these have two 
common properties: the use of a nuclease to excise or remove the damaged base(s) and a 
DNA polymerase and ligase to fill the resulting gaps with the correct bases and re-seal the 
DNA. Although these two properties are common between the different mechanisms, the 
specific proteins used to carry out the repair in each pathway differ greatly. These 
pathways will not be discussed further here. 
The second group of repair pathways, which act on double-strand DNA breaks has two 
primary distinct mechanisms (see Figure 1-9); non-homologous end-joining (NHEJ) and 
homologous recombination (HR) with the latter implicated in VSG switching, (see below 
Section 1.5 and above Section 1.2.2). As their name suggests, HR requires a region of 
homologous sequence to repair the DNA break while NHEJ does not (Symington, 2002). 
As HR requires base pairing with an unbroken template, normally the sequence integrity of 
the broken DNA molecule is maintained, whilst NHEJ involves re-ligation of the break 
ends and therefore, may result in loss of bases during the repair (see Section 1.4). HR can 
occur through different pathways depending on whether or not the DNA break ends invade 
a homologous DNA duplex, a process termed strand invasion. If the broken DNA ends do 
not invade the duplex DNA, but utilise base pairing around the DSB, this pathway is 
termed single-strand annealing (Figure 1-9B). If strand invasion occurs the HR pathway 
used depends on whether one or both strand ends invade the duplex DNA (Figure 1-9C, D, 
E) and these pathways will be discussed in more depth in Section 1.4 and Section 1.5 
below.  
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Figure 1-9: Pathways of DNA double strand break repair.  
A schematic representation of the two main mechanisms of double strand break (DSB) repair. The first is 
non-homologous end joining (NHEJ) (A) and the second is homologous recombination (HR) (B-E). DNA 
containing a DSB is represented by black lines, intact duplex DNA by blue lines, newly synthesised DNA by 
dashed lines, and NHEJ machinery by red circles. B: Single strand annealing (SSA) where the boxes indicate 
homology, C: Break induced replication (BIR), D-E: Gene conversion. Adapted from J.S. Bell, PhD thesis, 
2002.   
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1.4 End-Joining Double Strand Break repair 
The repair of double strand breaks (DSB) can occur by re-joining the two ends of the 
broken DNA. To achieve this, there is the classical non-homology end joining (NHEJ) 
repair pathway, which may or may not require DNA homology (0-5 bp) to facilitate repair 
(Roth & Wilson, 1986). In addition, there is another putative end-joining repair pathway, 
which acts by joining the ends through the use of DNA micro-homology (5-25 bp) around 
the DSB (McVey & Lee, 2008). 
1.4.1 Non-Homologous End Joining (NHEJ) 
As discussed above (Section 1.3), the NHEJ pathway involves ligating the DSB ends 
together and frequently results in changes in the DNA sequence and may result in loss or 
addition of sequence around the break ends (Pfeiffer et al., 1994; Roth & Wilson, 1986). 
Nevertheless, NHEJ has a major contribution in repair of the DSBs in mammalian cells, 
and is vital for cell survival (reviewed in: Dudasova et al., 2004; Hefferin & Tomkinson, 
2005; Weterings & van Gent, 2004).  
The NHEJ pathway uses five primary protein components. Three are subunits of the DNA-
dependent protein kinase, comprising the Ku70 and Ku80 proteins, which form a 
heterodimer DNA end-binding complex (Ku), and the catalytic subunit (DNA-PKcs) 
(Gottlieb & Jackson, 1993; Yaneva et al., 1997). The other components act as a 
multiprotein complex comprising a NHEJ-specific ligase, DNA ligase IV and a ligase IV 
interacting factor, the XRCC4 protein (Critchlow et al., 1997). Together these factors 
catalyze the DNA ligation step in the pathway. It has been shown that the Ku heterodimer 
binds with high affinity to both ends of the DSB, and once bound forms a bridge over the 
gap, leading to the recruitment of the other NHEJ factors (Bliss & Lane, 1997; Falzon et 
al., 1993; Ramsden & Gellert, 1998) (see Figure 1-10A). The first to be recruited is DNA-
PKcs (see Figure 1-10B). There is some evidence that DNA-PKcs phosphorylation alters 
or releases the DNA-PKcs DNA interaction (Block et al., 2004; Kurimasa et al., 1999). 
However, it is not yet fully understood the role that DNA-PKcs phosphorylation plays in 
NHEJ, nor whether DNA-PKcs autophosphorylates itself or whether it is phosphorylated 
by other means. DNA-PKcs is a member of the phosphatidylinositol 3-kinase-like kinase 
group (PIKK), of which ATM and ATR are also members (Weterings & Chen, 2007). 
Both ATM and ATR respond to DNA damage and may even act in the NHEJ pathway 
(Falck et al., 2005). Binding of DNA-PKcs allows the recruitment of other NHEJ factors 
such as the Artemis nuclease (Goodarzi et al., 2006). DNA Ligase IV-XRCC4 (see Figure 
Rachel Dobson, 2009   Chapter 1, 21 
1-10C) is then recruited and the gaps in the DNA are processed (or filled-in) and ligated 
together, resulting in the break being repaired (see Figure 1-10D). 
Ku
DNA - PKcs
Ligase IVXRCC4
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Figure 1-10: A simplified representation of the Non-Homologous End-Joining (NHEJ) pathway.  
Repair of a DSB by the NHEJ pathway. A: A DSB is recognised by the Ku70/80 heterodimer (Ku). B: DNA-
dependent protein kinase catalytic subunit (DNA-PKcs) is recruited. C: Processing of the ends follows with 
the LigaseIV-XRCC4 complex repairing the ends by ligation. D: The DSB is repaired. Other potential 
auxiliary factors in NHEJ such as the Artemis nuclease and Nej1/Lif1 in yeast and Cernunnos/XLF in 
mammals are not shown. Adapted from Weterings & Chen (2007). 
It has been shown that NHEJ is the main pathway in V(D)J recombination (see review: 
Gellert, 2002; Lieber et al., 2004). This recombination creates the diversity among the 
immunoglobulin (Ig) and the T cell receptor (TCR) genes found in the mammalian 
immune system (Abbas et al., 1994: Chapter 4). V(D)J recombination is the process where 
the variable (V) gene segments are joined to the segments encoding the constant (or non-
variable) regions of the Ig or TCR polypeptides. The variable gene segments can join to 
any number of the diversity (D) and joining (J) gene segments, and once joined, the three 
gene segments make up a new exon for generation of Ig and TCR heavy chains (Abbas et 
al., 1994: Chapter 4). As an Ig or TCR locus may contain tens or hundreds of V, D, and J 
segments, the different combinational possibilities are great. As a result, there is a large 
number of possible Ig or TCR molecules and the combinational possibilities could be as 
high as 107, allowing a diverse antibody response to many different agents (Gellert, 2002). 
There are specific recognition sequences between the gene segments called 
recombinational signal sequences (RSS). The RSS are moderately conserved and contain 
up to 7 or 9 conserved nucleotides separated by 12 or 23 non-conserved nucleotide spacers 
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(Tonegawa, 1983). The rearrangement occurs by excision of DNA sequence between the 
V, D, and J segments using the RSS as a guide, followed by ligation of the DNA ends 
(Dudley et al., 2005). It has been found that there are V(D)J specific proteins for excision 
at specific recombinational sequences and looping of the gene segments, named RAG1 and 
RAG2 (recombination activation gene) (Oettinger et al., 1990; Schatz et al., 1989). These 
proteins generate DSBs, which recruits Ku, DNA-PKcs, and Ligase IV-Xrcc4, causing 
NHEJ to have a prominent role in the joining of the segment ends (Dai et al., 2003).  
1.4.2 Micro-homology Mediated End-Joining (MMEJ) 
An accumulating number of reports have shown a distinct form of DSB end-joining 
mediated by short stretches of homology (5-25 bp) (reviewed in: McVey & Lee, 2008). 
Previously, it was thought that this alternative end-joining pathway was a “back-up” to the 
classical NHEJ pathway described above (Lieber et al., 2004; Wang et al., 2003). It has 
now been shown that MMEJ can play a prominent role in V(D)J recombination (Corneo et 
al., 2007) and in Ig class switch recombination (Yan et al., 2007). The MMEJ pathway is 
independent of NHEJ core factors such as Ku70/80 (Boulton & Jackson, 1996; Liang et 
al., 1996; Ma et al., 2003) and independent of HR core factors such as Rad51 and RAD52 
(Lee & Lee, 2007). All the proteins involved in the MMEJ pathway as not known but 
certain factors have been identified in S. cerevisiae such as the MRE11 complex (Ma et al., 
2003), Nej1, and Srs2 (Lee & Lee, 2007) which are known to also have roles in either 
NHEJ pathway or single strand annealing pathway (Section 1.5.3). 
It has also been reported that the Ku70 and Ku80 are not involved in VSG switching in T. 
brucei, as there was no detectable influence of the Ku mutants on the frequency of VSG 
switching (Conway et al., 2002a). Moreover, it was found that end-joining using T. brucei 
cell extracts in vitro occurred using the pathway of MMEJ while there was no detectable 
NHEJ (Burton et al., 2007). Interestingly, attempts in T. brucei as well as other 
Kinetoplastida have been unable to identify some components of the NHEJ machinery: 
DNA Ligase IV and XRCC4 (Burton et al., 2007). Potentially, therefore, NHEJ is absent 
in these organisms and as end-joining DSB repair proceeds by MMEJ. This suggestion 
may be supported by the observation that the MMEJ pathway was found to be the 
dominant end-joining pathway for induced DSBs in T. brucei  (Glover et al., 2008). MMEJ 
has also been implicated in mammalian chromosome translocation, which may lead to 
cancer (Bentley et al., 2004), and telomere dynamics in Arabidopsis (Heacock et al., 
2004). 
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1.5 Homologous Recombination (HR) 
Homologous recombination (HR) allows repair of DSBs by copying a template that has the 
same DNA sequence, thereby allowing accurate duplication of the sequence at the DSB 
and preservation of the genomes integrity by ensuring chromosome stability (reviewed in: 
Li & Heyer, 2008; Otero & Hsieh, 1995; San Filippo et al., 2008; Sung et al., 2000; 
Symington, 2002; Wyman et al., 2004). HR repairs DSB that have resulted from stalled or 
collapsed replication forks and exposure to DNA damaging agents (McGlynn & Lloyd, 
2002; Thompson & Schild, 2001). HR also has a role in exchange of genetic information 
between maternal and paternal alleles during the generation of haploid gametes (meiosis), 
generating genetic diversity (Richardson et al., 2004). HR has been shown to have a role in 
switching of mating types in yeast and in antigenic variation of pathogens, such as T. 
brucei.  
1.5.1 Mechanism of Homologous Recombination: Gene 
conversion  
The pathway of HR can be broken down into three stages, the presynaptic, the synaptic and 
the post-synaptic (Symington, 2002). In the presynaptic stage, the DSB is recognised and 
the DSB ends are processed to reveal 3’ single stranded overhangs (ssDNA) which then 
allows the recombinase Rad51/RadA/RecA (in eukaryotes/archaea/eubacteria respectively) 
to bind to the DNA, with the aid of co-factors (Figure 1-11 A-D) (Benson et al., 1994; 
Ogawa et al., 1993; Sandler et al., 1996). The synaptic or strand exchange stage occurs 
once a recombinase-ssDNA nucleoprotein filament has formed on the 3’ DSB tails; the 
broken strand invades a homologous duplex DNA molecule where a D-loop is formed at 
the point of base-pairing (Figure 1-11 E-F) (Symington, 2002). The post-synaptic stage is 
where resolution of the strand exchange intermediates occurs, and can involve branch 
migration and resolution of crossed DNA strands (Figure 1-11 G-H) (Symington, 2002). 
These three stages appear to be broadly conserved in HR pathways of all kingdoms of life, 
where the orthologous recombinases (Rad51/RadA/RecA) appear to act in a strikingly 
similar manner (Benson et al., 1994; Ogawa et al., 1993; Sandler et al., 1996). However, 
HR can occur by multiple pathways: gene conversion with or without a crossover event, 
break-induced replication and single strand annealing (reviewed in: Paques & Haber, 
1999).  
In eukaryotes the genes involved belong to an epistasis group initially defined in S. 
cerevisiae which include Rad50, Rad51, Rad52, Rad54, Rad55, Rad57, Rad59, Mre11, and 
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Xrs2 (Symington, 2002). Many of these factors are conserved proteins in most eukaryotes, 
and some in all the kingdoms of life. Recombination events must begin with a break in 
either one or both strands of the DNA helix, see Figure 1-11A. Once DSBs have occurred, 
the break ends are processed to reveal 3’ ssDNA, see Figure 1-11A. Genetic studies have 
revealed that in S. cerevisiae, the protein complex comprised of Mre11, Rad50 and Xrs2 
(the MRX complex; also called the MRN complex in mammals) has helicase and nuclease 
activities similar to the RecBCD complex, which aids this action in prokaryotic cells 
(Mimitou & Symington, 2008; Symington, 2002). The MRX complex also appears to 
function in the yeast NHEJ pathway, and similar to its role in HR, may be involved in 
processing of the break ends by nuclease activity although the enzymatic process of the 
MRX complex may differ for the two pathways (Dudasova et al., 2004; Mimitou & 
Symington, 2008).   
Replication protein A (RPA) binds with a high affinity to the free ssDNA, stimulates 
binding of Rad51 at the DSB and removes secondary DNA structures which could prevent 
effective base-pairing during strand exchange (Figure 1-11B and Figure 1-11C) (Baumann 
& West, 1998). The Rad51 protein wraps around the 3’ ssDNA and forms a helical 
nucleoprotein filament in which one Rad51 molecule binds to every three nucleotide bases, 
in the presence of ATP; this is discussed in more detail in Section 1.6 (Figure 1-11D) 
(Benson et al., 1994; Conway et al., 2004). The nucleoprotein filament is needed for strand 
invasion of an intact DNA duplex or binding to another single strand of DNA and 
facilitates base pairing in this process, see Figure 1-11E (Chen et al., 2008). Rad51 binding 
and nucleoprotein filament formation occurs with the help of a number of co-factors 
including a variable number of Rad51 paralogues (discussed in more detail, see Section 
1.7), BRCA2, and Rad52, see Figure 1-11C-D. The detailed roles of these factors are still 
being elucidated (San Filippo et al., 2008).  
It has been shown that S. cerevisiae Rad52 helps to displace the RPA from the ssDNA, 
facilitating Rad51 binding (New et al., 1998; Shinohara & Ogawa, 1998). S. cerevisiae 
Rad52 appears to have a role in all pathways of HR (Davis & Symington, 2004; Ivanov et 
al., 1996) and its mutation has a strong impact on radiation sensitivity and Rad51 foci 
formation (Gasior et al., 1998; Hays et al., 1995). Most likely, this is because Rad52 can 
also promote some DNA strand exchange and can therefore allow Rad51-independent 
recombination (Mortensen et al., 1996; Pohl & Nickoloff, 2008; Sugiyama et al., 1998). In 
contrast, mutation of mammalian Rad52 has little effect on radiation sensitivity, Rad51 
foci formation and has little effect on recombination rate (Rijkers et al., 1998; van Veelen 
et al., 2005; Yamaguchi-Iwai et al., 1998). Nevertheless, mammalian Rad52 does appear to 
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form Rad52 foci when induced by DNA damage (Liu & Maizels, 2000). Interestingly, 
Rad52 is not conserved in all organisms and has not been detected in the trypanosomatids  
(Berriman et al., 2005; El-Sayed et al., 2005). In these organisms, the breast cancer type 2 
susceptibility protein (BRCA2) may function in a similar manner to Rad52. Mutation in 
the BRCA2 gene of T. brucei, nematode and vertebrate cells results in sensitivity to DNA-
damaging agents and defects in HR (Hartley & McCulloch, 2008; Martin et al., 2005; 
Moynahan et al., 2001). BRCA2 interacts directly with Rad51 (Pellegrini et al., 2002; 
Yang et al., 2002). It has also been shown to bind to ssDNA and dsDNA, displacing RPA 
and aiding Rad51 binding (Martin et al., 2005; Yang et al., 2002). These studies may 
provide evidence that BRCA2 functions in a similar manner to Rad52 in Rad52-deficient 
cells. However, it is unclear why mammalian cells have both Rad52 and BRCA2, and why 
there appears to be many other mediators needed for this step in HR. For example, two 
Rad51 paralogues have also been shown to displace RPA which aids the loading of Rad51 
(Sigurdsson et al., 2001) (see Section 1.7 below). 
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Figure 1-11: Model for the homologous recombination DNA repair pathway.  
The diagram depicts one example of HR pathway, with the formation of two Holliday junctions leading to 
gene conversion with a crossover event. A: The DNA break ends are processed to reveal 3’ ssDNA. B: 
Replication Protein A (RPA) binds to the ssDNA. C: Mediators help Rad51 binding. D: Rad51 forms a 
nucleoprotein filament. E: With the aid of Rad54, Rad51 catalyses homology-based strand exchange of the 
single stranded end (Black lines) into the intact duplex DNA (Blue lines). The DSB can then be repaired by 
different pathways. Holliday junction (cross lines) formation and a crossover event are depicted here. F: The 
donor strand is displaced and copied. G: Resolving enzymes cleave along different axes for a crossover event 
to occur (Red and Yellow arrows) (Bhattacharyya et al., 2004; Symington, 2002). 
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It has been shown that Rad54, a member of the Swi2/Snf2 protein family, associates with 
the Rad51 nucleoprotein and homologous double stranded DNA, and probably acts in 
facilitating the strand exchange by promoting homologous DNA pairing (Petukhova et al., 
1998) (see Figure 1-11 E-F). It has also been suggested that as members of the Swi2/Snf2 
family, Rad54, may function in chromatin remodelling when strand exchange occurs 
(Alexiadis & Kadonaga, 2002; Zhang et al., 2007). Rad54 is present in T. brucei, but has 
not been examined functionally. Once the nucleoprotein has invaded the duplex DNA 
strands and has found homologous regions, a so-called D-loop is formed (Symington, 
2002), see Figure 1-11 F. Completion of HR pathway is now dependent on DNA 
polymerase extension from the 3’ end of the invading strand; DNA synthesis occurs using 
the 3’ end as a primer for new DNA synthesis and the donor strand as a template (Maloisel 
et al., 2004; Wang et al., 2004). One HR pathway involves the model proposed by Szostak 
with the formation of two Holliday junctions, four-stranded branched structures after the 
strand of the donor duplex is displaced and copied (Paques & Haber, 1999; Szostak et al., 
1983). The resolution of these Holliday junctions can either lead to a cross over event or a 
non crossover event, depending on the way the strands are cut by a resolvase (Ip et al., 
2008). If the non-crossover strand and cross over strand of both Holliday junction are 
cleaved in the same way, along the same axis, a crossover event will not take place, for 
example the yellow arrows on Figure 1-11 G. If the non-crossover strand and crossover 
strand of one junction are cleaved and the non-cross over and crossover strands of the other 
junction are cut along different axis, a crossover event will occur, for example the red 
arrows on Figure 1-11 G (Paques & Haber, 1999). 
It would be predicted that resolution of Holliday junctions formed during HR would lead to 
an equal generation of crossover and non-crossover events, if the resolution was a random 
process. This is not the case, as S. cerevisiae mitotic recombination rarely results in a 
crossover event (Kupiec & Petes, 1988). As a result, a second pathway called the 
synthesis-dependent strand annealing (SDSA) model was proposed (Nassif et al., 1994). 
SDSA occurs where one strand invades the DNA duplex, forming a D loop, and initiates 
DNA synthesis while the other strand remains unengaged (Paques & Haber, 1999). The 
newly synthesised strand from the D loop is then displaced from the template and anneals 
to the other 3’ssDNA tail, allowing DNA synthesis and ligation of the gaps (Haber et al., 
2004). It is proposed that SDSA occurs normally in non cross-over events but it can be 
modified to provide a crossover event as well (Ferguson & Holloman, 1996). Given the 
lack of gene crossover, it has been proposed that SDSA pathway may be a predominant 
mechanism for VSG switching (Barry, 1997; Borst et al., 1996). 
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1.5.2 Break induced replication 
Some significant variations on the relatively conserved HR pathway described above have 
been purposed (Section 1.5.1). DSB repair can also occur through a process called break 
induced replication (BIR) (Kraus et al., 2001: see Figure 1-9C). This pathway can be 
Rad51-dependent or independent but appears to be Rad52-dependent (Ira & Haber, 2002; 
Signon et al., 2001). In BIR, the DSB ends are also processed to reveal 3’ ssDNA, but then 
only one end of the DNA break invades the duplex DNA and a true replication fork is 
formed which can copy a large portion, if not all, of the chromosome (McEachern & 
Haber, 2006). The second end of the DSB does not invade the duplex DNA, which can 
result in the loss of genetic information in that region (McEachern & Haber, 2006; 
Symington, 2002). It is uncertain the contribution that BIR has on the repair of DSB, 
although it has been purposed that BIR has a significant contribution in DSB repair in 
recombinase mutants (Malkova et al., 2001) and potentially in telomere maintenance 
(McEachern & Haber, 2006). It has also been purposed that the BIR pathway plays a role 
in VSG switching for telomeric genes (Barry & McCulloch, 2001; Dreesen et al., 2007). 
1.5.3 Single strand annealing 
Another non-conservative variant of HR is the mechanism of single strand annealing 
(SSA) (Lin et al., 1990: see Figure 1-9B; Paques & Haber, 1999). This pathway can repair 
a DSB that is flanked by repetitive or homologous sequences. The DSB is processed by a 
5’-3’ exonuclease to reveal 3’ ssDNA ends, which are complementary to one another 
(White & Haber, 1990). As both ends are homologous, this allows base pair annealing. 
Non-homologous DNA sequence is excised with loss of the genetic information (Fishman-
Lobell et al., 1992). Once the base pairs anneal, DNA synthesis follows and ligation 
repairs the gaps in the DNA strand. SSA appears to be dependent on Rad52 (Fishman-
Lobell et al., 1992; Sugawara & Haber, 1992) and can occur in S. cerevisiae  rad51, rad54, 
rad55, and rad57 mutants (Ivanov et al., 1996). 
1.5.4 Other roles of homologous recombination  
1.5.4.1 Recombination and antigenic variation in T. brucei 
In T. brucei cells, little is known about the specific pathways that regulate and act in HR in 
VSG switching (see Section 1.2.2). In bloodstream stage trypanosomes, VSG switching 
occurs by two mechanisms. >90% of switches appear to occur by DNA recombination, 
which delivers a previously silent VSG into a bloodstream expression site (BES). 
Rachel Dobson, 2009   Chapter 1, 29 
Alternatively, the coat change can occur via transcriptional, or in situ, switching between 
different BESs (see Figure 1-5: Barry, 1997; Pays et al., 2004). HR events in VSG 
switching primarily involves a non-reciprocal gene conversion, where the archive gene 
sequence is copied into the active BES (McCulloch, 2004). Following nuclease-mediated 
removal of the active VSG gene, DNA repair processes replace the lost gene by copying a 
silent VSG. 
It is believed that the HR mechanisms, described above and in Figure 1-9, play a role in 
VSG switching, although there is a patchwork of different factors involved. It has been 
shown that mutants of MRE11 in T. brucei exhibit chromosomal instability and impairment 
of HR. However MRE11 does not contribute to recombination during antigenic variation in 
trypanosomes (Robinson et al., 2002), perhaps implying that another nuclease may be 
involved in the VSG switching mechanisms, or one that plays a more substantial role than 
MRE11. Mutation of RAD51, the central enzyme of HR, impairs, but does not completely 
disrupt VSG switching, demonstrating that there are RAD51-dependent and RAD51-
independent mechanisms involved (Conway et al., 2002b; McCulloch & Barry, 1999). 
Given that the mediation of homology recognition and initiation of strand exchange 
requires the action of additional proteins (Baumann et al., 1996), identification of the 
RAD51 paralogues may explain or perhaps control some of the RAD51-independent 
pathways of VSG switching. Studies of two of these RAD51-like genes (RAD51 
paralogues) in VSG switching have shown that mutation of RAD51-3 causes impairment of 
switching rates, while another, RAD51-5 does not seem to be involved (Proudfoot & 
McCulloch, 2005a), suggesting that RAD51 paralogues may have distinct roles in the 
process. Studies in the bloodstream stage demonstrated that mutation of a putative meiosis-
specific recombinase, DMC1, does not affect HR, repair nor VSG switching (Proudfoot & 
McCulloch, 2005b).  Finally, it has also been shown that T. brucei BRCA2, which is 
thought to act as a co-factor in HR, aiding RAD51 loading onto ssDNA, has a role in VSG 
switching, as brca2 -/- mutant cells have a decrease in VSG switching frequency of a very 
similar magnitude to the rad51 -/- mutant cells (Hartley & McCulloch, 2008; McCulloch & 
Barry, 1999). 
1.5.4.2 Meiosis 
Meiosis is a process that results in gametogenesis and allows genetic variability of 
progeny. It is a specialised cell division that produces four haploid cells from one 
replicating parental diploid cell (Mange & Mange, 1999). The haploid cells have half the 
number of chromosomes compared to the parental cell. Chromosomal duplication in the 
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parental cell results in the formation of two identical chromatids, and is followed by 
chromosomal segregation and cell division (Mange & Mange, 1999). These two daughter 
cells divide again with the separation of each pair of chromatids into the progeny haploid 
cells. Fertilisation occurs by fusion of two haploid cells which restores the diploidy 
(Mange & Mange, 1999).  
One important factor in meiosis is the arrangement of the recently replicated chromosomes 
into homologous pairs. This alignment of homologous chromosomes occurs in the stage of 
meiosis I called prophase I, and is characterised by synaptonemal complex (SC) assembly, 
genetic recombination and formation of chiasmata (Richardson et al., 2004; Roeder, 1997). 
In prophase I, there are five main stages: leptotene, zygotene, pachytene, diplotene and 
diakinesis (Roeder, 1997). In leptotene there is the development of a synapse where the 
pair of chromosomal homologues become intimately associated with one another by a 
proteinaceous structure, the synaptonemal complex (Mange & Mange, 1999; Roeder, 
1997). The SC is a ribbon-like structure that forms on the chromosomes and strengthens 
their synapsis (Mange & Mange, 1999). For a cross-over event to occur a DSB must form 
and strand exchange between the homologues occurs in the pachytene stage (Mange & 
Mange, 1999; Roeder, 1997). The cross-over event results in the exchange of genes 
between chromosomal homologues. Whether or not genetic exchange has occurred in the 
meiotic process is not physically evident until the diplotene stage as the chiasmata form 
(Mange & Mange, 1999). Chiasmata are visible under a light microscope for many cells 
and are where the two homologous, non-sister chromatids are connected. This is the 
location of the crossover event (Mange & Mange, 1999). The crossover events that occur 
during the process of meiosis enable the random shuffling of genetic information creating 
new combinations of genes. This allows an increase in the genetic diversity of the progeny 
compared to the parental cells, and strengthens the association between homologous 
chromosomes during meiosis. 
The double strand break repair pathway similar to the one described in Section 1.4 allows 
meiotic recombination to occur (Richardson et al., 2004). However, it is driven by some 
meiosis specific factors which have been described in different species. It has been shown 
that the topoisomerase-like Spo11 transesterase initiates the meiotic recombination by 
inducing DSBs in S. cerevisiae (Keeney et al., 1997; Lichten, 2001). The DSB occurs in 
the leptotene stage at locations on the chromatid that are determined by local chromatin 
and chromosomal structure (Roeder, 1997). At the DSB, the DNA is processed to reveal 3’ 
ssDNA ends probably by the complex of exonucleolytic proteins, Rad50 and Mre11 (Neale 
et al., 2005). On the ssDNA, a nucleoprotein filament forms and strand exchange occurs 
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which involve Rad51 and, additionally, a meiosis specific homolog of Rad51 called Dmc1 
(Bishop et al., 1992; Ogawa et al., 1993). It has also been shown that Rad52 and 
Rhd54/Tid1 are required for meiotic recombination (Lao et al., 2008; Shinohara et al., 
2000). The segregation and assortment of alleles during genetic exchange between two T. 
brucei different strains occurs when co-transmitted through the Tsetse fly and is thought to 
involve meiosis (MacLeod et al., 2005; Turner et al., 1990). Most of the components 
required for meiotic recombination have been retained in the T. brucei genome (Klingbeil 
et al., 2007), and one of which, DMC1, has been studied (Proudfoot & McCulloch, 2005b). 
DMC1 mutation in bloodstream stage cells causes no observable DNA repair or 
recombination defect, and perhaps this result is consistent with a function during a life 
cycle stage in the Tsetse fly in which meiosis occurs: the epimastigote stage (Gibson et al., 
2008; Gibson, 1995; MacLeod et al., 2007; Proudfoot & McCulloch, 2005b: see Section 
1.1.2). 
1.5.4.3 The switching of S. cerevisiae mating type  
In the budding yeast, S. cerevisiae, there are two sexes or mating types, a and α. This 
defines whether or not individual cells can sexually reproduce with the same or opposite 
mating type. The mating type is determined by the active gene present in the mating type 
locus (MAT). On the same chromosome as the MAT locus, there are two alleles that 
contain the information of the mating type, called HML and HMR (Klar, 1987). The HML 
is the locus that usually contains unexpressed mating type α information, and the HMR is 
the locus that usually contains unexpressed mating type a information (see review: Haber, 
2006; Symington, 2002). After meiosis and sporulation, each spore divides producing a 
mother and a daughter cell without a change in mating type. During the second mitotic 
division, it is only the mother cell which can switch mating type before the next round of 
cell division (Haber, 1992). Switching of the mating type occurs by gene conversion of the 
active gene with the other silent gene located in the donor locus.   
The product of the HO gene, an endonuclease, was found to control the frequency of 
mating type switching of the yeast cell. There are two HO alleles; the dominant allele 
causes the homothallic phenotype which has a high mating type switching frequency (can 
be one switch per cell division) (Weiffenbach & Haber, 1981). The recessive ho is 
responsible for the heterothallic phenotype which has a much lower mating type switching 
frequency (Weiffenbach & Haber, 1981). The switching occurs by gene conversion in a 
similar pathway of DSB repair, described in Section 1.5 (Strathern et al., 1982). It was 
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shown that that MAT switching was lethal in rad52 mutants, suggesting the process 
involved HR (Malone & Esposito, 1980). 
The existence of the enzymes Spo11 and HO, which generate a DSB that induces meiotic 
recombination and MAT switching respectively, suggest a mechanism by which HR can be 
targeted to drive a particular reaction (Haber, 1992). However, no evidence has been 
provided of such enzymes being involved in inducing breaks for VSG switching in 
trypanosomes, and nothing is known about the initiation events in this reaction. It may be 
the case that DSB arise randomly in specific hot spots in BES of a few percent of all 
parasites. It is equally possible a distinct process for initiation occurs, such as that used for 
MAT switching in yeast.  
1.6 The role of the HR recombinases 
As discussed previously (Section 1.5.1), the genes involved in HR (HR) and DSB repair 
were identified primarily as radiation (rad) sensitive mutants in E. coli, S. cerevisiae and in 
rodent cells (Collins, 1993; Cox, 2000; Symington, 2002). In S. cerevisiae, the genes 
involved in DSB repair belong to the Rad52 epistasis group which include Rad51 and the 
Rad51 paralogues, and have some role in DNA strand exchange. Here, Rad51 and its 
homologues in other organisms are referred to as the recombinases. 
1.6.1 Phylogeny of the recombinases and their role in 
strand exchange 
RecA is highly conserved among the eubacteria (Clark & Margulies, 1965).  RecA is a 
multifunctional protein, with involvement in the induction of the SOS response to DNA 
damage in prokaryotes, through regulation of the LexA repressor protein (Little & Mount, 
1982). RecA-mediated cleavage of LexA results in expression of many genes, most of 
which are involved in DNA repair pathways. Analysis of RecA also shows that it promotes 
the central steps of HR and can be defined as a DNA-stimulated ATPase (Craig & Roberts, 
1981). RecA binds to ssDNA or partially single stranded DNA to form a nucleoprotein 
filament which can promote strand exchange.  It has been shown that RecA binds with a 
higher affinity to ssDNA than dsDNA. The strand exchange-proficient RecA nucleoprotein 
filament forms in a 5’-3’ direction relative to the single strand (Register & Griffith, 1985), 
and with ATP hydrolysis, the exchange occurs in an unidirectional manner (Jain et al., 
1994). This nucleoprotein filament is helical and consists of approximately six monomers 
of RecA per helical turn, with 2-3 bound bases per RecA monomer (Di Capua et al., 1982).  
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Studies revealed that the prokaryotic RecA and its orthologs, RadA and Rad51 in archaea 
and eukaryotic respectively (Sandler et al., 1996; Shinohara et al., 1993), are conserved in 
all sequenced organisms, implying that they are essential for HR in living cells (Kawabata 
et al., 2005). Analysis comparing E. coli RecA and its Rad51 ortholog in yeast S. 
cerevisiae, revealed that over 30 % amino acid sequence was identical when the core 
domains of each protein were compared (Baumann & West, 1998; the red domains of 
Figure 1-12).  Sequence analysis also showed high homology of the archaean RadA, with 
RadA having 40 % identity to yeast Rad51 and around 20 % to RecA (Sandler et al., 
1996). The human Rad51 protein contains a core region that has 67 % identity to S. 
cerevisiae and 30 % identity with E. coli RecA (Baumann et al., 1996; Shinohara et al., 
1993). These core regions contain two highly conserved consensus motifs called the 
Walker A and Walker B motifs, or boxes (Lin et al., 2006). These motifs are conserved in 
ATPases and confer ATP binding and hydrolysis activities to the RecA/Rad51 proteins 
(Walker et al., 1982). The nucleoprotein filament formed by S. cerevisiae Rad51 was high 
analogous structurally and stoichiometrically to that formed by RecA, with the Rad51 
filament binding 2-3 nucleotides per monomer (Benson et al., 1994; Conway et al., 2004; 
Ogawa et al., 1993). Rad51, from yeast and mammals, was also shown to have a similar 
function to RecA, having a role in HR and DSB repair. 
 
Figure 1-12: Sequence comparisons of prokaryotic RecA with eukaryotic Rad51 from yeast and 
humans. 
Schematic representation of the domains of the three proteins and their relative amino acid sizes; E. coli 
RecA, S. cerevisiae Rad51 and H. sapiens Rad51. The conserved core domains are in red and the N-terminal 
sequences conserved in S. cerevisiae and H. sapiens RAD51 are in blue. The averages of the identity and 
similarity percentages of the amino acids residues within the core domains are shown. Reprinted with 
permission from Elsevier: Baumann et al. (1998), Trends in Biochemical Sciences, 23, pp 248. 
Despite these structural similarities and high identity between the core domains of the 
proteins, there are some other differences between RecA and Rad51. The proteins differ 
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significantly outside the core domain (Figure 1-12); The RecA and Rad51 proteins have 
variable N and C terminal domains (the white domains of Figure 1-12). The N-terminal 
region of Rad51 and RadA (not shown) have a Helix-hairpin-Helix (H-h-H) domain, which 
appears to be absent from RecA and may have a role in DNA binding (Aihara et al., 1999). 
The prokaryotic RecA and Arabidopsis thaliana RecA1 have a C-terminal domain absent 
in orthologous Rad51 or RadA proteins. This C-terminal domain of RecA has been shown 
to bind to dsDNA, although the function is unknown (Aihara et al., 1997). It may have a 
role in strand exchange due to its dsDNA binding properties and maybe even be important 
for the packing of adjacent polymers in the RecA-DNA filament (Aihara et al., 1997; Story 
et al., 1992).  
These structural differences between Rad51 and RecA could account for some observed 
functional differences. Firstly, the rate of ATP hydrolysis of Rad51 is much lower than that 
of RecA. Secondly, while RecA and Rad51 have been shown to form a filament on nicked 
duplex DNA and ssDNA in the same manner, it has been shown that human Rad51 can 
bind highly supercoiled DNA in vitro, while RecA was limited by the torsional stress 
caused by extensive unwinding (Benson et al., 1994). Thirdly, the DNA binding 
preferences of RecA and Rad51 appear to be different. RecA prefers to bind to single 
stranded or partially single stranded DNA, while the binding affinity of Rad51 proteins to 
ssDNA and dsDNA are similar. Fourthly, in strand exchange, the Rad51 filament forms on 
the complementary strand in the 3’-5’direction which is the opposite direction to that of 
RecA filament (Sung & Robberson, 1995). Finally, RecA has been shown to form as a 
large nucleoprotein filament across the DNA, while this is not the case for Rad51 (van der 
Heijden et al., 2007). The Rad51 nucleoprotein formation consists of many small filament 
fragments that are only a few tens of monomers long (Galletto et al., 2006). This high 
flexibility and dynamic nature of this arrangement is likely to facilitate strand exchange of 
Rad51 (Galletto et al., 2006).  
Most eukaryotes possess a second recombinase, called Dmc1 (Disrupted meiotic cDNA 
protein 1), which potentially functions exclusively in meiosis and is not found in 
prokaryotes (Bishop et al., 1992). S. cerevisiae Dmc1 was shown to be highly homologous 
to Rad51 since 45 % of the amino acid residues are identical between S. cerevisiae Dmc1 
and Rad51. S. cerevisiae Dmc1 was also shown to have homology with E. coli RecA: with 
26 % identity and 41 % similarity of the amino acid residues in the core regions. Dmc1 is 
required for normal levels of meiotic recombination and progression (Bishop et al., 1992). 
H. sapiens Dmc1 was shown to bind to ssDNA, and have a weak ATPase activity 
compared to RecA. This study also concluded that H. sapiens Dmc1 has a role in strand 
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exchange (Li et al., 1997). Interestingly, Caenorhabditis elegans does not have Dmc1 
however, and the Ce-Rad51 (Ce-rdh-1) protein has been shown to have both Rad51 and 
Dmc1 properties, with Ce-Rad51 being 59 % identical to Mus musculus Rad51 and 51 % 
identical to M. musculus Dmc1. The Ce-Rad51 was also shown to be involved in DSB 
repair in mitotic and meiotic nuclei, and to act in meiotic progression (Takanami et al., 
1998). 
1.6.2 Phenotypes of recombinase mutants 
Studies have revealed that mutation of E. coli RecA results in an increased sensitivity to 
radiation, and a decrease in HR rates (Clark & Margulies, 1965). As with E. coli, S. 
cerevisiae rad51 mutants are viable and are observed to be defective in recombination as 
well as having an increased sensitivity to a DNA damaging agents, including MMS 
(Chanet et al., 1996). A RadA mutant has been generated in the archaeal extreme halophile, 
Haloferax volcanii (Woods & Dyall-Smith, 1997). This mutant has a slower growth rate 
than wildtype cells, had increased sensitivity to UV damage and DNA recombination was 
not detectable (Woods & Dyall-Smith, 1997). The T4 bacteriophage recombinase, UvsX, 
was first defined by mutation in “gene 49” that caused the phage to become sensitive to 
UV radiation, have a decreased level of genetic recombination, a decreased burst size, and 
an inability to replicate mature DNA (Miyazaki et al., 1983; Yonesaki et al., 1985). 
Mutated rad51 in T. brucei cells are viable (McCulloch & Barry, 1999), though such cells 
display phenotypes such as susceptibility to DNA damage with DNA damaging agents, 
MMS and phleomycin, and impaired HR, see Chapter 3 and Chapter 4 of this thesis.  
The above information leads to the realisation that RecA/Rad51/RadA proteins are crucial 
in HR but are not essential. In contrast, generation of conditional rad51 mutants in chicken 
DT40 cells showed chromosomal aberrations before cells underwent cell cycle arrest and 
death (Sonoda et al., 1998). Similarly, a fatal mutation of the rad51 gene in embryonic 
cells indicated that mammalian Rad51 is essential for proliferation and survival during 
embryogenesis (Lim & Hasty, 1996; Tsuzuki et al., 1996). Knockouts of the meiotic-
specific protein, dmc1, in embryonic mice are viable but are infertile. 
1.7 The roles of the eukaryotic RAD51 paralogues 
As discussed above, the recombinases are conserved throughout evolutionary but some 
differences between Rad51 and RecA have been described (see Section 1.6.1). These 
biochemical and structural differences may be explained, at least in part by the evolution of 
co-factors that aid the function of the recombinases. Such co-factors are found in different 
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numbers in different organism, and appear only to be semi-conserved. Prominent amongst 
this group of putative recombinase co-factors are the so-called Rad51 paralogues, Rad51-
like genes that are found in variable numbers of eukaryotes (see Chapter 7, Section 7.2.2).  
1.7.1 Identified Rad51 paralogues 
The identification and analysis of Rad51-like factors, the so called Rad51 paralogues, has 
suggested distinct functions of this set of proteins during HR. To date, no bacterial RecA 
paralogues have been identified, suggesting they are specific to eukaryotes and archaea. 
Within their Kingdoms, the roles and properties of the Rad51 paralogues have been best 
described in vertebrates and in yeast. H. sapiens and mammals in general, have five 
RAD51 paralogues named Rad51B (also called Rad51L1/HsRec2), Rad51C (Rad51L2), 
Rad51D (Rad51L3), XRCC2 and XRCC3 (Schild et al., 2000). Like mammalian cells, 
Arabidopsis thaliana has five Rad51 paralogues, which are named in the same way as the 
mammalian proteins, reflecting their likely orthology (Bleuyard et al., 2005). In contrast, 
the budding yeast, S. cerevisiae, has only two Rad51 paralogues, called Rad55 and Rad57. 
While the fission yeast, Schizosaccharomyces pombe, has four more recently identified 
paralogues called Rhp55, Rhp57, Rlp1 and Rdl1 (Khasanov et al., 2004; Martin  et al., 
2006; Tsutsui et al., 2001). Unusually, in some species only one Rad51 paralogue has been 
identified. For instance, the nematode Caenorhabditis elegans has RFS-1 (Boulton et al., 
2002; Ward et al., 2007), the phytopathologic fungus Ustilgo maydis has Rec2 (Holloman 
et al., 2008) and the archaea have RadB (Guy et al., 2006); in all cases these proteins have 
been shown to have a role in DNA repair. In Drosophila melanogaster, where the Rad51 
homologue is called SpnA, four SpnA paralogues are found, SpnB, SpnD, CG2412, 
CG6318, although only two of these have been functionally characterised (Abdu et al., 
2003). Even within the Kinetoplastida, the numbers of Rad51 paralogues are not 
conserved. Four RAD51 paralogues have been identified in T. brucei named RAD51-3, 
RAD51-4, RAD51-5, RAD51-6 and as well as the meiotic-specific protein DMC1 
(Proudfoot & McCulloch, 2005a), and each can be identified in T. cruzi. Leishmania major 
however has only three RAD51 paralogues and appears to lack the RAD51-5 (Proudfoot, 
2005). The varied number of the Rad51 paralogues throughout the major phylogenetic 
groups and the loss of RAD51-5 from Leishmania will be considered further in the 
discussion (see Chapter 7, Section 7.2.2). 
1.7.2 Phenotypes of rad51 paralogue mutants in yeast  
In S. cerevisiae null mutations of the two Rad51 paralogues, rad55 and rad57, have been 
described and each mutant causes cold sensitivity for DNA repair and recombination 
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(Game & Mortimer, 1974; Hays et al., 1995; Lovett & Mortimer, 1987). A mutation in the 
conserved lysine residue within the Walker A motif in Rad55 affects recombination, 
whereas a equivalent mutation in Rad57 has no affect (Johnson & Symington, 1995). 
Rad55 and Rad57 are both required for mating-type switching in the yeast, which is a 
specialised mitotic recombination event (Johnson & Symington, 1995; Sugawara et al., 
1995; see above Section 1.5.4.3). rad55 and rad57 mutants also result in a decrease in 
DNA damaged-induced Rad51 foci formation (Gasior et al., 1998), consistent with a role 
in the Rad51-mediated strand exchange stage in HR.  
As discussed above, S. pombe has Rhp55 and Rhp57 proteins that are orthologs of Rad55 
and Rad57 in S. cerevisiae, respectively, as well as two additional Rad51 paralogues 
named Rlp1 and Rdl1 (Khasanov et al., 2004; Martin  et al., 2006; Tsutsui et al., 2001). 
However, S. pombe rhp55 and rhp57 mutants display phenotypes that are different to that 
of rad55 or rad57 budding yeast mutants. For example, a mutation of the conserved lysine 
residue of the Walker A motif in Rhp55 and Rhp57 affected both cell lines when treated 
with the DNA-damaging agent, MMS (Tsutsui et al., 2001). Also, the S. pombe rhp55 and 
rhp57 mutants were more sensitive to MMS at lower temperatures compared to the S. 
cerevisiae rad55 and rad57 mutants (Johnson & Symington, 1995; Tsutsui et al., 2001). 
Rhp55 and Rhp57 have roles in spore viability, and all four fission yeast Rad51 paralogues 
have roles in meiotic recombination (Grishchuk & Kohli, 2003). 
1.7.3 Interactions and roles of yeast RAD51 paralogues 
S. cerevisiae rad55 and rad57 mutants display cold sensitivity, which is a property 
associated with proteins that complex as multiple subunits or with other proteins, 
indicating that the proteins act as a complex. This was shown to be the case, with Rad55 
and Rad57 found to interact in yeast-two hybrid analysis (Hays et al., 1995; Johnson & 
Symington, 1995) and that Rad55 and Rad57 form a stable heterodimer based on co-
immunoprecipitation data (Sung, 1997). It has been shown that Rad51-mediated strand 
exchange can be enhanced by the addition of Rad55 and Rad57, in vitro (Sung, 1997). 
Rad55 also interacts with Rad51 in yeast-two hybrid analysis, while there is no evidence 
that Rad57 interacts with Rad51 (Hays et al., 1995; Johnson & Symington, 1995; see 
Figure 1-13 ). In fission yeast, Rhp55 and Rhp57 also interact with one another but, in 
contrast to budding yeast, Rhp57 interacts Rad51 (Rhp51) (Tsutsui et al., 2001). It is 
noteworthy (see below) that mammalian Xrcc3 and Rad51C also interact with Rad51, 
since these have higher homology with Rhp57 compared Rhp55 (Grishchuk & Kohli, 
2003). S. cerevisiae Rad55 interaction with Rad51 has been shown to result in stabilisation 
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of the Rad51 nucleoprotein filament on the single-stranded DNA (Miyazaki et al., 2004). 
Rad55-Rad57 have also been shown to overcome the inhibition of Rad51 strand exchange 
caused by RPA (Sung, 1997), and overcome the DNA repair and HR defects of rad55 and 
rad57 mutants (Hays et al., 1995; Johnson & Symington, 1995). As a result of these 
analyses, it appears that the Rad55 and Rad57 paralogues interact as co-factors for the 
formation and stabilisation of Rad51 nucleoprotein filaments in DSB repair.  
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Figure 1-13: Predicted model of complex formations and interactions among S. cerevisiae Rad51 and 
the Rad51 paralogues.  
S. cerevisiae Rad51 paralogues, Rad55 (55) and Rad57 (57), are thought to act as a heterodimer. Rad55 
interacts with the S. cerevisiae recombinase, Rad51 (51), helping polymerisation of Rad51 on ssDNA, 
resulting in strand exchange and DSB repair. 
1.7.4 Phenotypes of rad51 paralogue mutants in 
vertebrate cells 
Two mammalian Rad51 paralogue proteins, XRCC2 and XRCC3, were identified by 
functional complementation of the irs1 and irs1SF mutant hamster cell lines. These cell 
lines had common phenotypes: they were sensitive to DNA damaging agents, extremely 
sensitive to DNA cross-linking agents and displayed gross chromosomal aberrations. 
These were so-called the x-ray repair cross complementing (XRCC) genes as 
complementation of the XRCC2 and XRCC3 in irs1 and irs1SF respectively efficiently 
restored cell function (Liu et al., 1998). In contrast, Rad51B (Albala et al., 1997), Rad51C 
(Dosanjh et al., 1998) and Rad51D (Pittman et al., 1998) were identified by sequence 
database analysis based on similarity to Rad51.  
Mutational analysis in mice has revealed that rad51B, rad51C, rad51D and xrcc2 
mutations are embryonic lethal where the foetuses were small and malformed (compared 
with a healthy foetus) and died in early-mid gestation  (Deans et al., 2000; Kuznetsov et 
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al., 2007; Pittman & Schimenti, 2000; Shu et al., 1999). Despite this lethality of embryonic 
cells, Rad51 paralogue somatic cell mutants, such as hamster cell lines (V79 and CHO) 
and chicken lymphocyte cell lines (DT40) are viable (Liu et al., 1998; Takata et al., 2000; 
Takata et al., 2001). This allowed phenotypic analysis of the mutant cell lines and potential 
roles to be assigned to the Rad51 paralogues. Studies by the Takeda group showed that 
mutation of rad51B, rad51C, rad51D, xrcc2 and xrcc3 in chicken DT40 cell lines resulted 
in very similar phenotypes, with a decreased growth rate, an increased sensitivity to DNA 
damaging agents (both γ-rays (mild) and cross-linking agents (strong)), and a reduced 
ability to undergo HR relative to wildtype cells (Takata et al., 2000; Takata et al., 2001). 
These phenotypes were similar to the ones seen in the irs1 and irs1SF mutants lacking in a 
functional XRCC2 and XRCC3 respectively (Liu et al., 1998). It has also been observed 
that mutation of xrcc2 and xrcc3 affected HR rates compared to hamster wildtype cells 
(Johnson et al., 1999; Pierce et al., 1999). Rad51 paralogue mutants in chicken DT40 cells 
also showed a decrease in DNA damage-induced Rad51 foci formation (Takata et al., 
2000; Takata et al., 2001). This was especially relevant, showing a role for the Rad51 
paralogues in relocalisation of Rad51 into foci when DNA damage occurred or in 
stabilisation of the Rad51 foci (Haaf et al., 1995).  
It is interesting to note that the phenotypes seen in the Rad51 paralogue mutant chicken 
DT40 cell lines can be fully or partially overcome by over-expression of human Rad51 and 
with complementation of the corresponding human Rad51 paralogue gene (Takata et al., 
2000; Takata et al., 2001). Also, two studies have shown that the early-mid embryonic 
lethality of Rad51B and Rad51D mutation in mice could be partially overcome by their 
generation in a p53 -/- background. p53 has a role in checkpoint cell cycle control and 
apoptosis, and loss of p53 is sufficient for an increase in proliferation of the highly 
comprised Rad51B and Rad51D mutant foetuses (Shu et al., 1999; Smiraldo et al., 2005). 
1.7.5 Interactions and roles of Rad51 paralogues in 
vertebrate cells 
Yeast-two hybrid and co-immunoprecipitation analyses have been carried out to examine 
the interaction between the mammalian Rad51 paralogue proteins. These experiments 
showed that Rad51 paralogues in human cell extracts form two discrete protein sub-
complexes, one containing Rad51B-Rad51C-Rad51D-XRCC2 (BCDX2) and the other 
Rad51C-XRCC3 (CX3) (Masson et al., 2001b; see Figure 1-14 ; Schild et al., 2000). Later 
analysis supported these findings, confirming that Rad51C was indeed present in the two 
Rad51 paralogue complexes, BCDX2 and CX3 (Liu et al., 2002b). 
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Figure 1-14: Predicted model of complex formations and interactions among mammalian Rad51 and 
the Rad51 paralogues.  
Rad51, Rad51B, Rad51C, Rad51D, XRCC2 and XRCC3 are shown in the diagram as 51, B, C, D, 2 and 3 
respectively. XRCC2-Rad51D and Rad51B-Rad51C dimers combine to form the Rad51B-Rad51C- Rad51D-
XRCC2 complex. XRCC3 may promote the dissociation of Rad51C from this complex to produce the 
XRCC3-Rad51C dimer that binds to Rad51 (Liu et al., 2002a).  
Further analysis of the Rad51 paralogue complexes has attempted to determine their 
function. The first of these studies examined the sub-complex comprising of the two Rad51 
paralogues, Rad51B-Rad51C (BC). As mentioned in Section 1.5.1 above, RPA is needed 
for Rad51-mediated strand exchange. RPA binds to the ssDNA and is thought to remove 
any secondary structures that may hinder the HR pathway. As RPA is bound to the ssDNA, 
it competes with Rad51 for binding sites to the ssDNA template. It was shown in vitro that 
this inhibitory effect of RPA could be overcome by the BC complex, with an increase of 
strand exchange products when BC complex was added to the reaction containing Rad51, 
RPA and ssDNA (Sigurdsson et al., 2001). Another biochemical analysis focused on 
another Rad51 paralogue complex, Rad51C-XRCC3 (CX3). This suggested that CX3 had 
Holliday junction resolvase activity (Liu et al., 2004). As described in Section 1.5.1, some 
recombination events require the formation of a Holliday junction intermediates, where 
rrecombining DNA strands cross. Resolution of these junctions in bacteria is carried out by 
RuvABC. It was found that rad51C and xrcc3 mutant human cell extracts had reduced 
levels of resolvase activity, while addition of purified complexes with Rad51C such as the 
BC complex to the extract restored all activity (Liu et al., 2004). Additionally, it has been 
shown that Rad51C stabilises XRCC3, as knocking down Rad51C levels in HeLa cells by 
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RNAi also greatly reduced XRCC3 levels (Lio et al., 2004). The data above have been 
used to generate the interaction model in Figure 1-14, which suggest that the Rad51 
paralogues form at least two distinct complexes, which potentially provide distinct 
functions within the mammalian cell. 
1.7.6 Phenotypes of the rad51-3 and rad51-5 mutants in T. 
brucei cells 
Four RAD51 paralogues have been identified in T. brucei, RAD51-3, RAD51-4, RAD51-
5, RAD51-6 and the meiotic-specific protein DMC1 (Proudfoot & McCulloch, 2005a). To 
date, mutations in only RAD51-3 and RAD51-5 have been generated. Both mutations result 
in HR impairment (but not complete abolishment) and phenotypic sensitivity to DNA 
damage (Proudfoot & McCulloch, 2005a).  In addition, both mutants show a reduced 
capacity for Rad51 re-localisation into discrete foci following phleomycin DNA damage. 
Together, these preliminary data are consistent with the hypothesis that the two proteins act 
as RAD51 mediators (Proudfoot & McCulloch, 2005a) similar to the suggestion in yeast 
and mammals (this is discussed in Chapter 4). In contrast to this, studies in the bloodstream 
stage could find no evidence that T. brucei DMC1 acts in HR, DNA repair, or in antigenic 
variation (Proudfoot & McCulloch, 2005b). 
1.7.7 Some examples of the phenotypes of the Rad51 
paralogue mutants in other eukaryotic cells 
1.7.7.1 The Rad51 paralogue in Caenorhabditis elegans 
RFS-1 is the only identified C. elegans Rad51 paralogue and is closely related to human 
and mouse Rad51D (Boulton et al., 2002; Martin et al., 2005). RFS-1 was suggested not to 
have a role in meiosis as meiotic crossover events and meiotic Rad51 foci form in rfs-1 
mutants (Ward et al., 2007). The phenotype of rfs-1 mutants was found to be different to 
that seen in C. elegans brca2 mutants, where there was a decrease in Rad51 foci formation 
(Martin et al., 2005; Ward et al., 2007). The rfs-1 mutant was also moderately sensitive to 
irradiation-induced DSBs and severely sensitive to cross linking agents, such as cisplatin, 
compared with wildtype cells (Ward et al., 2007). It was concluded that RFS-1 had a role 
in genome integrity primarily due to a role in replication as rfs-1 mutants were severely 
sensitive to agents that are thought to impact on replication fork progression. Interestingly, 
successive generations of nutritionally starved rfs-1 mutant cells results in progressive 
sterility which can be defined as Mortal germline mutants (Mrt). These Mrt mutants also 
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develop telomere erosion suggesting another role of the RFS-1 in genome stability 
(Yanowitz, 2008).  
1.7.7.2 The Rad51 paralogue in Ustilago maydis 
The fungus Ustilago maydis also has only one Rad51 paralogue, Rec2. This is an unusually 
large protein relative to the other Rad51 paralogues, with an amino acid sequence of 782 
which is twice the size of the U. maydis Rad51 protein. Comparisons between the U. 
maydis Rad51 and Rec2 amino acid sequences show that the Walker A and B boxes have 
52 % and 21 % identity and 76 % and 65 % similarity, respectively (Ferguson et al., 1997). 
Mutants of rec2 have an increased sensitivity to DNA damaging agents (UV, MMS and γ-
radiation) and recombination rates are also decreased. The phenotypes of rec2 mutants was 
similar to that observed in the U. maydis Rad51 mutant cells (Ferguson et al., 1997). 
Strikingly, analysis of the purified 110 kDa REC2 protein showed that this Rad51 
paralogue is able to bind to ssDNA, has DNA-dependent ATPase activity and is able pair 
sequences that have homology (Kmiec et al., 1994), activities not found for any other 
Rad51 paralogue. 
1.8 Aims of the project 
The overall aim of this thesis was to examine further the roles of the T. brucei RAD51 
paralogues in the DSB repair pathway of HR and, in particular, to assess whether or not 
this group of related proteins provide a single function or multiple functions. To this end, 
three approaches were adopted. 
1.8.1 Examining the role of RAD51-4 and RAD51-6 
To date, generation and analyses of rad51, rad51-3, rad51-5, and dmc1 mutants have been 
conducted (McCulloch & Barry, 1999; Proudfoot & McCulloch, 2005a; Proudfoot & 
McCulloch, 2005b). It was therefore necessary to examine the functions of the two 
remaining RAD51 paralogues, RAD51-4 and RAD51-6, to build a complete picture of the 
possible roles of these genes in T. brucei.  If T. brucei RAD51-4 and RAD51-6 have 
similar roles to RAD51-3 and RAD51-5 and potentially to Rad51 paralogues of other 
species, it would be predicted that the proteins will contribute to general HR and DNA 
damage repair. It is difficult to predict whether or not RAD51-4 and RAD51-6 will be 
involved in VSG switching, given the conflicting data on RAD51-3 and RAD51-5, see 
Chapter 4, Section 4.6. To this end, heterozygous and homozygous mutants of the T. 
brucei RAD51-4 and RAD51-6 genes were generated by gene disruption. This involved 
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replacing the open reading frame (ORF) of the gene with one of two antibiotic resistance 
cassettes, puromycin and/or blasticidin. Phenotypic analyses of the confirmed mutants 
were carried out: growth rates, sensitivity to DNA-damage agents, transformation 
efficiencies, ability to form DNA damage induced RAD51 foci and VSG switching were 
analysed (Chapter 3). These phenotypes were then compared to those observed in the 
rad51-3 -/- and rad51-5 -/- cells (Chapter 4).  
1.8.2 Analysing the association between the RAD51-
paralogues 
To determine if the RAD51 paralogues form discrete sub-cellular complexes similar to that 
of the Rad51 paralogues in mammals, or a single complex analogous to yeast 
Rad55/Rad57, interaction between the proteins was assessed. Two approaches were used 
(Chapter 5). The first approach involved yeast-two-hybrid assays. For this, the genes were 
cloned into bait and hunter plasmids, pHybLex/Zeo and pYesTrp, respectively 
(Invitrogen). Western analysis was used to show protein expression and analysis of any 
interaction(s) was performed using the Yeast β-galactosidase Assay kit (Pierce), X-gal 
filter lift assay, and histidine auxotrophy analysis. In the second approach, 
immunoprecipitation of the RAD51 paralogues was attempted to determine interactions 
between the proteins within T. brucei cells. To aid testing for protein-protein interactions, 
anti-sera was generated against the RAD51 paralogues and used for co-
immunoprecipitation. Where such anti-sera was found to be inappropriate due non-specific 
binding, T. brucei strains were generated in which the RAD51 paralogues were expressed 
with an epitope tag, PTP (Schimanski et al., 2005a; Schimanski et al., 2005b). This tag 
allows immunoprecipitation of the proteins which can be followed by western analysis.  
1.8.3 A luciferase assay for T. brucei homologous 
recombination 
The third experimental approach of this thesis was to design a novel assay to test for HR 
rates and pathways in T. brucei. To date, all general HR in T. brucei has been assayed by a 
relatively artificial route, evaluating the ability of the parasite to undergo HR by measuring 
the rate of integration of a construct containing an antibiotic resistance marker. This 
assures that the number of antibiotic resistant transformants will directly relate to the 
efficiency of HR. In fact, this assays, measures transformation rather than recombination, 
and may be prone to experimental fluctuation. The objective of this approach was to 
develop an alternative assay, which is more physiological and adaptable (Chapter 6). 
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Chapter 2. Materials and Methods 
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2.1 Cell culturing 
2.1.1 Trypanosome growth 
T. brucei bloodstream stage 3174.2, a derivative of the strain Lister 427, was used and 
analysed in all the experiments described in this thesis. Lister 427 strain is primarily 
monomorphic, and has adapted to life in laboratory conditions and has the ability to infect 
rodents (Melville et al., 2000). The derivative of Lister 427 strain, 3174.2, has two 
resistance markers, (neomycin and hygromycin resistance cassettes) in the bloodstream 
expression site that expresses MITat1.2a, VSG221. Therefore the 3174.2 strain enables the 
VSG switching frequencies and mechanisms to be analysed, and is discussed in more detail 
in Section 3.4.5  (McCulloch et al., 1997; Rudenko et al., 1996).  
All T. brucei bloodstream stage strain 3174.2 cells were grown in HMI-9 medium (Hirumi 
& Hirumi, 1994). This media contains a powder supplied by Invitrogen containing 
hypoxanthine, L-cysteine, pyruvic acid, thymidine, bathocuproedisulfonic acid and β-
mercaptoethanol. The medium was made by addition of tissue culture water (Sigma) to the 
sachet of powder (Invitrogen) and completed with 10 % (v/v) fetal bovine serum and 1 % 
penicillin/streptomycin (Invitrogen). The cells were passaged on a twice/thrice weekly 
basis and grown in a 37 oC, 5 % CO2 incubator. 
2.1.2 Transfecting of T. brucei 
T. brucei bloodstream stage strain 3174.2 cells were grown in HMI-9 medium (see above). 
An aliquot of 5 x 107 cells was centrifuged at 600 x g for 10 minutes at room temperature. 
The cells were then resuspended in 0.5 ml of prewarmed Zimmerman Medium with 
glucose [132 mM NaCl, 8 mM KCl, 8 mM Na2HPO4, 1.5 mM KH2PO4, 0.5 mM Mg 
acetate, 0.09 mM Ca acetate, 0.25 mM D-glucose (Sigma)]. Cells were electroporated in 
0.2 cm cuvettes (Bio-Rad) with approximately 5 µg of plasmid DNA at 1.5 kV and 25 µF 
capacity. The construct DNA had been linearised using restriction enzyme digestion 
followed by phenol/chloroform purification and ethanol precipitation. After 
electroporation, cells were added to 10 ml of HMI-9 for 24 hour recovery at 37 oC. The 
recovered cells were centrifuged at 600 x g for 10 minutes at room temperature and 
resuspended in fresh HMI-9 medium. A volume of 5 x 106 cells were diluted in 36 ml of 
HMI-9 medium containing the appropriate drug concentration and plated over a 24 well 
plate at 1.5 ml per well, i.e. approximately 2.08 x 105 cells per well. Growing cells were 
counted after 7-10 days by imaging each well of the plate under a light microscope (Leitz). 
The number of wells that contained transformants was recorded. The population of 
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transformants in a well were considered clonal, if the number of wells with growing cells 
did not exceed 10 out of 24. 
Once the clones were confirmed, each cell line was stabilated, and stored in liquid 
nitrogen. This was carried out by adding 0.9 ml of cells at log phase density of 2 x 106 per 
ml with 0.1 ml of 100 % glycerol. This was then gently mixed thoroughly and added to a 
cyro-vial (Nunc) and frozen at -80 oC over 48 hours. This was then moved to liquid 
nitrogen storage and given a Wellcome Centre for Molecular Parasitology (WCMP) 
stabilate number.  
2.2 Isolation of DNA  
2.2.1 Methods of DNA extraction 
The QIAprep spin miniprep kit was used to extract plasmid DNA from E. coli cells. For 
larger preparations of DNA from E. coli cells, GenElute HP plasmid kit (Sigma) was used. 
The manufacturer’s protocols were followed for all extraction methods using Qiagen and 
Sigma kits. 
DNeasy blood and tissue kit (Qiagen) was used to extract DNA from T. brucei cells. For 
larger preparations of DNA from T. brucei cells, 1 x 107 cells were centrifuged at 600 x g 
for 10 minutes and resuspended in 500 µl of lysis buffer [50 mM Tris-HCl (pH 8.0), 1 mM 
EDTA, 100 mM NaCl], and SDS and Proteinase K (Sigma) were added to final 
concentrations of 0.01 % and 0.1 mg.ml-1 respectively. This was incubated at 37 oC 
overnight; protein and lipid were removed using phenol/chloroform extraction and the 
genomic DNA recovered by ethanol precipitation (see below).  
2.2.2 Phenol/Chloroform extraction and ethanol 
precipitation of DNA 
To purify genomic or plasmid DNA from solution, a phenol/chloroform extraction and 
ethanol precipitation was carried out. This was done by adding an equal volume of buffer-
saturated phenol:chloroform:isoamyl alcohol (25:24:1) (Sigma) to the DNA solution. The 
solution was mixed well by vortexing for plasmid DNA and gently inverted for genomic 
DNA. The two phases were separated by centrifugation in a microcentrifuge at 16,000 x g 
for one minute. The aqueous layer was removed carefully to a new tube. 
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One tenth of the total volume of 3 M sodium acetate (CH3COONa) (pH 5.2) (BDH) was 
added along with three times the total volume of 100 % ethanol (Fisher). The solution was 
then frozen at -20 oC for 20 minutes, after which the DNA was centrifuged in a 
microcentrifuge at 20,000 x g for 30 minutes at 4 oC. The DNA pellet was washed with 
100 µl of 70 % ethanol and re-centrifuged for one minute. The pellet was air dried and 
resuspended in the required volume of dH2O. 
2.3 RNA extraction  
2.3.1 RNA extraction from T. brucei cells 
For extraction of RNA, RNeasy mini kit (Qiagen) was used. The RNA extract was then 
treated with deoxyribonuclease I (DNase; Invitrogen) to remove any DNA contamination 
from the sample. The manufacturer’s protocols were used for all methods.  
2.3.2 Reverse Transcriptase-PCR (RT-PCR) 
To convert RNA into first-strand cDNA, the SuperScript™ First-Strand Synthesis System 
for RT-PCR (Invitrogen) was used. The manufacturer’s instructions were followed using 
random hexamers. Briefly, 5 µg of DNase treated RNA, 1 µl of random hexamers (50 
ng.µl-1), and 1 µl of 10 mM dNTP mix was added to a final volume of 10 µl with DEPC-
treated H2O. Two reactions were carried out for each sample, one the positive sample and 
the other as a negative control containing no reverse transcriptase (RT). Each sample was 
incubated at 65 oC for 5 minutes, followed by cooling on ice. To each sample, 9 µl 
RNaseOUT reaction [2 µl of 10X RT buffer, 4 µl of 25 mM MgCl2, 2 µl of 0.1 M DTT, 1 
µl of RNaseOUT recombinant ribonuclease inhibitor] was added. The reaction was 
incubated at 25 oC for 2 minutes. To the positive sample (and not the negative control), 1 
µl (50 U) of SuperScript™ II RT was added and incubated at 25 oC for 10 minutes. The 
reaction was then incubated at 42 oC for 50 minutes followed by 70 oC for 15 minutes, then 
chilled on ice. The RNA template was degraded by addition of RNase H to each tube and 
incubated at 37 oC for 20 minutes. The cDNA was used as template for amplification using 
standard PCR (see below). 
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2.4 Cloning procedure 
2.4.1 Polymerase Chain Reaction (PCR) 
PCR reactions were carried out for cloning and screening. Routinely, the PCR mixture 
contained 1 U of either Taq (Biolabs) or Herculase (Stratagene), 0.5 µl (100 pmoles) of the 
primer pair, see Table 2.1, the required buffer concentration, 1 µl (10 mM) dNTPs and 1-5 
ng of template DNA to a final volume of 50 µl per reaction. DNA from T. brucei strain 427 
was used as DNA template for cloning of the ORFs and gene fragments. PCR 
amplification was carried out in either a thermal cycler Robocycler® (Stratagene) or a TC-
3000 (Techne), under the PCR conditions: denaturation at 94 oC for 5 minutes, followed by 
30 cycles of denaturation at 94 oC for one minute, annealing of primers at 50-60 oC for one 
minute and extension at 72 oC for one minute per kilobase amplified. A final extension 
time of 10 minutes at 72 oC ensured the PCR amplification had reached its completion. For 
purification of the amplified DNA, the PCR cleanup kit (Qiagen) was used. 
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Table 2-1: Description of the primers used in the experiments described in this thesis. 
Description of the primers used for PCR amplification in the separate Chapters of this thesis, Chapters 3, 4, 
and 6. This gives a brief description showing any restriction enzyme sites in colour and gives the specific 
DNA sequence of the primer. This Table is continued on two following pages, 50-51. 
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2.4.2 Restriction enzyme digestion of DNA 
Restriction enzyme digestion of DNA was performed using Biolabs enzymes using the 
manufacturer’s instructions. Routinely, for restriction mapping approximately 10 µg of 
DNA was digested in a final reaction volume of 20 µl, and for transfecting into T. brucei 
approximately 1 mg of DNA was digested in a final reaction volume of 200 µl. 
2.4.3 Gel electrophoresis and DNA fragment purification 
Standard electrophoresis techniques using 1 % (w/v) agarose LE analytical grade gel 
(Cambrex) in 1x Tris[hydromethyl]methylamine Acetate buffer (TAE) was employed for 
routine analysis (Sambrook et al., 1989). Electrophoresis was performed at 100 volts using 
a Bio-Rad PowerPac Mini. To the gel an aliquot of 1:20,000 dilution of Sybr®Safe stain 
(Invitrogen) was added before it set. The gel was visualized by a U.V. transilluminator 
(Bio-Rad) and digitised using Quantity One 4.6 (Bio-Rad). 
For extraction of the DNA, fragments were excised from the agarose gel and then extracted 
using MinElute gel extraction kit (Qiagen) according to the manufacturer’s instructions.  
The DNA was routinely eluted with 30-50 µl TE buffer or dH2O.  
2.4.4 DNA Ligation 
DNA ligations were performed using 1:1, 1:3, and 1:0 (as a negative control) ratios of 
vector:insert in volume, 2.5 U T4 ligase (Biolabs) with 2 µl 10X ligase buffer in a final 
volume of 20 µl. The reaction took place at 4 oC overnight. Table 2-2 describes the 
plasmids used in this thesis.  
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Table 2-2: Description of the vectors used in the experiments described in this thesis. 
The names, brief description and source of the vectors used in the experiments in this thesis. 
Promegasource of Luciferase ORFpGL3-Basic
Schimanski et al. (2005b)PTP tagging the N terminus of a proteinpN-PTP
Schimanski et al. (2005b)PTP tagging the C terminus of a proteinpC-PTP
Invitrogenyeast-two hybrid "prey" vectorpYesTrp2
Invitrogenyeast-two hybrid "bait" vectorpHybLex/Zeo
Stratagenecloning vectorpBluescript II KS+
Invitrogencloning vectorTOPO 2.1 pCR®2.1
McCulloch giftsource of βα IR-BLE-Actin IR-αβ IRpRM481
Proudfoot & McCulloch (2005b)source of βα IR-PUR-Actin IRpCP121
Proudfoot & McCulloch (2005b)source of βα IR-BSD-Actin IRpCP101
ReferenceApplicationVector Name
 
2.4.5 Transformation into E. coli 
All E. coli growth was on Luria broth [LB; 5 g yeast extract (Melford), 10 g tryptone 
(Formedium), 5 g NaCl (low salt) or 10 g NaCl (high salt) in 1 L pH 7.0] and agar 
(Melford) was added if plates were required. Ligations were transformed into chemically 
competent E. coli XL1-Blue MRF [∆(mcrA)183 ∆(mcrCB-hsdSMR-mrr)173 endA1 
supE44 thi-1 recA1 gyrA96 relA1 lac [F´ proAB lacIqZ∆M15]; Stratagene] by heat 
shocking the cells at 42 oC for 45 seconds with the required amount of DNA. An aliquot of 
900 µl of LB was added to the cells and cells were incubated for 50 minutes at 37 oC. 
Approximately 200 µl cells were then plated onto selective LB agar plates containing 40 
µg.ml-1 of 5-bromo-4-chloro-3-indolyl-β-D-galactoside (X-gal; Sigma) and 100 µg.ml-1 of 
ampicillin (Sigma). The plates were incubated at 37 oC overnight. Addition of X-gal 
allowed blue/white selection; a few white colonies were screened by restriction digestion 
and positives were sent to be sequenced by the University of Dundee DNA sequencing 
service. The M13 forward and reverse primers were usually used for sequencing. All 
alignments and manipulations were carried out using BlastN (Pubmed), AlignX 
(Invitrogen) and Vector NTI Suite 9 (Invitrogen). 
2.4.6 Transformation into S. cerevisiae 
Preparation of competent S. cerevisiae L40 strain [MATa his3∆200 trp1-901 leu2-3 
122ade2 LYS2::(4 lexAop-HIS3) URA3::(8lexAop-lacZ) GAL4; Invitrogen] was performed 
using the S. c. EasyComp Transformation Kit (Invitrogen) following manufacturer’s 
instructions. Co-transformations of both pHybLex/Zeo-Bait and pYesTrp2-Prey 
(Invitrogen) into yeast L40 strain was carried out and selected using minimal media (see 
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Section 2.10 for media details). The pHybLex/Zeo-Bait and pYesTrp2-Prey constructs 
were made by Sandra Terry. 
2.4.7 TOPO TA cloning 
For one-step cloning of a PCR fragment into a plasmid vector, Invitrogen’s TA cloning kit 
was used. This involved direct insertion of Taq polymerase-amplified PCR products into 
the plasmid vector pCR®2.1-TOPO®. A reaction of 1.0 µl of PCR product (approximately 
10 ng), 1 µl of NaCl solution, 1 µl pCR®2.1 vector, and 3 µl dH2O was incubated at room 
temperature for 5 minutes. Then, 2.0 µl of this reaction was added to the OneShot® 
competent cells (Invitrogen). The cells were transformed by heat shocking (see Section 
2.4.5).  
2.5 Southern blotting 
Southern blotting analysis (Southern, 1975) demonstrated that the alleles of RAD51-4 and 
RAD51-6 were disrupted. The purified genomic DNAs from wildtype, heterozygous, and 
homozygous mutants were digested using restriction enzymes at 37 oC overnight. These 
were then electrophoresed on a 0.8 % agarose gel overnight as previously described (see 
Section 2.4.3). The gel was imaged on a U.V. transilluminator (Bio-Rad) with a ruler 
parallel to the gel so that the sizes of the bands detected by hybridisation could be 
measured. To nick the DNA, the gel was soaked in 0.25 M HCl (Fisher) for 15 minutes and 
washed in dH2O. The DNA was then denatured by soaking the gel in denaturing solution 
[0.5 M NaOH and 1.5 M HCl (Sigma)] for 30 minutes. This denaturating solution was 
washed off with dH2O and the gel was soaked in neutralising solution [1 M Tris-HCl pH 
8.0, 1.5 M NaCl (Sigma)] for a further 30 minutes. The DNA was transferred to a nylon 
membrane (Hybond-XL; Amersham) by capillary blotting using 20 X SSC [3 M NaCl, 0.3 
M Na3C6H5O7.2H2O] as a transfer buffer overnight. The DNA was crosslinked to the 
membrane using a UV stratalinker (Stratagene).  
PCR-amplification (see Section 2.4.1) provided the DNA fragments used for the probe. 
These products were gel extracted (see Section 2.4.3). The probe was made using the Gene 
Images Random Prime Labelling Kit from Amersham and hybridisation of the probe to the 
membrane was performed following the manufacturer’s instructions. The probe was 
detected using the Gene Images CDP-Star Detection Module (Amersham). 
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2.6 Protein analysis 
2.6.1 Protein extraction from S. cerevisiae cells 
The following protocol, adapted from procedures described by Hybrid Hunter 
Invitrogen, was used to extract proteins from yeast co-transformants. A single colony 
transformant was inoculated into 10 ml of the appropriate media and grown at 30 oC while 
shaking at 250 x g for 24 hours. The cells were pelleted by centrifugation for 5 minutes at 
2500 x g and the supernatant was decanted. The cell pellet was frozen for 10 minutes at –
80 oC, then thawed and resuspended in 100 µl of pre-warmed cracking buffer [8 M urea 
(BDH), 5 % SDS (BDH), 40 mM Tris-HCl pH 6.8 (Fisher), 0.1 M EDTA, 1 % β-
mercaptoethanol, 0.4 mg.ml-1 bromophenol blue (Sigma)]. The cell suspension was 
transferred to a tube containing 100 µl of glass beads (Sigma) and then incubated at 70 oC 
for 10 minutes. The solution was mixed by vortexing for one minute and centrifuged at 
14,000 x g for 5 minutes at room temperature. 50 µl of the supernatant was boiled at 100 
oC for 5 minutes and electrophoresed on a 10 % polyacrylamide SDS gel (Bio-Rad). 
2.6.2 Protein extraction from T. brucei cells 
2.6.2.1  Crude protein extraction from T. brucei cells 
For protein preparations from T. brucei cells, 2 x 108 cells were pelleted at 1000 x g for 10 
minutes and washed twice in 1 ml of PBS.  The cells were re-centrifuged and resuspended 
in 200 µl lysis buffer [500 mM Tris HCl (pH 6.8), 10 % glycerol, 10 % SDS, 5 % β-
mercaptoethanol, 0.05 % bromophenol blue (Sigma)]. The extract (20-50 µl) was 
electrophoresed on a 10 % polyacrylamide SDS gel (Bio-Rad). 
2.6.2.2  Whole cell and nuclear protein extraction from T. brucei 
cells 
For larger protein preparations from T. brucei cells, 1 x 1010 cells were centrifuged at 1000 
x g for 10 minutes and washed twice in 1 ml of PBS. The cell pellet was frozen on dry ice 
and stored at -80 oC until required, for up to three months. The protocol was adapted from 
Smeaton et al. (2007). Frozen pellets were resuspended in 300 µl of  hypotonic lysis buffer 
[HLB: 10 mM Tris-HCl (pH 7.9), 1 mM EDTA, 10 mM NaCl, 1 mM DL-dithiothreitol 
(DTT) (Sigma) and protease inhibitor cocktail (Roche)], incubated on ice for 20 minutes 
and vortexed for 30 seconds. The mixture was centrifuged at 800 x g for 2 minutes at room 
temperature, to collect the nuclei. The supernatant was retained. The pelleted nuclei were 
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resuspended in nuclear extract buffer [NEB: 20 mM Tris-HCl (pH 7.9), 1 mM EDTA, 400 
mM NaCl (Sigma), 1 mM DTT, protease inhibitor cocktail (Roche), and 10 % glycerol 
(Riedel dettaёn)] and incubated on ice for 20 minutes. The retained supernatant was added 
back to the reaction and the cell debris was removed by a centrifugation at 20,000 x g for 
20 minutes at 4 oC. The supernatant was aliquoted and quickly frozen using dry ice and 
stored at -80 oC (Smeaton et al., 2007). The protein concentration of the extract was 
quantified using the Bradford assay (Bio-Rad). 
2.6.3 Electrophoresis of SDS-polyacrylamide gels and 
Western blotting 
To examine expression of protein in T. brucei, cell lysates were analysed by western blot 
(Towbin & Gordon, 1984). Protein samples were loaded onto a 10 % polyacrylamide gel 
(Bio-Rad ready gels) and electrophoresed at 180 V in 1 X SDS running buffer (Bio-Rad) 
for approximately one hour or until required separation was achieved. 
For western blotting, the proteins were then transferred to a nylon membrane (Amersham), 
at 100 V for 60-70 minutes in transfer buffer [25 mM Tris, 192 mM glycine and 20 % 
methanol (Sigma)]. The membrane was first blocked for one hour then probed with the 
appropriate concentration of primary antibody in blocking solution [5% powdered-milk 
(Marvel), 0.01% tween20 (Sigma) in PBS] for 1-18 hours. The membrane was washed 
with blocking solution and probed with the appropriate concentration of secondary 
antibody for one hour at room temperature. To detect antibody binding, horseradish 
peroxidise (HRP) fused secondary antibodies were used. The HRP was detected by 
enhanced chemi-luminescence (Supersignal by Pierce). Film was exposed to the chemi-
luminescence. This film was processed in developer and fixer using a Kodak Ex-omat. 
Most membranes were then stripped with stripping buffer (Pierce) and re-probed with a 
different antibody.  
2.7 Purification of anti-RAD51 and the anti-RAD51 
paralogue anti-sera 
Antibodies were raised against the RAD51 and RAD51 paralogue purified proteins 
containing a C-terminal 10 X HIS tag (RAD51-HIS and RAD51 paralogues-HIS); this was 
carried out by Dr Chris Stockdale. One rabbit was used to raise anti-serum against the 
RAD51 and RAD51-4 recombinant proteins, a sheep was used to raise anti-serum against 
RAD51-3, two chickens were used to raise anti-serum against RAD51-5, and a rat was 
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used to raise anti-serum against RAD51-6 by the Scottish Blood Transfusion Board, 
Edinburgh. 
2.7.1 Anti-RAD51-5 purification from chicken egg yolks 
Pierce® Chicken IgY Purification Kit was used to purify IgY from the egg yolk of 
chickens. This was carried out using the manufacturer’s instructions. Briefly, the total 
volume of the egg yolk was calculated. Five times this volume of delipidation reagent was 
added to the yolk. This mixture was mixed thoroughly using a magnetic stirrer overnight at 
4 oC. Then the mixture was pelleted at 10,000 x g for 15 minutes at 4 oC. The supernatant 
volume was measured and filtered to remove all particulate material. An equal volume to 
the supernatant of IgY precipitation reagent was added and mixed for two minutes. This 
mixture was left overnight at 4 oC. After this settling period, the mixture was gently mixed 
and then centrifuged at 10,000 x g for 15 minutes at 4 oC and the supernatant was 
discarded. The pellet obtained contains the purified IgY. To dissolve the IgY out of the 
pellet, an equal amount to the original egg yolk volume of PBS was added and gently 
mixed until it was completely dissolved. 
2.7.2 Affinity Purification of anti-RAD51 and the anti-
RAD51 paralogue anti-sera 
For purification of the anti-sera, purified proteins containing an N-terminal GST tag were 
used (GST-RAD51 and GST-RAD51 paralogue proteins). These GST protein purifications 
were coupled to beads (Aminolink resin; Pierce) which were then used as an affinity 
column. The protein purifications and affinity columns were prepared by Dr Chris 
Stockdale. Once made, the affinity column was stored in 0.05 % sodium azide/PBS at 4 oC. 
For affinity purification of the anti-sera, the affinity column was allowed to rest at room 
temperature. The resin was washed with 5 ml of 0.05 % sodium azide/PBS (Sigma). The 
anti-sera was added to the column in 750 µl aliquots and allowed to flow through. This was 
repeated until the entire sample had been loaded to the column. 100 µl of 0.05 % sodium 
azide/PBS was added to the column and allowed to flow through, after which the column 
was closed at the bottom. 500 µl of 0.05 % sodium azide/PBS was added to the column 
and the top was capped. This was incubated at room temperature upright for one hour, after 
which, the column was washed with 12 ml of PBS. The antibody was eluted off the column 
by addition of 4 ml of 100 mM glycine-HCl (pH 2.7). The elutant was collected in 0.5 ml 
fractions, and quickly neutralized with the addition of 50 µl of 1 M Tris-HCl (pH 7.5). The 
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column was washed with 10 ml of PBS and 2 ml of 0.05 % sodium azide/PBS was added 
as a storage buffer. 
The protein concentrations of the fractions were analysed using the Bradford assay (Bio-
Rad). As the Bio-Rad assay could only tolerate 2.5 mM of glycine, the fractions were 
diluted to a ratio of 1:40 with dH2O. The fractions with the highest concentrations of 
protein were pooled and their buffer was exchanged into PBS using the Bio-Rad Econo-
Pac 10DG column, using the manufacturer’s instructions. 
2.7.3  Acetone protein extraction for purification of anti-
RAD51-4 anti-serum 
The acetone protein extraction method was adapted to purify anti-serum, in this case, anti-
RAD51-4 anti-serum (Sambrook et al., 1989). This method uses an acetone extract of a 
cell line, in this case T. brucei rad51-4 -/-, that is known not to express the target antigen, 
in this case T. brucei RAD51-4. The cells were growth in 500 ml to a density of 
approximately 2 x 106 per ml, and were pelleted, washed in PBS and finally resuspended in 
8 ml of PBS and left on ice for 10 minutes. After chilling, 64 ml of cold acetone was added 
to each and left on ice for a further 30 minutes. This solution was pelleted at 11,600 x g for 
10 minutes and the supernatant discarded. 10 ml of cold acetone was added to each and left 
on ice for a further 10 minutes. The solution was then centrifuged again at 11,600 x g for 
10 minutes and the supernatant discarded. The pellet was transferred to filter paper 
(Wattman) and spread out as much as possible to allow the mixture to completely dry. This 
dried protein was then weighed. For every 1 gram of dried protein, 100 ml of unpurified 
anti-serum can be added. In this case, 1 ml of anti-RAD51-4 anti-serum was added in a 1 
ml eppendorf along with the dried protein/cell mixture. This was then incubated at 4 oC for 
30 minutes and then pelleted at 11,600 x g for 30 minutes. The supernatant contains the 
purified antibodies. 
2.8 Analysing the knockout phenotypes 
2.8.1 Growth curve and doubling times 
To determine if the growth of rad51-4 -/- and rad51-6 -/- mutants differed to wildtype 
cells, population doubling time was measured. To examine this, wildtype, heterozygous 
and homozygous mutants were inoculated (in triplicate) at 5 x 104 cells per ml in HMI-9 
and cell densities were counted at fixed time points, at 24 hour intervals. The results were 
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plotted on a semi-logarithmic graph (MS Excel, Microsoft). The doubling time for the cell 
lines were calculated by comparing the cell count in mid-log phase using the following 
equation: Time Elapsed ÷ (3.3 x Log(Cell count at the end of time elapsed ÷ Cell count at 
the beginning), where the time elapsed is in hours, and the cell count is in cells per ml.  
2.8.2 DNA damage sensitivity 
2.8.2.1 Clonal survival with DNA damaging agents 
The cell lines were grown to mid-log phase, approximately 2 x 106 cells per ml and the 
cells were counted using a haemocytometer. The cells were then diluted to 1 cell per 200 µl 
of HMI-9 medium. The diluted cells were plated over a 96 well plate with 200 µl in each 
well (i.e. 1 cell per well). Five different concentrations of methyl methanesulphonate 
(MMS) and phleomycin were added to the cells at final concentrations of 0.0 %, 0.0001 %, 
0.0002 %, 0.0003 %, 0.0004 %, and 0.0 µg.ml-1, 0.025 µg.ml-1, 0.05 µg.ml-1, 0.075 µg.ml-1, 
0.1 µg.ml-1, respectively. These plates were left in the incubator for 14 days. Growth per 
well was checked and at day 14. This was done in triplicate and the average clonal survival 
was calculated. 
2.8.2.2 Alamar blue analysis of IC50 values for MMS and 
phleomycin 
The cell lines were grown to mid-log phase, approximately 2 x 106 cells per ml and the 
cells were counted using a haemocytometer. First, the 96 well plate (Nunclon) was 
prepared; 100 µl of HMI-9 media was added to all the wells except for the first column. To 
the first column, 200 µl of the stock of MMS and phleomycin were added (0.01 % and 4 
µg.ml-1 respectively). Serial dilutions were made, by taking 100 µl from the first column 
and mixing it with the next column. With clean pipette tips, 100 µl from the second column 
was added to the third column and mixed, and so on. To each well, 100 µl of cells at a 
density of 2 x 105 cells per ml were added. These cells were allowed to grow for 48 hours 
after which 20 µl of 0.125 % resazurin/PBS (Sigma) was added. This was then incubated 
for 24 hours at 37 oC. The plate was read by a spectrometer using filter of 540 nm 
excitation and 590 nm emission (Wallac Envision, 2102 Multi-label reader) and the data 
was analysed using MS Excel and GraphPrism. 
2.8.3 Transformation efficiency assay 
To assay for recombination rate, a linearised piece of DNA containing a drug resistant 
cassette was transformed into each cell line. A maxi preparation (GenElute HP plasmid kit, 
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Sigma) of pRM450 was digested for which approximately 200 µg of cleaned linearised 
plasmid was required. This construct contained a phleomycin resistance cassette flanked 
with tubulin intergenic regions. The cell lines were grown to mid-log phase, approximately 
2 x 106 cells per ml, in a final volume of 25 ml. The cell density was measured by counting 
with a haemocytometer. A total of 5 x 107 cells were transfected with 5 µg linearised DNA 
(see Section 2.1.2). The cells were allowed to recover for three generations before plating 
out on selective HMI-9 medium containing 2 µg.ml-1 of phleomycin. A total of 5 x 106 of 
wildtype and heterozygous mutant cells were diluted in 36 ml of selective media. Then 1.5 
ml of the diluted cells were plated in each well of a 24 well plate, which is equivalent to 
2.08 x 105 cells per well. As the homozygous mutant cells were more likely to have a 
deficiency in recombination ability, 2 x 107 cells were plated over 48 wells, which is 
equivalent to 4.16 x 105 cells per well. The cells were incubated for 14 days at 37 oC and 
the number of wells with cell growth was scored. Each cell line was analysed in triplicate 
with the same linearised DNA, for consistency. The transformation efficiency was 
described as the number of wells with growth per 106 cells plated out on selective medium. 
2.8.4 VSG switching frequency and mechanism analysis 
Use of the T. brucei BSF strain 3174.2 enabled the analysis of the VSG switching 
frequency and mechanisms (McCulloch et al., 1997; McCulloch & Barry, 1999; Rudenko 
et al., 1996). This was carried out by generating acquired immunity against T. brucei cells 
expressing a specific VSG in mice, and then re-infecting the mice with T. brucei cells that 
were allowed to switch their VSG in vitro. The T. brucei cells were recovered from the 
mice, only those that switched to a different VSG could have survived the host immune 
system. Female adult ICR mice were used and each was approximately 20 grams in 
weight. Analysis of the switched T. brucei cells recovered from the mice allowed VSG 
switching frequency and mechanisms to be calculated, this is described in detail in Chapter 
3, Section 3.4.5, whilst the experimental details are described below. All animal handling 
was carried out by Dr Richard McCulloch. 
To generate mice immune to a specific VSG the following method was used. Wildtype 
cells strain 3174.2 was engineered to express a specific VSG, named VSG221, by selecting 
the cells on HMI-9 containing hygromycin B (5.0 µg.ml-1; Calbiochem) and G418 (2.5 
µg.ml-1; Calbiochem) for a period of 5 days (McCulloch et al., 1997; McCulloch & Barry, 
1999; Rudenko et al., 1996). A total of 2 x 105 cells expressing VSG221 were injected 
intraperitaneally into each mouse. For each cell line to be examined, at least three 
individual mice were injected. When the infection reached 3-7 x 108 cells per ml (typically 
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3-4 days), the mice were cured by injection of cymelarsan (Rhone Merieux; 5 mg.kg-1). 
The cured mice were then allowed to recover for at least 1-5 weeks prior to further 
challenge.  
To generate switched variants in vitro, each cell line which had been previously grown on 
hygromycin B (5.0 µg.ml-1) and G418 (2.5 µg.ml-1) in HMI-9 for a period of 5 days to 
express VSG221, were allowed to grow for a period of nine generations off antibiotic 
selection. This was carried out by passaging the cells into 25 ml of HMI-9 at a specific 
dilution such that the final concentration was approximately 2 x106 cells per ml: for 
example, a volume of 7.8 x 103 wildtype cells were added to 25 ml of HMI-9 and allowed 
to grow for 63 hours without passage. Three independent passages were set up of each cell 
line, and the differences in in vitro growth rate were also accounted for.  
Once the cells had grown for nine generations, each culture was counted and a total of 4 x 
107 cells were pelleted at 600 x g and resuspended in 200 µl of HMI-9 media. This 
suspension was then used to challenge the mice. After a period of 24 hours post-challenge, 
the surviving T. brucei cells were recovered from the mice by cardiac puncture. The in vivo 
growth rates were not examined for the experiments described in this thesis, as there was 
only a modest defect in in vivo rad51 -/- mutant population doubling times compared to 
that of the wildtype, as described by McCulloch & Barry (1999). An aliquot of 400 µl of 
the recovered blood was transferred into a sterile Greiner tube, and centrifuged at 4500 x g 
for 5 minutes. This separated the blood into different layers, serum, buffy coat (containing 
white blood cells, platelets and T. brucei cells) and red blood cells. Since there was 
sufficient blood recovered from each mouse, this was done in duplicate. The number of T. 
brucei cells recovered from the mouse could not be counted because the switch frequency 
was so low, as only eight wildtype 3174.2 cells switch and survive per 107 cells injected. 
To ensure the maximum number of T. brucei cells were collected, the serum, buffy coat 
and the top of the red blood cell layer were transferred to 20 ml of HMI-9 medium. This 
was then mixed well and distributed over a 96 well plate for each duplicate pair. These 
plates were incubated at 37 oC for 14-21 days. The growing populations were 
microscopically monitored and 10 clones from each mouse were passaged into HMI-9 
medium. To analyse the mechanism of VSG switching, the DNA was extracted from these 
cells as previously described (see Section 2.2.1) and replica passages of each selected 
clone were carried out in media containing hygromycin B (5.0 µg.ml-1) or G418 (2.5 
µg.ml-1).  
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The switching frequency was calculated by counting the number of recovered T. brucei 
cells over 96 well plates. This number was multiplied by 2.5, as the recovered blood from 
the mouse was only 40 % of the total approximate blood volume of the animal. This 
number was then divided by the number of doubling times that had occurred during the 24 
hour period following injection into the mouse. A selection of recovered clonal populations 
were plated on hygromycin or G418, and the DNA from each population was extracted. 
PCR-amplification and drug sensitivity allowed the VSG switching mechanism to be 
deduced and the three possible switching events are described in Chapter 3, Section 3.4.5, 
depending of the presence of the ORF of hygromycin phosphotransferase, neomycin 
phosphotransferase, and VSG221 genes, as well as analysing whether or not these are 
expressed by selection with hygromycin B (5.0 µg.ml-1) and G418 (2.5 µg.ml-1).  
2.9  Immuno-localisation 
2.9.1 Fixing T. brucei cells to slides 
Cells were grown to a density of approximately 1 x 106 cells per ml, and pelleted at 600 x g 
for 1 minute. The supernatant was removed, and the cells were completely resuspended in 
100 µl PBS (Sigma). To the evenly resuspended cells, 1 ml of 1 % (v/v) 
formaldehyde/PBS was added and the solution was inverted several times. This was then 
stored at 4 oC for 1-24 hours. The formaldehyde fixed cells were then centrifuged at 600 x 
g for 1 minute at 4 oC. The pellet was washed twice in 1 ml chilled PBS followed by a 
wash of 1 % Triton X 100 (Sigma) to a final concentration of 0.1 %. This was incubated at 
room temperature for 10 minutes and glycine (Sigma) was added to a final concentration of 
0.1 M. Another incubation at room temperature commenced for 10 minutes. The cells were 
pelleted and resuspended in 200 µl of PBS and spread evenly onto a glass slide (Menzel-
glaser). The cell suspension was allowed to dry completely for 2-18 hours. 
2.9.2 in situ fluorescence microscopy and DAPI staining 
of T. brucei cells 
Once the cells had been fixed and dried on to the slide (Section 2.9.1), the cells were ready 
to probe with indirect fluorescent antibodies (IFA) and counter stain with 4’, 6-diamidino-
2-phenylindole (DAPI; VectaShield mounting medium with DAPI, Vector Labs). First the 
slides were washed with 1 x PBS for 5 minutes in Coplin jars. The cells were then blocked 
with TB buffer (0.1 % Triton X 100, 0.1 % BSA in PBS) for 15 minutes. This was 
removed and the primary antibody which was diluted in TB buffer was added and left for 
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55 minutes. The primary antibody was washed off by soaking the slides thrice, in PBS for 
5 minutes each time. The secondary antibody diluted in TB buffer was added for 45 
minutes. The slides were covered to prevent light bleaching of the sample. The slides were 
then washed as before and counter stained with two drops of VectorShield (Vector Labs). 
A cover slip was then placed on the slides and sealed with nail polish (Boots). Once dried, 
the slides were visualised using an Axioskop 2 microscope and Openlab 5.00 software. 
The images were cropped using PhotoShop 6 (Adobe). 
2.10 Assaying yeast two-hybrid interaction 
S. cerevisiae wildtype L40 strain was grown on YPD media (10 g of yeast extract 
(Melford), 20 g of bactopeptone (Melford), and 20 g of dextrose (Fisher) in 1 L at pH 5.8) 
at 30 oC for 24 hours. If plates were required, agar was added per manufacturer’s 
instructions (Melford). The L40 strain also requires adenine (0.01 %; Sigma) for growth. 
Minimal media (YC-W; Clontech) was used for the growth of cells containing pYesTrp2-
Prey constructs, while selection with 300 µg.ml-1 zeocin (Invitrogen) was used for cells 
containing pHybLex/Zeo-Bait constructs. Cells co-transformed with both pHybLex/Zeo 
and pYesTrp2-Prey were grown up on YC-W media with 300 µg.ml-1 zeocin at 30 oC for 
at least 48 hours. The pHybLex/Zeo-Bait and pYesTrp2-Prey plasmids are described in 
more detail in Chapter 5, Section 5.3. 
2.10.1 To test for histidine auxotrophy 
This was performed by inoculating 10 µl of yeast overnight culture onto an agar plate 
containing minimal media lacking histidine and containing increasing concentrations of 3’ 
aminotriazole which is a competitive inhibitor of imidazole-glycerolphosphate 
dehydratase, the product of the HIS3 gene (Kanazawa et al., 1988). The same yeast 
overnight cultures were used to inoculate medium containing histidine as a positive 
control. The cultures from this plate were then used in the β-galactosidase filter lift assay 
(see Section 2.10.2). 
2.10.2 β-galactosidase filter lift assay 
A colony of each pHybLex/Zeo-Bait and pYesTrp2-Prey co-transformation, X and Y, was 
grown up on selective media, on YC-W with 300 µg.ml-1 zeocin at 30 oC for 48 hours. The 
colonies were transferred to a nitrocellulose membrane (Hybond-C super, Amersham). The 
filter was cooled on a foiled boat over liquid nitrogen for 30 seconds then submerged for 5 
seconds to permeabilise the cells. The filter was thawed and placed in the lid of a Petri dish 
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containing a filter paper (#1 Whatmann) saturated with 1.5 ml of Z buffer (60 mM 
Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4, (Sigma) pH 7.0) containing 30 
µl of 50 mg.ml-1 of X-gal (Sigma). This was wrapped in moist tissue and incubated at 30 
oC for 30 minutes. The blue colouration of the colonies showed the β-galactosidase activity 
occurred, when the X-gal was cleaved forming 5-bromo-4-chloro-3-hydroxyindole. This 
by-product was then oxidised, resulting in an insoluble blue product, 5,5’dibromo-4, 4’-
dichloro-indigo. The plate was then allowed to cool to 4 oC and a photograph was taken of 
it. 
2.10.3 Yeast β-galactosidase assay kit 
The yeast β-galactosidase assay kit by Pierce was used to detect and quantify 
transcriptional activation of β-galactosidase gene, following manufacturer’s instructions. 
Briefly, two independent clones of each pHybLex/Zeo-Bait and pYesTrp2-Prey co-
transformant were grown as liquid cultures in YC-W with 300 µg.ml-1 zeocin at 30 oC for 
48 hours. Cell density was quantified by measuring the optical density (OD) at 620 nm. 
Cell lysis solution and o-nitrophenyl-β-D-galactopyranoside (ONPG) was added to the 
cells. β-galactosidase mediated conversion of ONPG to o-nitrophenol, a yellow precipitate, 
was quantified by measuring absorbance at 420 nm using a 96 well plate reader (Wallac 
Envision, 2102 Multi-label reader). Each measurement was performed in triplicate. β-
galactosidase activity was calculated using the following equation: (1000 x Absorbance 
420 nm) ÷ (t x V x OD 620nm) where t is the assay reaction time in minutes and V is the 
volume of culture used in the assay in ml. The calculation and graphs were completed in 
MS Excel (Microsoft). 
2.11 Co-immunoprecipitation 
The Pierce ProFound™ co-immunoprecipitation kit was used to isolate native protein 
complexes from T. brucei extract. The whole cell protein extraction from T. brucei method 
was used (see Section 2.6.2.2); this allowed extraction a large concentration of proteins 
without the presence of cell debris. Pierce’s ProFound™ co-immunoprecipitation protocol 
was followed. Briefly, the antibody coupling gel (AminoLink® Plus Gel) was washed 
three times with 400 µl of Coupling Buffer (BupH™ Modified Dulbecco’s PBS). 
Approximately 400-500 µg of concentrated affinity purified antibody (see Section 2.7) was 
coupled to the antibody coupling gel. An overnight incubation at room temperature was 
performed to allow the resin to couple to the antibody, after which approximately 1-2 mg 
of total extracted protein was added to the antibody-resin mixture.  
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2.12 PTP purification of protein complexes 
A standard purification was carried out with 4 ml of protein extracted using the method 
described above, Section 2.6.2.2. Firstly 200 µl of the IgG beads were equilibrated in a 
poly-prep chromatography column (BioRad) with 50 ml of PA-150 [150 mM KCl, 20 mM 
Tris-HCl pH 7.7, 3 mM MgCl2, 0.5 mM DTT and 0.1 % of Tween 20 (Sigma)]. The 
extracted proteins were pooled and 0.5 ml of protease inhibitor tablet (Complete Mini, 
Roche) dissolved in 1 ml of PA-150 was added. Tween20 was then added to a final 
concentration of 0.1 % (v/v) to the extract. The column was closed at the bottom and the 
cell extract was added to the IgG matrix. The top was then closed and left to rotate at 4 oC 
for two hours at a low speed. After this period of time, the column was then placed in the 
upright position on a clamp and beads were left to settle. The flow through was then 
collected, and washed with 10 ml of PA-150 by rotation for 10 minutes at 4 oC. The matrix 
was washed again with another 15 ml of PA-150 by flow through. All flow through washes 
were kept.  
For further purification, TEV protease removes the Protein A and IgG. This was carried 
out by washing the IgG-protein A-bound proteins with 15 ml of TEV buffer [150 mM KCl, 
20 mM Tris-HCl pH 7.7, 3 mM MgCl2, 0.5 mM EDTA, 1.0 mM DTT and 0.1 % of Tween 
20 (Sigma)] by rotation for 10 minutes at 4 oC.  2 ml of the TEV buffer and 200 Units of 
TEV protease was added to the beads and left to rotate in the column for 16 hours at 4 oC.  
The anti-protein C affinity matrix was allowed to equilibrate in a second poly-prep 
chromatography column (BioRad) with 50 ml of PC-150 [150 mM KCl, 20 mM Tris-HCl 
pH 7.7, 3 mM MgCl2, 1 mM CaCl2, and 0.1 % of Tween 20 (Sigma)]. The top and bottom 
plugs from the IgG column were removed and the eluate was recovered by gravity flow 
and the columns dead volume was eluted by addition of 4 ml of PC-150. To titrate the 
EDTA in the TEV buffer, 7.5 µl of 1 M CaCl2 was added as well as 0.5 ml of the dissolved 
protease inhibitor tablet (Roche). This was then transferred to the anti-protein C affinity 
matrix equilibrated column. The column was closed at the bottom and top plugs were 
closed. This was allowed to rotate at 4 oC for two hours at a low speed.  After this period of 
time, the column was then placed in the upright position on a clamp and the beads were left 
to settle. The flow through was then collected. The matrix was washed with a total of 60 
ml of PC-150 buffer, with the first and last washes rotating. When the washes were 
complete, the bottom plug was closed and 600 µl of EDTA elution buffer [5 mM Tris-HCl 
pH 7.7, 10.0 mM EGTA, 5.0 mM EDTA] was added to the matrix. This was incubated for 
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10 minutes at room temperature and the eluate was collected. This was repeated three 
times in total.  
The eluted protein was then concentrated using the StrataClean resin (Stratagene) by 
incubating the 10 µl of the resin with the eluate for 20 minutes rotating at room 
temperature. The beads were then pelleted by centrifugation at 5,000 x g for 1 minute. The 
supernatant was removed and the proteins were released from the beads by boiling for 5 
minutes in 20 µl of SDS-PAGE loading buffer. This was then loaded on to a 10 % SDS-
PAGE gel. 
2.13 Bioluminescence detection 
T. brucei bloodstream form cells expressing the luciferase ORF were analysis to confirm 
that there were detectable levels of bioluminescence. The cells were counted and washed in 
PBS to remove the HMI-9, and serial dilution of the cells was carried out in PBS. The cells 
were diluted from a starting density of 2 x 106 to a final density of 1.56 x 104 cells in a total 
volume of 200 µl of PBS. To each well, 20 µl of 1 mM of d-luciferin/PBS (Promega) was 
then added. The plate was incubated at 37 oC for 30 minutes. After this, the plate was 
removed from the incubator and left at room temperature for 15 minutes. Bioluminescence 
was then read using a 404 nm filter (Envision). Bioluminescene was measured in Relative 
Light Units and a graph was generated using MS Excel. 
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Chapter 3. Role of two RAD51 
paralogues in T. brucei, RAD51-4 
and RAD51-6.  
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3.1 Introduction 
DNA sequencing of the genome of T. brucei has determined that there are 9,068 predicted 
genes within the 11 megabase chromosomes (Berriman et al., 2005). Out of these predicted 
genes only 50.5 % have been assigned a function. Reverse genetics approaches allow gene 
function to be ascertained, based on the ability to predict function from the protein 
sequence. These approaches identify a gene from the DNA sequence, disrupt or delete the 
main open reading frame (ORF) or products of the ORF, and analyse the resulting 
phenotype. Gene disruption techniques, such as generating null mutants, can help 
understand the gene product’s effect on a phenotype, and allow the biological role of the 
protein to be established. The complete genome sequence and reverse genetic approaches 
at the disposal of the researcher are valuable tools and allow pin pointed genotyping. 
One such prediction was made by Proudfoot & McCulloch (2005a), where six single copy 
T. brucei RAD51-related genes were identified. One gene encoded RAD51, while another 
encoded the closely-related factor, DMC1, which is inferred to act in meiotic 
recombination (Proudfoot & McCulloch, 2005b). The four other genes are designated 
RAD51 paralogues; for more details, see Discussion, Section 7.2.2. To examine the role of 
two of these genes, RAD51-3 and RAD51-5, gene disruption techniques were used to create 
homozygous mutants in T. brucei, and the resulting phenotypes were analysed (Proudfoot 
& McCulloch, 2005a). It was shown that the two RAD51 paralogues, RAD51-3 and 
RAD51-5, have a role in DNA repair and homologous recombination and in the case of 
RAD51-3, VSG switching (Proudfoot & McCulloch, 2005a). As there is comprehensive 
published data on the phenotypes of rad51 -/-, rad51-3 -/-, and rad51-5 -/- mutants 
(McCulloch & Barry, 1999; Proudfoot & McCulloch, 2005a), for completeness, it was 
necessary to generate rad51-4 -/- and rad51-6 -/- mutants. In this chapter, the RAD51-4 
and RAD51-6 mutant cell lines are generated and analyses of the resulting phenotypes are 
described. This will help to understand the role of the four RAD51 paralogues and 
ascertain whether or not each act in DNA repair and recombination, as predicted by 
sequence homology. 
To investigate the role of RAD51-4 and RAD51-6, heterozygous and homozygous mutants 
were generated by gene disruption of the RAD51-4 and RAD51-6 ORFs, respectively. As 
T. brucei is diploid two rounds of transformations were required. To make comparable 
gene disruption mutants to those generated previously for rad51 -/-, rad51-3 -/-, and 
rad51-5 -/-, the middle of each ORF was replaced by a different resistance marker. To do 
this, antibiotic resistance cassettes for the blasticidin S deaminase (BSD) gene of 
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Streptomyces griseochromogenes, encoding blasticidin resistance and the puromycin N-
acetyl transferase (PUR) gene of Streptomyces alboniger, encoding puromycin resistance 
were integrated into the two alleles of each gene, generating first heterozygous mutants and 
then homozygous mutants. As a result of the integration, the Walker A and B boxes, 
conserved in all the RAD51 paralogue proteins, were deleted. These mutants were 
generated in T. brucei bloodstream stage strain 3174.2 cells, to allow direct comparison 
with previous studies with the other RAD51 paralogue mutants, RAD51-3 and RAD51-5, 
which has been shown in Chapter 4 of this thesis. In particular this strain enables analysis 
of the VSG switching frequencies and mechanisms during antigenic variation (Hartley & 
McCulloch, 2008; McCulloch et al., 1997; McCulloch & Barry, 1999; Rudenko et al., 
1996). 
3.2 Generation of the RAD51-4 gene disruption 
mutant 
3.2.1 Design of the RAD51-4 knockout constructs 
The constructs for generating RAD51-4 mutants were designed to allow homologous 
recombination of targeted homologous regions using the left hand flank (LHF) and the 
right hand flank (RHF) derived from the start and end of the RAD51-4 ORF respectively. 
581 bp of the centre of the RAD51-4 ORF is replaced with antibiotic cassettes in this 
approach; see Figure 3.1. The nucleotide sequence of the RAD51-4 ORF and the primer 
binding sites are shown in Appendix 1. The LHF of RAD51-4 was PCR-amplified using 
primers RAD51-4 StartORF For and RAD51-4 StartORF Rev. The RHF of RAD51-4 was 
PCR-amplified using primers RAD51-4 EndORF For and RAD51-4 EndORF Rev, (see 
Materials and Methods, Section 2.4, Table 2-1). The LHF and RHF PCR fragments, of 290 
bp and 402 bp respectively were PCR-amplified from genomic DNA extracted from strain 
3174.2 using Herculase (Stratagene) DNA polymerase enzyme, and were digested with 
XbaI and EcoRV, and XhoI and EcoRV respectively. The two fragments were cloned into 
XbaI and XhoI digested pBluescript KS (Stratagene) in a three way ligation reaction. 
Antibiotic resistance cassettes containing the BSD (400 bp) and PUR (650 bp) ORFs were 
PCR-amplified from the plasmids pCP101 and pCP121 (Proudfoot & McCulloch, 2005a). 
Each resistance cassette is flanked by RNA processing sites: upstream βα-tubulin (240 bp) 
and downstream actin (400 bp) intergenic regions. For each PCR-amplification, the 
primers Tubulin For and Actin Rev were used, (see Materials and Methods, Section 2.4, 
Table 2-1). These primers have blunt restriction enzyme sites, EcoRV for the BSD and 
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NruI for the PUR resistance cassettes. The resulting PCR fragments (approximately 1040 
bp for the BSD cassette and 1340 bp for the PUR cassette) were cloned into Topo2.1 vector 
(pCR®2.1) (Invitrogen, see Materials and Methods, Section 2.4.7) and sequenced.  
From the Topo clones, the antibiotic resistance cassettes were excised using blunt 
restriction enzymes, EcoRV for the BSD cassette and NruI for the PUR cassette. The 
excised constructs were then gel purified and ligated between the LHF and RHF of 
RAD51-4 in pBluescript which had been digested with EcoRV. Insertion and correct 
orientation of the resistance cassettes between the LHF and RHF were confirmed by 
restriction mapping; the resulting constructs were sequenced and called ∆RAD51-4::BSD 
and ∆RAD51-4::PUR. 
ATG TAGRAD51-4 ORF
581 bp 402 bp290 bp
RHFLHF Antibiotic Resistance Cassetteβα IR Actin IR
Eco
RV/N
ruI
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RV/N
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Figure 3-1: RAD51-4 gene disruption construct and gene disruption strategy. 
LHF: Left hand targeting flank has homology to the 5’ region of the RAD51-4 ORF. RHF: Right hand 
targeting flank has homology to the 3’ region of the RAD51-4 ORF. The 5’ targeting flank (LHF) was 290 bp 
and the 3’ targeting flank (RHF) was 402 bp. The antibiotic resistance cassettes (blasticidin: BSD/puromycin: 
PUR) have βα tubulin intergenic region (βα IR) and actin intergenic region (Actin IR) processing signals. 
The total length of the ORF for RAD51-4 is 1273 bp and the sizes of individual the components (in bp) and 
restriction sites used in the cloning are indicated. 
3.2.2 Generating the RAD51-4 mutant cell lines 
To generate rad51-4 -/- mutants, two consecutive transformations were performed for each 
of the above constructs ∆RAD51-4::BSD and ∆RAD51-4::PUR. Two independent 
transformations using the construct ∆RAD51-4::BSD, generated two independent RAD51-4 
heterozygous mutant cell lines respectively, which were named X+/- and Y+/-. Integration 
of the constructs into the expected gene locus was screened by PCR using a forward primer 
upstream of the ORF (Upstream of RAD51-4 ORF For) and the reverse primer of the RHF 
(RAD51-4 EndORF Rev) (data not shown). Following selection of the two clones, each 
was subjected to a second round of transformation using construct ∆RAD51-4::PUR to 
generate homozygous mutant cell lines, X-/- and Y-/-. For each transformation, both 
constructs were linearised using the restriction enzymes XbaI and XhoI and then 
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phenol/chloroform extracted and ethanol precipitated. 5 x 107 bloodstream stage T. brucei 
3174.2 cells were transformed by electroporation in 0.2 cm cuvettes with approximately 5 
µg of each of the digested constructs (see Materials & Methods, Section 2.1.2). The 
electroporated cells were incubated for 24 hours in non-selective HMI-9 media to allow 
recovery. A volume of 1 x 107 cells were diluted in 36 ml of selective HMI-9 media. The 
diluted cells were then plated over a 24 well plate at 1.5 ml per well, i.e. 4.16 x 105 cells 
per well. Blasticidin (Calbiochem) at a concentration of 2.5 µg.ml-1 was used for selection 
of the heterozygous mutant cells following the first transformation and puromycin 
(Calbiochem) at a concentration of 0.5 µg.ml-1 of was used to generate homozygous 
mutant cells following the second transformation.  
The RAD51-4 +/- and rad51-4 -/- cell lines were confirmed by PCR, Southern, reverse 
transcriptase-PCR and western analysis (see Section 3.2.3, below). Each cell line was 
given a WCMP number and stabilates were made (see Materials and Methods, Section 
2.1.2). For the following section, the heterozygous mutant cell lines are defined as +/- and 
the homozygous mutant cell lines are defined as -/-. 
3.2.3 Confirmation of RAD51-4 gene disruption mutants  
3.2.3.1 Confirmation of RAD51-4 gene disruption by PCR 
To determine if the RAD51-4 locus had been disrupted PCR-amplification of the entire 
ORF, using a forward primer that bind upstream of the LHF (Upstream of RAD51-4 ORF 
For, see Material and Methods, Section 2.4.1, Table 2-1) and a reverse primer that binds 
the 3’ end of the RHF (RAD51-4 EndORF Rev), was performed (see the black arrows in 
Figure 3-1). PCR-amplification was carried out using Taq DNA polymerase (Biolabs) and 
the reaction products were separated on a 1.0 % agarose gel. Figure 3-2 shows the PCR 
fragments obtained from the PCR reactions using genomic DNA extracted from the 
wildtype (wt), +/- and -/- cells. From the wt genomic DNA, one product of the size 
expected for the intact ORF was PCR-amplified (1273 bp). From the RAD51-4 +/-, two 
products were PCR-amplified, one corresponding to the wildtype allele and the other to 
BSD-disrupted allele following integration into the ORF: integration of the βα-tubulin-
BSD-actin construct (1040 bp) creates an allele that is approximately 460 bp larger than the 
wt ORF. This size difference was observed. From the rad51-4 -/-, no PCR product of the 
size of the wt allele was amplified. Instead, two larger PCR-products of sizes consistent 
with integration of both antibiotic cassettes were seen (BSD and PUR), disrupting both 
alleles: the βα-tubulin-PUR-actin (1340 bp) construct is approximately 760 bp larger than 
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the wt ORF and 300 bp larger than the RAD51-4::BSD allele. These data indicate that the 
RAD51-4 locus has been mutated as expected but cannot say if the RAD51-4 gene has been 
copied to another part of the genome during transformation. 
 
Figure 3-2: Analysis of the RAD51-4 gene disruption by PCR-amplification. 
An agarose gel separation of the PCR products generated by PCR amplification of the RAD51-4 locus using 
the forward primer: Upstream of RAD51-4 ORF For and reverse primer: RAD51-4 EndORF Rev is shown. 
PCR reactions were performed on genomic DNA from wildtype (wt) 3174.2 T. brucei cells, for two 
independent putative RAD51-4 heterozygous mutants (X+/- and Y+/-) and two putative rad51-4 homozygous 
mutants (X-/- and Y-/-). The DNA fragments of the sizes expected from the wt genes or from alleles 
disrupted by integration of the BSD resistance cassette (∆RAD51-4::BSD) or the PUR resistance cassette 
(∆RAD51-4::PUR) are indicated, as are the size markers. 
3.2.3.2 Confirmation of RAD51-4 gene disruption mutants by 
Southern blot analysis 
Southern blot analysis was next carried out on the wildtype, RAD51-4 +/- and rad51-4 -/- 
cell lines, to confirm disruption of the ORF predicted by PCR amplification. Genomic 
DNA was extracted from each of the cell lines and digested with AgeI, (see Material and 
Methods, Section 2.2.1), separated on a 0.8 % agarose gel and transferred on to a nylon 
membrane. The membrane was probed with the LHF of the ORF, part of the RAD51-4 
gene disruption constructs, RAD51-4::BSD and RAD51-4::PUR. The probe was made by 
PCR-amplifying the LHF using primers RAD51-4 StartORF For and RAD51-4 StartORF 
Rev. This resulting product was then gel extracted and labelled using the Gene Images 
CDP-Star Detection Module from Amersham, (see Materials and Methods, Section 2.5). 
The results of the Southern blot analysis are shown in Figure 3-3.  
The Southern blot analysis shows that in wildtype cells, one fragment of the size expected 
(2840 bp) was obtained when the genomic DNA was digested with AgeI. In the putative 
RAD51-4 +/- mutants two products were obtained, one corresponded to the wildtype allele 
and the other of the size expected for the BSD-disrupted allele (3300 bp). In the rad51-4 -/- 
mutants, no wildtype band fragment was observed but there were two larger products of 
the sizes corresponding to the BSD-disrupted (3300 bp) and PUR-disrupted alleles (3600 
bp) (see Figure 3-3). As explained in Section 3.2.3.1 above, the ∆RAD51-4::BSD construct 
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adds 460 bp to the wt RAD51-4 allele, while the ∆RAD51-4::PUR construct added 760 bp. 
These data confirm the PCR analysis of the RAD51-4 locus, showing the ORF has been 
disrupted as expected. There was no apparent sign of the intact RAD51-4 sequence in the 
rad51-4 -/- cells, indicating these are mutated and no compensatory rearrangements have 
retained the RAD51-4 gene. 
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Figure 3-3: Analysis of RAD51-4 gene disruption by Southern blot.  
Figure 3-3A: Southern blot showing AgeI-digested genomic DNA and probed with the LHF of the RAD51-4 
ORF, see Figure 3-1. The extracted genomic DNA from wildtype (wt) 3174.2 T. brucei cells, from the two 
independent putative heterozygous mutants (X+/- and Y+/-) and from the two independent putative 
homozygous mutants (X-/- and Y-/-) was digested with AgeI, and separated on a 0.8 % agarose gel. The 
DNA was then transferred to a nylon membrane and probed with the LHF of the RAD51-4 ORF. The DNA 
fragments of the size expected from the wt genes or from alleles disrupted by integration of the BSD 
resistance cassette (∆RAD51-4::BSD) or the PUR resistance cassette (∆RAD51-4::PUR) are indicated, as are 
the size markers. Figure 3-3B shows the locations of AgeI restriction enzyme sites around the RAD51-4 
ORF, predicted by sequence analysis (GeneDB). 
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3.2.3.3 Confirmation of RAD51-4 gene disruption mutants by RT-
PCR 
To see whether or not RAD51-4 mRNA was transcribed in each of the cell lines RT-PCR 
was carried out on cDNA generated from total RNA (see Material and Methods, Section 
2.3). PCR-amplification of the entire ORF was attempted using a forward primer that binds 
to the LHF (RAD51-4 StartORF For) and a reverse primer that binds to the RHF (RAD51-4 
EndORF Rev). Figure 3-4 shows the resulting PCR products separated on a 1.0 % agarose 
gel. In wildtype and RAD51-4 +/- cell lines, one product of the size expected (1273 bp) 
was PCR-amplified from the cDNA. In the rad51-4 -/- mutants, no RAD51-4 mRNA was 
detected. A fragment of DNA polymerase I was amplified from the cDNA of all the cell 
lines, as confirmation that the RNA present from the extract was converted to cDNA. 
Control RT reactions performed without RT enzyme (RT-) confirmed that the PCR 
products amplified were not from contaminating genomic DNA which was not destroyed 
by the DNase treatment. This analysis confirmed that in the homozygous mutant cell lines 
RAD51-4 mRNA is not detectably present.  
 
Figure 3-4: Analysis of the expression of the RAD51-4 mRNA in the mutant cell lines by RT-PCR 
amplification.  
Using the reverse transcriptase (RT) enzyme, cDNA was generated from mRNA extracted from the wildtype 
(wt) 3174.2 T. brucei cells, from the two independent putative RAD51-4 heterozygous mutants (X+/- and 
Y+/-) and from the two independent putative rad51-4 homozygous mutants (X-/- and Y-/-). This cDNA was 
used as template in the PCR reaction. PCR amplification was attempted using the forward primer (RAD51-4 
StartORF For) and reverse primer (RAD51-4 EndORF Rev). The PCR products were then separated on a 1.0 
% gel. As a positive control the DNA polymerase I ORF (DNA PolI) was amplified from the cDNA of all the 
mutant cell lines. RT + and - indicates the presence of RT enzyme (+) and the absence of RT enzyme (-). 
3.3 Generation of RAD51-4 re-expressor cell lines 
Having confirmed that the rad51-4 -/- mutants could be generated and are viable, it was 
necessary to re-express the RAD51-4 in the mutant background, to show that the mutant 
phenotypes were due to the RAD51-4 gene knockout. To this end, the entire RAD51-4 ORF 
was PCR-amplified using the RAD51-4 REX primers, (see Materials and Methods, Section 
2.4.1, Table 2-1) and cloned using blunt restriction sites, NruI, into EcoRV digested 
pRM481 vector (McCulloch, gift). The pRM481 contains a phleomycin resistance cassette 
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(BLE; from Streptoalloteichus hindustanus) flanked upstream with a βα tubulin intergenic 
region, and downstream with an actin intergenic region followed by a αβ tubulin intergenic 
region (βα-BLE-Act-αβ). Following the cloning, the RAD51-4 ORF is placed downstream 
of the actin intergenic region and upstream of the αβ tubulin intergenic sequences (βα-
BLE-Act-RAD51-4-αβ). This construct can be integrated into the βα tubulin locus of T. 
brucei, and selection is provided by phleomycin. Recombination occurs on the βα and αβ 
targeting regions, integrating the construct into the βα tubulin array replacing the α tubulin 
ORF, and allows expression of the RAD51-4 mRNA through the flanking non-endogenous 
intergenic sequence (see Figure 3-5). This βα-BLE-Act-RAD51-4-αβ construct was 
digested with NotI and ApaI and transformed into the rad51-4 -/- mutant cell lines and 
were allowed to recover for 24 hours in non-selective media. These were then clonally 
plated on 2.5 µg.ml-1 of phleomycin (Calbiochem). 
 
β β
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Figure 3-5: Strategy for re-expression of the RAD51-4 by recombination into the βα tubulin array. 
The ORF of RAD51-4 was cloned into the restriction site NruI of the pRM481 (top part of the diagram). NotI 
and ApaI digestion liberates the construct which was then transformed into the rad51-4 -/- cell line. 
Recombination occurs on the βα and αβ targeting regions, integrating the construct including the RAD51-4 
ORF into the βα tubulin array replacing one of the α tubulin ORFs. 
3.3.1 Confirmation of the RAD51-4 re-expressor cell lines 
by PCR and RT-PCR 
Possible RAD51-4 re-expressor clones following transformation of rad51-4 -/- cell lines 
with the pRM481 re-expressor construct (βα-BLE-Act-RAD51-4-αβ) were screened using 
PCR primers that bind to the LHF and RHF of RAD51-4 (RAD51-4 StartORF For and 
RAD51-4  EndORF Rev, see Materials and Methods, Section 2.4.1). These primers PCR-
amplified the integrated intact ORF and also the disrupted ORFs meaning that the re-
expressor cell lines had three amplified fragments: one represented the re-expressor 
RAD51-4 ORF, and the other two bands corresponded to the BSD and PUR disrupted 
alleles. From this, putative re-expressors were chosen for each independently generated 
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rad51-4 -/- mutant (data is not shown), and were analysed in more detail. Firstly, RT-PCR-
amplification analysis, using the primers that bind to the RAD51-4 LHF and RHF (RAD51-
4 StartORF For and RAD51-4 EndORF Rev) were used to detect the intact mRNA in the 
putative re-expressor (-/-/+), see Materials and Methods, Section 2.3). In wildtype (wt), 
RAD51-4 +/- (X+/-) and RAD51-4 re-expressor (X-/-/+ and Y-/-/+) cell lines, one product 
of the size expected was amplified from the cDNA. In the rad51-4 -/- (X-/-), no product 
was amplified from the cDNA. DNA polymerase I was amplified from the cDNA of all the 
cell lines, confirming that extracted RNA was converted to cDNA. The RT negative 
control has no RT enzyme (-) in the reaction and confirms that the PCR products generated 
arose from the cDNA and not from contaminating gDNA (Figure 3-6).  
wt           +/- -/- -/-/+         -/-/+
RAD51-4
DNA Pol I
+      - +      - +      - +      - +      -
X          X             X             Y
RT
 
Figure 3-6: Analysis of the expression of the RAD51-4 mRNA in the RAD51-4 re-expressor cell lines by 
RT-PCR amplification.  
Using the reverse transcriptase (RT) enzyme, cDNA was generated from mRNA extracted from the wildtype 
(wt) 3174.2 T. brucei cells, from the one putative RAD51-4 heterozygous mutants (X+/-), from one putative 
rad51-4 homozygous mutants (X-/-) and from the two independently generated RAD51-4 re-expressor cell 
lines. This cDNA was used as template in the PCR reaction. PCR amplification was attempted using the 
forward primer (RAD51-4 StartORF For) and reverse primer (RAD51-4 EndORF Rev). The PCR products 
were then separated on a 1.0 % gel. As a positive control the DNA polymerase I ORF (DNA PolI) was 
amplified from the cDNA of all the mutant cell lines. RT + and - indicates the presence of RT enzyme (+) 
and the absence of RT enzyme (-). 
3.3.2 Confirmation of the RAD51-4 re-expressors by 
Western blot analysis 
To determine if the RAD51-4 protein was expressed in the RAD51-4 re-expressor cell lines 
(-/-/+), western blot analysis was carried out, using purified anti-RAD51-4 anti-serum, (see 
Section 2.6.2.1). Whole cell extracts from wt, rad51-4 -/- (X-/-) and RAD51-4 re-
expressors (X-/-/+ and Y-/-/+) were separated on a 10 % SDS-PAGE gel and transferred to 
a nylon membrane (see Materials and Methods, Section 2.6.3). The blot was probed with 
rabbit anti-RAD51-4 anti-serum primary antibody at a dilution of 1:1000, and was detected 
with HRP-conjugated anti-rabbit IgG antibody (Molecular Probes) at a dilution of 1:5000. 
This data is shown in Figure 3-7. In wildtype cells (wt) two bands were seen, one of the 
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size expected for the RAD51-4 (45 kDa) and another smaller band of ~40 kDa which was 
non-specific binding of the anti-serum. In the homozygous mutant analysed (X-/-), no 
wildtype band of 45 kDa indicating that RAD51-4 is absent. The protein levels look 
comparable in the cell lines as the non-specific band appears to be similar in all the lanes. 
In both the putative re-expressor cell lines, the two bands were seen, one of these was the 
non-specific band, while the other was ~45 kDa and is therefore RAD51-4 expressed from 
tubulin. However it appears that this is slightly bigger than the species in the wildtype 
cells. It is unknown why the re-expressed RAD51-4 is larger than the wildtype RAD51-4. 
This may be due to the location of the ORFs. The endogenous RAD51-4 may differ in 
trans-splicing compared to the transcribed RAD51-4 gene from the βα tubulin array (see 
Section 1.1.5). It could also be the case that the slightly bigger re-expressed RAD51-4 may 
have been modified post-translation, for example, by phosphorylation. 
 
Figure 3-7: Analysis of the RAD51-4 protein levels in the RAD51-4 re-expressor cell lines by western 
blot analysis. 
Western blot analysis showing the cell line extracts probed with anti-RAD51-4 anti-serum. Protein extracts 
from the wildtype (wt), rad51-4 -/- and the re-expressor cell lines (X-/-/+ and Y-/-/+) were separated on a 10 
% SDS-PAGE gel, and then transferred to a nylon membrane. This was then probed with rabbit anti-RAD51-
4 anti-serum primary antibody at a dilution of 1:1000, and was detected with HRP-conjugated anti-rabbit IgG 
antibody at a dilution of 1:5000. The predicted sizes are indicated in kDa. 
3.4 Phenotypic analysis of RAD51-4 mutants and 
re-expressor cell lines 
Once the RAD51-4 mutant cell lines were generated and confirmed, phenotypic analysis of 
the cell lines was carried out. The phenotypes observed for the homozygous mutant cell 
lines were compared to that of the wildtype and heterozygous mutant cell lines. To this 
end, growth rate, DNA-damage sensitivities, ability to form RAD51 foci and VSG 
switching frequency were analysed. The following sections described these results.  
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3.4.1 Analysis of in vitro growth rate of RAD51-4 mutant 
cell lines 
To determine if knockout of RAD51-4 has any gross effects on the growth of T. brucei, 
population doubling time was measured. Since mutation of the mammalian RAD51 
paralogues, and RAD51-3 and RAD51-5 of T. brucei caused reduced growth rates, similar 
growth impairment may be expected (Proudfoot & McCulloch, 2005a; Takata et al., 2001). 
To examine this, wildtype (wt), heterozygous (+/-) and homozygous (-/-) mutants were 
inoculated (in triplicate) at 5 x 104 cells per ml in HMI-9 media and cell densities were 
counted at fixed time points subsequently (see Materials and Methods, Section 2.8.1). The 
results were plotted on a semi-logarithmic graph (see Figure 3-8), and the doubling time 
for both the RAD51-4 +/- (X, Y) and rad51-4 -/- (X, Y) mutants were calculated and 
compared to that of the wt (see Table 3-1). The same analysis was conducted with the 
RAD51-4 -/-/+ (X, Y), where the RAD51-4 ORF has been integrated into the homozygous 
mutants. 
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Figure 3-8: Analysis of growth of RAD51-4 mutants in vitro.  
A semi-logarithmic plot of cell densities against fixed time points (24 h, 48 h, and 72 h) is shown. Wildtype 
strain 3174.2 (wt) is compared with two independent RAD51-4 heterozygous mutants (X+/-, Y+/-), two 
independent rad51-4 homozygous mutants (X-/-, Y-/-) and RAD51-4 re-expressor cell lines (X-/-/+, Y-/-/+). 
The graph shows the means of triplicate data with the 95 % confidence intervals indicated.  
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Table 3-1: in vitro doubling times for RAD51-4 mutant cell lines.  
The population doubling time for the two independently generated RAD51-4 heterozygous (X+/-, Y+/-), 
rad51-4 homozygous (X-/-, Y-/-) and the RAD51-4 re-expressor cell lines (X-/-/+, Y-/-/+) are compared with 
the doubling time for wildtype strain 3174.2 (wt). This data are the means of triplicate experiments (in hours) 
with the 95 % confidence intervals indicated (in brackets).  
6.82      
(+/-0.17)
6.78      
(+/-0.25)
9.08     
(+/-0.37)
9.03     
(+/-0.55)
7.43      
(+/-0.47)
7.12      
(+/-0.46)
7.23     
(+/-0.24)
Y-/-/+X -/-/+Y-/-X -/-Y+/-X +/-wt 
 
Table 3-2 : Statistical analysis of the in vitro doubling times for RAD51-4 mutants. 
Unpaired, two-tailed Student’s t-tests were carried out to compare the mean of the triplicate doubling time 
results for the RAD51-4 heterozygous (X+/-, Y+/-), rad51-4 homozygous (X-/-, Y-/-) and RAD51-4 re-
expressor cell lines (X-/-/+, Y-/-/+) against the wildtype (wt). Significant differences between the means is 
shown by a p-value of p ≤ 0.05; Not significantly different results are shown as “-“. [NA is not applicable]  
--0.00120.0041--NAwt 
Y-/-/+X-/-/+Y-/-X-/-Y+/-X+/-wt 
 
Table 3-2 shows that the doubling times for each independent homozygous mutant is 
significantly different to that of the wildtype. This analysis was carried out using unpaired, 
two-tailed Student’s t-test, and all other pair-wise comparisons of the other cell lines are 
shown in Appendix 3, Table 1.  
These data show that rad51-4 -/- mutants had a reduced growth rate, with each 
independent homozygous mutant, X-/- and Y-/-, having a decrease in growth of 44.3 % 
and 39.8 % compared to the wildtype at 48 h (see Figure 3-8). As a result, there was also 
an increased doubling time compared to the wildtype and RAD51-4 heterozygous mutants: 
X-/- had a doubling time of 9.03 h (+/- 0.55) and Y-/- had a doubling time of 9.08 h (+/- 
0.37) compared with the wildtype doubling time of 7.23 h (+/- 0.24); see Table 3-1. Re-
addition of functional RAD51-4 back into the homozygous mutant cell line enabled the 
cells to recover from the growth deficiency. This confirmed that lack of RAD51-4 was 
responsible for the slow growth of the cell lines. The basis for this slow growth was not 
explored further, but could be due to increased cell death in the population or increased 
length of the cell cycle in each cell of the population. A growth phenotype due to increased 
cell death could be analysed by clonal survival assays similar to those described in Section 
3.4.2.1 and Section 3.7.2.1. An increase in population doubling times, due to the cells 
taking longer to complete some stage(s) of the cell cycle or due to a cell cycle stall, could 
be analysed by quantification of the kinetoplast and nucleus. The nuclear and kinetoplast 
DNA replication and segregation are asynchronous, leading to differing copy numbers over 
the cell cycle (see Figure 3-9; McKean, 2003), which can be analysed microscopically by 
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DAPI staining. If there is a cell cycle defect in the mutant population, the percentage of 
cells in a specific cell cycle stage will differ from the wildtype. 
 
Figure 3-9: Replication and division of the nucleus and kinetoplast at specific cell cycle stages of T. 
brucei bloodstream form. 
T. brucei cells contain 1 nucleus (large purple circle) and 1 kinetoplast (small purple circle) (1N 1K) during 
G1 phase of the cell cycle. Synthesis of the kinetoplast DNA (SK) starts shortly before the nuclear DNA 
synthesis (SN). Kinetoplast division (D) occurs before nuclear division, resulting in the cells having 1 
nucleus and 2 kinetoplasts (1N 2K). Nuclear division or mitosis (M) results in the cells having 2 nuclei and 2 
kinetoplasts (2N 2K), and occurs before cytokinesis (C) The apportioning (A) phase of the cell cycle is when 
single copy organelles separate, for example basal bodies (white circles). Cytokinesis generates two daughter 
cells containing 1N 1K. Taken from C. Hartley Thesis (2008) and adapted from McKean (2003). 
3.4.2 Analysis of DNA-damage sensitivity of RAD51-4 
mutant cell lines 
To analyse if disruption of the RAD51-4 ORF leads to increased DNA-damage sensitivity, 
growth of the mutant cell lines was compared following treatment with two different DNA 
damaging agents, methyl methanesulfonate (MMS) and phleomycin. MMS (Sigma) is a 
DNA alkylating agent which modifies two DNA bases: guanine (to 7-methylguanine) and 
adenine (to 3-methlyladenine) (Beranek, 1990; Lundin et al., 2005). Historically, MMS 
was used as a ‘radiomimetic’ compound in yeast studies because many of the original 
radiation sensitive (rad) mutants were found to be sensitive to the compound (Wyatt & 
Pittman, 2006). It is still used to induce mutagenesis due to its DNA-damaging properties. 
It is also exploited in recombination experiments, as it is known to cause DNA-damage 
induced sister chromatid exchange (SCE) (Fasullo et al., 1994). DNA-damage induced by 
MMS results in single strand and double strand breaks (Lundin et al., 2005), although it is 
not known whether MMS directly causes DNA strand breaks, or whether the strand breaks 
observed result from events subsequent to the DNA damage for instance by triggering base 
excision repair or causing stalling/collapse of replication forks (Wyatt & Pittman, 2006). 
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Phleomycin (Calbiochem) is a glycopeptide and a member of the bleomycin group of 
antibiotics and anti-neoplastics (Dumas et al., 1994). Bleomycin causes both single strand 
and double strand breaks, with the latter being the most predominant, due to the ability of 
the compound to intercalate into DNA (Claussen & Long, 1999). It acts through the 
oxidation of a DNA-Fe(II)-bleomycin complex, with the formation of free radicals (Giloni 
et al., 1981). This oxidation of Fe(II) and reduction of oxygen when bound to pyrimidine 
nucleotides induces the DNA damage and can result in chromosomal aberrations (Claussen 
& Long, 1999). DNA cleavage by Fe(II)-bleomycin has also been shown to be a selective 
process of strand-scission, occurring preferentially at guanine-pyrimidine base sequence 
(5′-GC and 5′-GT) (Claussen & Long, 1999).  
Two assays were used to ascertain whether or not the rad51-4 -/- mutants display increased 
sensitivity to phleomycin or MMS induced DNA-damage. The first assay was clonal 
survival, measuring the outgrowth of the population from a single cell in the presence of 
the two different DNA-damaging agents. The second was assaying the sensitivity to the 
DNA-damaging agents by measuring absorbance of alamar blue and calculating IC50 
values for each cell line. IC50 is a measure of the effectiveness of a compound, in this case 
DNA-damaging agents MMS and phleomycin, in inhibiting biological survival or growth. 
It is a quantitative measure and indicates how much of the DNA-damaging agents are 
required to inhibit metabolic capability by 50 %. The IC50 values of the DNA-damaging 
agents were determined by constructing a dose-response curve (GraphPad Prism 4). 
3.4.2.1  Clonal survival of RAD51-4 mutant cell lines 
Clonal survival assay was performed by diluting mid-log phase (2 x 106 cells per ml) cell 
lines to a concentration of 1 cell per well over a 96 well plate, measuring the number of 
cells that grew out to an observable population with varying concentrations of MMS and 
phleomycin, (see Materials and Methods, Section 2.8.2.1 for more details). Each drug 
concentration was plated in triplicate and growth in the well was scored microscopically up 
to 14 days after cloning. This was graphed to show cell survival as a percentage of clonal 
growth when compared with non-treated cells. Figure 3-10 shows the clonal survival of 
RAD51-4 mutant cell lines compared to that of the wildtype cells at increasing 
concentrations of MMS as follows: 0.0001 %, 0.0002 %, 0.0003 %, and 0.0004 %. 
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Figure 3-10: Clonal survival of RAD51-4 mutants in vitro when treated with methyl methanesulfonate 
(MMS). 
Cell survival is shown as percentage of clonal growth when treated with MMS compared to growth in the 
absence of MMS. Each cell line, wildtype strain 3174.2 (wt), two independent RAD51-4 heterozygous 
mutants (X+/-, Y+/-), rad51-4 homozygous mutants (X-/-, Y-/-) and RAD51-4 re-expressor cell lines (X-/-/+, 
Y-/-/+) was treated with increasing concentration of MMS (0.0001 %, 0.0002 %, 0.0003 %, 0.0004 %). The 
graph shows the means of triplicate data, with 95 % confidence intervals indicated by the error bars. 
With increasing concentrations of MMS, from 0.0001 % to 0.0004 %, there was clear 
evidence for decreased survival of each independent rad51-4 -/- mutant, X-/- and Y-/-, 
compared to the other cell lines. At a MMS concentration of 0.0003 % this distinction was 
clearest: wildtype survival was 53.9 % (+/- 13.2) of untreated cells, whereas rad51-4 X-/- 
mutant survival was 14 % (+/- 3.3) and rad51-4 Y-/- was 4.3 % (+/- 1.4). Analysis of the 
results by the Student’s t-tests for clonal survival at this MMS concentration (0.0003 %) is 
shown in Table 3-3. This confirms that clonal survival of each independent rad51-4 -/- 
mutant is significantly different to that of the wildtype cell line.  
Table 3-3: Statistical analysis of the clonal survival of RAD51-4 mutants when treated with 0.0003 % 
methyl methanesulfonate (MMS). 
Unpaired two-tailed Student’s t-tests were carried out to compare the mean of the triplicate clonal survival 
results for the cell lines against the wildtype. Significant difference between the results is shown by a p-value 
of p ≤ 0.05, while not significantly different results are shown as “-“. [NA is not applicable] Each cell line is 
indicated as follows:  wildtype strain 3174.2 (wt), two independent RAD51-4 heterozygous mutants (X+/-, 
Y+/-), rad51-4 homozygous mutants (X-/-, Y-/-) and RAD51-4 re-expressor cell lines (X-/-/+, Y-/-/+). 
--0.04200.0349--NAwt 
Y-/-/+X-/-/+Y-/-X-/-Y+/-X+/-wt 
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Student’s t-tests to compare the mean of the triplicate clonal survival results for the cell 
lines against each other at the other concentrations of MMS, 0.0001 %, 0.0002 % and 
0.0004 %, were also carried out, and are shown in Appendix 3, Table 2. These results 
confirm that with increasing concentrations of MMS, there is a significant reduction of 
clonal survival of the rad51-4 -/- cells compared with the wildtype and RAD51-4 +/-. With 
the addition of a functional RAD51-4 gene back into the homozygous mutants, the 
percentage of survival is increased, indicating this phenotype is a consequence of RAD51-4 
mutation.  
Similar analysis was carried out using phleomycin as a DNA damaging agent. Figure 3-11 
shows the clonal survival of RAD51-4 mutant cell lines compared with that of the wildtype 
cells when treated with four increasing concentrations of the drug: 0.025 µg.ml-1, 0.05 
µg.ml-1, 0.075 µg.ml-1, and 0.1 µg.ml-1. 
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Figure 3-11: Clonal survival of RAD51-4 mutants in vitro when treated with phleomycin. 
Cell survival is shown as percentage of clonal growth when treated with phleomycin compared to growth in 
the absence of drug. Each cell line wildtype 3174.2 (wt), two independent RAD51-4 heterozygous mutants 
(X+/-, Y+/-), and rad51-4 homozygous mutants (X-/-, Y-/-) was treated with increasing concentration of 
phleomycin (0.025 µg.ml-1, 0.05 µg.ml-1, 0.075 µg.ml-1, 0.1 µg.ml-1). The graph shows the means of triplicate 
data, with the 95 % confidence intervals indicated by error bars. 
As was seen for MMS, increasing concentrations of phleomycin, from 0.025 µg.ml-1 to 0.1 
µg.ml-1, caused a clear decrease of survival of each independent rad51-4 -/- X and Y, 
compared with the wt and RAD51-4 +/-. At a phleomycin concentration of 0.025 µg.ml-1, 
wildtype survival was 96.5 % (+/- 17.3) compared with 21.6 % (+/- 6.8) and 16.8 % (+/- 
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6.4) for the rad51-4 -/- mutants, X-/- and Y-/- respectively. The results of the Student’s t-
tests for clonal survival at a phleomycin concentration of 0.025 µg.ml-1  are shown in Table 
3-4, confirming that the clonal survival of each independent homozygous mutant was 
significantly reduced compared to that of the other cell lines.  
Table 3-4: Statistical analysis of the clonal survival of RAD51-4 mutants when treated with 0.025 
µg.ml-1 of phleomycin. 
Unpaired, two-tailed Student’s t-tests were carried out to compare the mean of the triplicate clonal survival 
results for the cell lines against the wildtype (wt), significant difference between the results is shown by a p-
value of p ≤ 0.05, whereas not significantly different results are shown as “-“. [NA is not applicable] Each 
cell line is described:  wildtype strain 3174.2 (wt), two independent RAD51-4 heterozygous mutants (X+/-, 
Y+/-), and rad51-4 homozygous mutants (X-/-, Y-/-). 
0.03060.0412--NAwt 
Y-/-X -/-Y+/-X +/-wt 
 
Unpaired, two-tailed Student’s t-tests to compare the means of the triplicate clonal survival 
results for the cell lines against each other at the different concentrations of phleomycin, 
0.05 µg.ml-1, 0.075 µg.ml-1, and 0.1 µg.ml-1 are shown in Appendix 3, Table 3. At 
concentration of 0.05 µg.ml-1 and 0.075 µg.ml-1 of phleomycin, there was also a significant 
decrease of clonal survival of the rad51-4 -/- mutants compared with the wt and RAD51-4 
+/- mutants. Note that the RAD51-4 re-expressor cell lines were not analysed, as 
reintegration of RAD51-4 was selected using phleomycin resistance. 
Taken together, these data show that the rad51-4 -/- mutants are more sensitive to DNA-
damaging agents, MMS and phleomycin, than the wildtype and RAD51-4 +/- mutants. 
Most likely, this is due to impairment in the ability of the cells to repair these types of 
induced DNA damage. 
3.4.2.2  IC50 values of MMS and Phleomycin for RAD51-4 mutant 
cell lines 
In order to quantify the extent of rad51-4 -/- mutants DNA damage sensitivity, IC50 values 
of the different cell lines were determined after MMS and phleomycin treatment. This was 
performed using an Alamar blue assay (see Materials and Methods, Section 2.8.2.2). 
Resazurin (or Alamar blue) is an indicator redox dye and is a quantitative measure of 
proliferating cells.  The assay is based on the ability of viable, metabolically active cells to 
reduce resazurin to resorufin (Anoopkumar-Dukie et al., 2005). This reduction results in a 
colour change from blue (resazurin) to pink (resorufin), which can be measured 
colorimetrically. This compound is non-toxic to cells and stable in the HMI-9 culture 
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medium, allowing measurement of cell proliferation in vitro. If the DNA-damaging agents 
impair the cell viability and proliferation, the capacity of cultures to reduce resazurin is 
also reduced. The rate of dye reduction is directly proportional to the number of viable 
cells present in the culture. Therefore, as a direct measure of the metabolic competence of 
cell cultures, colour change provides a convenient indicator of cell proliferation following 
DNA-damage which then allows the IC50 values to be calculated.  
Figure 3-12 shows the calculated mean IC50 values for MMS of wildtype, RAD51-4 +/-, 
rad51-4 -/- and RAD51-4 re-expressor cell lines. The wildtype cells’ mean IC50 value was 
0.000389 % (+/- 0.000048) which was approximately 2.5 fold higher compared than the 
two independent rad51-4 -/- mutants: 0.000154 % (+/- 0.000025) and 0.000178 % (+/- 
0.000013) for rad51-4 -/- X and Y respectively. 
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Figure 3-12: IC50 values for methyl methanesulfonate (MMS) for RAD51-4 mutant cell lines 
Resazurin was used as an indicator of growth and IC50 values were calculated for each cell line. Wildtype 
3174.2 (wt), two independent RAD51-4 heterozygous mutants (X+/-, Y+/-), two independent rad51-4 
homozygous mutants (X-/-, Y-/-) and two independent RAD51-4 re-expressor cell lines (X-/-/+, Y-/-/+) were 
treated with serial dilutions of MMS. The graph shows the mean IC50 values determined from the triplicate 
data, with the 95 % confidence intervals indicated by the error bars. 
The reduction of the IC50 value of the rad51-4 -/- mutants compared to the wt cells was 
found to be significantly different (see Table 3-5) as judged by the results of the unpaired, 
two-tailed Student’s t-test comparisons of the means of the triplicate results when plotted 
by nonlinear regression on a sigmoid dose response graph. In contrast, there was no 
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evidence that the RAD51-4 +/- mutants or the RAD51-4 -/-/+ cells displayed this 
impairment (Appendix 3, Table 4). 
Table 3-5: Statistical analysis of the IC50 values for methyl methanesulfonate (MMS) of the RAD51-4 
mutants. 
Student’s t-tests were carried out to compare the mean of the triplicate IC50 values for the cell lines against 
the wildtype (wt), a significant difference between the results is shown by a p-value of p ≤ 0.05, not 
significantly different results are shown as “-“. [NA is not applicable.] Each cell line is indicated as follows:  
wildtype strain 3174.2 (wt), two independent RAD51-4 heterozygous mutants (X+/-, Y+/-), rad51-4 
homozygous mutants (X-/-, Y-/-) and RAD51-4 re-expressors (X-/-/+, Y-/-/+). 
--0.03870.0120--NAwt 
Y-/-/+X-/-/+Y-/-X-/-Y+/-X+/-wt 
 
Figure 3-13 shows the mean IC50 values for phleomycin of the wildtype, RAD51-4 +/-, and 
rad51-4 -/- cell lines. For this DNA damaging compound, the wildtype cells’ mean IC50 
value was 0.26 µg.ml-1 (+/- 0.05), which was 2.3 fold greater than the rad51-4 -/- mutants: 
X-/- mean IC50 value was 0.08 µg.ml-1 (+/- 0.2) and Y-/- was 0.09   µg.ml-1 (+/- 0.01).  
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Figure 3-13: IC50 values for phleomycin in RAD51-4 mutant cell lines. 
Resazurin was used as an indicator of growth and IC50 values were calculated for each cell line. Wildtype 
3174.2 (wt), two independent RAD51-4 heterozygous mutants (X+/-, Y+/-), RAD51-4 homozygous mutants 
(X-/-, Y-/-) and RAD51-4 re-expressor cell lines (X-/-/+, Y-/-/+) were treated with serial dilutions of 
phleomycin. The graph shows the mean IC50 derived from the triplicate data, with the 95 % confidence 
intervals indicated by the error bars. 
The results of Student’s t-test analysis of these data are shown in Table 3-6. The reduction 
of the IC50 value for phleomycin treatment of the rad51-4 -/- mutant relative to wildtype 
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was significant. The complete statistical analysis of all pair-wise comparisons can be found 
in Appendix 3, Table 5. 
Table 3-6: Statistical analysis of the IC50 values for phleomycin of the RAD51-4 mutants. 
Student’s t-tests were carried out to compare the mean of the triplicate IC50 values for the cell lines against 
the wildtype, a significant difference between the results is shown by a p-value of p ≤ 0.05 and not 
significantly different results are shown as “-“. [NA is not applicable.] Each cell line is initiated as follows:  
wildtype strain 3174.2 (wt), two independent RAD51-4 heterozygous mutants (X+/-, Y+/-), and rad51-4 
homozygous mutants (X-/-, Y-/-). 
0.04990.0280--NAwt 
Y-/-X-/-Y+/-X+/-wt
 
These data confirm the findings of the clonal survival analysis and confirms that the rad51-
4 -/- mutants are more sensitive to two different DNA-damaging agents, due to the lack of 
functional RAD51-4 in the cell. The re-expressor restores most or all of the resistance to 
the MMS, in both assays, although this could not be confirmed for the sensitivity of 
phleomycin (Section 3.3).  
3.4.3 Analysis of the recombination efficiency of RAD51-
4 mutant cell lines 
The analysis of the rad51-4 -/- mutants ability to undergo homologous recombination was 
analysed next. To do this, the cells’ ability to take up DNA and integrate into the genome 
was quantified using a transformation efficiency test. To assay for transformation 
efficiency, a linearised DNA construct containing the ORF of phleomycin resistance, 
flanked by βα and αβ intergenic regions, was transformed into the wildtype and each of the 
mutant cell lines (see Materials and Methods, Section 2.8.3). If homologous recombination 
can occur, the targeting regions of βα and αβ intergenic flanks allow the resistance cassette 
to integrate into the α tubulin array, and as result the cells become resistant to phleomycin. 
Each cell line at a total volume of 5 x 107 cells was transformed by electroporation with 5 
µg of linearised DNA. After transformation, the cells were allowed to recover for 24 hours 
prior to phleomycin selection. The cells were incubated for 14 days at 37 oC on 2.0 µg.ml-1 
of phleomycin and the number of wells with transformants was scored. The transformation 
efficiency was described as the number of wells with growth per 106 cells plated out.  
Figure 3-14 shows the results of this analysis and indicates that the rad51-4 -/- mutants 
have a decreased ability to undergo transformation, since the transformation efficiency of 
wildtype cells was 1.2 x 10-6 (+/- 4.75 x 10-7) compared with 3.92 x 10-7 (+/- 1.2 x 10-7) 
and 3.8 x 10-7 (+/- 8.92 x 10-8) for the two rad51-4 -/- mutants, X-/- and Y-/- respectively. 
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Figure 3-14: Transformation efficiency assay for the RAD51-4 mutant cell lines. 
To assay for recombination rate, a transformation efficiency assay was used. Each cell line is indicated as 
follows:  Wildtype strain 3174.2 (wt), two independent RAD51-4 heterozygous mutants (X+/-, Y+/-), and 
two independent rad51-4 homozygous mutants (X-/-, Y-/-). The values plotted are mean numbers of 
phleomycin resistant transformants per 106 cells transformed. These experiments were done in triplicate with 
the same linearised DNA, and error bars of the 95 % confidence intervals are indicated. 
In contrast, disruption of any one RAD51-4 allele did not affect the cells ability to undergo 
transformation, since the RAD51-4 +/- cells had comparable transformation rates to that of 
wt cells. The decreased transformation rates of the rad51-4 -/- cells were confirmed to be 
significantly different, using unpaired, two-tailed Student’s t-test, and are shown in Table 
3-7. The complete statistical analysis of all pair-wise comparisons is shown in Appendix 3, 
Table 6. 
Table 3-7: Statistical analysis of the transformation efficiency of RAD51-4 mutant cell lines. 
Unpaired, two-tailed Student’s t-tests were carried out to compare the mean of the triplicate transformation 
efficiency results for the wildtype cell (wt) relative to the other cell lines. A significant difference between 
the results is shown by a p-value of p ≤ 0.05. Not significantly different results are shown as “-“. NA is not 
applicable. Each cell line is indicated as follows: wildtype strain 3174.2 (wt), two independent RAD51-4 
heterozygous mutants (X+/-, Y+/-), and rad51-4 homozygous mutants (X-/-, Y-/-). 
0.00470.0089--NAwt
Y-/-X-/-Y+/-X+/-wt
 
This analysis has indirectly shown that the rad51-4 -/- mutants have a decrease in their 
ability to undergo homologous recombination compared to the wildtype and RAD51-4 +/- 
mutants. This phenotype is highly similar to that observed in the rad51 -/-, rad51-3 -/-, 
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rad51-5 -/- and brca2 -/- cell lines, where there was also a decrease in transformation 
efficiency, but notably there was no obliteration of the cell recombination capacity 
(Hartley, 2008; McCulloch & Barry, 1999; Proudfoot & McCulloch, 2005a). In all 
previous cases, the residual recombination occurred by homologous recombination, 
indicating a number of pathways operate. Similar analysis was not conducted here, 
however. 
3.4.4 Analysis of RAD51 foci formation in the RAD51-4 
mutant cell lines 
In eukaryotic cells, it has been shown that RAD51 forms discrete foci in sub-nuclear 
complexes contributing to the repair of damaged DNA including stalled/collapsed 
replication forks, and during meiosis (Bishop, 1994; Haaf et al., 1995; Haaf et al., 1999; 
Lisby et al., 2004; Plug et al., 1996; Scully et al., 1997; Tarsounas et al., 2004a; Ward et 
al., 2007). It has also been shown that RAD51 foci formation can be induced by DNA 
damaging agents such as UV radiation (Raderschall et al., 1999; Tarsounas et al., 2004a; 
Tashiro et al., 2000). RAD51 foci are most probably formed at the sites of DNA damage 
(Sugawara et al., 2003). It has been previously shown that DNA damage by phleomycin 
treatment of T. brucei causes a similar re-localisation of RAD51 into distinct foci, and that 
RAD51-3, RAD51-5 and BRCA2 all influence the formation of these complexes (Glover 
et al., 2008; Hartley, 2008; Proudfoot & McCulloch, 2005a). The number of RAD51 foci 
per cell varies, including in T. brucei, presumably in correlation with the amount of DNA-
damage induced in the cell, although this has not been quantitatively analysed in T. brucei. 
Figure 3-15 shows examples of these foci following phleomycin treatment of wildtype 
bloodstream stage cells in which one to five distinct foci are seen. The Figure 3-15 also 
shows treated rad51 -/- cell lines, which do not form foci due to RAD51 being absent. 
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Figure 3-15: RAD51 sub-nuclear foci in T. brucei. 
The first row of pictures shows an example of a phleomycin treated rad51-/- cell: no distinct RAD51 foci are 
detected. The other rows are examples of the number of RAD51 foci formed in treated wildtype BSF T. 
brucei cells, (1, 2, 3, 4 and many). RAD51 was imaged by indirect immuno-fluorescence (FITC) (first 
column), the DNA was stained with DAPI (second column), FITC and DAPI were merged (third column), 
the cells are visualised by DIC (fourth column) and all the images were merged (fifth column). 
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To examine the role of RAD51-4 in RAD51 foci formation immuno-fluorescence was 
performed on the rad51-4 -/- mutant cell lines (see Materials & Methods, Section 2.9) 
using rabbit anti-RAD51 anti-serum at a dilution of 1:500 and detected using goat anti 
rabbit anti-serum conjugated with SFX (fluorescein, succinimidyl ester: Molecular 
Probes). This was performed for wildtype, and each independent RAD51-4 +/- and rad51-4 
-/- mutants, all of which had been grown on varying concentrations of phleomycin for 18 
hours. All cell lines in the absence of phleomycin treatment showed minimal RAD51 foci 
formation, with only 1-3 % having detectable foci, as no DNA damage was induced; an 
example of this is shown in Figure 3-16. At varying concentrations of phleomycin, from 
0.25 µg.ml-1 to 2.0 µg.ml-1, 80 % - 100 % of wt cells produced RAD51 foci (Table 3-8). 
The RAD51-4 +/- cell lines also had a similar pattern to wildtype, with 65 % - 93 % of 
cells forming RAD51 foci.   
 
 
Figure 3-16: RAD51 sub-nuclear foci in rad51-4 -/- mutant cell lines. 
The first row of pictures shows an example of a non-treated rad51-4 -/- cell: no distinct RAD51 foci are 
detected. The second row is an example of a phleomycin treated rad51-4 -/- cell where no foci are present. 
The last row is an example of a phleomycin treated rad51-4 -/- cell where five RAD51 foci are present in the 
nucleus. RAD51 was imaged by indirect immuno-fluorescence (FITC) (first column), the DNA was stained 
with DAPI (second column), these two were merged (third column), the cells are visualised by DIC (fourth 
column) and all the images were merged (fifth column). 
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Table 3-8: Percentage of rad51-4 -/- mutant cells with a specific number of RAD51 foci. 
The percentage of cells with a specific number of sub-nuclear RAD51 foci formed (0, 1, 2, 3, 4, ≥5) when the 
cell lines were treated with increasing concentrations of phleomycin, 0.25 µg.ml-1, 1.0 µg.ml-1  and 2.0 µg.ml-
1
 is shown. The total indicates the number of cells counted. [Wildtype strain 3174.2 is indicated by wt, two 
independent RAD51-4 heterozygous mutants are indicated by X+/- and Y+/-, rad51-4 homozygous mutants 
are indicated by X-/- and Y-/-. 
8018.88.813.83.815.040.02.0 µg.ml-1
1080.92.812.317.923.642.51.0 µg.ml-1
2033.41.58.919.729.137.40.5 µg.ml-1
1031.00.00.01.99.787.40.25 µg.ml-1Y-/-
1482.74.16.89.512.864.22.0 µg.ml-1
2095.32.910.011.516.354.11.0 µg.ml-1
2001.02.53.514.530.048.50.5 µg.ml-1
2351.72.63.411.919.161.30.25 µg.ml-1X-/-
18917.510.619.625.419.07.92.0 µg.ml-1
1068.53.812.318.921.734.91.0 µg.ml-1Y+/-
20916.318.225.420.612.96.72.0 µg.ml-1
1009.81.014.726.516.731.41.0 µg.ml-1X+/-
10639.612.320.822.64.70.02.0 µg.ml-1
22510.76.712.923.125.321.31.0 µg.ml-1
1001.01.09.014.043.032.00.25 µg.ml-1wt
≥543210
Cells
Counted
Number of RAD51 fociConcentration
of phleomycin
 
The rad51-4 -/- mutants appear to less able to form RAD51 foci. At a phleomycin 
concentration of 1.0 µg.ml-1, 21 % of wildtype cells did not produce detectable RAD51 
foci (see Table 3-8 and Figure 3-17), while in the two independent rad51-4 -/- cell lines, 54 
% and 42 % of the total counted do not produce RAD51 foci, for X-/- and Y-/- 
respectively. This difference was more marked on increasing the phleomycin concentration 
to 2.0 µg.ml-1 (see Figure 3-18). In these conditions, all of the wildtype cells produce 
RAD51 foci, while 64 % and 40 % of the rad51-4 -/- mutants cells (X-/- and Y-/- 
respectively) do not produce RAD51 foci. Similarly, at the lower concentration of 0.25 
µg.ml-1, 87 % and 61 % of the rad51-4 -/- cells displayed no foci, compared to only 32 % 
of the wildtype cells. These data indicate the lack of RAD51-4 in the cell causes a defect in 
RAD51 re-localisation to or within the nucleus when the cells are treated with 2.0 µg.ml-1 
of phleomycin. It is noticeable however, that discernible RAD51 foci do occur, indicating 
this re-localisation is not abolished.  
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Figure 3-17: Percentage of RAD51-4 mutant cell lines with a specific number of the RAD51 foci when 
treated with 1.0 µg.ml-1 of phleomycin. 
The percentage of cells with a specific number of the sub-nuclear RAD51 foci formed (0, 1, 2, 3, 4, ≥5) is 
shown when the cell lines were treated with 1.0 µg.ml-1 of phleomycin. The cell lines are labelled as follows: 
wildtype strain 3174.2 (wt), the two independent RAD51-4 heterozygous mutants (X+/-, Y+/-), and the two 
independent rad51-4 homozygous mutants (X-/-, Y-/-). 
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Figure 3-18: Percentage of RAD51-4 mutant cells with a specific number of the RAD51 foci when 
treated with 2.0 µg.ml-1 of phleomycin. 
The percentage of cells with a specific number of the sub-nuclear RAD51 foci formed (0, 1, 2, 3, 4, ≥5) is 
shown when the cell lines were treated with 2.0 µg.ml-1 of phleomycin. The cell lines are labelled as follows: 
wildtype strain 3174.2 (wt), the two independent RAD51-4 heterozygous mutants (X+/-, Y+/-), and the two 
independent rad51-4 homozygous mutants (X-/-, Y-/-). 
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3.4.5 Analysis of VSG switching of mutant cell lines 
The 3174.2 strain of T. brucei was used to generate the rad51-4 mutants in bloodstream 
stage cells (see Materials and Methods, Section 2.1.1). This strain has been described 
before and can be used to analyse the VSG switching frequency and mechanisms (Bell & 
McCulloch, 2003; Conway et al., 2002a; McCulloch et al., 1997; Proudfoot & McCulloch, 
2005a; Robinson et al., 2002). As previously described, rad51, rad51-3 and brca2 
mutations cause a decrease of VSG switching frequency (Hartley, 2008; McCulloch & 
Barry, 1999; Proudfoot & McCulloch, 2005a). In contrast, there is no evidence that 
RAD51-5 acted in this process which may suggest some specialised role of the RAD51 
paralogue (Proudfoot & McCulloch, 2005b). The 3174.2 strain was also used to determine 
if the absence of RAD51-4 affects antigenic variation by analysing the VSG switching 
frequency and mechanism. This cell line has a modified active VSG expression site (ES) as 
it contains two antibiotic resistance cassettes inserted upstream of the telomeric VSG, 
named VSG221. The frequency of VSG switching was measured by an in vivo assay 
involving mice immunised against VSG221 (see Materials and Methods, Section 2.8.4). 
The resistance cassettes, hygromycin (Hyg, HYG) and neomycin (G418, NEO), ensure 
expression of the VSG221 when the cells are grown on the antibiotic in vitro, allowing 
injection of and immunisation of the mice against VSG221-expressing cells. Once the mice 
have recovered from challenge and cure of T. brucei expressing VSG221, they were re-
infected with the cell lines grown for nine generations in vitro without the selection of Hyg 
and G418, allowing VSG switching to occur and switched variants to arise. By measuring 
the number of T. brucei cell survivors after re-infection of the mice, the rate of switching 
was calculated. The switching mechanisms used in cloned variants that were recovered 
were also determined by identification of the resistance markers and their expression in the 
ES (see Figure 3-19). 
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Figure 3-19: Use of the transgenic T. brucei strain 3174.2 allows characterisation of the VSG switching 
events. 
On the left, the diagram shows the active expression site (ES) with VSG221 (purple box) with the two 
antibiotic cassettes, hygromycin (HYG; green box) and neomycin (NEO; red box) which are separated by the 
70 bp repeats (grey box). In this active ES, there is also expression site associated gene 1 (ESAG1; blue box). 
The primer binding sites are denoted by the black arrows. On the right of the diagram, the three possible 
switching events, in situ transcriptional switch, expression site gene conversion/loss or VSG gene conversion 
are shown. G418 and Hyg resistance (R) or sensitivity (S) along with the PCR product presence (+) or 
absence (-) are indicated. Taken from Hartley, C thesis and adapted from McCulloch et al., 1997. 
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The switching frequency was calculated by counting the number of wells in a 96 well plate 
that contained growing trypanosome populations up to 14 days after the cells were 
recovered from the re-challenged immune mice. A selection of recovered, clonal 
populations was then grown on Hyg and G418 to ascertain if the genes were expressed and 
the genomic DNA from each population was extracted to allow PCR-amplification to test 
for the presence or absence of the HYG, NEO and VSG221 ORFs (see Materials and 
Methods, Section 2.4.1). This allowed the VSG switching mechanism to be deduced by 
PCR-amplification and drug resistances/sensitivities. The three possible switching events 
are described in Figure 3-19. During an in situ transcriptional switch the VSG221 
expression site is inactivated. There is no loss or replacement of the genes, and an inactive 
expression site containing a different VSG, VSG(X) is transcriptionally activated. As a 
result, any cells that have undergone this type of switching mechanism are sensitive to both 
drugs, (Hyg and G418 sensitive: Hygs and G418s respectively). As there is no loss of the 
genes, PCR of the expression site shows that the HYG, NEO and VSG221 gene are present 
(Hyg+, Neo+, VSG+). In an expression site gene conversion event, a different VSG(X) 
replaces all or a significant part of the VSG221 expression site. As a result, any cells that 
have undergone this type of switching mechanism are Hygs and G418s  and as there is loss 
of the genes the PCR-amplified products of the expression site markers shows that HYG, 
NEO and VSG221 gene are not present (Hyg-, Neo-, VSG-). In a VSG gene conversion 
event, a different VSG(X) replaces the region from the 70 bp repeats to the end of the 
VSG221. As a result, any cells that have undergone this type of switching mechanism are 
Hyg resistant because it is still actively transcribed (Hygr) and G418 sensitive as the 
neomycin resistance cassette is in between the 70 bp repeats and the VSG221 gene 
(G418s); PCR-amplification products of the expression site markers shows that HYG is 
present, and NEO and VSG221 genes are not present (Hyg+, Neo-, VSG-). 
3.4.6 Analysis of VSG switching of RAD51-4 mutant cell 
lines 
The switching frequencies and mechanisms for the RAD51-4 cell lines were analysed as 
described in Section 3.4.5, and Materials and Methods, Section 2.8.4. Briefly, each cell 
line at a cell density of 4 x 107 cells, was injected into the previously immunised mice. 
VSG switching frequency was calculated as follows: The isolated and cloned surviving 
switched T. brucei cells were counted over 96-well plates. This number was multiplied by 
2.5, as the recovered blood from the mouse (plated out 0.4 ml) was only 40 % of the total 
approximate blood volume of the animal. This number was then divided by the number of 
doubling times that had occurred during the 24 hour period following injection into the 
Rachel Dobson, 2009   Chapter 3, 98 
mouse. Finally this value was divided by the number of cells grown in vitro that had been 
injected into the VSG221-immunised mice. For each VSG switch frequency, a minimum of 
three independent experiments were performed. 
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Figure 3-20: The mean VSG switching frequencies of the RAD51-4 cell lines. 
Wildtype cells (wt), the two independent RAD51-4 heterozygote cell lines (X+/-, Y+/-), the two independent 
rad51-4 homozygote cell lines (X-/-, Y-/-) and one RAD51-4 re-expressor cell line (X-/-/+) was injected into 
a minimum of three mice to analyse whether or not the rad51-4 -/- mutant had an effect on VSG switching 
frequencies. The graph shows the mean VSG switching frequencies and is described as events per 107 cells 
per generation. The 95 % confidence intervals are indicated as error bars. 
Figure 3-20 shows the mean VSG switching frequencies of the cell lines examined. The 
wildtype cells’ VSG switching frequency was 8.36 (+/- 3.06) switched variants per 107 
cells per generation, while the rad51-4 -/- mutants (X-/-, Y-/-) had a VSG switching 
frequency of 4.06 (+/- 1.57) and 5.64 (+/- 1.8) switched variants per 107 cells per 
generation respectively. Each RAD51-4 heterozygote mutant (X+/-, Y+/-) had a high 
recovery rate, with growth in all 96 wells for all three mice. It is unknown why this was the 
case. RAD51-4 X+/- had a VSG switching frequency of 15 switched variants per 107 cells 
per generation compared the significantly different rad51-4 X-/-. The same was true for the 
other heterozygote independent clone (Y+/-) which also had a VSG switching frequency of 
15 switched variants per 107 cells per generation, and was significantly different to the 
rad51-4 Y-/-. This analysis showed that rad51-4 mutants had an impaired ability to 
undergo VSG switching as the VSG switching frequencies of the rad51-4 -/- were greatly 
reduced compared with the cell lines from which they were derived: RAD51-4 +/- mutants. 
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This is not unequivocal evidence that RAD51-4 is involved in VSG switching, as there was 
no significant difference between both independent homozygous mutants and the wildtype 
cells.  
Table 3-9 shows that there was a significant difference between the data for the wildtype 
compared to the X homozygous mutant and not the Y homozygous mutant, as well as a 
significant difference between the wildtype and one of the RAD51-4 +/- heterozygous 
mutants (X+/-). This is mostly likely due to the high variability and nature of the in vivo 
experiment. Unpaired two-tailed Student’s t-tests were carried out on all the data, and are 
shown in Appendix 3, Table 7. 
Table 3-9: Statistical analysis of the VSG switching frequencies of RAD51-4 mutant cell lines. 
Unpaired, two-tailed Student’s t-tests were carried out to compare the mean of the VSG switching 
frequencies for the cell lines against the wildtype. A significant difference is shown by a p-value of p ≤ 0.05. 
Not significantly different results are shown as “-“. [NA is not applicable.] Wildtype strain 3174.2 (wt), two 
independent RAD51-4 heterozygous mutants (X+/-, Y+/-), two independent rad51-4 homozygous mutants 
(X-/-, Y-/-) and the RAD51-4 re-expressor (X-/-/+) are shown. 
wt X+/- Y+/- X-/- Y-/- X-/-/+
wt NA 0.0107 - 0.0285 - -
 
A selection of recovered clones from each cell line (10 from each mouse; a total of 30 for 
each cell line) were analysed to differentiate the switching mechanisms that occurred, 
described in Section 3.4.5 and Materials and Methods, and Section 2.8.4. As RAD51-4 act 
in homologous recombination and DNA repair it might be suggested that the rad51-4 -/- 
would not undergo gene conversion events to switch their VSG as this mechanism relies on 
homologous recombination. Figure 3-21 shows the switching mechanisms in the rad51-4 -
/- mutants. This data does not fit the prediction, and shows that the rad51-4 -/- mutant, 
clone Y-/-, can undergo expression site and VSG gene conversion. In contrast, there is an 
observable difference between the wildtype in situ switch compared with the rad51-4 X-/- 
mutant clone. It was observed that 15 % (+/- 9.7 %) of wildtype cells used an in situ switch 
whilst 65 % (+/- 8.0 %) of the rad51-4 X-/- had switched their VSG by an in situ switch. 
This clear difference was not observed in the other rad51-4 Y-/-. It should also be noted 
that both rad51-4 -/- mutants were still able to undergo expression site and VSG gene 
conversion. The drug resistance and sensitivities along with the PCR-banding pattern of a 
number of switchers, which can not define by the three mechanism described in Figure 3-
19, are shown as “unknown”. These unknown mechanisms may be the result of single-
strand annealing pathway as a way of switching the VSG gene in the expression site. 
Rachel Dobson, 2009   Chapter 3, 100 
0
10
20
30
40
50
60
70
80
90
100
wt X+/- Y+/- X-/- Y-/- X-/-/+
Sw
itc
h 
N
u
m
be
r 
(%
)
in situ
ES GC
VSG GC
Unknown
RAD51-4 cell line
 
Figure 3-21: Analysis of the switching mechanisms of the RAD51-4 mutant cell lines. 
The graph shows the switching mechanism of RAD51-4 mutant cell lines as a percentage of the total 
analysed. Wildtype strain 3174.2 (wt), two independent RAD51-4 heterozygous mutants (X+/-, Y+/-), two 
independent rad51-4 homozygous mutants (X-/-, Y-/-) and the RAD51-4 re-expressor (X-/-/+) are shown. 
The assay allowed differentiation of in situ transcriptional switching (in situ), expression site gene conversion 
(ES GC) and VSG gene conversion (VSG GC). Switch reactions that could not be assigned in these 
categories are indicated as “unknown”. The graph shows the means of triplicate data, with the 95 % 
confidence intervals indicated by the error bars. 
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3.5 Generation of the RAD51-6 gene disruption 
mutants 
3.5.1 Design of the RAD51-6 knockout constructs 
The constructs for generating RAD51-6 disruption mutants were of the same design as the 
RAD51-4 knockout constructs (Section 3.2). In this case, recombination on the LHF and 
RHF targeting regions of the RAD51-6 ORF, resulted in the deletion of 790 bp of the ORF 
which was replaced with the BSD and PUR antibiotic cassettes (see Figure 3-22). The 
nucleotide sequence of the RAD51-6 ORF and the primer binding sites are shown in 
Appendix 2. The LHF of RAD51-6 was PCR-amplified using primers RECA2 StartORF 
For and RECA2 StartORF Rev. The RHF of RAD51-6 was PCR-amplified using primers 
RECA2  EndORF For and RECA2 EndORF Rev, see Materials and Methods, Section 2.4.1, 
Table 2-1. These PCR-amplified products, of 290 bp and 354 bp respectively, were cloned 
into XbaI and XhoI digested pBluescript KS (Stratagene) using the same strategy as for the 
RAD51-4 knockout constructs. The BSD and PUR antibiotic resistance cassettes were 
ligated between the LHF and RHF of RAD51-6 having previously been PCR-amplified and 
cloned into pCR®2.1 (see Section 2.4.7). Once the insertion and correct orientation of the 
resistance cassettes between the RAD51-6 LHF and RHF were confirmed by restriction 
mapping and sequencing, the resulting constructs were called ∆RAD51-6::BSD and 
∆RAD51-6::PUR.  
ATG TGARAD51-6 ORF
790 bp 354 bp290 bp
RHFLHF Antibiotic Resistance Cassetteβα IR Actin IR
Eco
RV/N
ruI
Eco
RV/N
ruI
Xho
I
Xba
I
240 bp 400 bpBSD: 400 bp / PUR: 650 bp
 
Figure 3-22: RAD51-6 gene disruption construct and gene disruption strategy.  
LHF: Left hand targeting flank which has homology to the 5’ region of the RAD51-6 ORF. RHF: Right hand 
targeting flank which had homology to the 3’ region of the RAD51-6 ORF. The 5’ targeting flank (LHF) was 
approximately 290 bp and the 3’ targeting flank (RHF) was 354 bp. The antibiotic cassettes have βα tubulin 
intergenic region (βα IR) and actin intergenic region (Actin IR) processing signals. The total length of the 
ORF for RAD51-6 is 1434 bp, and the size of the individual components (in bp), restriction sites used in the 
cloning and primer binding sites used to confirm the generation of the mutants are indicated. 
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3.5.2 Generating the RAD51-6 mutant cell lines 
The ∆RAD51-6::BSD and ∆RAD51-6::PUR constructs were linearised using the restriction 
enzymes XbaI and XhoI. The DNA was phenol/chloroform extracted and ethanol 
precipitated. Two transformations using constructs ∆RAD51-6::BSD were carried out to 
generate two independent RAD51-6 heterozygous mutants, named X+/- and Y+/-. A total 
of 5 x 107 T. brucei bloodstream stage 3174.2 cells were transformed by electroporation 
with approximately 5 µg of the digested ∆RAD51-6::BSD construct. The cells were 
incubated at 37 oC for 24 hours in non-selective HMI-9. After the recovery period, 5 x 106 
cells were diluted in 36 ml of selective HMI-9 and plated over a 24 well plate at 1.5 ml per 
well, i.e. approximately 2.08 x 105 cells per well. A blasticidin concentration of 2.5 µg.ml-1 
was used for selection of the heterozygous mutant cell lines. Integration of the constructs 
into the expected gene locus was confirmed by PCR using a forward primer upstream of 
the ORF (Upstream of RECA2 ORF For) and the reverse primer of the RHF (RECA2 
EndORF Rev); this data is not shown. Subsequently, to disrupt the second RAD51-6 allele, 
a second round of transformation was carried out using constructs ∆RAD51-6::PUR with 
the two independent cell lines, X+/- and Y+/-, to generate the homozygous cell lines, X -/- 
and Y -/-. The resistance marker for the second round of transformants was puromycin at a 
concentration of 0.5 µg.ml-1. The X-/- and Y-/- cell lines were then confirmed by PCR-
amplification, Southern blot, and reverse transcriptase-PCR analysis (see Section 3.6). 
3.5.3 Confirmation of RAD51-6 mutant cell lines 
3.5.3.1 Confirmation of RAD51-6 mutants by PCR 
As for RAD51-4 (see Section 3.2), PCR-amplification of the entire RAD51-6 ORF, using 
forward primers that bind upstream of the LHF (Upstream of RECA2 ORF For; see 
Material and Methods, Section 2.4.1, Table 2-1) and the reverse primer of the RHF 
(RECA2 EndORF Rev), was used to analyse the putative RAD51-6 heterozygous (+/-) and 
homozygous mutants (-/-) T. brucei strain 3174.2. Figure 3-22 shows the primer binding 
sites and Figure 3-23 show the PCR products obtained from this PCR amplification, using 
Taq polymerase and genomic DNA as template from the wildtype (wt) 3174.2, the two 
RAD51-6 +/- and two RAD51-6 -/- cell lines. One product of the size expected for the 
intact RAD51-6 ORF was amplified (1435 bp) from wildtype genomic DNA. From each of 
the RAD51-6 +/- mutants, two products were amplified: one corresponded to the wildtype 
allele and the other to the size expected of the BSD-disrupted allele following integration 
of the antibiotic resistance cassettes into the ORF. The ∆RAD51-6::BSD construct is 
approximately 350 bp larger than the deleted fragment of the RAD51-6 ORF and the 
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resulting band is 1785 bp in length. From the two independent rad51-6 -/- mutants, no 
wildtype PCR product was amplified and the two larger products are consistent with 
integration of both antibiotic cassettes, disrupting both alleles. The ∆RAD51-6::PUR 
construct is 550 bp larger than the deleted fragment of the RAD51-6 ORF and the resulting 
band is 1985 bp in length. 
 
Figure 3-23: Analysis of the RAD51-6 gene disruption by PCR-amplification. 
An agarose gel separation of the PCR products generated by PCR amplification of the RAD51-6 locus using 
the forward primer: Upstream of RECA ORF For and reverse primer: RECA2 EndORF Rev is shown. PCR 
reaction were performed on genomic DNA from wildtype (wt) 3174.2 T. brucei cells, for two independent 
putative RAD51-6 heterozygous mutants (X+/- and Y+/-) and two putative rad51-6 homozygous mutants (X-
/- and Y-/-). The DNA fragments of the size expected from the wt genes or from alleles disrupted by 
integration of the BSD resistance cassette (∆RAD51-6::BSD) or the PUR resistance cassette (∆RAD51-
6::PUR) are indicated, as are the size markers. 
3.5.3.2 Confirmation of RAD51-6 mutants by Southern blot 
analysis 
Southern blot analysis was next carried out to confirm the PCR prediction of the generation 
of RAD51-6 mutant cell lines (Materials and Methods, Section 2.5). The genomic DNA 
from each of the cell lines was extracted and digested with NdeI. This was then separated 
on a 0.8 % agarose gel and transferred to a nylon membrane, which was probed with the 
LHF of the RAD51-6 ORF. The probe was made by PCR-amplifying the LHF using the 
primers RECA2 StartORF For and RECA2 StartORF Rev. The resulting PCR-product was 
then gel extracted, and labelled using the Gene Images CDP-Star Detection Module from 
Amersham. 
Figure 3-24A shows the results of the Southern blot analysis. In wildtype cells, two 
products of ~1100 bp and ~1900 bp were obtained. It was predicted by sequence analysis 
that digestion with NdeI should generate one band of 3041 bp, (see Figure 3-24B). It is 
therefore possible that an allelic difference between the sequence TREU927 genomic DNA 
and Lister 427 genomic DNA used here resulted in the presence of an NdeI site. In the 
putative heterozygous mutants three hybridizing bands were obtained: two corresponded to 
the fragment observed in the wildtype cells (~1.1 kbp and ~1.9 kbp) and the other was of a 
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size consistent with the BSD-disrupted allele following integration of the RAD51-6::BSD 
construct into the RAD51-6 ORF (3291 bp). In the putative homozygous mutants, both 
bands seen in the wildtype genomic DNA were absent and replaced with two larger 
fragments that are consistent in size with integration of both antibiotic cassettes, disrupting 
both RAD51-6 alleles (RAD51-6::BSD: 3291 bp and RAD51-6::PUR: 3591 bp).  
 
Figure 3-24: Analysis of RAD51-6 gene disruption by Southern blot analysis.  
Figure 3-24A: Southern blot showing NdeI-digested genomic DNA and probed with the LHF of the RAD51-
6 ORF, see Figure 3-22. The extracted genomic DNA from wildtype (wt) 3174.2 T. brucei cells, from the 
two independent putative heterozygous mutants (X+/- and Y+/-) and from the two independent putative 
homozygous mutants (X-/- and Y-/-) was digested with NdeI, and separated on a 0.8 % agarose gel. The 
DNA was then transferred to a nylon membrane and probed with the LHF of the RAD51-6 ORF. The DNA 
fragments of the size expected from the wt genes or from alleles disrupted by integration of the BSD 
resistance cassette (∆RAD51-6::BSD) or the PUR resistance cassette (∆RAD51-6::PUR) are indicated, as are 
the size markers. Figure 3-24B: shows the predicted locations of NdeI restriction enzyme sites around the 
RAD51-6 ORF of the T. brucei strain TRUE927, predicted by sequence analysis (GeneDB). 
3.5.3.3 Confirmation of RAD51-6 mutants by RT-PCR 
To confirm that mRNA of RAD51-6 was not transcribed in the putative rad51-6 -/- 
mutants, RT-PCR amplification was carried. Briefly, the total RNA was extracted from wt, 
RAD51-6 +/-, and rad51-6 -/- cells and converted into cDNA using random primers and 
reverse transcriptase (RT) enzyme (see Materials and Methods, Section 2.3). This cDNA 
was then used as template in the PCR reactions that amplified the entire RAD51-6 ORF, 
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using a forward primer that binds to the LHF (RecA2 StartORF For) and reverse primers 
that bind to the RHF (RecA2 EndORF Rev).  
Figure 3-25 shows the PCR fragments amplified from the cDNA. From wildtype and 
RAD51-6 +/- cell lines, one product of the size expected for the RAD51-6 ORF was 
amplified from the cDNA (1435 bp). From the rad51-6 -/- cells, no RAD51-6 mRNA was 
detected. DNA polymerase I RT-PCR positive controls confirmed that cDNA was present 
in the -/- cell samples, while RT- control confirmed that the PCR product generated from 
the cDNA and not from the contaminated genomic DNA.  
 
Figure 3-25: Analysis of the expression of the RAD51-6 mRNA in the mutant cell lines by RT-PCR 
amplification.  
Using the reverse transcriptase (RT) enzyme, cDNA was generated from mRNA extracted from the wildtype 
(wt) 3174.2 T. brucei cells, from the two independent putative RAD51-6 heterozygous mutants (X+/- and 
Y+/-) and from the two independent putative rad51-6 homozygous mutants (X-/- and Y-/-). This cDNA was 
used as template in the PCR reaction. PCR amplification was attempted using the forward primer (RECA2 
StartORF For) and reverse primer (RECA2 EndORF Rev). The PCR products were then separated on a 1.0 % 
gel. As a positive control the DNA polymerase I ORF (DNA PolI) was amplified from the cDNA of all the 
mutant cell lines. RT + and - indicates the presence of RT enzyme (+) and the absence of RT enzyme (-). 
3.6 Generation of RAD51-6 re-expressor cell lines 
Having confirmed the generation of the rad51-6 -/- mutants, it was necessary to re-express 
the RAD51-6 gene product in these cell lines, in order to see if any phenotypes that arose 
were due to RAD51-6 gene disruption (see Section 3.7) and not a secondary mutation. This 
was carried out using the same method to generate the RAD51-4 re-expressor (see Section 
3.3). The ORF of RAD51-6 was PCR amplified using RECA2 REX primers, (see Materials 
and Methods, Section 2.4.1, Table 2-1) and cloned using the restriction sites EcoRV, into 
pRM481 vector. As mentioned in Section 3.3 above, this cloning placed the RAD51-6 ORF 
downstream of the phleomycin resistance cassette (BLE) and actin intergenic region and 
upstream of the αβ intergenic region in the pRM481 vector, (βα-BLE-Act-RAD51-6-αβ). 
This construct was digested with NotI and ApaI and transformed into the rad51-6 -/- 
mutant cell lines. Then the cells were allowed to recover for 24 hours in non-selective 
HMI-9 media and were plated on 2.5 µg.ml-1 of phleomycin (Calbiochem).The flanking 
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target βα and αβ regions allows integration of the RAD51-6 and phleomycin resistance 
cassette by recombination into the tubulin locus with the removal of the α tubulin gene and 
generation of the RAD51-6 re-expressor cell lines (-/-/+; see Figure 3-26). 
β β
βα IR αβ IR
βα IR αβ IRα
BLE Act IR RAD51-6 ORF
NotI ApaI
240 bp 400 bp 400 bp 1435 bp 330 bp
1329 bp 1356 bp 1329 bp
βα tubulin array
EcoR
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Figure 3-26: Strategy for re-expression of the RAD51-6 by recombination into the βα tubulin array. 
The ORF of RAD51-6 was cloned into the restriction site EcoRV of the pRM481 (top part of the diagram). 
NotI and ApaI digestion liberates the construct which was then transformed into the mutant cell lines and the 
integration of the RAD51-6 ORF into the βα tubulin array. 
3.6.1 Confirmation of the RAD51-6 re-expressor cell lines 
by RT-PCR 
RT-PCR-amplification analysis, using the primers that bind to the RAD51-6 LHF and RHF 
(RECA2 StartORF For and RECA2 EndORF Rev), was used to detect cDNA in the 
putative RAD51-6 -/-/+ cell lines (see Material and Methods, Section 2.3). The PCR-
amplification products are shown in Figure 3-27. One product of the size expected was 
amplified from the cDNA from the wildtype, RAD51-6 X+/- and RAD51-6 re-expressor 
(X-/-/+ and Y-/-/+) cell lines. From the rad51-6 X-/- cDNA, no product was detected. 
DNA polymerase I was amplified from the cDNA of all the cell lines, confirming that the 
extracted RNA was converted to cDNA. The RT negative control had no RT enzyme (-) in 
the reaction and confirmed that the PCR products generated arose from the cDNA and not 
from contaminating genomic DNA. 
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Figure 3-27: Analysis of the expression of the RAD51-6 mRNA in the RAD51-6 re-expressor cell lines 
by RT-PCR amplification.  
Using the reverse transcriptase (RT) enzyme, cDNA was generated from mRNA extracted from the wildtype 
(wt) 3174.2 T. brucei cells, from the one putative RAD51-6  heterozygous mutants (X+/-), from one putative 
rad51-6 homozygous mutants (X-/-) and from the two independently generated RAD51-6  re-expressor cell 
lines. This cDNA was used as template in the PCR reaction. PCR amplification was attempted using the 
forward primer (RECA2StartORF For) and reverse primer (RECA2EndORF Rev). The PCR products were 
then separated on a 1.0 % gel. As a positive control the DNA polymerase I ORF (DNA PolI) was amplified 
from the cDNA of all the mutant cell lines. RT + and - indicates the presence of RT enzyme (+) and the 
absence of RT enzyme (-). 
3.6.2 Confirmation of the RAD51-6 re-expressors by 
Southern analysis 
Southern analysis was carried out as a further test, to confirm the generation of RAD51-6-/-
/+ cell lines (Materials and Methods, Section 2.5). The genomic DNA from the wildtype, 
RAD51-6 +/-, rad51-6 -/- and RAD51-6 -/-/+ cell lines was extracted and digested with 
BclI. This was then separated on a 0.8 % agarose gel and transferred on to a nylon 
membrane. The membrane was probed with labelled DNA derived from the middle of the 
RAD51-6 ORF, which was made by PCR-amplification using the primers PTP-RAD51-6 
For and RAD51-6 middle Rev (see Materials & Methods, Section 2.4.1, Table 2-1), this 
product was then gel extracted, and labelled using the Gene Images CDP-Star Detection 
Module (Amersham). 
Figure 3-28A shows the results of this Southern blot analysis. In wildtype and RAD51-6 
+/- cells, one fragment of approximately 4000 bp was observed, consistent with the 
prediction by sequence analysis, as the endogenous RAD51-6 has two BclI sites either side 
of it (see Figure 3-28B). In the rad51-6 -/- mutants, there were no bands visible, although 
DNA was loaded into the gel, as shown by the UV picture of the gel before transfer to the 
membrane. In the re-expressor cell lines, the RAD51-6 ORF was integrated into the βα 
tubulin array, resulting in a different restriction pattern: BclI digests the array in the α 
tubulin gene, and resulted in a 7430 bp fragment which is larger than the endogenous 
RAD51-6 band (see Figure 3-28C), 
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Figure 3-28: Analysis of the generation of the RAD51-6 re-expressor cell lines by Southern blot. 
Figure 3-28A: Southern blot showing BclI-digested genomic DNA and probed with the middle of the 
RAD51-6 ORF. The extracted genomic DNA from wildtype (wt) 3174.2 T. brucei cells, from the two 
independent putative heterozygous mutants (X+/- and Y+/-), from the two independent putative homozygous 
mutants (X-/- and Y-/-) and from the two independent putative RAD51-6 re-expressor (X-/-/+ and Y-/-/+) 
was digested with BclI, and separated on a 0.8 % agarose gel. The DNA was then transferred to a nylon 
membrane and probed with the middle of the RAD51-6 ORF. The DNA fragments of the size expected from 
the wt gene, from alleles disrupted by integration of the BSD resistance cassette (∆RAD51-6::BSD) and 
integration of re-expressor RAD51-6 into the tubulin array (RAD51-6:βα) are indicated, as are the size 
markers. Figure 3-28B: shows the locations of BclI restriction enzyme sites up and down stream of the 
RAD51-6 ORF. Figure 3-28C: shows the locations of BclI site in the α-tubulin array predicted by sequence 
analysis. 
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3.7 Phenotypic analysis of RAD51-6 mutants and 
re-expressor cell lines 
Phenotypic analysis of the RAD51-6 mutant cell lines was carried out in a similar manner 
to that of the RAD51-4 mutant cell lines. To avoid repetition, see the corresponding 
Sections above (Section 3.4) and associated Materials and Methods for description of 
experimental details (Chapter 2) and Appendices for statistical analysis (Appendix 3). 
3.7.1 Analysis of in vitro growth rate of RAD51-6 mutant 
cell lines 
To determine if mutation of RAD51-6 had any effect on the growth of T. brucei, population 
doubling time were measured, as described in Section 3.4.1. Briefly, to examine growth 
rates, each cell line was inoculated at 5 x 104 cells per ml into HMI-9 medium and cell 
densities were counted at fixed time points. The results of this are plotted on a semi-
logarithmic graph in Figure 3-29 and the population doubling times shown in Table 3-10. 
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Figure 3-29: Analysis of growth of RAD51-6 mutant cell lines in vitro.  
The semi-logarithmic of cell densities were plotted against fixed time points, (24 h, 48 h, and 72 h) is shown. 
Wildtype 3174.2 strain (wt) is compared with two independent RAD51-6 heterozygous mutants (X+/-, Y+/-), 
rad51-6 homozygous mutants (X-/-, Y-/-) and RAD51-6 re-expressor cell lines (X-/-/+, Y-/-/+). The graph 
shows the means of triplicate data, with the 95 % confidence intervals indicated. 
 
Rachel Dobson, 2009   Chapter 3, 110 
Table 3-10: in vitro doubling times for RAD51-6 mutant cell lines.  
The population doubling time for the two independently generated RAD51-6 heterozygote (X+/-, Y+/-), 
rad51-6 homozygous mutants (X-/-, Y-/-) and RAD51-6 re-expressor cell lines (X-/-/+, Y-/-/+) are compared 
with the doubling time for wildtype strain 3174.2 (wt). The data are the means of the triplicate experiments 
(in hours) with the 95 % confidence intervals indicated (in brackets).  
7.01      
(+/-0.20)
6.73      
(+/-0.18)
9.72      
(+/-0.50)
9.98      
(+/-0.63)
6.95      
(+/-0.18)
6.90      
(+/-0.03)
6.93      
(+/-0.05)
Y-/-/+X -/-/+Y+/-X -/-Y+/-X +/-wt 
 
These data show that rad51-6 -/- mutants had a reduced growth rate, with each 
independent mutant X-/- and Y-/-, displaying a decrease in growth of 25.3 % and 27.5 % 
compared to the wildtype at the 48 h time point (Figure 3-29). This was confirmed by 
increased population doubling times compared with the wildtype and RAD51-6 +/- 
mutants. rad51-6 X-/- have a population doubling time of 9.98 h (+/- 0.63) and rad51-6 Y-
/- have a population doubling time of 9.72 h (+/- 0.50), compared with the wildtype’s 6.93 
h (+/- 0.05); see Table 3-10. These results are significantly different as evaluated by the 
Student’s t-tests for the population doubling time (Table 3-11; all other pair-wise statistical 
comparisons are shown in Appendix 3, Table 8). Re-expression of the RAD51-6 in each of 
the homozygous mutant cell lines enabled the cells to recover from the growth deficiency. 
This confirmed that lack of RAD51-6 was responsible for the slow growth of the cell lines. 
Interestingly, the rad51-6 -/- mutant was also slower growing than the rad51-4 -/- mutants; 
this is discussed in Chapter 4 (Section 4.2). 
Table 3-11: Statistical analysis of the in vitro population doubling times for RAD51-6 mutants. 
Unpaired, two-tailed Student’s t-tests were carried out to compare the mean of the triplicate doubling time 
results for the two independently generated RAD51-6 heterozygote (X+/-, Y+/-) and rad51-6 homozygous 
mutants (X-/-, Y-/-) and RAD51-6 re-expressor cell lines (X-/-/+, Y-/-/+) against the wildtype Significant 
difference between the means is shown by a p-value of p ≤ 0.05; Not significantly different results are shown 
as “-“. [NA is not applicable.]  
--0.00040.0007--NAwt 
Y-/-/+X-/-/+Y-/-X-/-Y+/-X+/-wt 
 
3.7.2 Analysis of DNA damage sensitivity of RAD51-6 
mutant cell lines 
To analyse if RAD51-6 mutation lead to increased DNA-damage sensitivity, again two 
different assays were carried out: clonal survival in the presence of DNA-damaging agents, 
and measuring the metabolic capacity through absorbance of resazurin to determine the 
IC50 values for each cell line exposed to the DNA damaging agents, MMS and phleomycin. 
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3.7.2.1  Clonal Survival of RAD51-6 mutant cell lines 
As for the RAD51-4 mutant cell lines (see Section 3.4.2.1), the clonal survival assay 
involved diluting 2 x 106 cells per ml to a concentration of 1 cell per well over a 96 well 
plate and determining the number of wells that yield growing populations in the presence 
of varying concentrations of MMS (%) and phleomycin (µg.ml-1). Figure 3-30 shows the 
clonal survival of rad51-6 -/- mutants compared with that of the wildtype, RAD51-6 +/- 
and RAD51-6 -/-/+ cell lines when treated with 0.0001 %, 0.0002 %, 0.0003 %, and 0.0004 
% of MMS. The data is represented as a percentage of growth when treated with MMS 
compared to growth its absence. 
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Figure 3-30: Clonal survival of RAD51-6 mutants in vitro when treated with methyl methanesulfonate 
(MMS). 
Cell survival is shown as a percentage of clonal growth when treated with MMS compared to growth in the 
absence of MMS. Each cell line wildtype 3174.2 (wt), two independent RAD51-6 heterozygous mutants 
(X+/-, Y+/-), rad51-6 homozygous mutants (X-/-, Y-/-) and re-expressor cell lines (X-/-/+, Y-/-/+) was 
treated with increasing concentration of MMS (0.0001 %, 0.0002 %, 0.0003 %, 0.0004 %). The graph shows 
the means of triplicate data, with 95 % confidence intervals indicated by error bars. 
With increasing concentrations of MMS, there was a clear decrease in survival of each 
rad51-6 -/- mutant, X-/- and Y-/-, compared with all other cell lines. At a MMS 
concentration of 0.0002 %, for instance, wildtype survival was 74.4 % (+/- 17.6) relative to 
the untreated cells, while the rad51-6 X-/- displayed 11.5 % (+/- 1.1) survival and rad51-6 
Y-/- displayed 12.5 % (+/- 3.3) survival. The results of unpaired, two tailed Student’s t-
tests for clonal survival at this MMS concentration is shown in Table 3-12, confirming that 
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clonal survival of each rad51-6 -/- mutant is significantly reduced compared with the 
wildtype cells.  
Table 3-12: Statistical analysis of the clonal survival of RAD51-6 mutants when treated with 0.0003 % 
methyl methanesulfonate (MMS). 
Unpaired two-tailed Student’s t-tests were carried out to compare the mean of the triplicate clonal survival 
results for the cell lines against the wildtype. Significant difference between the results is shown by a p-value 
of p ≤ 0.05, while not significantly different results are shown as “-“. [NA is not applicable] Each cell line is 
indicated as follows: wildtype strain 3174.2 (wt), two independent RAD51-6 heterozygous mutants (X+/-, 
Y+/-), rad51-6 homozygous mutants (X-/-, Y-/-) and RAD51-6 re-expressor cell lines (X-/-/+, Y-/-/+). 
--0.01320.0043--NAwt 
Y-/-/+X-/-/+Y-/-X-/-Y+/-X+/-wt 
 
Student’s t-tests were also carried out to compare the mean survival rate if all the cell lines 
against each other at all different concentrations of MMS, and these data are shown in 
Appendix 3, Table 9. These results show that with increasing concentration of MMS, there 
was a significant reduction of clonal survival of the rad51-6 -/- mutants compared with 
wildtype and RAD51-6 +/- cells. In addition, re-expression of the functional RAD51-6 in 
each of homozygous mutant cell line caused survival to increase.  
Clonal survival data generated following treatment with four concentrations of phleomycin 
0.025 µg.ml-1, 0.05 µg.ml-1, 0.075 µg.ml-1, and 0.1 µg.ml-1 are shown in Figure 3-31.  
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Figure 3-31: Clonal survival of RAD51-6 mutants in vitro when treated with phleomycin. 
Cell survival is shown as a percentage of clonal growth when treated with phleomycin compared to growth in 
the absence of drug. Each cell line, wildtype 3174.2 (wt), two independent RAD51-6 heterozygous mutants 
(X+/-, Y+/-), and rad51-6 homozygous mutants (X-/-, Y-/-) was treated with increasing concentration of 
phleomycin (0.025 µg.ml-1, 0.05 µg.ml-1, 0.075 µg.ml-1, 0.1 µg.ml-1). The graph shows the means of triplicate 
data, with 95 % confidence intervals indicated by error bars. 
As for the MMS, increasing concentrations of phleomycin from 0.025 µg.ml-1 to 0.075 
µg.ml-1, caused a clear decrease in survival of each rad51-6 cell line, X-/- and Y-/-, 
compared with the other cell lines. At a phleomycin concentration of 0.025 µg.ml-1, 
wildtype survival was 87.6 % (+/- 16.0) compared with 1.9 % (+/- 23.2) and 4.5 % (+/- 
20.0) for rad51-6 X-/- and Y-/- respectively. The statistical significance of this finding is 
shown in Table 3-13.  
Table 3-13: Statistical analysis of the clonal survival for RAD51-6 mutants when treated with 0.025 
µg.ml-1 phleomycin. 
Unpaired, two-tailed Student’s t-tests were carried out to compare the mean of the triplicate clonal survival 
results for the cell lines against the wildtype, a significant difference between the results is shown by a p-
value of p ≤ 0.05, while a non-significantly different results are shown as “-“. [NA is not applicable.] Each 
cell line is indicated as follows: wildtype 3174.2 (wt), two independent RAD51-6 heterozygous mutants 
(X+/-, Y+/-), and rad51-6 homozygous mutants (X-/-, Y-/-). 
0.00030.0002--NAwt 
Y-/-X-/-Y+/-X+/-wt 
 
Unpaired, two-tailed Student’s t-tests to compare the survival rates of all cell lines relative 
to each other, at all the different concentrations of phleomycin are shown in Appendix 3, 
Rachel Dobson, 2009   Chapter 3, 114 
Table 10. At a concentration of 0.05 µg.ml-1 of phleomycin, there was also a significant 
decrease of clonal survival of the rad51-6 -/- mutant compared with wildtype and RAD51-
6 +/- mutants. However, at the higher concentrations of 0.075 µg.ml-1 and 0.1 µg.ml-1, this 
analysis was not possible, as the rad51-6 -/- mutants were killed. Re-expressor cell lines 
were not analysed, as functional add-back of the RAD51-6 gene was selected by 
phleomycin resistance (Section 3.6). 
These data show that the rad51-6 -/- mutants, like rad51-4 -/- mutants, are more sensitive 
to both DNA-damaging agents, MMS and phleomycin, than the wildtype and heterozygous 
cell lines.  
3.7.2.2  IC50 values of MMS and Phleomycin for RAD51-6 mutant 
cell lines 
Determination of the IC50 values of MMS and phleomycin of the RAD51-6 mutant cell 
lines was conducted by measuring conversion of resazurin to resorufin as described as for 
the RAD51-4 mutant cell lines in Section 3.4.2.2. The same starting concentrations of cells, 
titration of MMS and phleomycin, and growth and measurement by spectrometry were 
performed (see Materials and Methods, Section 2.8.2.2). 
Figure 3-32 shows the calculated mean IC50 values for MMS of wildtype, RAD51-6 +/-, 
rad51-6 -/- and RAD51-6 -/-/+ cell lines. The wildtype cells mean IC50 value was 0.000406 
% (+/- 0.000046), which is 2.5 – 4.0 fold higher than that of the two rad51-6 -/- mutants: 
0.000143 % (+/- 0.000017) and 0.000119 % (+/- 0.000015) for X-/- and Y-/-, respectively. 
In contrast, each RAD51-6 +/- mutant’s IC50 value was equivalent to the wildtype cells.  
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Figure 3-32: IC50 values of MMS for RAD51-6 mutant cell lines 
Resazurin was used as an indicator of growth and IC50 values were calculated for each cell line. Wildtype 
3174.2 (wt), two independent RAD51-6 heterozygous mutants (X+/-, Y+/-), two independent rad51-6 
homozygous mutants (X-/-, Y-/-) and two independent RAD51-6 re-expressor cell lines (X-/-/+, Y-/-/+) were 
treated with serial dilutions of MMS. The graph shows the mean IC50 values derivative from the triplicate 
data, with the 95 % confidence intervals indicated by the error bars. 
The reduction of the IC50 value of the rad51-6 -/- mutants compared with the wildtype 
cells was significantly different, based on the unpaired, two-tailed Student’s t-test 
comparisons of the data (Table 3-14). Student’s t-tests of all other pair-wise comparisons 
are shown in Appendix 3, Table 11. 
Perhaps surprisingly, re-expression of functional RAD51-6 in the RAD51-6 -/-/+ cell lines 
appeared not to revert the MMS sensitivity to equivalent levels of resistance as found in 
the wildtype or RAD51-6 +/- cells. The reason for this is unclear, in particular as the same 
findings were not the case in the clonal survival assay, see Figure 3-30. 
Table 3-14: Statistical analysis of the IC50 values for MMS of the RAD51-6 mutants. 
Student’s t-tests were carried out to compare the mean of the triplicate IC50 values for the cell lines against 
the wildtype. A significant difference between the results is shown by a p-value of p ≤ 0.05 and not 
significantly different results are shown as “-“. [NA is not applicable.] Each cell line is indicated as follows, 
wildtype strain 3174.2 (wt), two independent RAD51-6 heterozygous mutants (X+/-, Y+/-), two independent 
rad51-6 homozygous mutants (X-/-, Y-/-) and two independent RAD51-6 re-expressors (X-/-/+, Y-/-/+). 
--0.00100.0048--NAwt 
Y-/-/+X-/-/+Y-/-X-/-Y+/-X+/-wt
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Figure 3-33 shows the mean IC50 values calculated for phleomycin. Here, the wildtype 
cells display a mean IC50 value of 0.214 µg.ml-1 (+/- 0.021) and was approximately four 
fold higher than that of rad51-6 -/- mutants whose mean IC50 values were 0.046 µg.ml-1 
(+/- 0.007) and 0.051 µg.ml-1 (+/- 0.004) for X-/- and Y-/- respectively.  
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Figure 3-33: IC50 values of phleomycin for RAD51-6 cell lines 
Resazurin blue was used as an indicator of growth and IC50 values were calculated for each cell line. 
Wildtype 3174.2 (wt), two independent RAD51-6 heterozygous mutants (X+/-, Y+/-), two independent 
rad51-6 homozygous mutants (X-/-, Y-/-) and two independent RAD51-6 re-expressor cell lines (X-/-/+, Y-/-
/+) were treated with serial dilutions of phleomycin. The graph shows the means of the triplicate data, with 
the 95 % confidence intervals indicated by the error bars. 
Student’s t-tests (Table 3-15) confirm that the reduction of the IC50 value for phleomycin 
of the wildtype cells compared with the rad51-6 -/- mutants was significant. In contrast, no 
difference in phleomycin sensitivity was found for the RAD51-6 +/- cells relative to the 
wildtype cells. The complete statistical analysis of all pair-wise comparisons can be found 
in Appendix 3, Table 12. 
Table 3-15: Statistical analysis of the IC50 values for phleomycin of the RAD51-6 mutants. 
Student’s t-tests were carried out to compare the mean of the triplicate IC50 values for the cell lines against 
the wildtype. A significant difference between the results is shown by a p-value of p ≤ 0.05 and not 
significantly different results are shown as “-“. [NA is not applicable.] Each cell line is described:  wildtype 
strain 3174.2 (wt), two independent RAD51-6 heterozygous mutants (X+/-, Y+/-), and two independent 
rad51-6 homozygous mutants (X-/-, Y-/-). 
0.01080.0060--NAwt 
Y-/-X-/-Y+/-X+/-wt
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These results largely confirm the findings of the clonal survival assays and show that 
survival in the presence of two DNA-damaging agents is reduced for rad51-6 -/- mutants 
relative to wildtype cells and RAD51+/- mutants. Most likely, the lack of functional 
RAD51-6 in the cell causes an impairment in the parasite’s ability to repair the DNA 
damage. 
3.7.3 Analysis of recombination efficiency of RAD51-6 
mutant cell lines 
To assay for recombination efficiency, a transformation assay was used, following the 
procedure described for RAD51-4 mutants, see Section 3.4.3. The results of these 
experiments are shown in Figure 3-34.  
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Figure 3-34: Transformation assay for the RAD51-6 mutant cell lines. 
To assay for recombination rate, a transformation efficiency assay was used. Each cell line is indicated as 
follows:  Wildtype strain 3174.2 (wt), two independent RAD51-6 heterozygous mutants (X+/-, Y+/-), and 
two independent rad51-6 homozygous mutants (X-/-, Y-/-). The values plotted are mean numbers of 
phleomycin resistant transformants per 106 cells transformed. These experiments were done in triplicate with 
the same linearised DNA, and error bars of the 95 % confidence intervals are indicated. 
These data indicate that the rad51-6 -/- mutants had a defect in transformation efficiency 
compared with the wildtype and RAD51-6 +/- mutant cell lines. The transformation 
efficiency for the wildtype cells was 1.2 x 10-6 (+/- 3.4 x 10-7) whereas the transformation 
efficiencies of the rad51-6 X-/- and Y-/- were 3.3 x 10-7 (+/- 7.3 x 10-8) and 2.4 x 10-7 (+/- 
1.8 x 10-7) respectively. These results were confirmed to be significantly different by 
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unpaired, two-tailed Student’s t-tests (Table 3-16, and Appendix 3, Table 13). In contrast, 
the RAD51-6 +/- mutants were as efficient as the wildtype cells in transformation.  
Table 3-16: Statistical analysis of the transformation efficiency of RAD51-6 mutant cell lines. 
Unpaired, two-tailed Student’s t-tests were carried out to compare the mean of the triplicate transformation 
efficiency results for the wildtype cells relative to the other cell lines. A significant difference between the 
results is shown by a p-value of p ≤ 0.05 and not significantly different results are shown as “-“. [NA is not 
applicable.] Each cell line is described:  wildtype strain 3174.2 (wt), two independent RAD51-6 heterozygous 
mutants (X+/-, Y+/-), and two independent rad51-6 homozygous mutants (X-/-, Y-/-). 
0.01480.0220--NAwt
Y-/-X-/-Y+/-X+/-wt
 
This analysis has shown that mutation of RAD51-6 causes a decrease in the ability of T. 
brucei to undergo homologous recombination, a finding that is similar to that obtained for 
the rad51-4 -/- mutants, see Section 3.4.3. It is also comparable with the finding for rad51, 
rad51-3, and rad51-5 homozygous mutant cell lines (McCulloch & Barry, 1999; Proudfoot 
& McCulloch, 2005a). As a result, therefore, it appears that all four T. brucei RAD51 
paralogues act in HR. 
3.7.4 Analysis of RAD51 foci formation in RAD51-6 
mutant cell lines 
In Section 3.4.4, it was demonstrated that DNA damage by phleomycin treatment of T. 
brucei causes a re-localisation of RAD51 into distinct foci, and that RAD51-3, RAD51-5 
and BRCA2 all contribute to the formation or stabilisation of RAD51 foci (see Chapter 4, 
Section 4.5 of this thesis, Hartley & McCulloch, 2008, Proudfoot & McCulloch, 2005b). 
To examine if RAD51-6 also acts in the RAD51 relocalisation, immuno-fluorescence was 
carried out on fixed phleomycin treated and control non-treated cells using rabbit anti-
RAD51 antiserum, as described in Section 3.4.4 and Materials & Methods, Section 2.9. In 
this case a more limited range of phleomycin concentrations were examined: growth of 
RAD51-6 +/-, and rad51-6 -/- for 18 hours in either 0.25 µg.ml-1 or 1.0 µg.ml-1 phleomycin. 
Wildtype data are those generated previously for comparison with the RAD51-4 cell lines 
(Section 3.4.4). The RAD51-6 +/- cell lines displayed a similar pattern to wildtype, with 
70-75 % of cells forming discernable RAD51 foci at 1.0 µg.ml-1, compared with 78 % of 
the wildtype cells.  
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Figure 3-35: RAD51 sub-nuclear foci in rad51-6 -/- mutant. 
The first row of pictures shows an example of a non-treated rad51-6 -/- cell: no distinct RAD51 foci are 
detected. The second row is an example of a rad51-6 -/- cell treated with 1.0 µg.ml-1 phleomycin for 18 
hours. RAD51 was imaged by indirect immuno-fluorescence (FITC) (first column), the DNA was stained 
with DAPI (second column), FITC and DAPI were merged (third column), the cells are visualised by DIC 
(fourth column) and all the images were merged (fifth column). 
 
 
Table 3-17: Percentage of rad51-6 -/- mutant cells with a specific number of RAD51 foci. 
The percentage of cells with a specific number of the sub-nuclear RAD51 foci formed (0, 1, 2, 3, 4, ≥5) when 
the cell lines were treated with increasing concentrations of phleomycin, 0.25 µg.ml-1 and 1.0 µg.ml-1 is 
shown. The total indicates the number of cells counted. Wildtype strain 3174.2 (wt), two independent 
RAD51-6 heterozygous mutants (X+/-, Y+/-), and two independent rad51-6 homozygous mutants (X-/-, Y-/-) 
were analysed. 
1000.02.01.03.011.083.01.0 µg.ml-1
1000.00.00.90.91.796.60.25 µg.ml-1Y-/-
1000.00.00.03.310.386.41.0 µg.ml-1
1000.00.01.11.12.795.20.25 µg.ml-1X-/-
1006.07.012.023.022.030.01.0 µg.ml-1Y+/-
1023.92.914.728.422.527.51.0 µg.ml-1X+/-
22510.76.712.923.125.321.31.0 µg.ml-1
1005.01.09.014.043.032.00.25 µg.ml-1wt
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In the rad51-6 -/- mutants, 86-95 % of the cells did not display visible sub-nuclear RAD51 
foci when treated with phleomycin either at a concentration of 0.25 µg.ml-1 and 1.0 µg.ml-1 
(see Figure 3-36), compared with 21-32 % of wildtype cells.  This result shows that cells 
lacking RAD51-6 are severely impaired in re-localisation of RAD51 in the nucleus, or in 
the maintenance of RAD51 foci once formed. It is, indeed, possible that the very small 
number of RAD51 foci scored are artefacts of punctate staining, which is seen in the 
absence of DNA damage (see Figure 3-35, and Section 3.4.4, Figure 3-15). This supports 
the theory that RAD51 re-localisation in response to DNA damage is aided by multiple 
factors, including RAD51-6, the other RAD51 paralogues and BRCA2 (Hartley, 2008; 
Proudfoot & McCulloch, 2005a). It also appears that the rad51-6 -/- mutants are more 
severely impaired in this process than the rad51-4 -/- mutants; this is considered further in 
Chapter 4, (Section 4.5). 
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Figure 3-36: Percentage of rad51-6 -/- mutant cells with a specific number of RAD51 foci. 
The percentage of cells with a specific number of the sub-nuclear RAD51 foci formed (0, 1, 2, 3, 4, ≥5) when 
the cell lines were treated with 1.0 µg.ml-1 of phleomycin for 18 hours. Wildtype strain 3174.2 (wt), two 
independent RAD51-6 heterozygous mutants (X+/-, Y+/-), and two independent rad51-6 homozygous 
mutants (X-/-, Y-/-) are shown. 
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3.7.5 Analysis of VSG switching in RAD51-6 mutant cell 
lines 
To examine the role of RAD51-6 in VSG switching, the rad51-6 -/- mutants were 
compared with wildtype, RAD51-6 +/- and the RAD51-6 -/-/+ mutant cell lines in the VSG 
switching assay whose details are discussed in Section 3.4.5 and in Materials and Methods, 
Section 2.8.4. The results of this are shown in Figure 3-37 and Figure 3-38. 
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Figure 3-37: The mean of the VSG switching frequencies in RAD51-6 mutant cell lines. 
The graph shows the mean of the VSG switching frequencies of RAD51-6 mutant cell lines. Wildtype strain 
3174.2 (wt), two independent RAD51-6 heterozygous (X+/-, Y+/-,) two independent rad51-6 homozygous 
mutants (X-/-, Y-/-) and one RAD51-6 re-expressor (X-/-/+) are shown. The graph shows the means of 
triplicate data, with the 95 % confidence intervals indicated by the error bars. 
Analysis of the VSG switching frequencies suggests that rad51-6 -/- mutants have an 
impaired ability to undergo VSG switching as the VSG switching frequencies show a trend 
in which the rad51-6 -/- switch at a lower frequency compared with the RAD51-6 +/- cells 
from which they are derived, and compared with wildtype and re-expressor cells, see 
Figure 3-37. Unpaired two-tailed Student’s t-tests were carried out on the data, and are 
shown in Table 3-18 and in Appendix 3, Table 14. In the independent clone X, the RAD51-
6 X+/- had a VSG switching frequency of 10.7 (+/- 3.9) switched variants per 107 cells per 
generation, which is significantly different from the related rad51-6 X-/-, which had a 
VSG switching frequency of 2.7 (+/- 1.5) events per 107 cells per generation. The same 
was true for the other independent clone Y: RAD51-6 Y+/- had a VSG switching frequency 
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of 14.8 (+/- 0.1) switched variants per 107 cells per generation, which is significantly 
different from rad51-6 Y-/-, which had a VSG switching frequency of 4.9 (+/- 3.2) 
switched variants per 107 cells per generation. Table 3-18 shows that there was also a 
significant difference between the switch frequencies of the wildtype compared with the 
rad51-6 X-/- mutant and not the rad51-6 Y-/- mutant. Similar to the results for the rad51-4 
-/- mutants, the large error bars (Figure 3-37) and lack of significant difference between the 
wildtype and both independent homologous mutants (Table 3-18) may suggest that 
RAD51-6 is not involved in VSG switching.  
Table 3-18: Statistical analysis of the VSG switching frequency of RAD51-6 mutant cell lines. 
Unpaired, two-tailed Student’s t-tests were carried out to compare the mean of the triplicate VSG switching 
frequencies for the cell lines against the wildtype. A significant difference is shown by a p-value of p ≤ 0.05. 
Not significantly different results are shown as “-“. [NA is not applicable.] Wildtype strain 3174.2 (wt), two 
independent RAD51-6 heterozygous (X+/-, Y+/-,) two independent rad51-6 homozygous mutants (X-/-, Y-/-) 
and one RAD51-6 re-expressor (X-/-/+) are shown. 
--0.0328--NAwt 
X-/-/+Y-/-X-/-Y+/-X+/-wt 
 
To examine this further, a selection of recovered switched clones from each cell line were 
analysed to differentiate the switching mechanisms that occurred, as described in Section 
3.4.5 and Materials and Methods, Section 2.8.4. This analysis uses PCR amplification and 
drug sensitivity or resistance to predict the mechanism undertaken by the cells to switch 
their VSG coat. Given the involvement of RAD51-6 in recombination and repair, it might 
be predicted that the rad51-6 -/- cells would not undergo gene conversion events to switch 
their VSG, since this mechanism relies on homologous recombination. Figure 3-36 show 
the switching mechanisms in the rad51-6 -/- mutant cell lines, which demonstrates that 
these data did not fit this prediction, and expression site and VSG gene conversion 
reactions could be detected readily in both the rad51-6 -/- mutants. It is also not clear 
whether or not in situ switching becomes more predominant, given the considerable 
variation of the data. 
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Figure 3-38: Analysis of the switching mechanisms of the RAD51-6 mutant cell lines. 
The graph shows the switching mechanism of RAD51-6 mutant cell lines as a percentage of the total 
analysed. Wildtype strain 3174.2 (wt), two independent RAD51-6 heterozygous mutants (X+/-, Y+/-), two 
independent rad51-6 homozygous mutants (X-/-, Y-/-) and the RAD51-6 re-expressor (X-/-/+) are shown. 
The assay allowed differentiation of in situ transcriptional switching (in situ), expression site gene conversion 
(ES GC) and VSG gene conversion (VSG GC). Switch reactions that could not be assigned in these 
categories are indicated as “unknown”. The graph shows the means of triplicate data, with the 95 % 
confidence intervals indicated by the error bars. 
3.8 Summary 
This chapter describes the generation and confirmation of gene knockouts of the two of 
remaining unstudied RAD51 paralogues, RAD51-4 and RAD51-6, in T. brucei blood 
stream form strain 3174.2. The RAD51-4 and RAD51-6 genes were disrupted by 
integration of antibiotic resistant cassettes in both alleles of each gene. These knockouts 
were generated using a reverse genetics approach, where the gene sequencing and 
phylogeny predicted the function of the T. brucei RAD51 paralogues having a role in one 
or more HR pathways. The phenotypic analyses described here confirmed this prediction 
and showed that RAD51-4 and RAD51-6 act in the HR pathway, with the two rad51-4 -/- 
and rad51-6 -/- mutants having a decrease in transformation efficiency. RAD51-4 and 
RAD51-6 may also affect antigenic variation, since the mean VSG switching frequencies 
were decreased in the homozygous compared to the heterozygous mutant cell lines. The 
rad51-4 -/- and rad51-6 -/- mutant cell lines also had a decreased growth rate and 
increased sensitivity to the DNA damaging agents, phleomycin and MMS. This analysis 
confirmed the prediction that RAD51-4 and RAD51-6 have roles in the RAD51-dependent 
pathway as the rad51-4 -/- and rad51-6 -/- mutants had a decrease in the amount of DNA-
damage induced RAD51 foci formation. This result also confirms that the two paralogues 
Rachel Dobson, 2009   Chapter 3, 124 
interact with RAD51 either directly or indirectly. As the rad51-4 -/- and rad51-6 -/- mutant 
cell lines are viable, this supports the belief that there are other RAD51-independent 
pathways involved in the double strand break repair of T. brucei DNA. The lack of 
functional repair pathways involving the RAD51 paralogues is therefore not completely 
detrimental to the cell. 
It is interesting that the phenotype of the rad51-4 -/- mutant cell lines appear to be less 
severely compromised compared to the rad51-6 -/- mutants. This was especially true for 
the phleomycin sensitivities; where the IC50 value of the rad51-4 -/- mutants is 
approximately double that of the rad51-6 -/- mutants. This can also been seen when 
analysing the phleomycin-induced RAD51 foci formation percentages. Although the other 
phenotypic analyses are not truly comparable, the rad51-4 -/- mutant cell lines are 
apparently affected to a lesser extent in comparison to the rad51-6 -/- mutant cell lines 
when growth rate, HR rates and VSG switching frequencies are measured. 
The impairment of growth rate, homologous recombination, DNA-damage induced repair 
and VSG switching of the rad51-4 -/- and rad51-6 -/- mutants are of a similar level 
compared with the other two RAD51 paralogue mutants, rad51-3 -/- and rad51-5 -/-, 
described previously by Proudfoot & McCulloch, 2005b. Chapter 4 of this thesis describes 
a more in depth analysis of the comparisons and contrasts all four rad51 paralogue mutants 
alongside the wildtype and rad51 -/- cell lines. 
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Chapter 4. Comparing the impact 
of gene knockout of RAD51 and 
the RAD51 paralogues in T. 
brucei 
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4.1 Introduction 
The aim of this chapter was to compare the severity of the different phenotypes of RAD51 
mutant and each of the four RAD51 paralogue mutant cell lines. The rationale behind this 
was to attempt to determine if each factor contributes equally to DNA repair and 
recombination functions, and thereby ask if they act in a single or multiple pathways. To 
do this, all experiments were carried out, with the exception of the VSG switching assays, 
at the same time using the same equipment and methods. Therefore, this is a 
comprehensive re-analysis of the phenotypic data described in Chapter 3 and in Proudfoot 
& McCulloch (2005a), and allows direct comparison without the potential for experimental 
variation, due to unforeseen technical differences between experiments performed at 
different times and by different researchers.  
The generation and confirmation of rad51-3 -/- and rad51-5 -/- cell lines is described in 
Proudfoot & McCulloch (2005a), and for rad51-4 -/- and rad51-6 -/- cell lines in the 
previous Chapter 3 of this thesis. The rad51 -/- mutant was generated by Rebecca Barnes 
(unpublished). This was based on the constructs generated for the RAD51 mutation by 
McCulloch & Barry (1999), but the phleomycin resistance construct was altered to provide 
blasticidin resistance. All the homozygous mutants were generated in an equivalent 
manner, with the disruption of the ORF by constructs that target the gene using left and 
right hand flanks of the start and end of the ORF respectively (Figure 4-1).  
Antibiotic Resistance Cassetteβα IR Actin IRLHF RHF
ORF
ATG Stop
 
Figure 4-1: Diagram showing a generic construct for the generation of RAD51 and the RAD51 
paralogue mutants. 
The main ORF of RAD51 and each of the RAD51 paralogues were disrupted with an antibiotic resistance 
cassette, encoding resistance to blasticidin and puromycin. This was carried out through integration of the 
cassette by homologous recombination of targeting regions, the left hand flank (LHF) and right hand flank 
(RHF) of the gene. 
In all cases the two alleles were disrupted using the blasticidin and puromycin antibiotic 
resistance cassettes. Use of these resistance cassettes, allowed analysis of phleomycin 
sensitivities of the cell lines. These constructs are shown in Figure 4-2 indicating the 
amount of ORF sequence deleted as a result of integration of the resistance cassette. Also 
shown are the intergenic regions flanking the resistance cassettes. For the rad51 -/- mutant 
Rachel Dobson, 2009   Chapter 4, 127 
generation, the ∆RAD51::PUR construct had processing flanks derived from procyclin 
(McCulloch & Barry, 1999; Figure 4-2 A ). The ∆RAD51-3::BSD, ∆RAD51-3::PUR and 
∆RAD51-5::PUR constructs differed in that both intergenic sequence (IR) flanking the 
antibiotic resistance ORFs were derived from tubulin, βα and αβ IR (Proudfoot & 
McCulloch, 2005a; Figure 4-2 B, D). All the other constructs, ∆RAD51-4::BSD/PUR, 
∆RAD51-5::BSD and ∆RAD51-6::BSD/PUR had one intergenic region derived from the 
tubulin and the other from actin (Figure 4-2 C, D, E). All these homozygous mutants were 
generated in the same T. brucei strain 3174.2 in which the VSG switching frequencies and 
mechanisms were analysed (McCulloch et al., 1997; McCulloch & Barry, 1999). 
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Figure 4-2: Diagram showing the knockout constructs for the generation of rad51 and the RAD51 
paralogue mutant cell lines. 
The main ORF of RAD51 and each RAD51 paralogue was disrupted with an antibiotic resistance cassette, 
encoding resistance to blasticidin (BSD) and puromycin (PUR). This was carried out through integration of 
the cassette by homologous recombination of targeting regions, the left hand flank (LHF) and right hand 
flank (RHF) of the gene, and the sequence sizes are shown in base pairs (bp). The diagram shows the 
constructs used: Figure 4-2A: ∆RAD51::PUR, ∆RAD51::BSD, Figure 4-2B: ∆RAD51-3::BSD/PUR, Figure 
4-2C: ∆RAD51-4::BSD/PUR, Figure 4-2D: ∆RAD51-5::BSD, ∆RAD51-5::PUR, and Figure 4-2E: 
∆RAD51-6::BSD/PUR, each indicating the amount of the ORF deleted by integration of the construct, ∆391 
bp, ∆798 bp, ∆581 bp, ∆673 bp, and ∆790 bp respectively. The intergenic regions flanking the antibiotic 
resistance genes are indicated as follows: βα and αβ tubulin (βα IR and αβ IR), actin intergenic region (Actin 
IR) and procyclin intergenic regions (PARP 5’ and PARP 3’).  
The rad51 -/- mutant cells and the equivalent homozygous RAD51 paralogue mutants, 
rad51-3 -/-, rad51-4 -/-, rad51-5 -/- and rad51-6 -/-, were all viable. Thus, phenotypic 
analysis of each cell line is possible, as described in this chapter. These results will be 
considered in comparison with single RAD51 paralogue gene mutation analysis in other 
species, in particular vertebrate cells where the proteins appear to adopt overlapping, yet 
distinct functions (Liu et al., 2004; Sigurdsson et al., 2001; Takata et al., 2000; Takata et 
al., 2001; Tarsounas et al., 2004b). 
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4.2 Analysis of the in vitro growth rates of RAD51 
and RAD51 paralogue mutants 
Previous work has shown that homozygous mutants of rad51 and each of the RAD51 
paralogues had a reduced in vitro growth rate (McCulloch & Barry, 1999; Proudfoot & 
McCulloch, 2005a). In some cases, this was also seen in vivo (McCulloch & Barry, 1999). 
To compare the extent of this impairment, growth curves and population doubling time 
were calculated (this was performed as before; see Materials and Methods, Section 2.8). 
Figure 4-3 and Table 4-1 confirms that the RAD51 and each RAD51 paralogue 
homozygous mutant, (rad51-3 -/-, rad51-4 -/-, rad51-5 -/- and rad51-6 -/-) have a growth 
impairment compared with that of the wildtype. However, it is notable that, rad51-4 -/- and 
rad51-5 -/- mutant growth rates (green and red lines of Figure 4-3) appear to be faster than 
that of the other rad51 -/-, rad51-3 -/- and rad51-6 -/- (see Table 4-1). The same trend was 
observed previously, in a more limited sample: Proudfoot & McCulloch, (2005a) observed 
that rad51-5 -/- mutants appeared to grow quicker than the rad51-3 -/- mutants. The 
implications of this are unknown because the basis for slow growth in the mutants is 
unclear, but it may suggest that these two RAD51 paralogue proteins, RAD51-4 and 
RAD51-5, may have less central functions in cell viability or cell cycle progression, 
perhaps due to having less crucial roles in DNA repair. It may be, for instance, that 
RAD51-4 and RAD51-5 are not as integral to DNA repair as RAD51 and the other RAD51 
paralogues, or that they have a role or roles that can be performed by some other protein or 
protein complexes. It may be that their role is to aid or stabilise the other RAD51 
paralogues that are more centrally involved in repair, which has been suggested for some 
members of the mammalian RAD51 family (Lio et al., 2004).  
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Figure 4-3: Analysis of the growth of RAD51 and RAD51 paralogue mutants in vitro 
A semi logarithmic plot of the cell densities at fixed time points, 24 h, 48 h, and 72 h is shown. This plot 
shows the growth of rad51 -/- (51-/-), rad51-3 -/- (3-/-), rad51-4 -/- (4-/-), rad51-5 -/- (5-/-), and rad51-6 -/- 
(6-/-) mutants compared with the wildtype strain 3174.2 (wt). The means of three independent experiments 
are shown, with the 95 % confidence intervals indicated by error bars.  
 
 
Table 4-1:  in vitro population doubling times for the homozygous mutants of RAD51 and the RAD51 
paralogues. 
The population doubling time of each homozygous mutant, rad51 -/-, rad51-3 -/-, rad51-4 -/-, rad51-5 -/-, 
and rad51-6 -/-, are displayed in hours. These data are compared with the population doubling time for the 
wildtype strain 3174 (wt). 
9.52          
(+/- 0.79)
8.37          
(+/- 0.31)
7.87          
(+/- 0.73)
9.80          
(+/- 0.89)
9.99          
(+/- 1.0)
6.69          
(+/- 0.019)
rad51-6-/-rad51-5-/-rad51-4-/-rad51-3-/-rad51-/-wt
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Table 4-2: Statistical analysis of the in vitro population doubling times for the homozygous mutants of 
RAD51 and the RAD51 paralogues. 
Unpaired, two-tailed Student’s t-tests were carried out to compare the mean of the triplicate growth rates for 
the wildtype (wt) and rad51 -/-, rad51-3 -/-, rad51-4 -/-, rad51-5 -/- and rad51-6 -/- mutants. A significant 
difference between the means is shown by a p-value of p ≤ 0.05. Not significantly different results are shown 
as “-“. NA is not applicable. 
NA-0.0400--0.0022rad51-6-/-
-NA-0.04190.03950.0005rad51-5-/-
0.0400-NA0.03090.02900.0338rad51-4-/-
-0.04190.0309NA-0.0025rad51-3-/-
-0.03950.0290-NA0.0030rad51-/-
0.00220.00050.03380.00250.0030NAwt
rad51-6-/-rad51-5-/-rad51-4-/-rad51-3-/-rad51-/-wt
 
It has been observed in chicken DT40 cells, that the growth rates of the Rad51 paralogue 
mutants, rad51b, rad51c, rad51d, xrcc2 and xrcc3, are significantly lower when compared 
with the wildtype cells (Takata et al., 2000; Takata et al., 2001). The authors noted that the 
cell cycle profiles were the same for the wildtype and rad51 paralogue mutants, and 
suggested that the lower growth rates were due to the high percentage (~20-30 %) of cell 
death in the rad51 paralogue mutant cell lines (Takata et al., 2000; Takata et al., 2001). 
This has also been suggested to be true for rad51-3 -/- and rad51-5 -/- mutants in T. brucei 
(Proudfoot & McCulloch, 2005a), but the cell cycle profiles of rad51-4 -/- and rad51-6 -/- 
mutant cell lines were not examined. It is also noteworthy that the rad51 paralogue 
mutants in the DT40 cells display chromosomal aberrations, as do the T. brucei brca2 -/- 
cells, and this may be the underlying cause of cell death in the population and reduced 
growth rates (Hartley & McCulloch, 2008; Liu et al., 1998; Takata et al., 2001). However, 
the reduced growth rate in T. brucei brca2 -/- is partly due to defects in the nuclear DNA 
replication or cell division (Hartley, PhD thesis), although this has not been observed in 
rad51 -/- nor in the RAD51 paralogue homozygous mutants. Nevertheless, further reasons 
why the rad51 paralogue mutants in all species studied have reduced growth rates could 
yet be uncovered. In addition, determining whether T. brucei rad51 or RAD51 paralogue 
homozygous mutants display chromosomal aberrations has not been tested. 
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4.3 Analysis of the DNA-damage sensitivity of 
RAD51 and RAD51 paralogue mutants 
To analyse whether mutations in RAD51 and the RAD51 paralogues lead to the same level 
of DNA-damage sensitivity, IC50 values for two DNA-damaging agents, methyl 
methanesulfonate (MMS) and phleomycin, were calculated. As previously described in 
Chapter 3 (Section 3.4.2.2), each homozygous mutant cell line was treated with serial 
dilutions of the DNA-damaging agents and the resulting proliferation was measured by 
resazurin, which was used as an indicator of growth. Both DNA-damaging agents have 
been observed to directly or indirectly induce double strand breaks (Claussen & Long, 
1999; Giloni et al., 1981; Lundin et al., 2005; Wyatt & Pittman, 2006). Figures 4-4 and 4-5 
confirms the previously described data that the rad51 -/- mutant and each RAD51 
paralogue homozygous mutant are more sensitive than wildtype cells to both DNA-
damaging agents. The significantly different results are indicated in Table 4-3 and Table 4-
4. The mutants are 2.0 - 3.5 fold more sensitive to MMS and 2.5 – 5.0 fold more sensitive 
to phleomycin compared with treated wildtype cells. However, the rad51-4 -/- mutant 
appears to be more resistant to phleomycin treatment than the rad51 -/- mutant and the 
other RAD51 paralogue homozygous mutants. As for the growth rate difference, the reason 
for this greater resistance is unknown but appears to be reflected by analysing the 
formation of RAD51 foci in response to DNA-damage by phleomycin (see Section 4.5 
below). Arguably, these differences, in growth rates and DNA-damage sensitivities, are the 
result of distinct functions for RAD51-4 in the DNA repair pathways used by T. brucei. 
However, it is not clear why the rad51-4 -/- cells are not also more resistant to MMS, 
which also causes DNA breaks. Furthermore, rad51-5 -/- cells appeared not to have as 
severe growth defects as rad51 -/-, rad51-3 -/-, and rad51-6 -/- mutants, but displays 
essentially equivalent levels of DNA damage sensitivity.  
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Figure 4-4: IC50 values of MMS for the homozygous mutants of RAD51 and the RAD51 paralogues. 
Each cell line was treated with serial dilutions of MMS and the resulting proliferation was measured by 
resazurin, which was used as an indicator of growth. The IC50 values are shown for the following cell lines: 
rad51 -/- (51-/-), rad51-3 -/- (3-/-), rad51-4 -/- (4-/-), rad51-5 -/- (5-/-), and rad51-6 -/- (6-/-), and compared 
with wildtype 3174 strain (wt). The values are the mean of three independent experiments, and 95 % 
confidence intervals are indicated by the error bars. 
 
Table 4-3: Statistical analysis of the IC50 values of MMS for the homozygous mutants of RAD51 and 
the RAD51 paralogues. 
Unpaired, two-tailed Student’s t-tests were carried out to compare the IC50 values of MMS for the wildtype 
(wt) and rad51 -/-, rad51-3 -/-, rad51-4 -/-, rad51-5 -/- and rad51-6 -/- mutant cell lines. A significant 
difference between the means is shown by a p-value of p ≤ 0.05. Not significantly different results are shown 
as “-“. NA is not applicable. 
wt rad51-/- rad51-3-/- rad51-4-/- rad51-5-/- rad51-6-/-
wt NA 0.0092 0.0098 0.0195 0.0130 0.0127
rad51-/- 0.0092 NA - 0.0364 - -
rad51-3-/- 0.0098 - NA 0.0453 - -
rad51-4-/- 0.0195 0.0364 0.0453 NA - -
rad51-5-/- 0.0112 - - - NA -
rad51-6-/- 0.0127 - - - - NA
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Figure 4-5: IC50 values of phleomycin for the homozygous mutants of RAD51 and the RAD51 
paralogues. 
Each cell line was treated with serial dilutions of phleomycin and the resulting proliferation was measured by 
resazurin, which was used as an indicator of growth. The IC50 values are shown for the following cell lines: 
rad51 -/- (51-/-), rad51-3 -/- (3-/-), rad51-4 -/- (4-/-), rad51-5 -/- (5-/-), and rad51-6 -/- (6-/-), and compared 
with wildtype 3174 strain (wt). The values are the mean of three independent experiments, and 95 % 
confidence intervals are indicated by the error bars. 
 
Table 4-4: Statistical analysis of the IC50 values of phleomycin for the homozygous mutants of RAD51 
and the RAD51 paralogues. 
Unpaired, two-tailed Student’s t-tests were carried out to compare the IC50 values of phleomycin for the 
wildtype (wt) and rad51 -/-, rad51-3 -/-, rad51-4 -/-, rad51-5 -/- and rad51-6 -/- mutant cell lines. A 
significant difference between the means is shown by a p-value of p ≤ 0.05. Not significantly different results 
are shown as “-“. NA is not applicable. 
wt rad51-/- rad51-3-/- rad51-4-/- rad51-5-/- rad51-6-/-
wt NA 0.0173 0.0224 0.0372 0.0181 0.0211
rad51-/- 0.0173 NA - 0.0140 - 0.0459
rad51-3-/- 0.0224 - NA 0.0495 - -
rad51-4-/- 0.0372 0.0140 0.0495 NA 0.0174 0.0277
rad51-5-/- 0.0181 - - 0.0174 NA -
rad51-6-/- 0.0211 0.0459 - 0.0277 0.0438 NA
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The mammalian V79 and CHO Chinese hamster cell lines irs1 and irs1SF (defective in the 
mammalian Rad51 paralogues, XRCC2 and XRCC3, respectively) were first described to 
be moderately sensitive to x-rays and gamma radiation, and extremely sensitive to DNA 
cross-linking agents (Liu et al., 2007; Tebbs et al., 1995). Later, it was shown that all the 
Rad51 paralogue mutants in chicken DT40 cell lines were similarly moderately sensitive to 
gamma radiation, and extremely sensitive to DNA cross-linking agents, as assayed by 
clonal survival (Takata et al., 2000; Takata et al., 2001). In S. cerevisiae, rad55 and rad57 
null mutants were more sensitive to x-rays at 23 oC compared with wildtype at the same 
temperature (Hays et al., 1995). Complementation studies using these mutant cell lines 
have shown that overexpression of other DNA repair proteins such as Rad51 and Rad52, 
overcome these phenotypes (Hays et al., 1995; Johnson & Symington, 1995). Both Rad52 
and Rad55/57 are required to promote Rad51 filament assembly in irradiated mitotic cells, 
whereas either Rad52 or Rad55/57 alone are insufficient (Gasior et al., 2001). Also 
addition of corresponding human cDNA to the chicken rad51 paralogue mutants restores 
some if not all of the DNA-damage resistance (Takata et al., 2001). These findings suggest 
that the Rad51 paralogues support and facilitate the function of Rad51. 
There is diversity among the different DNA-damaging agents used in the experiments 
described above, and there is a precedent for the eukaryotic Rad51 paralogue mutants to 
respond differently to various DNA-damaging agents (Game & Mortimer, 1974; Jones et 
al., 1987; Jones et al., 1988). The T. brucei RAD51 paralogues have also been shown to 
act in response to DNA-damaging agents, MMS and phleomycin, which most likely yield a 
similar profile of DNA breaks. The effect of other types of DNA-damaging agents on the 
RAD51 paralogue mutants has not been assessed. For instance, there is no information on 
how the T. brucei RAD51 paralogue homozygous mutants would react to DNA-
crosslinking agents such as cisplatin or to replication stalling compounds such as 
hydroxyurea. Analysis of DNA-damaging agents with differing modes of action may 
reveal more information on the roles of the RAD51 paralogues. 
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4.4 Analysis of the recombination efficiency of 
RAD51 and the RAD51 paralogue mutants 
To analyse the ability of the different mutants to undergo homologous recombination 
(HR), quantification of the cells’ abilities to integrate a transformed DNA construct that is 
targeted to the βα tubulin array was performed (see Chapter 6 for a more detailed 
discussion). Briefly, to assay for transformation efficiency, a linearised construct 
containing the drug resistant gene for phleomycin resistance, flanked by βα and αβ 
intergenic regions, was transformed into the wildtype and each of homozygous mutant cell 
lines (see Materials and Methods, Section 2.8.3). If HR can occur, the βα and αβ intergenic 
flanks allow the resistance cassette to integrate into the βα tubulin array, and following 
expression of the cassette the cells become resistant to phleomycin. This is potentially a 
highly variable assay, and can depend on many factors, including quantity and purity of the 
linearised DNA, density and growth conditions of the T. brucei cells, efficiency of 
electroporation, and concentration of phleomycin used for selection. For this reason, it was 
important to analyse the cells lines at the same time with the same reagents, in order to 
ascertain if differences or similarities in recombination efficiency are observed.  
Figure 4-6 confirms all previous data suggesting that the rad51 and each of the RAD51 
paralogue homozygous mutants have a decrease in transformation efficiency compared to 
wildtype cells. It is notable, however, that the rate of transformation in this data set is 
approximately 4 fold higher for all the cell lines, than observed previously in Chapter 3 
(Section 3.4.3 and Section 3.7.3). This illustrates the importance of comparing results 
within a single experiment. Nevertheless, the rad51 -/- mutant appears to have a greater 
decrease in its ability to undergo HR than any of the RAD51 paralogue homozygous 
mutants, and may reflect the central importance of RAD51 directly in the pathway, 
compared with the putative accessory functions of the RAD51 paralogues. Of the four 
RAD51 paralogue mutants, the rad51-6 -/- mutant appears to have the greatest impairment, 
which is nearly comparable with that of the rad51 -/- cells and the transformation 
efficiencies of the two cell lines, rad51 -/- and rad51-6 -/-, are not significantly different 
from one another (see Table 4-5). This result may imply that RAD51-6 has a more 
fundamental role in this form of homologous recombination compared with the other 
RAD51 paralogues, though further analysis would be needed to support this suggestion. It 
should be highlighted that mutation of either RAD51 or any of the RAD51 paralogues, did 
not result in total obliteration of HR, suggesting that other pathways can act to recombine 
DNA, assuming that all these proteins contribute to RAD51-directed recombination. 
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Figure 4-6: Transformation assay for RAD51 and the RAD51 paralogue mutants 
To assay for recombination rate, a transformation efficiency assay was used. Each cell line is indicated as 
follows:  Wildtype strain 3174.2 (wt), rad51 -/- (51-/-), rad51-3 -/- (3-/-), rad51-4 -/- (4-/-), rad51-5 -/- (5-/-), 
and rad51-6 -/- (6-/-). The values plotted are mean numbers of phleomycin resistant transformants per 106 
cells transformed. These experiments were done in triplicate with the same linearised DNA, and error bars of 
the 95 % confidence intervals are indicated. 
 
Table 4-5: Statistical analysis of the transformation efficiency for the homozygous mutants of RAD51 
and the RAD51 paralogues. 
Unpaired, two-tailed Student’s t-tests were carried out to compare the transformation efficiency for the 
wildtype (wt) and rad51 -/-, rad51-3 -/-, rad51-4 -/-, rad51-5 -/- and rad51-6 -/- mutant cell lines. A 
significant difference between the means is shown by a p-value of p ≤ 0.05. Not significantly different results 
are shown as “-“. NA is not applicable. 
wt rad51-/- rad51-3-/- rad51-4-/- rad51-5-/- rad51-6-/-
wt NA 0.0000 0.0000 0.0000 0.0000 0.0000
rad51-/- 0.0000 NA 0.0073 0.0008 0.0015 -
rad51-3-/- 0.0000 0.0073 NA - - -
rad51-4-/- 0.0000 0.0008 - NA - 0.0189
rad51-5-/- 0.0000 0.0015 - - NA 0.0260
rad51-6-/- 0.0000 - - 0.0189 0.0260 NA
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It has been shown that XRCC2, XRCC3 and Rad51C in mammalian cells have a role in 
HR (Johnson et al., 1999; Lio et al., 2004; Pierce et al., 1999). These studies used assay 
systems (such as those discussed in Chapter 6) where HR is measured using markers 
located within or between chromosomes, as opposed to the indirect transformation method 
described here for T. brucei. Despite the different methods used, both the T. brucei and 
mammalian Rad51 paralogues have been shown to have a role in HR, with mutants of the 
Rad51 paralogues having a decrease in the rate of recombination. This was also the case 
with the T. brucei brca2 -/- mutants (Hartley & McCulloch, 2008). These analyses confirm 
that the RAD51 paralogues have a role in HR along with RAD51 and BRCA2. 
4.5 Analysis of the role of the RAD51 paralogues in 
RAD51 foci formation 
It has been shown that RAD51 forms discrete foci in sub-nuclear complexes in response to 
different forms of DNA-damage (Bishop, 1994; Haaf et al., 1995; Tarsounas et al., 2004a). 
It has similarly been shown that following phleomycin damage of T. brucei cells, RAD51 
forms distinct foci (Glover et al., 2008; Hartley & McCulloch, 2008; Proudfoot & 
McCulloch, 2005a). RAD51 foci are most probably formed at the sites of DNA damage 
and may represent regions of repair of DNA lesions (Raderschall et al., 1999; Tarsounas et 
al., 2004a; Tashiro et al., 2000). As discussed in previous publications and Chapter 3 
(Section 3.4.4), the number of RAD51 foci formed in the T. brucei damaged cells varies 
and can be counted using indirect immuno-fluorescence using anti-RAD51 anti-sera. 
However, although it has been shown that the rad51-4 -/- and rad51-6 -/- mutants have a 
reduced ability to form RAD51 foci in response to phleomycin (Chapter 3, Section 3.4.4 
and 3.7.4), similar to that described previously for rad51-3 -/-, rad51-5 -/-, and brca2 -/-, 
the method used here (Materials and Methods, Section 2.9). As a result, comparable 
quantification of the RAD51 foci in all the RAD51 paralogue homozygous mutants was 
required, in order to determine if each factor contributes equally in this process.  
To examine the RAD51 foci formation response to phleomycin in more detail, 1 x 106 cells 
per ml of each RAD51 paralogue homozygous mutant were grown in the presence of 0.0 
µl.ml-1, 0.25 µl.ml-1 and 1.0 µl.ml-1 of phleomycin for 18 hours (see Materials & Methods, 
Section 2.9). Briefly, the treated cells were washed in PBS, and fixed using 1 % 
formaldehyde/PBS. After fixing, the cells were washed again with PBS and permeablised 
with 1 % Triton X-100 and spread on to a glass slide. The cells were probed with rabbit 
anti-RAD51 anti-serum at a dilution of 1:500 and detected with goat anti rabbit-conjugated 
with SFX (fluorescein, succinimidyl ester). The addition of mounting solution containing 
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DAPI allowed detection of the nucleus and kinetoplast. Once the slide had dried 
completely, the number of RAD51 foci per cell was scored microscopically. For 
comparison, this was also performed for wildtype and non-treated cell lines.  
In the cells not treated with phleomycin minimal RAD51 foci formation (1-3 %) were 
observed, as no DNA damage was induced (data not shown). Phleomycin-treated rad51 -/- 
mutants also did not produce any RAD51 foci, because RAD51 is absent in these cells, see 
Figure 4-7. Table 4-6 and Figure 4-8 show the percentage of RAD51 paralogue mutant 
cells with a specific number of RAD51 foci observed when treated with phleomycin. The 
data for the rad51-4 -/- and rad51-6 -/- mutants are those described in Chapter 3 (Sections 
3.4.4 and 3.7.4). In the treated rad51-3 -/- and rad51-5 -/- mutants, there were few 
observable RAD51 foci (Table 4-6 and Figure 4-8) and the percentage of cells that 
produced RAD51 foci is much lower when compared with the treated wildtype cells. The 
number of treated rad51-3 -/- and rad51-5 -/- cells with distinct RAD51 foci is lower in 
this analysis than in the study of Proudfoot & McCulloch (2005a). When treated with a 
phleomycin concentration of 0.25 µg.ml-1, 93 % of rad51-3 -/- and 82 % of rad51-5 -/- 
mutant cells had no observable RAD51 foci using the technique described above (Table 4-
6), while 89 % and 83 % of cells treated with 1.0 µg.ml-1 phleomycin had no foci 
respectively. At a near equivalent phleomycin concentration, Proudfoot & McCulloch 
(2005a) found a higher percentage of cells with RAD51 foci. 60-80 % and 52-64 % of 
rad51-3 -/- mutant cells did not show RAD51 foci formation when treated with 0.3 µg.ml-1 
and 1.5 µg.ml-1 phleomycin respectively. A similar result was seen when rad51-5 -/- 
mutant cells were treated with 0.5 µg.ml-1 and 1.5 µg.ml-1 phleomycin, as 64-67 % and 60-
64 % of cells respectively, did not have detectable RAD51 foci. It was apparent that the 
amount of overall anti-RAD51 staining was greater in the previous study than in this, 
perhaps due to greater amounts of non-specific antibody binding, and therefore one 
explanation is that a greater number of “false” foci were scored.  
A striking observation from the data presented in Figure 4-8 is that the rad51-4 -/- mutant 
appears less impaired in its ability to support relocalisation of RAD51 into foci than the 
other three RAD51 paralogue mutants. RAD51 foci formation in the treated rad51-3 -/-, 
rad51-5 -/-, and rad51-6 -/- cell lines appear to be broadly similar, with very few distinct 
RAD51 foci observed. This appears to be consistent with the findings in Section 4.3 above, 
which shows that the rad51-4 -/- mutants are less sensitive to phleomycin DNA damage 
than in the other mutants. This appears to suggest a less central role for RAD51-4 in this 
form of DNA repair. 
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Figure 4-7: Detection of the RAD51 foci by indirect immuno-fluorescence. 
The first row of pictures shows an example of a rad51 -/- cell treated with 1.0 µg.ml-1 phleomycin for 18 
hours: no distinct RAD51 foci are detected. The other two rows are examples of similarly treated rad51-3 -/- 
and rad51-5 -/- cell lines. RAD51 was imaged by indirect immuno-fluorescence (FITC; first column); the 
DNA was stained with DAPI (second column); and these two were merged (third column); the cells were 
also visualised by differential interference contrast (DIC; fourth column) and all the images were merged 
(fifth column). 
 
Table 4-6: Percentage of RAD51 paralogue mutant cells with a specific number of RAD51 foci when 
treated with phleomycin. 
The percentage of cells with a specific number of sub-nuclear RAD51 foci formed (0, 1, 2, 3, 4, ≥5) when the 
cells were treated with 0.25 µg.ml-1 or 1.0 µg.ml-1 of phleomycin is shown. The different cell lines, rad51-/- 
(51-/-), rad51-3 -/- (3-/-), rad51-4 -/- (4-/-), rad51-5 -/- (5-/-), and rad51-6 -/- (6-/-) were compared with the 
wildtype strain 3174 (wt). The total refers to the number of cells analysed. 
2840.01.00.53.110.784.71.0 µg.ml-1
3040.00.01.01.02.295.90.25 µg.ml-1RAD51-6
1000.00.00.05.012.083.01.0 µg.ml-1
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3173.22.911.214.719.948.31.0 µg.ml-1
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22510.76.712.923.125.321.31.0 µg.ml-1
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Figure 4-8: Percentage of the RAD51 paralogue mutant cells with a specific number of RAD51 foci. 
The percentage of cells with a specific number of sub-nuclear RAD51 foci formed (0, 1, 2, 3, 4, ≥5) when the 
cells were treated with 1.0 µg.ml-1 of phleomycin is shown. The different cell lines, rad51 -/- (51-/-), rad51-3 
-/- (3-/-), rad51-4 -/- (4-/-), rad51-5 -/- (5-/-), and rad51-6 -/- (6-/-), were compared with the wildtype strain 
3174 (wt). 
 
To ensure that these results were not due to abolishment of RAD51 expression in the 
RAD51 paralogue mutants, western blot analysis was performed. This showed that each of 
the RAD51 paralogue mutant cell lines were expressing RAD51 (see Figure 4-9), and 
apparently at the same levels to each other and to the wildtype cells. Analysis to determine 
if RAD51 is a constitutively nuclear protein was not carried out, but one potential 
explanation for these findings is that lack of the RAD51 paralogues prevents RAD51 
relocalisation or retention in the nucleus.  
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Figure 4-9: Western blot analysis showing RAD51 expression in the RAD51 paralogue mutant cell 
lines. 
Protein extracts from each cell line (wildtype (wt), rad51 -/- (51-/-), rad51-3 -/- (3-/-), rad51-4 -/- (4-/-), 
rad51-5 -/- (5-/-) and rad51-6 (6-/-)) were separated on a 10 % SDS-PAGE gel and then transferred to a 
nylon membrane. This was then probed with affinity purified rabbit anti-RAD51 anti-serum at a dilution of 
1:50 and detected using anti-rabbit anti-serum conjugated with HRP at a dilution of 1:5000 (Molecular 
probes). The RAD51 band is indicated with the black arrow (40.5 kDa) and the size markers are shown. 
It was shown that there was a decrease in the formation of RAD51 foci in response to 
irradiation in S. cerevisiae rad52 mutants, as well as mutants of both Rad51 paralogues, 
rad55 and rad57 (Gasior et al., 1998). In Chinese hamster irs1 mutant cells (xrcc2 mutant), 
damage-dependent Rad51 foci formation was severely decreased compared to wildtype 
and complementation with a functional XRCC2 restored the Rad51 foci formation to 
normal (O'Regan et al., 2001). This phenotype was also described in irs1SF mutant cells 
(xrcc3 mutant), where the mutant cells did not product Rad51 foci when treated with 
cisplatin and γ-radation (Bishop et al., 1998). Studies by Takata, et al. confirmed these 
finding in the chicken cell line DT40, and showed that the Rad51 paralogue mutants, 
rad51b, rad51c, rad51d, xrcc2 and xrcc3, have a decrease in the formation of RAD51 foci 
in response to γ-radiation treatment (Takata et al., 2000; Takata et al., 2001). In one of 
these studies, it was shown that mutant cells transfected with the corresponding human, 
rad51c, xrcc2, xrcc3 cDNAs, or with mouse rad51d cDNAs were able to efficiently form 
Rad51 foci when treated with γ-radiation (Takata, et al., 2001). These studies confirmed 
that Rad51 was present in the nucleus, and lack of focus formation was not the result of 
absent Rad51. These data from yeast, chicken, mammalian and T. brucei cells supports the 
proposal that the Rad51 paralogues are required for Rad51 localisation to sub-nuclear foci, 
or movement and formation of Rad51 on damaged DNA, or perhaps even in the 
stabilisation of RAD51 foci.  
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4.6 Comparison of VSG switching in RAD51 and 
the RAD51 paralogue mutants 
The switching frequencies of RAD51 paralogue homozygous mutant cell lines were 
analysed as described previously in McCulloch & Barry, 1999, Proudfoot & McCulloch, 
2005a and Chapter 3 (Section 3.4.5 and Section 3.7.5). Due to time constraints, the VSG 
switching experiments were not repeated in parallel and instead the data from this study, 
Proudfoot & McCulloch (2005a) and McCulloch & Barry (1999) were compared for the 
rad51-4 -/-, rad51-6 -/-; rad51-3 -/-, rad51-5 -/-; and rad51 -/- mutant cell lines 
respectively. In all cases, the VSG switching frequency was calculated in the same way 
from the raw data: isolated and cloned surviving switched T. brucei cells were counted 
over 96-well plates. This number was multiplied by 2.5, as the recovered blood used to 
seed the 96-well plates from the mouse was only 40 % of the total approximate blood 
volume of the animal. This number was then divided by the number of doubling times that 
had occurred during the 24 hour period following injection into the mouse and stated 
relative to the number of cells injected into the VSG221 immune mice. These data are 
shown in Figure 4-10 and Table 4-7.  
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Figure 4-10: Compiled data for VSG switching frequencies of rad51 and RAD51 paralogue homozygous 
mutants. 
The graph shows the VSG switching frequencies of the different cell lines: wildtype strain 3174 (wt), rad51 -
/- (51-/-), rad51-3 -/- (3-/-), rad51-4 -/- (4-/-), rad51-5 -/- (5-/-), and rad51-6 -/- (6-/-). The means of 
triplicate data are shown, with 95 % confidence intervals indicated by the error bars. 
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Table 4-7: VSG switching frequencies of rad51 and RAD51 paralogue homozygous mutants. 
The table shows the VSG switching frequencies of the different cell lines as the mean number of switched 
variants per 107 cells per generation (top row). The VSG switching frequencies are shown for wildtype strain 
3174 (wt), rad51 -/-, rad51-3 -/-, rad51-4 -/-, rad51-5 -/-, and rad51-6 -/- mutant cell line. The 95 % 
confidence intervals are indicated by +/-. 
wt rad51-/- rad51-3-/- rad51-4-/- rad51-5-/- rad51-6-/-
7.18
(+/- 1.32)
0.44
(+/- 0.33)
1.07
(+/- 0.69)
4.85
(+/- 1.55)
4.47
(+/- 3.17)
3.79
(+/- 2.05)
 
This analysis suggests firstly, that all the mutants have to some extent, an impaired ability 
to undergo VSG switching relative to wildtype cells. Secondly, the data suggests that 
rad51 -/- and rad51-3 -/- mutants have a lower mean VSG switching frequency compared 
with the three other RAD51 homozygous mutants, rad51-4 -/-, rad51-5 -/- and rad51-6 -/- 
(see Table 4-7). In the cases of rad51-3 -/-, rad51-4 -/- and rad51-6 -/-, these impairments 
are also seen relative to the heterozygous mutants from which the homozygous mutants 
were derived (Chapter 3, Section 3.4.5 and 3.7.5, Proudfoot & McCulloch, 2005a). For 
rad51-5 -/-, this was not the case, and it was concluded that RAD51-5 may not act in VSG 
switching (Proudfoot & McCulloch, 2005a). This data also suggests that RAD51-4 and 
RAD51-6 may not act in VSG switching.  
The 95 % confidence intervals indicated by the error bars are large for the rad51-4 -/-, 
rad51-5 -/- and rad51-6 -/- cell lines. This is most likely due to the high variability and 
nature of the in vivo experiment. Nevertheless, one interpretation is that a distinct 
phenotype is seen, whereby loss of RAD51 or RAD51-3 substantially impairs the ability of 
VSG switching although some switching events still occurred. In contrast, loss of RAD51-
4, RAD51-5 and RAD51-6 has less of an impact. The rad51 -/- and rad51-3 -/- phenotypes 
are very similar to those described for the brca2 -/- mutant (Hartley & McCulloch, 2008), 
where there was a strong and comparable reduction in VSG switching. This suggests that 
there are a considerable number of factors that regulate RAD51 function during antigenic 
variation which may suggest that it is a randomly initiated process, where many forms of 
initiation can induce VSG switching. This may explain why all the mutants examined can 
still undergo antigenic variation by expression site and VSG gene conversion reactions, 
mechanisms which require HR. It rests on the assumption, however, that there are multiple 
roles for the RAD51 paralogues in recombination, and these are reflected in antigenic 
variation. This assumption requires further testing. 
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4.7 Summary 
The aim of this summary chapter was to show direct comparisons between mutant cell 
lines of all four RAD51 paralogues, RAD51 and wildtype cell lines. With one exception, 
all these experiments were carried out at the same time, allowing direct comparisons. The 
data described in this chapter confirms all previously published data by McCulloch & 
Barry (1999) and Proudfoot & McCulloch (2005a), as well as the results described in 
Chapter 3 of this thesis. Only small differences in quantification of specific phenotypes 
were seen. 
The results described here verify that all four T. brucei RAD51 paralogues have a role in 
DNA damage repair, with the mutants having an increased sensitivity to DNA damaging 
agents. Most likely, this is due to impairment in the parasite cell’s ability to undergo HR, 
as this pathway was found to be operating at reduced efficiency in each mutant. It is also 
likely that the decreased growth rate of the mutant cells stems from the above 
repair/recombination defect. It has also been confirmed that the T. brucei RAD51 
paralogues have a part to play in the formation or stabilisation of phleomycin induced 
RAD51 foci formation. Although the phenotypes of all the RAD51 paralogue mutants are 
similar to one another, they are not equivalent. Two of the RAD51 paralogue proteins, 
RAD51-4 and RAD51-5, appear have different functions within the DNA repair pathways. 
The growth rates of rad51-4 -/- and rad51-5 -/- mutant cells are quicker than that of the 
rad51 and the other RAD51 paralogue homozygous mutants. Furthermore, rad51-4 -/- 
appears to be more resistant to the DNA-damaging agent, phleomycin, and is more able to 
produce DNA-damage induced RAD51 foci than the other RAD51 paralogue mutants. The 
implications of these results are unknown, but may suggest that they have a role or roles 
which can be performed by some other protein, such as another RAD51 paralogue. It may 
also be the case that the role of RAD51-4, is aiding or stabilising the functions of other 
RAD51 paralogues see Chapter 5 (Section 5.8). 
These suggestions are only speculative, and there is the need to develop these theories. It 
will be important to examine the direct roles of each RAD51 paralogue by biochemical 
analysis to build a better picture regarding their function, such as testing the DNA binding 
ability or ATP hydrolysis capacity of the proteins, as well as assessing how they influence 
RAD51 function in vivo. Other potentially complementary experiments could be carried 
out directly in T. brucei: over-expression of RAD51 in the RAD51 paralogue mutant cells 
would determine if they have indispensible roles in aiding RAD51 function; the generation 
of double knockout mutants of the RAD51 paralogues would distinguish between potential 
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functions in one pathway, or their action in separate pathways. These experiments would 
enable a complete model of the roles of the T. brucei RAD51 paralogues to be formed. 
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Chapter 5. Examining the 
associations between T. brucei 
RAD51 and the RAD51 
paralogues 
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5.1 Introduction 
In T. brucei, there are four RAD51 paralogue proteins, RAD51-3, RAD51-4, RAD51-5, 
and RAD51-6, which share limited sequence homology with each other and RAD51 and 
DMC1 (Proudfoot & McCulloch, 2005a). To date, no analysis has been done to evaluate if 
and how these T. brucei RAD51 paralogues interact, although there is good evidence to 
suggest that each RAD51 paralogue in T. brucei has a role in DNA damage repair 
requiring the homologous recombination (HR) pathway (see Chapter 3, Chapter 4 and 
Proudfoot & McCulloch, 2005a). Extensive study of the mammalian Rad51 paralogues 
(XRCC2, XRCC3, Rad51B, Rad51C and Rad51D) confirms that they physically interact 
with each other, possibly providing discrete protein complexes that act in DNA 
recombination (Liu et al., 2002b; Schild et al., 2000). The current model for mammalian 
Rad51 paralogue interactions suggests two main complexes, incorporating all five 
paralogues, with Rad51C interacting with XRCC3 (CX3) in one complex and Rad51B-
Rad51C-Rad51D-XRCC2 (BCDX2) in another (Liu et al., 2002b; Masson et al., 2001a). 
Rad51C appears to play an important role, and is a component of both complexes (Liu et 
al., 2002b; Miller et al., 2004). The extent of the conservation of these two complexes in 
other eukaryotes has not been examined, but preliminarily results show that that two of the 
Arabidopsis thaliana Rad51 paralogues interact: AtRad51C and AtXRCC3. This study 
also showed that AtXRCC3 interacts with AtRad51 (Osakabe et al., 2002). In 
Saccharomyces cerevisiae, the two RAD51 paralogues, RAD55 and RAD57, form a single 
stable complex (Hays et al., 1995; Johnson & Symington, 1995). By these precedents, it is 
likely that the T. brucei proteins will also form a complex or complexes. However, as there 
are low levels of sequence homology among these proteins between the species, the 
interactions are not simple to predict. In addition, the potential conservation of such 
complexes in other eukaryotes, such as Drosophila, has not been examined (Abdu et al., 
2003; Ghabrial et al., 1998).  
To determine if the T. brucei RAD51 paralogues interact with each other and to establish 
the number and composition of such complexes, three approaches were adopted. The first 
was yeast two-hybrid analysis, where interaction between RAD51 and the RAD51 
paralogues was assayed using two reporter systems, β-galactosidase activity and histidine 
auxotrophy. Second, co-immunoprecipitation was employed; antisera were raised against 
His-tagged recombinant RAD51 and RAD51 paralogue proteins.  These antisera were then 
used in co-immunoprecipitation analyses to determine direct in-vivo interaction. Third, by 
generating T. brucei strains expressing epitope-tagged RAD51 paralogues, in-vivo co-
purification analyses were performed. 
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5.2 Principles of the yeast two-hybrid system 
The yeast two-hybrid system is used to detect protein-protein interactions, exploiting the 
knowledge that most eukaryotic transcription activator proteins have two functional 
domains, a DNA-binding domain and an activating domain (Fields & Song, 1989). The 
DNA-binding domain attaches to a DNA sequence called the upstream activation site 
(UAS) and the activating domain recruits the RNA polymerase II machinery to allow 
expression of the genes downstream of the UAS (Luban & Goff, 1995; Figure 5-1). 
Individually these domains cannot activate gene expression, and both domains must be in 
close proximity to the DNA for activation. GAL4 is a budding yeast transcriptional 
activator with a DNA-binding and activating domain, and is required for the activation of 
the GAL genes in response to galactose (Giniger et al., 1985). It has been proposed that the 
first 147 amino acid residues of GAL4 is the DNA-binding domain and the last 113 
residues is the activating domain, showing that up to 80 % of GAL4 protein could be 
deleted without drastic loss of transcriptional activation function (Ma & Ptashne, 1987a). 
It has also been shown that transcriptional activation can occur when the domains originate 
from independent and different polypeptides, and prokaryotic proteins can provide the 
function for either or both of the DNA-binding and activating domains. For instance, Brent 
& Ptashne (1985) created a functional transcription activator protein in yeast from the 
DNA-binding domain from the Escherichia coli repressor protein LexA fused to the 
activating domain of S. cerevisiae GAL4. The same group found that yeast transcriptional 
activators could be encoded by non-homologous DNA fragments from E. coli, fused to the 
encoding sequence of the DNA-binding domain of yeast GAL4 (Brent & Ptashne, 1985; 
Ma & Ptashne, 1987b). 
Fields & Song (1987) first suggested constructing independent fusions of the two 
potentially interacting proteins, with one protein fused to the DNA-binding domain, and 
the other protein to the activating domain. In this study, the authors used two proteins 
known to interact with each other, SNF1 and SNF4, the former fused to the DNA-binding 
domain of the GAL4 protein amino acids (1-147) and the latter fused to the activating 
domain of GAL4 (768-881) (In Figure 5-1, SNF1 would be X and SNF4 would be Y). The 
two vectors expressing fusion polypeptides were introduced into a yeast strain that had the 
native GAL4 gene deleted and also contained a GAL1-LacZ reporter gene in the yeast 
genome. The SNF1 fusion to the DNA-binding domain was defined as the “bait” protein 
and the SNF4 fusion to the activating domain was defined as the “prey” protein. As SNF1 
Rachel Dobson, 2009   Chapter 5, 150 
and SNF4 interact, the activating domain came into close proximity with the DNA-binding 
domain, and activated transcription of the reporter gene, LacZ encoding β-galactosidase.  
 
Figure 5-1: Model of the yeast two-hybrid system. 
BD: DNA binding domain LexA, X: Bait protein, AD: Activation domain B42, Y: Prey protein, RNA pol II: 
Yeast RNA polymerase II and associated proteins, UAS: Upstream activation sequence. The black arrow 
indicates transcription of the reporter genes. (Adapted from: Causier & Davies, 2002). 
These initial experiments demonstrated the possibility of using GAL4 to examine protein-
protein interaction and led to the discovery of other DNA-binding and activating domains 
(Fields & Song, 1989). Indeed, yeast two-hybrid analysis is now widely used to study 
protein interaction networks in many organisms (Gyuris et al., 1993; Vojtek et al., 1993). 
The work in this thesis used LexA as the DNA-binding domain (BD) and B42 as the 
activating domain (AD), (Figure 5-1).  
5.3 Components of the yeast two-hybrid system  
5.3.1 The role of LexA 
The LexA protein is a bacterial repressor protein which binds to DNA (Brent & Ptashne, 
1980). This DNA binding protein acts as a dimer, and recognises the LexA operator 
sequence.  Brent & Ptashne (1985) showed that a fusion of a fragment of the E. coli LexA 
protein (1-87 amino acids) to the S. cerevisiae Gal4 activating domain (74-881 amino 
acids) activated transcription of the reporter genes. In contrast, LexA alone did not activate 
transcription when the LexA binding sites were cloned upstream of the reporter genes in 
the yeast genome. LexA enters the yeast nucleus independently and further studies have 
validated that E. coli LexA could be used as a DNA-binding domain in the application of 
yeast two-hybrid screens (Vojtek et al., 1993).  
Invitrogen’s yeast two-hybrid system vector, pHybLex/Zeo (see Materials and Methods, 
Section 2.10) was used to provide the DNA-binding domain. In this, the full length LexA 
protein (202 amino acids) was expressed, and the Streptoalloteichus hindustanus ble gene 
under the control of TEF1 and EM-7 promoters, allowed zeocin resistance selection in S. 
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cerevisiae and E. coli, respectively. Using this vector to provide the DNA-binding 
domains, LexA fusions were made with T. brucei RAD51 and the four T. brucei RAD51 
paralogues. Figure 5-2 shows the fragment size of each ORF and also shows the enzyme 
restriction sites used in the cloning of each ORF into pHybLex/Zeo. pHybLex/Zeo-
RAD51, pHybLex/Zeo-RAD51-3, pHybLex/Zeo-RAD51-4, pHybLex/Zeo-RAD51-6 were 
made by Sandra Terry. These constructs were confirmed to be correct and to be in frame 
with LexA by sequence analysis, with the exception of LexA-RAD51-5 (which is 
described in Section 5.4.4). 
RAD51 ORF (1119 bp)LexA
ATG TAG
EcoR
I
NotI
RAD51-3 ORF (1521 bp)LexA
ATG TGA
SacI NotI
RAD51-4 ORF (1269 bp)LexA
ATG TAG
SacI NotI
RAD51-5 ORF (1173 bp)LexA
ATG TAG
ApaI
: 
ggga
ccc Sa
lI
RAD51-6 ORF (1432 bp)LexA
ATG TAG
KpnI XhoI
 
Figure 5-2: Diagram showing the LexA fusions with RAD51 and RAD51 paralogues. 
The complete lexA gene (606 bp) is part of the pHybLex/Zeo vector and allows expression of a fusion protein 
with the LexA DNA-binding domain. The LexA polypeptide adds 32 kDa to the N terminus of RAD51 and 
the RAD51 paralogue proteins in this configuration. The length of the ORF of RAD51 and each RAD51 
paralogue, and the restriction sites used for the cloning into the vector pHybLex/Zeo, are shown.  
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5.3.2 The role of B42  
Ma & Ptashne (1987b) identified a number of different activating domains when the DNA-
binding domain of the GAL4 gene was fused to polypeptides encoded from random DNA 
fragments of the E. coli genome. All transcriptional activating sequences identified were 
acidic, having a net negative charge (Ma & Ptashne, 1987b). One of these random DNA 
fragments, named B42, was shown to be amongst the strongest activator polypeptides 
when fused to the DNA-binding domain of GAL4 (Ma & Ptashne, 1987b). A fusion of the 
DNA binding domain of LexA and B42 was also generated, and was shown to activate a 
lacZ reporter gene downstream of a lexA operator. This confirmed that DNA-binding and 
activator polypeptides from E. coli could be used to activate genes on the yeast 
chromosome (Ma & Ptashne, 1987b), with the advantage that they should not be subjected 
to regulation by other yeast proteins. A further study confirmed that B42 could be used as 
an activating domain in the yeast two-hybrid analysis (Gyuris et al., 1993). In the 
Invitrogen system used here, the pYesTrp2 vector expresses a fusion of the haemagglutinin 
epitope tag V5, the SV40 nuclear-localisation sequence (NLS) and B42 as the activating 
domain. The complete ORF of T. brucei RAD51 and the RAD51 paralogues were cloned 
downstream of, and in frame with, the V5-NLS-B42 ORF to generate N terminal fusions 
with the three polypeptides (see Figure 5-3), this was performed by Sandra Terry. Also 
present in pYesTrp2 is the TRP1 gene, which allows for auxotrophic selection of the vector 
in a tryptophan negative yeast host, and the ampicillin resistance gene which allows 
selection in E. coli. 
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V5 NLS B42 RAD51 ORF (1119 bp)
ATG TAG
Hind
III
BstX
I
ATG TGA
RAD51-3 ORF (1521 bp)V5 NLS B42
Hind
III
NotI
ATG TAG
RAD51-4 ORF (1269 bp)V5 NLS B42
SacI NotI
ATG TAG
RAD51-5 ORF (1170 bp)V5 NLS B42
Hind
III
SphI
ATG TAG
RAD51-6 ORF (1431 bp)V5 NLS B42
KpnI Xho
I
 
Figure 5-3: Diagram showing the V5-NLS-B42 fusions with RAD51 and the RAD51 paralogues. 
The V5 epitope allows detection of the fusion proteins using Anti-V5 antibody. SV40 large T antigen nuclear 
localisation sequence (NLS) allows the V5-NLS-B42-RAD51 fusion and V5-NLS-B42-RAD51 paralogue 
fusions to enter the nucleus for potential interactions with LexA-RAD51 and LexA-RAD51 paralogue 
fusions. B42 is the transcriptional activation domain. The V5-NLS-B42 peptide adds 12 kDa to the RAD51 
and the RAD51 paralogue polypeptides. The length of the ORF of RAD51 and each RAD51 paralogue, and 
the restriction sites used for cloning into the vector pYesTrp2 are shown. 
5.3.3 S. cerevisiae L40 strain 
The S. cerevisiae L40 strain is commonly used with LexA-based yeast two-hybrid systems 
(Invitrogen). The strain contains two reporters, HIS3 and lacZ, both under the control of a 
minimal GAL1 promoter. Both reporter genes have multiple copies of the lexA operator 
sequences that act as upstream activating sequences (UAS): four copies are positioned 
upstream of the HIS3 reporter gene and eight copies are upstream of the lacZ reporter gene 
(Vojtek et al., 1993). The L40 strain is auxotrophic for histidine (his), adenine (ade), 
tryptophan (trp), and prototrophic for leucine (leu) and uracil (ura). The requirement for 
tryptophan allows selection of transformants containing the pYesTrp2 vector. 
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5.3.4 Independent testing of protein interactions 
Protein interaction of the RAD51 and RAD51 paralogues was examined by three 
independent tests, histidine auxotrophy, and two methods of testing β-galactosidase 
activity: filter lift assay and Pierce β-galactosidase kit. Invitrogens pHybLex/Zeo-Fos2 and 
pYesTrp-Jun are positive controls and interact in the yeast-two hybrid system, while 
pHybLex/Zeo-Lamin is the negative control for the bait plasmid. These positive and 
negative controls for the yeast-two hybrid analysis were not done. Nevertheless, the three 
independent methods of interaction analyses were performed and two independent 
transformants for each test were carried out. As a negative control the empty vector 
pYesTrp2 was used in combination with the pHybLex vectors. To verify that all fused 
proteins were expressed western analyses were performed on the cell lysates co-
transformed with the LexA and V5 fusions. In addition, the histidine auxotrophy tests were 
performed at least twice. 
5.3.4.1 To test for histidine auxotrophy 
One method to examine protein-protein interactions in the yeast two-hybrid system used 
here involves testing whether or not different co-transformants of pHybLex/Zeo and 
pYesTrp2 fusion vectors grow in the absence of histidine. As mentioned above, the L40 
strain used is auxotrophic for histidine and contains the HIS3 reporter gene under the 
control of minimal GAL1 promoters fused to lexA-operator sequences. If the LexA and V5-
NLS-B42 fused proteins interact, transcription of the minimal GAL1 promoter allows 
expression of imidazole-glycerolphosphate dehydratase (HIS3), which catalyses the sixth 
step in histidine biosynthesis (Alifano et al., 1996; SGD-project, Saccharomyces Genome 
Database), allowing growth on media lacking histidine. Use of a “minimal” GAL1 
promoter allows identification of protein-protein interactions that may otherwise be toxic 
to yeast growth (Invitrogen manual). In the following experiments to test for histidine 
auxotrophy, 3-amino-1,2,4-triazole (3’ aminotriazole) was added to the histidine negative 
(his-) selective media plates (see Materials and Methods, Section 2.10.1). 3’ aminotriazole 
is a competitive inhibitor of imidazole-glycerolphosphate dehydratase, the product of the 
HIS3 gene (Kanazawa 1998), and allows titration of the level of HIS3 expression. Non-
specific and very weak interactions will produce some imidazole-glycerolphosphate 
dehydratase, which would result in false positives in the test. To circumvent this, small and 
increasing concentrations (5 mM, 10 mM, and 15 mM) of 3’ aminotriazole were added. 
Specific and strong interactions would produce more imidazole-glycerolphosphate 
dehydratase and as a result, co-transformants expressing ‘true’ interactors will grow on the 
his- media plates even in the presence of the highest concentration of 3’ aminotriazole. 
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5.3.4.2 To test for β-galactosidase activity using the filter lift 
assay 
Since the S. cerevisiae L40 strain also contains a lacZ marker gene under the control of a 
minimal GAL1 promoter fused to eight copies of the LexA-operator sequences, interaction 
between and amongst RAD51 and the RAD51-paralogues can be assayed though induction 
of β-galactosidase activity. This was assayed in two ways: the β-galactosidase filter lift 
assay and the yeast β-galactosidase assay kit (Pierce). 
In the first method, β-galactosidase activity was determined qualitatively using the X-gal 
filter lift assay (Breeden & Nasmyth, 1985). This is a quick screening method based on a 
blue/white visualisation of yeast colonies immobilized on filters (see Materials and 
Methods, Section 2.10.2). Expression of the lacZ should only occur if RAD51 and the 
RAD51 paralogue fused proteins interact, resulting in blue colouration of the colonies. 
This method uses 5-bromo-4-chloro-3-indolyl-β-D-galactoside commonly known as X-Gal. 
Colourless X-gal is hydrolyzed by the β-galactosidase enzyme, forming 5-bromo-4-chloro-
3-hydroxyindole. This by-product is then oxidized, resulting in an insoluble blue product, 
5,5’dibromo-4, 4’-dichloro-indigo.  This method also allows imaging of the plates, and due 
to its sensitivity enables detection of low levels of β-galactosidase activity (Lehninger et 
al., 1993). 
5.3.4.3 To test for β-galactosidase activity using a “Yeast β-
galactosidase assay kit” 
In the second method, the β-galactosidase activity was determined quantitatively using a 
yeast β-galactosidase assay kit from Pierce. The kit was used to detect and quantify 
transcriptional activation of the β-galactosidase gene to examine the extent of any 
interactions between RAD51 and the RAD51 paralogue fused proteins. The same kit was 
used for all the analyses, and all required solutions were provided and used according to 
manufacturer’s instructions. β-galactosidase activity was assayed by measuring the 
cleavage of the lactose like compound ONPG (o-nitrophenyl-β-D-galactopyranoside) by 
the β-galactosidase enzyme to produce o-nitrophenol. o-nitrophenol is an insoluble yellow 
precipitate and its generation was quantified by spectrophotometry at an absorbance of 420 
nm. The measurement of β-galactosidase activity considers the optical density of the cells, 
the amount of cells used, and time of incubation of the reactions using the following 
equation:  
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(1000 x Absorbance 420 nm) ÷ (t x V x OD 620nm) 
where t is the assay reaction time (in minutes) and V is the volume of culture used in the 
assay (in ml). The enzymatic reaction time varies depending on the levels of the β-
galactosidase expression. The cell volume and density will also affect the β-galactosidase 
activity units. This information allows quantification of the β-galactosidase activity within 
each co-transformant, and comparisons are easily carried out. 
5.4 Results for yeast two-hybrid assays 
To examine the interactions between all the combinations of T. brucei RAD51 and the four 
RAD51 paralogues, each corresponding ORF was cloned into the two yeast two-hybrid 
vectors (pHybLex/Zeo and pYesTrp2; Invitrogen) which were described in Section 5.3.1 
and Section 5.3.2. This should allow expression of each full length protein as an N terminal 
fusion with the LexA-DNA binding domain from pHybLex/Zeo, or with the V5-NLS -B42 
activating domain from pYesTrp2. All pair-wise combinations of pHybLex/Zeo-RAD51 
and the pHybLex/Zeo-RAD51 paralogue vectors were then co-transformed into S. 
cerevisiae L40 cells with the pYesTrp2-RAD51 and pYesTrp2-RAD51 paralogue vectors 
(Materials and Methods, Section 2.4.6). Two independent co-transformants of each pair-
wise combination were analysed, and named X and Y. As a negative control, each of the 
pHybLex/Zeo-RAD51 and the pHybLex/Zeo-RAD51 paralogue vectors were co-
transformed with the empty activator vector pYesTrp2 (EV). If V5-NLS-B42-RAD51 or 
V5-NLS-B42-RAD51-paralogue fusions act as interaction-dependent activating domains 
the reporter genes are transcribed, i.e. the reporter genes should remain silent if there is no 
interaction, unless the LexA fusions act as activators themselves. 
Following selection for the presence of the two vectors, western blots were performed to 
test for expression of both LexA and V5-NLS-B42 fusions in the transformants prior to 
examination of their interaction by histidine auxotrophy and β-galactosidase activity.  
5.4.1 Yeast two-hybrid analysis with LexA-RAD51 as the 
DNA-binding domain fusion  
To begin examining potential interactions, RAD51 was first used as the “bait” (expressed 
as a LexA fusion) and its interactions assayed with RAD51 and the RAD51 paralogues as 
the “prey” (expressed as V5-NLS-B42 fusions). To do this, pHybLex/Zeo-RAD51 was co-
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transformed with pYesTrp2-RAD51, pYesTrp2-RAD51-3, pYesTrp2-RAD51-4, 
pYesTrp2-RAD51-5 and pYesTrp2-RAD51-6; see Materials and Methods, Section 2.4.6. 
As a negative control, pHybLex/Zeo-RAD51 was also co-transformed with empty vector 
pYesTrp2. Two independent co-transformants (X and Y) were analysed for each 
combination to determine if the LexA-RAD51 fusion protein was expressed as well as the 
V5-NLS-B42-RAD51 fusion and the V5-NLS-B42-RAD51 paralogue fusion proteins, (see 
Figure 5-4). To do this, cell extracts were prepared from each of the co-transformed cells, 
and the proteins were separated on a 10 % SDS-PAGE gel. The proteins were then 
transferred to a nylon membrane and probed with goat anti-Lex IgG anti-serum (Santa 
Cruz) at a 1:1000 dilution and detected with anti-goat IgG-HRP anti-serum (Santa Cruz) at 
a 1:5000 dilution (Figure 5-4A). The blot was then stripped and reprobed with mouse anti-
V5 IgG anti-serum (Invitrogen) at a dilution of 1:5000 and detected with anti-mouse IgG-
HRP anti-serum (Sigma) at a 1:2500 dilution (Figure 5-4B).  
In all the co-transformants, a protein of the expected size for the LexA-RAD51 fusion was 
detected (72 kDa) by the anti-LexA anti-serum (Figure 5-4). This LexA-RAD51 fusion 
was absent in the untransformed S. cerevisiae L40 wildtype cell extract. Proteins of the 
expected sizes of RAD51 and the four RAD51 paralogues expressed as V5-NLS-B42 
fusions were also detected by the anti-V5 anti-serum. It is unclear why the apparent 
expression or reactivity of the V5-NLS-B42-RAD51-5 fusion is much greater than the 
others, but is must be pointed out that no loading controls were performed.  
 
Figure 5-4: Western analysis of LexA-RAD51 expression with V5-NLS-B42-RAD51 and the RAD51 
paralogues in S. cerevisiae L40 co-transformants. 
Two co-transformants (X and Y) expressing LexA-RAD51 and each V5-NLS-B42 fusion of RAD51 (R51), 
RAD51-3 (R-3), RAD51-5 (R-5), RAD51-6 (R-6) or RAD51-4 (R-4) are shown. Figure 5-4A: Protein 
extracts from the co-transformants, and from the untransformed S. cerevisiae L40 cells (wt) were separated 
by SDS-PAGE, blotted and probed with anti-LexA anti-serum. Figure 5-4B: The blot was then stripped and 
reprobed with anti-V5 anti-serum. The inferred sizes of the proteins (kDa) are between 52 and 66 kDa as 
shown. The predicted sizes of the fusion polypeptides are as follows: LexA-RAD51: 72 kDa and V5-NLS-
B42 fusions- RAD51: 52 kDa, RAD51-3: 66.5 kDa, RAD51-4: 57.7 kDa, RAD51-5: 53.6 kDa and RAD51-
6: 62.4 kDa. The fusion of V5- NLS-B42 adds 12 kDa and the fusion of LexA adds 32 kDa to the proteins. 
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To examine interactions, the histidine auxotrophy test was first used and showed that 
RAD51 interacts with itself as revealed by the clear growth on the plates lacking histidine 
and containing 15 mM 3’ aminotriazole (Figure 5-5). In contrast, there was no evidence 
that RAD51 interacts with any of the other RAD51 paralogues in this system, as there is an 
absence of growth in all these co-transformants for reasons discussed in Section 5.3.4.1. To 
ensure that the cultures of each co-transformant were viable, a positive control plate was 
used. The cultures were plated on media containing all the essential amino acids, including 
histidine. As histidine was provided, all the inoculated cultures grew as small circular 
colonies. This plate was then used in the X-gal filter lift assay, see Figure 5-6. 
 
Figure 5-5: Histidine auxotrophy analysis of LexA-RAD51 with V5-NLS-B42-RAD51 and the V5-NLS-
B42-RAD51 paralogues. 
Figure 5-5 shows growth or absence of growth of the LexA-RAD51 fusion with V5-NLS-B42-RAD51 and 
each V5-NLS-B42-RAD51-paralogue fusion on medium lacking histidine. The two co-transformants (X and 
Y) are shown for LexA-RAD51 with each combination of V5-NLS-B42 fusion [Labelled: RAD51 (R51), 
RAD51-3 (R-3), RAD51-5 (R-5), RAD51-6 (R-6) or RAD51-4 (R-4)]. As a negative control, the LexA-
RAD51 expression vector was co-transformed with the pYesTrp2 vector (empty vector: EV). The plates have 
three different concentrations of histidine inhibitor, 3’ aminotriazole, Figure 5-5A: 5 mM, B: 10 mM, C: 15 
mM.  
The histidine auxotrophy test was performed at least twice and the plates in Figure 5-5 
were part of multiple experiments. It is noteworthy that the L40 strain has a mutation in 
ADE2 gene and as a result cannot produce phosphoribosylaminoimidazole carboxylase. 
This carboxylase is a requirement of the adenine biosynthetic pathway converting 5’-
phosphoribosyl-5-aminoimidazole to 5’-phosphoribosyl-5-aminoimidazole-4-carboxylate 
(Rolfes, 2006; Ugolini & Bruschi, 1996). As a result, the L40 strain is auxotrophic for 
adenine, as mentioned in Section 5.3.3 and addition of adenine to the medium is required 
for growth of the wildtype and co-transformants. An accumulation of 5’-phosphoribosyl-5-
aminoimidazole in the yeast cell results in a pink/red pigment, which is clearly seen in 
Figure 5-5C. 
In order to verify the results of the histidine auxotrophy test, β-galactosidase activity was 
analysed. As a positive control for the histidine auxotrophy test, the cultures of each co-
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transformant were plated on media containing all the essential amino acids, including 
histidine. These colonies were then analysed using the X-gal filter lift assay (see Material 
and Methods, Section 2.10.2). In the transformant expressing LexA-RAD51 and V5-NLS-
B42-RAD51, there was a clear colour change from pink to blue in the X-gal filter lift 
assay, confirming self-interaction of RAD51 (Figure 5-6). No such evidence for β-
galactosidase activity was seen in any of the other transformants, or in the control cells 
expressing only LexA-RAD51. These results are consistent with the histidine auxotrophy 
assay. 
 
Figure 5-6: X-gal filter lift analysis of LexA-RAD51 with V5-NLS-B42-RAD51 and the V5-NLS-B42-
RAD51 paralogues. 
As a positive control for the histidine auxotrophy test, the cultures of each co-transformant (X and Y) were 
plated on medium containing all the essential amino acids. These transformants were then analysed using the 
X-gal filter lift assay. LexA-RAD51 was co-expressed with each combination of V5-NLS-B42 fusion 
[Labelled: RAD51 (R51), RAD51-3 (R-3), RAD51-5 (R-5), RAD51-6 (R-6) or RAD51-4 (R-4)]. As a 
negative control, the LexA-RAD51 expression vector was co-transformed with the pYesTrp2 vector (empty 
vector: EV). Interactions are identified by a colour change from pale pink to blue, where β-galactosidase 
expression was induced from a lacZ reporter gene. 
Finally, the interaction of LexA-RAD51 with the V5-NLS-B42 RAD51 and V5-NLS-B42 
RAD51 paralogue fusions were quantified by measuring the β-galactosidase activity in the 
lysate of the co-transformants, using the yeast β-galactosidase assay kit by Pierce (see 
Materials and Methods, Section 2.10.3). As a negative control, the LexA-RAD51 
expression vector was co-transformed with the pYesTrp2 vector (empty vector: EV). The 
results of this are shown in Figure 5-7 and again demonstrate RAD51 self interaction, and 
no other interaction between RAD51 and any of the RAD51 paralogues. Only in the two 
co-transformants (X and Y) expressing LexA-RAD51 and V5-NLS-B42-RAD51 were the 
levels of the β-galactosidase higher than the control expressing only LexA-RAD51. 
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Figure 5-7: Quantification of β-galactosidase activity of LexA-RAD51 with V5-NLS-B42-RAD51 and 
the V5-NLS-B42-RAD51 paralogues.  
β-galactosidase activity was analysed for cells expressing the LexA-RAD51 fusion with V5-NLS-B42-
RAD51 and each V5-NLS-B42-RAD51-paralogue fusion using the yeast β-galactosidase assay kit by Pierce. 
The measurement of β-galactosidase activity considers the generation of o-nitrophenol which was quantified 
by spectrophotometry at an absorbance of 420 nm. Two independent co-transformants (X and Y) are shown. 
As a negative control, the LexA-RAD51 expression vector was co-transformed with the pYesTrp2 vector 
(empty vector: EV). The values represent the mean of three independent experiments with the 95 % 
confidence intervals indicated by error bars.  
This yeast two-hybrid analysis indicates that there is self-interaction between RAD51 
molecules, which is consistent with published data from other eukaryotes, such as 
mammals (Benson et al., 1994; Schild et al., 2000) 
5.4.2 Yeast two-hybrid analysis with LexA-RAD51-3 as 
the DNA-binding domain fusion  
The next protein used as the “bait” was RAD51-3 and its interactions were assayed with 
RAD51 and the RAD51 paralogues as the “prey”. The vector pHybLex/Zeo-RAD51-3, 
expressing RAD51-3 as a LexA fusion, was co-transformed into S. cerevisiae L40 cells 
with pYesTrp2-RAD51, pYesTrp2-RAD51-3, pYesTrp2-RAD51-4, pYesTrp2-RAD51-5 
and pYesTrp2-RAD51-6, expressing RAD51 and the RAD51 paralogues as V5-NLS-B42 
fusions (see Materials and Methods, Section 2.4.6). As before, two independent co-
transformants were analysed for each LexA-RAD51-3 fusion (X and Y) in combination 
with V5-NLS-B42-RAD51 and the V5-NLS-B42-RAD51 paralogue fusions. Figure 5-8A 
shows the western blot analysis of the co-transformants, demonstrating that each expressed 
Rachel Dobson, 2009   Chapter 5, 161 
a protein of the predicted size of LexA-RAD51-3 (86 kDa) detected by the anti-LexA anti 
serum. This LexA-RAD51-3 fusion was absent in the untransformed S. cerevisiae L40 
wildtype cell extract. Proteins of the expected sizes of the V5-NLS-B42 fusions to RAD51 
and the RAD51 paralogues were also detected by the anti-V5 anti-serum (see Figure 5-8B).  
 
Figure 5-8: Western analysis of LexA-RAD51-3 expression with V5-NLS-B42-RAD51 and RAD51 
paralogues in S. cerevisiae L40 co-transformants. 
Two co-transformants (X and Y) expressing LexA-RAD51-3 and each V5-NLS-B42 fusions of RAD51 
(R51), RAD51-3 (R-3), RAD51-5 (R-5), RAD51-6 (R-6) or RAD51-4 (R-4) are shown. Figure 5-8A: 
Protein extracts from the co-transformants, and from the untransformed S. cerevisiae L40 cells (wt) were 
separated by SDS-PAGE, blotted and probed with anti-LexA anti-serum. Figure 5-8B: The blot was then 
stripped and reprobed with anti-V5 anti-serum. The inferred sizes of the proteins (kDa) are shown. The 
predicted sizes of the fusion polypeptides are as follows: LexA-RAD51-3: 86.5 kDa and V5-NLS-B42 
fusions- RAD51: 52 kDa, RAD51-3: 66.5 kDa, RAD51-4: 57.7 kDa, RAD51-5: 53.6 kDa and RAD51-6: 
62.4 kDa. The fusion of V5- NLS-B42 adds 12 kDa and the fusion of LexA adds 32 kDa to the proteins. 
The results of the histidine auxotrophy test to examine interactions are shown in Figure 5-
9, and reveal growth of the co-transformants expressing both LexA-RAD51-3 and each of 
V5-NLS-B42-RAD51-4 and V5-NLS-B42-RAD51-6 on media lacking histidine. This 
result indicates that RAD51-3 interacts with RAD51-4, and with RAD51-6. The absence of 
growth of the other co-transformants indicates that RAD51-3 does not interact with 
RAD51, RAD51-5 or with itself in this system. 
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Figure 5-9: Histidine auxotrophy analysis of LexA-RAD51-3 with V5-NLS-B42-RAD51 and the V5-
NLS-B42-RAD51 paralogues.  
Figure 5-9 shows growth or absence of growth of the LexA-RAD51-3 fusion with V5-NLS-B42-RAD51 and 
each V5-NLS-B42-RAD51-paralogue fusion on medium lacking histidine. The two co-transformants (X and 
Y) are shown for LexA-RAD51-3 with each combination of V5-NLS-B42 fusion [Labelled: RAD51 (R51), 
RAD51-3 (R-3), RAD51-5 (R-5), RAD51-6 (R-6) or RAD51-4 (R-4)]. As a negative control, the LexA-
RAD51-3 expression vector was co-transformed with the pYesTrp2 vector (empty vector: EV). The plates 
have three different concentrations of histidine inhibitor, 3’ aminotriazole, Figure 5-9A: 5 mM, B: 10 mM, 
C: 15 mM.  
As for LexA-RAD51, the histidine auxotrophy assay of LexA-RAD51-3 interaction was 
verified by assaying for the β-galactosidase activity, firstly by the X-gal lift assay (see 
Figure 5-10), and secondly by quantifying the β-galactosidase activity in the yeast lysates 
(see Figure 5-11). A strong colour change from pink to blue was seen in the LexA-RAD51-
3:V5-NLS-B42-RAD51-4 co-transformant in the X-gal filter lift assay (Figure 5-10), 
indicative of a relatively stable interaction. There was also evidence for a weak interaction 
between the LexA-RAD51-3 and V5-NLS-B42-RAD51-6 confirmed by colour change 
from pink to pale blue. No other interaction between LexA-RAD51-3 and V5-NLS-B42-
RAD51, V5-NLS-B42-RAD51-3 or V5-NLS-B42-RAD51-5 could be detected with this 
assay. 
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Figure 5-10: X-gal filter lift analysis of LexA-RAD51-3 with V5-NLS-B42-RAD51 and the V5-NLS-
B42-RAD51 paralogues. 
As a positive control for the histidine auxotrophy test, the cultures of each co-transformant (X and Y) were 
plated on medium containing all the essential amino acids. These transformants were then analysed using the 
X-gal filter lift assay. LexA-RAD51-3 was co-expressed with each combination of V5-NLS-B42 fusion 
[Labelled: RAD51 (R51), RAD51-3 (R-3), RAD51-5 (R-5), RAD51-6 (R-6) or RAD51-4 (R-4)]. As a 
negative control, the LexA-RAD51-3 expression vector was co-transformed with the pYesTrp2 vector 
(empty vector: EV). Interactions are identified by a colour change from pale pink to blue, where β-
galactosidase expression was induced from a lacZ reporter gene.  
These weak and strong interactions were confirmed by quantitatively measuring β-
galactosidase activity. The LexA-RAD51-3:V5-NLS-B42-RAD51-4 co-transformants 
displayed ~5-6 fold greater β-galactosidase activity than the LexA-RAD51-3 expressor 
control. The LexA-RAD51-3:V5-NLS-B42-RAD51-6 co-transformants also displayed an 
increase of β-galactosidase activity, but this was only ~3 fold higher than the control (see 
Figure 5-11). The data also confirm that RAD51-3 does not interact with RAD51, RAD51-
3 or RAD51-5 in the yeast two-hybrid system. 
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Figure 5-11: Quantification of β-galactosidase activity of LexA-RAD51-3 with V5-NLS-B42-RAD51 
and the V5-NLS-B42-RAD51 paralogues.  
β-galactosidase activity was analysed for cells expressing LexA-RAD51-3 fusion with V5-NLS-B42-RAD51 
and each V5-NLS-B42-RAD51-paralogue fusion using the yeast β-galactosidase assay kit by Pierce. The 
measurement of β-galactosidase activity considers the generation of o-nitrophenol which was quantified by 
spectrophotometry at an absorbance of 420 nm. Two independent co-transformants (X and Y) are shown. As 
a negative control, the LexA-RAD51-3 expression vector was co-transformed with the pYesTrp2 vector 
(empty vector: EV). The values represent the mean of three independent experiments with the 95 % 
confidence intervals indicated by error bars.  
The results of all three assays are therefore consistent, showing an interaction between 
RAD51-3 and RAD51-4, and an interaction between RAD51-3 and RAD51-6. 
5.4.3 Yeast two-hybrid analysis with LexA-RAD51-4 as 
the DNA-binding domain fusion  
RAD51-4 was the next LexA fusion to be expressed to test for interactions with RAD51 
and the other RAD51 paralogues. As before, all pair-wise combinations of pHybLex/Zeo-
RAD51-4, expressing LexA-RAD51-4, and pYesTrp2-RAD51 and the four pYesTrp2-
RAD51 paralogue vectors expressing V5-NLS-B42 fusions, were co-transformed into S. 
cerevisiae L40 cells (see Materials and Methods, Section 2.4.6). In this case, the LexA-
RAD51-4 fusion appeared to act as a transcriptional activator, independently of the V5-
NLS-B42 fusions. This is illustrated in Figure 5-12A, which show the β-galactosidase 
activity of LexA-RAD51-4 co-transformed with V5-NLS-B42-RAD51 and the V5-NLS-
B42-RAD51 paralogue fusions. In all cases, including where LexA-RAD51-4 is expressed 
alone, very high levels of β-galactosidase activity were detected (~15-30 fold higher than 
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in the previous LexA-RAD51 and LexA-RAD51-3 experiments, which showed ~200 units 
of β-galactosidase activity; Figure 5-7 and Figure 5-11 respectively).  
However, there was an apparent decrease of β-galactosidase activity when LexA-RAD51-4 
was co-expressed with V5-NLS-B42-RAD51-3. It is conceivable that this indicates that 
LexA-RAD51-4 was bound by V5-NLS-B42-RAD51-3 in these conditions, sequestering 
the protein and resulting in less LexA-RAD51-4-mediated auto-induction of transcription 
by the B42 domain of the RAD51-3 fusion. To test this hypothesis, three further 
independent co-transformants expressing LexA-RAD51-4 and V5-NLS-B42-RAD51-3 
were analysed (Figure 5-12B). In this case no apparent decrease in β-galactosidase activity 
was observed compared with LexA-RAD51-4 co-transformed with empty V5-NLS-B42 
vector. This suggests that the potential interaction was not reproducible. Furthermore, the 
auto-induction catalysed by the full length RAD51-4 prevents interpretation of potential 
interactions in this yeast two-hybrid analysis.  
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Figure 5-12: Quantification of β-galactosidase activity of LexA-RAD51-4 co-expressed with pYesTrp2, 
V5-NLS-B42-RAD51 and each V5-NLS-B42-RAD51-paralogue fusion  
β-galactosidase activity was analysed for cells expressing the LexA-RAD51-4 fusion with V5-NLS-B42-
RAD51 and each V5-NLS-B42-RAD51-paralogue fusion assayed using the yeast β-galactosidase assay kit. 
Figure 5-12A shows the auto-induction of the LexA-RAD51-4 fusion with the V5-NLS-B42-RAD51 and the 
V5-NLS-B42-RAD51 paralogue fusions. As a negative control, the LexA-RAD51-4 expression vector was 
co-transformed with the pYesTrp2 vector [Labelled EV: empty vector]. As a further control, the LexA-
RAD51-4 expression vector alone was analysed [Labelled LexA-RAD51-4]. The plot shows the values 
representing the mean of three independent experiments with the 95 % confidence intervals indicated by 
error bars. Figure 5-12B shows the auto-induction of LexA-RAD51-4 co-transformed with the pYesTrp2 
vector (EV) and three independent LexA-RAD51-4:V5-NLS-B42-RAD51-3 transformants (A-C). 
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One possible reason for the auto-induction by LexA-RAD51-4 is that the sequence of the 
N terminus of RAD51-4 is rich in acidic amino acid residues; previous studies have shown 
that acidic sequences with no homology to proteins encoded elsewhere in the yeast genome 
can act as transcription activators (Ma & Ptashne, 1987b). To test this and to see if 
RAD51-4 interactions could be mapped, DNA encoding the C and N terminal fragment of 
the RAD51-4 protein were cloned into pHybLex/Zeo, based on the domains mapped in the 
human Rad51 paralogues (Miller et al., 2004). Miller et al., (2004) showed by yeast two-
hybrid analysis, that the N terminal domain and the linker region of HsRad51B were 
required for interaction with the HsRad51C. The authors also showed that the N terminal 
domain of HsRad51B without the linker region could not interact with HsRad51C. 
Although highly speculative, and at present there is no direct evidence that the functions of 
the T. brucei and mammalian Rad51 paralogues are the same, there are some similarities 
between the species. For instance, both groups of paralogues have been shown to function 
in HR, and also have been shown to interact as complexes (Masson et al., 2001; Liu et al., 
2002; Section 5.4 & Section 5.6 of this chapter). There are also potential Walker A and B 
boxes in both sub-sets of proteins, which allows some deduction of different domains from 
their relative positions (Miller et al., 2004; Proudfoot & McCulloch, 2005a). The 
hypothesis behind making the truncations of the RAD51-4 protein was based on the 
findings of Miller et al., 2004, with the aid of their predicted ribbon diagram and model of 
topology of the HsRad51 paralogues. The N terminal fragment of RAD51-4 encompassed 
the first 151 amino acids, which included a putative N terminal domain as well as the 
predicted helix-hairpin-helix linker region (Proudfoot & McCulloch, 2005a; Figure 5-13 ). 
It was this region of the HsRad51B that was necessary for binding to HsRad51C (Miller et 
al., 2004). If the interacting domain is similar to the mammalian Rad51B paralogue and if 
the LexA-RAD51-4 N terminal fragment did not auto-induce, this truncation would allow 
interpretation of interactions with the other RAD51 paralogues. The C terminal fragment 
of RAD51-4 encompassed the amino acids 94 to 423, which again included the predicted 
helix-hairpin-helix linker region and the C terminal domain with the predicted Walker A 
and B boxes (Figure 5-13). It was this region of the HsRad51C that was necessary for 
binding to HsRad51B, HsRad51D and XRCC3 (Miller et al., 2004). This could also act as 
a control, if LexA-RAD51-4 N terminal domain was shown to interact with one or more of 
the RAD51 paralogues, and the LexA-RAD51-4 C terminal domain did not interact and 
did not auto-induce, it could be deduced that the N terminus of the proteins is required for 
interaction, like the mammalian paralogue, HsRad51B. 
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Figure 5-13: A comparison of the RAD51 paralogue proteins highlighting the N and C terminal amino 
acid sequence domain used for truncation of RAD51-4. 
This alignment shows the predicted positions of the Walker A and B domains (A and B), and the helix-
hairpin-helix (h-H-h) linker region. Also highlighted are the regions used for the RAD51-4 truncation: LexA-
RAD51-4 N terminal domain is indicated with the brown arrow (1-151 amino acids) and the LexA-RAD51-4 
C terminal domain is indicated with the green arrow (94-423 amino acids). Reprinted with permission from 
Oxford Journals, Proudfoot & McCulloch (2005a), Nucleic Acid Research 33, pp 6909. 
To this end, the coding sequence for the N terminus of RAD51-4 (from 1-453 bp) was 
PCR-amplified using primers N-TermR51-4 For and N-TermR51-4 Rev (see Materials and 
Methods, Section 2.4.1, Table 2-1). The resulting PCR fragment (453 bp) was then cloned 
into pHybLex/Zeo using the EcoRI and PstI sites, creating a LexA fusion to the first 1-151 
amino acids of RAD51-4, as shown in Figure 5-14. The coding sequence for the C 
terminus of RAD51-4 (from 282-1272 bp) was PCR-amplified using primers C-TermR51-
4 For and C-TermR51-4 Rev (see Materials and Methods, Section 2.4.1, Table 2-1). The 
990 bp PCR-amplified fragment was then cloned in to pHybLex/Zeo using the EcoRI and 
PstI sites. 
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Figure 5-14: Diagram showing the LexA fusions with the RAD51-4 truncations. 
The complete lexA gene is part of the pHybLex/Zeo vector and allows expression of a fusion protein with the 
LexA DNA-binding domain. LexA has 202 amino acids, the N-terminal domain of RAD51-4 has 151 amino 
acids and the C-terminal domain of the RAD51-4 has 330 amino acids. 
To determine if these fusions activated the expression of lacZ and HIS3 genes, each 
construct, LexA-RAD51-4-N term and LexA-RAD51-4-C term, was co-transformed with 
the V5-NLS-B42 empty vector. Two co-transformants of each (X and Y) were examined. 
Both the β-galactosidase activity measurement (Figure 5-15) and histidine auxotrophy tests 
(Figure 5-16) showed that the truncations of RAD51-4 were also auto-inducers, resulting 
in equivalent levels of induction compared to the full length RAD51-4. The basis of this 
induction is unclear, but may reside in the 57 amino acids that overlap the two truncations. 
Nevertheless, this was not dissected further and evaluation of the LexA-RAD51-4 
interactions by yeast two-hybrid cannot be interpreted. 
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Figure 5-15: Auto-induction of the LexA-RAD51-4 C and N termini truncated fusions co-expressed 
with pYesTrp2 (EV) assayed using the yeast β-galactosidase assay kit. 
β-galactosidase activity was analysed for cells expressing LexA-RAD51-4 C and N termini truncated fusions 
co-expressed with the pYesTrp2 vector expressing only V5-NLS-B42. Auto-induction was apparent for both 
the independent co-transformants (X and Y) for LexA-RAD51-4 C and LexA-RAD51-4 N termini truncated 
fusions. As a control, the LexA-RAD51-4 expression vector alone showed auto-induction [Labelled LexA-
RAD51-4].  The plot shows the values representing the mean of three independent experiments with the 95 
% confidence intervals indicated by error bars.  
 
 
Figure 5-16: Auto-induction of the truncated LexA-RAD51-4 C and N termini truncated fusions co-
expressed with pYesTrp2 (EV) assayed by histidine auxotrophy.  
Figure 5-16 shows the growth of the LexA-RAD51-4 C and N terminal fusion without a V5-NLS-B42 
fusion protein, on medium lacking histidine. Two independent co-transformants (X and Y) are shown for 
each of the LexA-RAD51-4 C and N termini truncated fusions. The plates have three different concentrations 
of histidine inhibitor, 3’ aminotriazole, Figure 5-16A: 5 mM, B: 10 mM, C: 15 mM. 
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5.4.4 Yeast two-hybrid analysis with LexA-RAD51-5 as 
the DNA-binding domain fusion  
The fourth protein expressed as a LexA fusion to examine interaction was RAD51-5. The 
pHybLex/Zeo-RAD51-5 construct was generated by PCR-amplification of the RAD51-5 
ORF using the primers R51-5 For and R51-5 Rev (see Materials and Methods, Section 
2.4.1, Table 2-1). This fragment was then cloned into pHybLex/Zeo using flanking ApaI 
and SalI sites (Figure 5-13). This strategy resulted in a frame shift, and therefore meant 
that the LexA and RAD51-5 ORFs were out of frame. Site directed mutagenesis was 
carried out to rectify this: an extra nucleotide (A) was added to the ApaI site, resulting in 
disruption of the ApaI restriction site, which allowed possible mutated clones to be 
screened. This also resulted in correction of the frame shift, making the RAD51-5 ORF in 
frame with LexA; the corrected construct was verified by DNA sequencing. 
pHybLex/Zeo-RAD51-5 expressing a LexA-RAD51-5 fusion, was co-expressed with  
pYesTrp2-RAD51 and pYesTrp2-RAD51 paralogues as V5-NLS-B42 fusions in S. 
cerevisiae L40 cells (see Materials and Methods, Section 2.4.6). Two independent co-
transformants were analysed for each combination (X and Y). LexA-RAD51-5 fusion 
expression was verified by western blotting using anti-LexA anti-serum (Figure 5-17A) 
and the appropriately sized V5-NLS-B42 fusions were found to be expressed in the 
cognate co-transformants by detection with anti-V5 anti-serum (Figure 5-17B).  
 
Figure 5-17: Western analysis of LexA-RAD51-5 expression with V5-NLS-B42-RAD51 and RAD51 
paralogues in S. cerevisiae L40 co-transformants. 
Two co-transformants (X and Y) expressing LexA-RAD51-5 and each V5-NLS-B42 fusion of RAD51 
(R51), RAD51-3 (R-3), RAD51-5 (R-5), RAD51-6 (R-6) or RAD51-4 (R-4) are shown. Figure 5-17A: 
Protein extracts from the co-transformants were separated by SDS-PAGE, blotted and probed with anti-LexA 
anti-serum. The predicted size of LexA-RAD51-5 is 73.6 kDa. The negative control (EV) shows a 
pHybLex/Zeo empty vector transformant and indicates the predicted size of the non-fused LexA: 32 kDa. 
Figure 5-17B: The blot was then stripped and reprobed with anti-V5 anti-serum. The inferred sizes of the 
proteins (kDa) are shown. The predicted sizes of the fusion polypeptides are as follows: V5-NLS-B42 
fusions- RAD51: 52 kDa, RAD51-3: 66.5 kDa, RAD51-4: 57.7 kDa, RAD51-5: 53.6 kDa and RAD51-6: 
62.4 kDa. The fusion of V5-NLS-B42 adds 12 kDa. 
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The histidine auxotrophy test showed no evidence for transcriptional activation when the 
LexA-RAD51-5 fusion was co-expressed with V5-NLS-B42-RAD51 or any of the V5-
NLS-B42-RAD51 paralogues (Figure 5-18). The lack of observable interaction was 
confirmed by assaying for β-galactosidase activity, using both the X-gal filter lift assay 
(Figure 5-19) and measuring the β-galactosidase activity in cell lysates (Figure 5-20).  
 
Figure 5-18: Histidine auxotrophy analysis of LexA-RAD51-5 with V5-NLS-B42-RAD51 and the V5-
NLS-B42-RAD51 paralogues. 
The diagram shows growth or absence of growth of the LexA-RAD51-5 fusion with V5-NLS-B42-RAD51 
and each V5-NLS-B42-RAD51-paralogue fusion on medium lacking histidine. The two co-transformants (X 
and Y) are shown for LexA-RAD51-5 with each combination of V5-NLS-B42 fusion [Labelled: RAD51 
(R51), RAD51-3 (R-3), RAD51-5 (R-5), RAD51-6 (R-6) or RAD51-4 (R-4)]. As a negative control, the 
LexA-RAD51-5 expression vector was co-transformed with the pYesTrp2 vector (empty vector: EV). The 
plates have three different concentrations of histidine inhibitor, 3’ aminotriazole, Figure 5-18A: 5 mM, B: 
10 mM, C: 15 mM.  
 
Figure 5-19: X-gal filter lift analysis of LexA-RAD51-5 with V5-NLS-B42-RAD51 and the V5-NLS-
B42-RAD51 paralogues. 
As a positive control for the histidine auxotrophy test, the cultures of each co-transformant (X and Y) were 
plated on medium containing all the essential amino acids. These transformants were then analysed using the 
X-gal filter lift assay. LexA-RAD51-5 was co-expressed with each combination of V5-NLS-B42 fusion 
[Labelled: RAD51 (R51), RAD51-3 (R-3), RAD51-5 (R-5), RAD51-6 (R-6) or RAD51-4 (R-4)]. As a 
negative control, the LexA-RAD51-5 expression vector was co-transformed with the pYesTrp2 vector 
(empty vector: EV). Interactions are identified by a colour change from pale pink to blue, where β-
galactosidase expression was induced from a lacZ reporter gene. 
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Figure 5-20: Quantification of β-galactosidase activity of LexA-RAD51-5 with V5-NLS-B42-RAD51 
and the V5-NLS-B42-RAD51 paralogues.  
β-galactosidase activity was analysed for cells expressing the LexA-RAD51-5 fusion with V5-NLS-B42-
RAD51 and each V5-NLS-B42-RAD51-paralogue fusion using the yeast β-galactosidase assay kit by Pierce. 
The measurement of β-galactosidase activity considers the generation of o-nitrophenol which was quantified 
by spectrophotometry at an absorbance of 420 nm. Two independent co-transformants (X and Y) are shown. 
As a negative control, the LexA-RAD51-5 expression vector was co-transformed with the pYesTrp2 vector 
(empty vector: EV). The values represent the mean of three independent experiments with the 95 % 
confidence intervals indicated by error bars.  
Since the western analysis shows that the LexA-RAD51-5 fusion is detectably expressed, 
as are the V5-NLS-B42-RAD51 and the V5-NLS-B42-RAD51 paralogues fusions (Figure 
5-17), the lack of reporter gene expression is not simply explained by poor expression or 
rapid degradation of the proteins. These results may indicate that RAD51-5 may not 
interact with any other proteins as a “bait” in this assay. It may of course be the case that 
the LexA-RAD51-5 fusion is not localised to the nucleus, or the fusion cannot bind to the 
DNA. It could also be the case that the fusion to LexA causes incorrect folding of the 
RAD51-5 protein, disrupting the interaction binding sites. Nevertheless, these results may 
indicate that RAD51-5 does not interact with the other T. brucei RAD51 paralogues. 
5.4.5 Yeast two-hybrid analysis with LexA-RAD51-6 as 
the DNA-binding domain fusion  
Finally, RAD51-6 was used as the “bait” for interaction analysis. The pHybLex/Zeo-
RAD51-6 was co-transformed with all pair-wise combinations of pYesTrp2-RAD51 and 
each of the pYesTrp2-RAD51 paralogues into S. cerevisiae L40 cells (see Materials and 
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Methods, Section 2.4.6). As before, two independent co-transformants (X and Y) were 
analysed for expression of the LexA-RAD51-6 fusion and for the cognate V5-NLS-B42-
RAD51 or V5-NLS-B42-RAD51 paralogue fusions (Figure 5-21). LexA-RAD51-6 
expression in each co-transformant was identified: although weak, a band of the predicted 
size (~83 kDa) was detected using anti-LexA anti-serum. The V5-NLS-B42 fusions to 
RAD51 and to the RAD51 paralogues were also readily detected, using anti-V5 anti-
serum.  
 
Figure 5-21: Western analysis of LexA-RAD51-6 expression with V5-NLS-B42-RAD51 and RAD51 
paralogues in S. cerevisiae L40 co-transformants. 
Two co-transformants (X and Y) expressing LexA-RAD51-6 and each V5-NLS-B42 fusion of RAD51 
(R51), RAD51-3 (R-3), RAD51-5 (R-5), RAD51-6 (R-6) or RAD51-4 (R-4) are shown. Figure 5-21A: 
Protein extracts from the co-transformants, and for the untransformed S. cerevisiae L40 cells (wt) were 
separated by SDS-PAGE, blotted and probed with anti-LexA anti-serum. Figure 5-21B: The blot was then 
stripped and reprobed with anti-V5 anti-serum. The inferred sizes of the proteins (kDa) are shown. The 
predicted sizes of the fusion polypeptides are as follows: LexA-RAD51-6: 82.4 kDa and V5-NLS-B42 
fusions- RAD51: 52 kDa, RAD51-3: 66.5 kDa, RAD51-4: 57.7 kDa, RAD51-5: 53.6 kDa and RAD51-6: 
62.4 kDa. The fusion of V5-NLS-B42 adds 12 kDa and the fusion of LexA adds 32 kDa to the proteins. 
The histidine auxotrophy test revealed no evidence for transcriptional activation when the 
LexA-RAD51-6 fusion was co-expressed with V5-NLS-B42-RAD51 or the other V5-
NLS-B42-RAD51 paralogues (Figure 5-22).  This negative result was confirmed using 
with the X-gal filter lift assay (Figure 5-23) to detect β-galactosidase activity and was also 
confirmed by quantification of β-galactosidase activity in the lysates of the co-
transformants (Figure 5-24).  
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Figure 5-22: Histidine auxotrophy analysis of LexA-RAD51-6 with V5-NLS-B42-RAD51 and the V5-
NLS-B42-RAD51 paralogues. 
Figure 5-22 shows growth or absence of growth of the LexA-RAD51-6 fusion with V5-NLS-B42-RAD51 
and each V5-NLS-B42-RAD51-paralogue fusion on medium lacking histidine. The two co-transformants (X 
and Y) are shown for LexA-RAD51-6 with each combination of V5-NLS-B42 fusion [Labelled: RAD51 
(R51), RAD51-3 (R-3), RAD51-5 (R-5), RAD51-6 (R-6) or RAD51-4 (R-4)]. As a negative control, the 
LexA-RAD51-6 expression vector was co-transformed with the pYesTrp2 vector (empty vector: EV). The 
plates have three different concentrations of histidine inhibitor, 3’ aminotriazole, Figure 5-22A: 5 mM, B: 
10 mM, C: 15 mM.   
 
Figure 5-23: X-gal filter lift analysis of LexA-RAD51-6 with V5-NLS-B42-RAD51 and the V5-NLS-
B42-RAD51 paralogues. 
As a positive control for the histidine auxotrophy test, the cultures of each co-transformant (X and Y) were 
plated on medium containing all the essential amino acids. These transformants were then analysed using the 
X-gal filter lift assay. LexA-RAD51-6 was co-expressed with each combination of V5-NLS-B42 fusion 
[Labelled: RAD51 (R51), RAD51-3 (R-3), RAD51-5 (R-5), RAD51-6 (R-6) or RAD51-4 (R-4)]. As a 
negative control, the LexA-RAD51-6 expression vector was co-transformed with the pYesTrp2 vector 
(empty vector: EV). Interactions are identified by a colour change from pale pink to blue, where β-
galactosidase expression was induced from a lacZ reporter gene. 
 
Western analysis showed the LexA-RAD51-6 fusion is detectably expressed, as are the 
V5-NLS-B42 fusions in the co-transformants (Figure 5-21).  It was previously shown that 
LexA-RAD51-3 interacted with V5-NLS-B42-RAD51-6 (Section 5.4.2). It therefore is 
surprising that the reciprocal experiment, using LexA-RAD51-6 fusion as the “bait” and 
the V5-NLS-B42-RAD51-3 fusion as the “prey” did not reveal any interaction. One 
possible explanation is that the C terminal fusion of LexA to RAD51-6 inhibits the site of 
interaction between RAD51-6 and RAD51-3. Another explanation is that one or both of 
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the fusion proteins may not be localised to the nucleus. V5-NLS-B42-RAD51-3 fusion is 
the largest of the fused proteins at 86.5 kDa and did not activate transcription in 
combination with any of the other LexA fusion proteins. It is also possible that the B42 
domain might be unable to recruit RNA polymerase when fused to RAD51-3 or when 
RAD51-6 is bound to the RAD51-3.  
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Figure 5-24: Quantification of β-galactosidase activity of LexA-RAD51-6 with V5-NLS-B42-RAD51 
and the V5-NLS-B42-RAD51 paralogues.  
β-galactosidase activity was analysed for cell expressing the LexA-RAD51-6 fusion with V5-NLS-B42-
RAD51 and each V5-NLS-B42-RAD51-paralogue fusion using the yeast β-galactosidase assay kit by Pierce. 
The measurement of β-galactosidase activity considers the generation of o-nitrophenol which was quantified 
by spectrophotometry at an absorbance of 420 nm. Two independent co-transformants (X and Y) are shown. 
As a negative control, the LexA-RAD51-6 expression vector was co-transformed with the pYesTrp2 vector 
(empty vector: EV). The values represent the mean of three independent experiments with the 95 % 
confidence intervals indicated by error bars.  
5.5 Introduction to the raising of anti-RAD51 and 
anti-RAD51 paralogue anti-sera 
The section above attempts to determine if the T. brucei RAD51 paralogues interact with 
each other using yeast two-hybrid analysis. This showed that RAD51 interacts with itself 
and RAD51-3 interacts with RAD51-4 and RAD51-6, whilst no other interactions between 
RAD51 and the RAD51 paralogues were identified. In order to confirm that these 
interactions occur in vivo, and possibly to identify other interactions, co-
immunoprecipitation was carried out. To this end, anti-sera were raised against RAD51 
and the RAD51 paralogues which were then used in co-immunoprecipitation analysis from 
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T. brucei cell extracts. To describe this, Sections 5.5.1 to 5.5.5 below discuss the way these 
anti-sera were generated, tested and purified.  
The anti-sera were raised against C-terminal 10 X HIS-tagged recombinant variants of 
RAD51 and each of the RAD51 paralogues. This purification was carried out by Dr Chris 
Stockdale, and involved cloning each ORF of RAD51, RAD51-3, RAD51-4, RAD51-5, and 
RAD51-6 into the pET51b vector (Novagen), which allowed expression of the fusion 
proteins in E. coli BL21-rosetta2 (Novagen). Figure 5-25A shows a Coomassie stained 
SDS-PAGE gel of the different C-terminal HIS-tagged proteins after their purification by 
nickel column chromatography.  
Each of these purified proteins were quantified and sent to Scottish National Blood 
Transfusion Service, Edinburgh for injection into different host animals for collection of 
total anti-serum. Rabbit was used to raise anti-serum against the RAD51 and RAD51-4 
recombinant proteins, sheep was used to raise anti-serum against RAD51-3, chicken was 
used to raise anti-serum against RAD51-5, and rat was used to raise anti-serum against 
RAD51-6. 
 
Figure 5-25: C-terminal HIS-tagged and N-terminal GST-tagged recombinant RAD51 and the four 
RAD51 paralogues proteins  
Figure 5-25A: Coomassie stained SDS-PAGE gel of an example of the separated purified proteins used to 
raise the anti-sera. Each protein was tagged with the C-terminal HIS: Labelled RAD51 [51], RAD51-3 [3], 
RAD51-4 [4], RAD51-5 [5] and RAD51-6 [6]. This 10 X HIS tag fusion added 2.5 kDa to RAD51 and the 
RAD51 paralogues. The predicted sizes of the fusion proteins are RAD51-HIS: 42.5 kDa; RAD51-3-HIS: 57 
kDa; StrepII-RAD51-4-HIS: 54.6 kDa; RAD51-5-HIS: 44.1 kDa; and RAD51-6-HIS: 52.9 kDa. Figure 5-
25B: Coomassie stained SDS-PAGE gel of an example of the separated purified proteins used to purify the 
anti-serum. N terminal GST tagged proteins were coupled to beads and used in an affinity column, to purify 
the anti-RAD51 and anti-RAD51 paralogue anti-sera. This GST tag fusion added 26.3 kDa to RAD51 and 
the RAD51 paralogues. The predicted sizes of the fusion proteins are GST-RAD51: 66.3 kDa; GST-RAD51-
3: 80.3 kDa; GST-RAD51-4: 73.8 kDa; GST-RAD51-5: 67.9 kDa; and GST-RAD51-6: 76.7 kDa. These 
Figures were provided by Dr Chris Stockdale. 
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For anti-sera purification, N-terminal GST-tagged proteins were purified. Each ORF of the 
RAD51 paralogues were cloned into pGEX-4T3 (Amersham) and proteins purified from E. 
coli BL21-rosetta2 (Novagen) by Glutathione Affinity Chromatography; this work was 
completed by Dr Chris Stockdale. Figure 5-25B shows the Coomassie stained SDS-PAGE 
gel of an example of the separated GST-tagged purified proteins. These GST-tagged 
proteins were coupled to beads using Amino-Link (Pierce) and were then used as an 
affinity column for purification of the anti-sera. The affinity columns were made by Dr 
Chris Stockdale. Once made, the affinity column was stored at 4 oC until required. 
5.5.1 Anti-RAD51 anti-serum purification 
Specificity of the rabbit RAD51 anti-serum was analysed first. To do this, the RAD51 anti-
serum was used to probe all of the GST-tagged RAD51 and RAD51 paralogue 
recombinant proteins (see Figure 5-25B). For this, a concentration of 2 ng.µl-1 of each 
purified GST-tagged recombinant protein was separated on a 10 % SDS-PAGE gel. The 
proteins were transferred to a nylon membrane and probed with the rabbit anti-RAD51 
anti-serum (at a dilution of 1:500) and then detected with anti-rabbit IgG-HRP (Molecular 
Probes) anti-serum (at a 1:5000 dilution). Figure 5-26A shows the western blot that was 
generated. The GST tag adds 26.3 kDa to the size of RAD51 and the RAD51 paralogue 
proteins. The black arrow indicates the predicted size of the GST-RAD51 protein (66.4 
kDa). A very pronounced smear was seen in the lane containing GST-RAD51, possibly 
because of degradation of the recombinant protein. More likely, the anti-RAD51 serum 
bound to cross-contaminating proteins from E. coli during the GST-tag purification, as 
absolute purification is doubtful. These contaminants would also be targeted by the rabbit 
antibodies. Nevertheless, no bands of the predicted sizes in the other lanes for the GST-
tagged RAD51-3, RAD51-4, RAD51-5 or RAD51-6 proteins were seen, indicating that the 
anti-RAD51 anti-sera did not bind to the GST-tagged RAD51 paralogues. Next, the 
specificity of anti-RAD51 anti-serum was tested against whole cell protein extracts from T. 
brucei cells. This was done by separating the extracted proteins from wildtype bloodstream 
stage Lister strain 427 and from bloodstream stage 3174.2 rad51 homozygous mutant (-/-) 
on a 10 % SDS-PAGE gel; see Materials and Methods, Section 2.6.2.1 for protein 
extraction details and Section 2.6.3 for western blotting. The generation of the rad51-/- 
was described in McCulloch & Barry (1999) and Chapter 4 (Section 4.1). The separated 
extracts were then transferred to a nylon membrane, which was probed with the rabbit anti-
RAD51 anti-serum (at a dilution of 1:500) and then detected with anti-rabbit IgG-HRP 
(Molecular Probes) anti-serum (at a 1:5000 dilution; Figure 5-26B. Figure 5-26B shows a 
band of the predicted size of RAD51 in the wildtype cell extract of 40.5 kDa, whilst this 
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band is absent in the rad51 -/- protein extract. The blot shows a non-specific, cross-reactive 
band slightly larger than the predicted RAD51 band.  
 
Figure 5-26: Western analysis showing the specificity of the anti-RAD51 anti-serum. 
Figure 5-26A: Western blot shows the separated GST-RAD51 and GST-RAD51 paralogue recombinant 
proteins probed with anti-RAD51 anti-serum. [Labelled: RAD51 (51), RAD51-3 (3), RAD51-4 (4), RAD51-
5 (5), and RAD51-6 (6)]. The GST tag adds 26.3 kDa to RAD51 and the RAD51 paralogues. The predicted 
sizes of the fusion proteins are GST-RAD51-3: 80.8 kDa, GST-RAD51-4: 72 kDa, GST-RAD51-5: 67.9 kDa 
and GST-RAD51-6: 76.7 kDa. The black arrow indicates the predicted size of the GST-RAD51 protein of 
66.4 kDa. Figure 5-26B: Western blot shows protein extract from wildtype (wt) and rad51 homozygous 
mutant (-/-) T. brucei cells probed with the anti-RAD51 anti-sera. The black arrow indicates the predicted 
size of native RAD51 (40.5 kDa). The size markers are indicated for both blots. 
As this cross-reactive band may have interfered with further analysis, antibody purification 
from this anti-serum was performed. To do this, the purified GST-RAD51 protein (Figure 
5-25) was coupled to beads using Amino-link (Pierce) which were then used as an affinity 
column. Approximately 4 ml of anti-serum were added to the GST-RAD51 affinity 
column, and incubated for 1 hour to allow the anti-RAD51 antibodies to bind to the GST-
RAD51 (see Materials and Methods, Section 2.7.2). This was then washed thoroughly with 
PBS, with unbound or weakly bound proteins discarded in the flow-through. The purified 
anti-RAD51 antibodies were then eluted from the GST-RAD51 bound beads using 100 
mM glycine-HCl (pH 2.7) solution, in fractions of 0.5 ml. The protein concentration of 
each fraction was calculated using the Bradford quantification method (Biorad). The 
glycine from the elution buffer was then removed first by pooling the fractions with the 
highest amount of protein, then adding to an Econo-Pac 10 DG column (Bio-Rad), 
allowing capture of the proteins and re-elution in a suitable buffer, sterile PBS. The 
proteins were eluted from the column in 1 ml of PBS; this elution step was repeated seven 
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more times. The protein concentrations in these eight fractions were again quantified using 
the Bradford method. The fractions with the most protein were pooled and concentrated to 
a final volume of approximately 0.8 – 1.0 ml using Vivaspin columns (Sartorius) and 
quantified again (Bio-Rad).  
The affinity purified anti-RAD51 anti-serum was then used to probe the wildtype and 
rad51 -/- protein extracts. For a direct comparison, two 10 % SDS-PAGE gels were 
equally loaded with protein extracts from wildtype bloodstream stage cells (wt) and rad51 
-/- cells (-/-). The separated proteins were then transferred to a nylon membrane. One 
membrane was probed with the unpurified rabbit anti-RAD51 anti-serum (at a dilution of 
1:250) and the other was probed with the affinity purified anti-RAD51 anti-serum (at a 
dilution of 1:50) and both were detected with anti-rabbit IgG-HRP (Molecular Probes) 
anti-serum (at a 1:5000 dilution). Figure 5-27 shows these western blot analyses: Figure 5-
27A shows the protein extracts probed with the unpurified anti-serum; in this blot, there 
was the same banding pattern seen in Figure 5-26 above, where there was a non-specific 
band of around 45 kDa, slightly larger than the RAD51 band. Figure 5-27B shows the 
protein extracts probed with the affinity purified anti-serum. The purified antibody did not 
bind to the non-specific band of approximately 45 kDa, but, surprisingly did bind to 
another protein of approximately 60 kDa. Removal of the non-specific binding to the 
protein running at approximately 45 kDa was important, as this could cause masking of the 
RAD51-anti-serum binding to the RAD51 paralogue protein, as they are all of a similar 
size, ranging from 40-55 kDa. Since bands of this size are not seen, it is likely that the anti-
RAD51 anti-serum does not cross-react with the RAD51 paralogues. 
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Figure 5-27: Western analysis showing the specificity of the unpurified and affinity purified anti-
RAD51 anti-serum. 
Proteins extracted from wildtype bloodstream form cells (wt) and rad51 -/- (-/-) cells were separated on two 
10 % SDS-PAGE gels and the proteins were then transferred to a nylon membrane. Figure 5-27A: shows the 
membrane probed with the unpurified anti-RAD51 anti-serum. Figure 5-27B: shows the membrane probed 
with the affinity purified anti-RAD51 anti-serum. Both figures show the predicted band of RAD51 at 
approximately 40 kDa, and the size markers are indicated for reference. 
5.5.2 Anti-RAD51-3 anti-serum purification 
The next anti-serum to be analysed was the sheep anti-RAD51-3 anti-serum. Firstly, the 
anti-serum was used to probe the GST-tagged RAD51 and RAD51 paralogue recombinant 
proteins. Approximately 2 ng.µl-1 of each purified GST-recombinant protein was separated 
on a 10 % SDS-PAGE gel (see Figure 5-25B). The proteins were then transferred to a 
nylon membrane and probed firstly, with the sheep unpurified anti-RAD51-3 anti-serum 
(at a dilution of 1:1000) and secondly, detected with anti-sheep IgG-HRP (Santa Cruz) 
anti-serum (at a 1:5000 dilution; Figure 5-28A). The predicted size of the GST-RAD51-3 
fusion is 80.8 kDa, and the black arrow in Figure 5-28A shows the predicted location of 
the GST-RAD51-3, amongst considerable cross-reaction.  This analysis shows that anti-
RAD51-3 anti-serum bound specifically to the GST-RAD51-3 recombinant protein, while 
no other bands of the predicted size for GST-RAD51, GST-RAD51-4, GST-RAD51-5 or 
GST-RAD51-6 were detected in these lanes.  
Next, the specificity of the anti-RAD51-3 anti-serum was tested against whole cell protein 
extracts from T. brucei cells: wildtype BSF strain 427 protein extracts and BSF strain 427 
rad51-3 homozygous mutant (-/-) protein extracts. The extracted proteins were separated 
on a 10 % SDS-PAGE gel then transferred to a nylon membrane. The membrane was 
probed with the unpurified anti-RAD51-3 anti-serum (at a dilution of 1:1000) and detected 
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with anti-sheep IgG-HRP (Santa Cruz) anti-serum (at a 1:5000 dilution). Figure 5-28B 
does not show any distinct band of the predicted size of RAD51-3 (54.5 kDa) in the 
wildtype protein extract (wt), compared with the rad51-3 -/- protein extract. The 
predominant reaction was to a non-specific cross-reactive band of ~80 kDa in both cell 
extracts, and so affinity purification of the anti-serum was required for further analysis. 
 
Figure 5-28: Western analysis showing the specificity of the anti-RAD51-3 anti-serum 
Figure 5-28A: Western blot shows the separated GST-RAD51 and GST-RAD51 paralogue recombinant 
proteins probed with anti-RAD51-3 anti-serum. [Labelled: RAD51 (51), RAD51-3 (3), RAD51-4 (4), 
RAD51-5 (5), and RAD51-6 (6)]. The GST-tag adds 26.3 kDa to RAD51 and the RAD51 paralogues. The 
predicted sizes of the fusion proteins are GST-RAD51: 66.3 kDa, GST-RAD51-4: 72 kDa, GST-RAD51-5: 
67.9 kDa and GST-RAD51-6: 76.7 kDa. The black arrow indicates the predicted size of the GST-RAD51-3 
protein of 80.8 kDa. Figure 5-28B: Western blot shows protein extracts from the wildtype (wt) and rad51-3 
homozygous mutant (-/-) T. brucei cells probed with the anti-RAD51-3 anti-serum. The black arrow indicates 
the predicted size of RAD51-3 (54.5 kDa). The size markers are indicated for both blots. 
As a result of the poor specificity of the anti-RAD51-3 anti-serum, affinity purification was 
performed to improve the antibody’s specificity. This was carried out in a similar manner 
to that described above for the anti-RAD51 anti-serum (see Section 5.5.1 and Materials 
and Methods, Section 2.7.2). The purified GST-RAD51-3 protein (described in Figure 5-
25B) was coupled to beads which were then used as an affinity column. Approximately 5 
mls of anti-RAD51-3 anti-serum were added to the GST-RAD51-3 affinity column. The 
column was washed thoroughly, and then the antibody was eluted from the beads. The 
fractions with the most protein were pooled and concentrated to approximately 800 µl to 1 
ml. The affinity purified anti-RAD51-3 anti-serum was then used to probe the wildtype and 
rad51-3 -/- protein extracts. Figure 5-29 shows the affinity purified anti-RAD51-3 anti-
serum (at a dilution of 1:10) used to probe protein extracts from wildtype BSF (BS) and 
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rad51-3 -/- cells (-/-); anti-serum binding was detected with anti-sheep IgG-HRP (Santa 
Cruz) anti-serum (at a 1:5000 dilution). Affinity purification greatly improved specificity 
to endogenous T. brucei RAD51-3 as there was a band of the predicted size of the protein 
(54.5 kDa) that was only seen in the wildtype extract and was absent in the rad51-3 -/- 
mutant. At this anti-serum dilution, significant cross-reactivity was also seen. 
 
Figure 5-29: Western analysis showing the specificity of the affinity purified anti-RAD51-3 anti-serum. 
Proteins extracted from wildtype bloodstream stage (BS) and rad51-3 -/- mutant cells (-/-) were separated on 
a 10 % SDS-PAGE gel. The proteins were transferred to a nylon membrane and then probed with the affinity 
purified anti-RAD51-3 anti-serum at a dilution of 1:10. The predicted size of RAD51-3 (54.5 kDa) and the 
size markers are indicated. 
5.5.3 Anti-RAD51-4 anti-serum purification 
Rabbit anti-RAD51-4 anti-serum was next analysed to test its specificity and see whether 
or not it bound to RAD51-4. To this end, the unpurified anti-serum was used to probe 
against the GST-tagged RAD51 and RAD51 paralogue recombinant proteins. As before, 
approximately 2 ng.µl-1 of each purified GST-recombinant protein was separated on a 10 
% SDS-PAGE gel. The separated proteins were then transferred to a nylon membrane and 
probed with the unpurified rabbit anti-RAD51-4 anti-serum (at a dilution of 1:250), and 
detected with anti-rabbit IgG-HRP (Molecular Probes) anti-serum (at a 1:5000 dilution; 
Figure 5-30A). The predicted size of the GST-RAD51-4 fusion is 62 kDa, and in Figure 5-
30A the black arrow indicates the predicted location of the GST-RAD51-4 protein. The 
western blot indicates that the anti-RAD51-4 anti-serum binds to the GST-RAD51-4 
recombinant protein. It was also clear that the anti-serum bound to proteins of 
Rachel Dobson, 2009   Chapter 5, 184 
approximately the same size as GST-RAD51-4 in the GST-RAD51, GST-RAD51-5 and 
GST-RAD51-6. These non-specific bands are approximately the same size in all the lanes 
and are not the predicted sizes of GST-RAD51, GST-RAD51-5 and GST-RAD51-6 (66.3 
kDa, 67.9 kDa, and 76.7 kDa respectively), suggesting the anti-serum recognises an E. 
coli-derived protein of a similar size to the GST-RAD51-4 in these purifications.  
The specificity of rabbit anti-RAD51-4 anti-serum was next tested against whole cell 
protein extracts from T. brucei cells: wildtype BSF strain 427 protein extracts and BSF 
strain 3174.2 rad51-4 homozygous mutant (-/-) protein extracts. The generation and 
confirmation of this rad51-4 -/- mutant was described in Chapter 3, Section 3.2.3 of this 
thesis. The extracted proteins were separated on a 10 % SDS-PAGE gel then transferred to 
a nylon membrane. This was probed with the unpurified anti-RAD51-4 anti-serum at a 
dilution of 1:400 and detected with anti-rabbit IgG-HRP (Molecular Probes) anti-serum (at 
a 1:5000 dilution), see Figure 5-30B. A faint but distinct band of the predicted size of 
RAD51-4 (45.7 kDa) could be seen in the wildtype protein extract (wt) compared to the 
rad51-4-/- protein extract where it was absent. There was also considerable cross-reaction, 
but this suggests the anti-serum can recognise endogenous T. brucei RAD51-4.  
 
Figure 5-30: Western analysis showing the specificity of the anti-RAD51-4 anti-serum 
Figure 5-30A: Western blot shows the separated GST-RAD51 and GST-RAD51 paralogue recombinant 
proteins probed with anti-RAD51-4 anti-serum. [Labelled: RAD51 (51), RAD51-3 (3), RAD51-4 (4), 
RAD51-5 (5), and RAD51-6 (6)]. The GST tag adds 26.3 kDa to RAD51 and the RAD51 paralogues. The 
predicted sizes of the fusion proteins are GST-RAD51: 66.3 kDa, GST-RAD51-3: 80.8 kDa, GST-RAD51-5: 
67.9 kDa and GST-RAD51-6: 76.7 kDa. The black arrow indicates the predicted size of the GST-RAD51-4 
protein of 72 kDa. Figure 5-30B: Western blot shows the protein extract from wildtype (wt) and rad51-4 
homozygous mutant (-/-) T. brucei cells probed with the anti-RAD51-4 anti-serum. The black arrow indicates 
the predicted size of native RAD51-4, 45.7 kDa. The size markers are indicated for both blots. 
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Given the level of cross-reactive bands that were seen when the anti-RAD51-4 anti-serum 
was used to probe both the GST-tagged RAD51 and GST-tagged RAD51 paralogue 
recombinant proteins, as well as the wildtype and rad51-4 -/- cell extracts, affinity 
purification of the anti-serum was required for further analysis. This was done using the 
GST-tagged RAD51-4 recombinant protein coupled to beads and used in the affinity 
column. Approximately 4 ml of anti-RAD51-4 anti-serum was added to the affinity 
column. Incubation for 2 hours at room temperature allowed the anti-RAD51-4 anti-serum 
to bind to the GST-RAD51-4 and this was then washed thoroughly to allow all unbound 
proteins to be discarded (Materials and Methods, Section 2.7.2). The purified anti-RAD51-
4 anti-serum was then eluted from the GST-RAD51-4 beads in fractions of 0.5 ml. The 
protein concentration of each fraction was calculated and then the fractions with the most 
protein were pooled and concentrated. The unpurified and affinity purified anti-RAD51-4 
anti-serum was then used to probe wildtype and rad51-4 -/- protein extracts (Figure 5-31). 
The same amount of proteins extracted from wildtype (wt) and from bloodstream stage 
rad51-4 -/- cells were separated on two 10 % SDS-PAGE gels, and the protein transferred 
to a nylon membrane. Figure 5-31B shows the membrane probed with the affinity purified 
anti-RAD51-4 antibody at a dilution of 1:100 and detected with anti-rabbit IgG-HRP 
(Molecular Probes) anti-serum (at a 1:5000 dilution). A distinct band of the predicted size 
of RAD51-4 (45.7 kDa) was seen in the wildtype protein extract but was absent in the 
rad51-4 -/- cell extract. Comparisons of the affinity purified anti-RAD51-4 anti-serum with 
the unpurified anti-serum show that the detection of endogenous RAD51-4 is much more 
distinct in the former (compare Figure 5-31B and Figure 5-31A). However, there were 
more non-specific bands detected by the affinity purified anti-RAD51-4 anti-serum, and 
the pronounced band just smaller than 45 kDa remained. 
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Figure 5-31: Western analysis showing the specificity of the affinity purified anti-RAD51-4 anti-serum. 
Whole cell proteins extracted from wildtype bloodstream stage (wt) and rad51-4 -/- mutant cells were 
separated on two 10 % SDS-PAGE gels, and then transferred to a nylon membrane. Figure 5-31A: shows the 
membrane probed with the unpurified anti-RAD51-4 anti-serum at a dilution of 1:500. Figure 5-31B: shows 
the membrane probed with the affinity purified anti-RAD51-4 antibody at a dilution of 1:100. The predicted 
size of RAD51-4 (45.7 kDa) is indicated by the black arrow. The size markers are indicated for both blots. 
In an attempt to further purify the anti-serum and remove the detection of non-specific 
proteins, another method was adopted. This method uses an acetone extract of T. brucei 
rad51-4 -/- cells, which do not to express the target antigen, T. brucei RAD51-4 (see 
Material and Methods, Section 2.7.3 for the protocol). As there is no RAD51-4 in the 
protein in the extract from the rad51-4 -/- cells, addition of the anti-RAD51-4 anti-serum 
will result in non-specific antibodies binding to their target antigens in the total extracted 
protein while the anti-RAD51-4 antibodies remaining unbound and free in the supernatant. 
A total of 2 x 109 rad51-4 -/- cells were used to purify 1 ml of anti-RAD51-4 anti-serum. 
Briefly, 500 ml of rad51-4 -/- at a density of 2 x 106 cells per ml were pelleted, washed in 
PBS and then washed twice with cold 100 % acetone. In between each wash the cells were 
incubated on ice for 10 minutes. The final pellet was spread on filter paper and allowed to 
completely dry. After drying, the protein was placed in an eppendorf tube and the 
unpurified anti-sera was added to it. This solution was gently mixed and incubated at 4 oC 
for 30 minutes, and then spun for 30 minutes. The resulting supernatant contains the 
purified antibodies. 
To test if the acetone extraction method purified the anti-serum more effectively than the 
affinity purification method, the T. brucei wildtype and rad51-4 -/- protein extracts were 
separated on a 10 % SDS-PAGE gel and transferred to a nylon membrane. Figure 5-32 
shows the membrane probed with purified anti-serum at a dilution of 1:500. This was then 
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detected using anti-rabbit IgG-HRP (Molecular Probes) anti-serum (at a 1:5000 dilution). 
Western blot analysis showed that there was a band present in the wildtype extract which 
was absent in the rad51-4 -/- cell extract and is the predicted size of RAD51-4 (45.7 kDa). 
This purification method did not remove the non-specific cross-reactive bands and was not 
more efficient than affinity purification. As a result the affinity purified anti-RAD51-4 
anti-serum was used for further analyses. 
 
Figure 5-32: Western analysis showing the specificity of the purified anti-RAD51-4 anti-serum using 
the acetone extraction method of total proteins from cells not expressing RAD51-4. 
Whole cell proteins extracted from wildtype bloodstream stage cells (wt) and rad51-4 -/- mutant cells (-/-) 
were separated on a 10 % SDS-PAGE gel, and transferred to a nylon membrane. The membrane was probed 
with the purified anti-RAD51-4 anti-serum at a dilution of 1:500. This anti-serum was purified using the 
acetone extraction method. A band of the predicted size of RAD51-4 (45.7 kDa) is indicated with the black 
arrow. The size markers are indicated for the blot. 
5.5.4 Anti-RAD51-5 anti-serum purification 
The next anti-serum to be analysed was the chicken anti-RAD51-5 anti-serum. Firstly, the 
polyclonal antibodies were purified from the chicken egg yolk produced. This was carried 
out with the use of a Chicken IgY purification kit from Pierce (as per the manufacturer’s 
instructions and see Materials and Methods, Section 2.7.1). Once the polyclonal anti-serum 
had been extracted from the egg, it was used to probe the GST-tagged RAD51 and RAD51 
paralogue recombinant proteins (see Figure 5-25B). Each purified GST-recombinant 
protein was separated on a 10 % SDS-PAGE gel and western blot analysis was carried out. 
The proteins were transferred to a nylon membrane and probed with the chicken anti-
RAD51-5 anti-serum (at a dilution of 1:500) and detected with anti-chicken IgG-HRP 
(Jackson ImmunoResearch) anti-serum (at a 1:7500 dilution), see Figure 5-33A. The 
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predicted size of the GST-RAD51-5 fusion is 67.9 kDa and a band of the correct size was 
seen in the lane loaded with GST-RAD51-5. The band was absent in the other lanes 
containing GST-RAD51, GST-RAD51-3, GST-RAD51-4 and GST-RAD51-6, indicating 
that the anti-serum was specific for RAD51-5. Figure 5-33B shows the anti-RAD51-5 anti-
serum used to probe the T. brucei wildtype cell protein extract alongside T. brucei rad51-5 
-/- mutant cell protein extract (Proudfoot & McCulloch, 2005a). Again, the membrane was 
probed with the anti-RAD51-5 anti-serum (at a dilution of 1:500) and detected with anti-
chicken IgG-HRP (Jackson ImmunoResearch) anti-serum (at a 1:7500 dilution; Figure 5-
33B). The western blot analysis does not show any specific band of the predicted size of 
RAD51-5 (41.6 kDa) in the wildtype (wt) compared with the rad51-5 -/- cell protein 
extracts (-/-). The anti-RAD51-5 anti-serum detected a number of non-specific cross-
reactive bands in both cell extracts, and therefore affinity purification was required for 
further analysis. 
 
Figure 5-33: Western analysis showing the specificity of the anti-RAD51-5 antibodies purified from 
chicken eggs. 
Figure 5-33A: Western blot shows the separated GST-RAD51 and GST-RAD51 paralogue recombinant 
proteins probed with anti-RAD51-5 anti-serum. [Labelled: RAD51 (51), RAD51-3 (3), RAD51-4 (4), 
RAD51-5 (5), and RAD51-6 (6)]. The GST-tag adds 26.3 kDa to RAD51 and the RAD51 paralogues as a 
result the predicted sizes of the fusion proteins are GST-RAD51: 66.3 kDa, GST-RAD51-3: 80.8 kDa, GST-
RAD51-4: 72 kDa, and GST-RAD51-6: 76.7 kDa. The black arrow indicates the predicted size of the GST-
RAD51-5 protein of 67.9 kDa. Figure 5-33B: Western blot shows proteins extracted from wildtype (wt) and 
rad51-5 homozygous mutant (-/-) T. brucei cells probed with the anti-RAD51-5 anti-serum. The black arrow 
indicates the predicted size of RAD51-5, 41.6 kDa. The size markers are indicated for both blots. 
Affinity purification was performed using the same method as described above (Sections 
5.5.1, 5.5.2, and 5.5.3), and used GST-RAD51-5 coupled beads to bind to the anti-RAD51-
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5 anti-serum. Non-specific antibodies in the anti-serum were washed away in the flow-
through. The anti-RAD51-5 antibodies were then eluted off the beads, quantified and 
concentrated.  
Unfortunately, the affinity purification of the anti-RAD51-5 anti-serum was not effective. 
The anti-serum was used to probe wildtype and rad51-5 -/- protein extracts, but no specific 
bands were detected of the predicted size of RAD51-5 (41.6 kDa) in the wildtype 
compared with rad51-5 -/- mutant cell extracts, when probed with 1:50 dilution of affinity 
purified anti-RAD51-5. This was detected with anti-chicken IgG-HRP (Jackson 
ImmunoResearch) anti-serum (at a 1:7500 dilution; Figure 5-34).  
 
Figure 5-34: Western analysis showing the specificity of the affinity purified anti-RAD51-5 anti-serum. 
Proteins extracted from wildtype (wt) and rad51-5-/- mutant cells (-/-) were separated on a 10 % SDS-PAGE 
gel. The proteins were transferred to a nylon membrane and then probed with the affinity purified anti-
RAD51-5 anti-serum at a dilution of 1:50. The predicted size of RAD51-5 (41.6 kDa) is indicated by the 
black arrow and the size markers are also shown. 
If more time was available, one possible way of overcoming this would be to try a range of 
different egg yolks. The egg yolk used here was taken from an egg produced late after the 
injection of the recombinant protein (Day 26) and so extracting the antibodies from an 
earlier egg yolk may result in more specific anti-RAD51-5 antibodies. Time constraints did 
not allow this to be done. Instead, to overcome the lack of reactivity of the anti-serum, 
PTP-tagging of the RAD51-5 was performed to allow protein affinity purification: this is 
described in Section 5.7 of this chapter. 
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5.5.5 Anti-RAD51-6 anti-serum purification 
The final anti-serum to be analysed was rat anti-RAD51-6 anti-serum. Like the other anti-
sera, it was important to test its specificity and see whether or not it bound specifically to 
T. brucei RAD51-6. To this end, the unpurified anti-RAD51-6 anti-serum was used to 
probe the GST-tagged RAD51 and RAD51 paralogue recombinant proteins. As before, 
each purified GST-recombinant protein was separated on a 10 % SDS-PAGE gel, and the 
proteins were transferred to a nylon membrane. The membrane was probed with the 
unpurified anti-RAD51-6 anti-serum (at a dilution of 1:500) and detected with anti-rat IgG-
HRP (Sigma) anti-serum (at a dilution of 1:10,000; Figure 5-35A). The predicted size of 
the GST-RAD51-6 fusion is 76.7 kDa and a distinct reactivity of the anti-RAD51-6 anti-
serum to a protein of this size was seen (Figure 5-35A, Lane 6), while there was no 
evidence of cross-reactivity against GST-RAD51 and the other GST-RAD51 paralogue 
recombinant proteins. 
Figure 5-35B shows the anti-RAD51-6 anti-serum used to probe T. brucei wildtype and T. 
brucei rad51-6 -/- protein extracts. The generation and confirmation of the BSF strain 427 
rad51-6 -/- was described in this thesis (Chapter 3, Section 3.5.3). Both protein extracts 
were separated on a 10 % SDS-PAGE gel and transferred to a nylon membrane. The 
membrane was probed with the anti-RAD51-6 anti-serum (at a dilution of 1:250) and 
detected with anti-rat IgG-HRP (Sigma) anti-serum (at a dilution of 1:10,000; Figure 5-
35B). Specific bands of the predicted size of RAD51-6 (50.4 kDa) were not seen in the 
wildtype extract compared with the rad51-6 -/- protein extract. All bands appear instead to 
be non-specific, cross-reactive bands in both cell extracts (approximate sizes of 52 kDa and 
35 kDa) and affinity purification of anti-serum was required for further use of the antibody. 
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Figure 5-35: Western analysis showing the specificity of the anti-RAD51-6 anti-serum 
Figure 5-35A: Western blot shows the separated GST-RAD51 and GST-RAD51 paralogue recombinant 
proteins probed with anti-RAD51-6 anti-serum. [Labelled: RAD51 (51), RAD51-3 (3), RAD51-4 (4), 
RAD51-5 (5), and RAD51-6 (6)]. This GST tag fusion added 26.3 kDa to RAD51 and the RAD51 
paralogues. The predicted sizes of the fusion proteins are GST-RAD51: 66.3 kDa, GST-RAD51-3: 80.8 kDa, 
GST-RAD51-4: 72 kDa and GST-RAD51-5: 67.9 kDa. The black arrow indicates the predicted size of the 
GST-RAD51-6 protein of 76.7 kDa. Figure 5-35B: Western blot shows the separated wildtype (wt) and 
rad51-6 homozygous mutant (-/-) protein extracts. The black arrow indicates the predicted size of RAD51-6, 
50.4 kDa. The size markers are indicated for both blots. 
Affinity purification was completed using the same method as described above, (Section 
5.5.1, 5.5.2. 5.5.3, and 5.5.4), and used GST-RAD51-6 coupled beads to bind to the anti-
RAD51-6 antibodies. This allowed the non-specific antibodies in the anti-serum to be 
washed away in the flow-through. The anti-RAD51-6 antibodies were then eluted off the 
beads, quantified and concentrated. Similarly to the anti-RAD51-5 affinity purification, the 
affinity purification of anti-RAD51-6 antibodies was not effective. Wildtype and rad51-6 -
/- cell protein extracts were separated on a 10 % SDS-PAGE gel, transferred to a nylon 
membrane and probed with the affinity purified anti-RAD51-6 anti-serum (at a dilution of 
1:10). Anti-rat IgG-HRP (Sigma) anti-serum (at a dilution of 1:10,000) was used to detect 
the primary antibody. This western blot analysis detected no distinct bands in the wildtype 
extracts compared to rad51-6-/- mutant at the predicted size of RAD51-6 (~ 50 kDa) 
(Figure 5-36). 
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Figure 5-36: Western analysis showing the specificity of the affinity purified anti-RAD51-6 anti-serum. 
Proteins extracted from wildtype bloodstream stage (wt) and rad51-6 -/- mutant cells (-/-) were separated on 
a 10 % SDS-PAGE gel. The proteins were transferred to a nylon membrane and then probed with the affinity 
purified anti-RAD51-6 anti-serum at a dilution of 1:10. The predicted size of RAD51-6 (50.4 kDa) is 
indicated by the black arrow and the size markers are also shown. 
 
To overcome the fact that the anti-RAD51-6 anti-serum could not be used for further 
analyses such as co-immunoprecipitation, a PTP-tagged RAD51-6 was generated, and is 
described in Section 5.7. 
5.6 Co-immunoprecipitation of the RAD51 
paralogues 
5.6.1 Principles of co-immunoprecipitation 
Co-immunoprecipitation (Co-IP) is a method in which a target protein, or other antigen, is 
precipitated from a cell extract using specific antibodies that recognise the target protein or 
antigen. This technique involves immobilising the specific antiserum, and incubating it 
with cell extract. This allows binding of the protein or antigen from the cell extract solution 
to the specific antibodies. As a result the anti-serum not only immobilises the target protein 
or antigen but can also isolate other proteins with which it interacts, as long as the complex 
is maintained in the cell extract. This method involves coupling the anti-serum to Protein 
A, Protein G beads or gel matrix, and allowing the bound anti-serum to bind to its target 
antigen along with any protein or protein complexes attached to the target antigen. 
For the analysis, approximately 1-2 mg of extracted protein was prepared from wildtype 
cells and the rad51 paralogue homozygous mutant cells. A gentle method of whole cell 
protein extraction was performed to avoid disrupting the protein interactions; first the 
nuclear content was extracted, this was then pooled with the proteins extracted from the 
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non-nuclear material (see Materials and Methods, Section 2.6.2.2 for protocol). Briefly, the 
cells were grown to a density of 2-3 x 106 per ml, pelleted, washed twice with PBS and 
frozen quickly using dry-ice and stored at -80 oC until required. The frozen pellets were 
resuspended in hypotonic lysis buffer, incubated on ice for 20 minutes, vortexed for 30 
seconds and pelleted at 800 x g for 2 minutes to collect the nuclei. The supernatant was 
retained and stored on ice. The pelleted nuclei were resuspended in nuclear extract buffer 
and incubated on ice for 20 minutes. The retained supernatant was added back to the 
reaction and the cell debris was removed by a centrifugation at 20,000 x g for 20 minutes 
at 4 oC. This supernatant contained protein extracted from the entire cell and was 
quantified and used in the co-IP analyses. 
The Profound co-immunoprecipitation kit (Pierce) was used for the co-IP analyses here. 
The analysis was performed in a 1.5 ml eppendorf tube with the advantage that all spins 
can be completed in a table top centrifuge. This kit links the antibody using an “antibody 
coupling gel” to a gel matrix, with the retention of the anti-serum after the final elution 
step. This aids the analysis, as other methods that result in elution of the anti-serum along 
with the proteins may have the proteins of interest masked by the light or heavy chains of 
the antibody. The protein extract was added to the antibody-coupled-resin, incubated for 2 
hours at room temperature, and then washed thoroughly with the wash buffers provided. 
The protein bound to the anti-serum was then eluted off the antibody-coupled-resin in 
fractions. These fractions were then analysed by western blot.  
Section 5.5 above describes the affinity purification of the RAD51 and RAD51 paralogue 
anti-sera. It was concluded that only the affinity purified anti-RAD51-3 and anti-RAD51-4 
anti-sera could be used in co-immunoprecipitation (Co-IP) analyses. The lack of specific 
reaction by the anti-RAD51-5 and anti-RAD51-6 anti-sera prevented their use. 
5.6.2 Co-immunoprecipitation using the affinity purified 
anti-RAD51-3 anti-serum  
To perform the co-IP analyses, 400 µg of the affinity purified anti-RAD51-3 anti-serum 
was added to the antibody-coupled-resin. This was done for two independent tests. For one 
analysis, approximately 1.5 mg of protein extract was prepared from wildtype bloodstream 
stage T. brucei Lister 427 cells and from rad51-3 -/- cells. The co-IP analysis was 
conducted using the manufacturer’s instructions (Pierce) and is described in the Materials 
and Methods, Section 2.11. Figure 5-37 shows the western blot of the input protein extract 
from wildtype and rad51-3 -/- cells, the final wash from the wildtype cell extract, and the 
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three eluted fractions (E1, E2, E3). The membrane was probed with sheep anti-RAD51-3 
anti-serum (at a dilution of 1:10) and detected using anti-sheep IgG-HRP (1:5000). The 
Pierce West Femto was used in these experiments, which is a maximum sensitivity 
chemiluminescent substrate; as a result there is an increase in the background of non-
specific binding. There is a clear band in the wildtype of 50.4 kDa in size, compared to the 
rad51-3 -/- mutant. 
 
Figure 5-37: Western analysis of the eluates following the co-immunoprecipitation using affinity 
purified anti-RAD51-3 anti-serum. 
Affinity purified RAD51-3 anti-serum was used to perform a co-IP from wildtype (wt) and rad51-3 -/- (-/-) 
cells. The input from the wildtype and rad51-3 -/- mutant cells, the final wash of the beads containing the 
wildtype cell extract (FW) and the eluted fractions from the co-IP were separated on a 10 % SDS-PAGE gel 
and were then transferred to a nylon membrane. This was probed with sheep anti-RAD51-3 anti-serum. E1, 
E2 and E3 are the eluates of the co-IP from the wildtype cells. E1-/-, E2-/- and E3-/- are the eluates of the co-
IP from the rad51-3 -/- cells.  
As there was a clean band of the correct size in the second fraction, the rest of the eluates 
from the co-IP of the wildtype and rad51-3 -/- cells were loaded onto a 10 % SDS-PAGE 
gel in triplicate (~30 % of remaining second fraction). The proteins were then transferred 
to a nylon membrane, and this was cut into three. Each membrane was probed with the 
affinity purified rabbit anti-RAD51 anti-serum (at a dilution of 1:10), the affinity purified 
sheep anti-RAD51-3 anti-serum (at dilutions of 1:50) and the affinity purified rabbit anti-
RAD51-4 anti-serum (at a dilution of 1:1000). These were detected using IgG-HRP anti-
sera for each species, anti-rabbit (1:1000) or anti-sheep (1:5000). Figure 5-38 shows the 
results of this using the second eluted fraction from the co-IP. Figure 5-38A shows these 
fractions probed with anti-RAD51-3 anti-serum, demonstrating that the RAD51-3 was 
present in the eluate from the co-IP of wildtype but absent from the rad51-3 -/- mutant. 
When the eluate was probed with anti-RAD51-4 anti-serum (Figure 5-38B) it was shown 
that RAD51-4 was also present from the co-IP from the wildtype cell extract, but not from 
the rad51-3 -/- mutant cell extract. Anti-RAD51 anti-serum was used to probe the fraction, 
RAD51 was not detected in the elutant from the co-IP of either wildtype cell extract or 
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rad51-3 -/-, and therefore indicating RAD51 interaction with RAD51-3 was not observed 
(data not shown). The analysis confirms that in the eluted fraction, RAD51-3 and RAD51-
4 were both present indicating that these proteins interact in T. brucei while RAD51 was 
absent. 
 
Figure 5-38: Western analysis following the co-immunoprecipitation using affinity purified anti-
RAD51-3 anti-serum. 
Affinity purified RAD51-3 anti-serum was used to perform a co-IP from wildtype and rad51-3 -/- T. brucei 
bloodstream stage cells. Eluted fractions from the co-IP were separated on a 10 % SDS-PAGE gel and were 
then transferred to a nylon membrane. Figure 5-38A: Western blot of one fraction from the co-IP from 
wildtype (wt) and rad51-3 -/- (3-/-) cells when probed with anti-RAD51-3 anti-serum. Figure 5-38B: 
Western blot of one fraction from co-IP of wildtype (wt) and rad51-3 -/- (3-/-) cells when probed with the 
affinity purified anti-RAD51-4 anti-serum. 
5.6.3 Co-immunoprecipitation using the affinity purified 
anti-RAD51-4 anti-serum  
As the affinity purified anti-RAD51-4 anti-serum was specific to T. brucei RAD51-4 and 
had only a few cross-reactive bands, co-IP analyses was carried out using the Profound 
co-immunoprecipitation kit (Pierce) as before (Materials and Methods, Section 2.11). 
Briefly, a total of 350 µg of the affinity purified anti-RAD51-4 anti-serum was added to the 
antibody-coupled-resin. Again, this was done in duplicate for two independent tests. 
Approximately 1.5 mg of protein extract from wildtype cells was added to the antibody-
coupled-resin. The same amount of extracted protein from the rad51-4 -/- mutant cells was 
added to the other antibody-coupled-resin. The generation and confirmation of rad51-4 -/- 
mutant was completed and described in this thesis (Chapter 3, Section 3.2.3).  
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Figure 5-39 shows the input protein extract from wildtype (wt) and rad51-4 -/- (-/-) cells, 
the final wash (W) from the wildtype cell extract, and two eluted fractions (E1, and E2) 
were loaded onto a 10 % SDS-PAGE gel. The proteins were then transferred to a nylon 
membrane and probed with rabbit anti-RAD51-4 anti-serum (at a dilution of 1:500). These 
were detected using anti-rabbit IgG-HRP (1:5000). The Pierce West Femto, a maximum 
sensitivity chemiluminescent substrate, was used in these experiments. Use of this 
chemiluminescent substrate increases the non-specific binding in the wildtype and 
homozygous cell extracts, as well as increasing the background at the top of the membrane. 
As a result there is not a clear input band of 40.5 kDa in the wildtype compared to the 
rad51-4-/- cell extract because of the non-specific chemiluminescence. Despite this, there 
is a distinct band in the eluted fractions of the co-IP from the wildtype which is the correct 
size of 40.5 kDa and is not present in the co-IP from the rad51-4 -/- cells. 
 
Figure 5-39: Western analysis of the eluates following the co-immunoprecipitation using affinity 
purified anti-RAD51-4 anti-serum. 
Affinity purified RAD51-4 anti-serum was used to perform a co-IP from wildtype (wt) and rad51-4 -/- (-/-) 
cells. The input from the wildtype and rad51-4 -/- mutant cells, the final wash of the beads containing the 
wildtype cell extract (W) and the eluted fractions from the co-IP were separated on a 10 % SDS-PAGE gel 
and were then transferred to a nylon membrane. This was then probed with rabbit anti-RAD51-4 anti-serum. 
E1 and E2 are the eluates of the co-IP from the wildtype cells. E1-/- and E2-/- are the eluates of the co-IP 
from the rad51-4 -/- cells.  
Using the affinity purified anti-RAD51-4 anti-sera, equal amounts of the first eluted 
fraction from the co-IP of the wildtype and rad51-4 -/- cells were loaded in triplicate onto a 
10 % SDS-PAGE gel with each separated by a size marker. The proteins were then 
transferred to a nylon membrane and the membrane cut into three parts. Each part of the 
membrane was probed with a different affinity purified anti-sera: rabbit anti-RAD51 anti-
sera, sheep anti-RAD51-3 anti-sera and rabbit anti-RAD51-4 anti-sera (at a dilution of 
1:10, 1:50, 1:1000 respectively) as described above, and were then detected using the IgG-
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HRP anti-sera for each species, anti-rabbit and anti-sheep (at a dilution of 1:1000 and 
1:5000 respectively). Figure 5-40A shows the result of the co-IP analysis when the eluted 
fraction was probed with the affinity purified anti-RAD51-3 antibody. This demonstrates 
that when the anti-RAD51-4 anti-serum was used to precipitate RAD51-4, RAD51-3 was 
also present in the eluate indicating that RAD51-4 interacts with RAD51-3.  Figure 5-40B 
shows the same fractions probed with anti-RAD51-4 anti-serum, demonstrating that the 
RAD51-4 was present in the eluate from the co-IP wildtype cells while absent from the 
rad51-4 -/- mutant. Again, when the eluate from the co-IP of either wildtype cell extract or 
rad51-4 -/- was probed with anti-RAD51 anti-serum, no detectable bands were seen (data 
not shown), and indicate that RAD51 was absent from the complex. These results confirm 
that in the eluted fraction from the wildtype, RAD51-3 and RAD51-4 were both present. 
 
Figure 5-40: Western analysis following the co-immunoprecipitation using affinity purified anti-
RAD51-4 anti-serum. 
Affinity purified RAD51-4 anti-serum was used to perform a co-IP from wildtype and rad51-4 -/- T. brucei 
bloodstream form cells. Eluted fractions were separated on a 10 % SDS-PAGE gel and were then transferred 
to a nylon membrane. Figure 5-40A: Western blot of one fraction from co-IP of wildtype (wt) and rad51-4 -
/- (4-/-) cells when probed with anti-RAD51-3 anti-serum. Figure 5-40B: Western blot of one fraction from 
co-IP of wildtype (wt) and rad51-4 -/- (4-/-) cells when probed with the affinity purified anti-RAD51-4 anti-
serum. 
5.7 PTP-tag purification of protein complexes 
5.7.1 Principles of PTP-tag purifications 
The PTP-tag purification is a novel way of protein purification using a modified Tandem 
Affinity Purification (TAP) tag (Schimanski et al., 2005b). The TAP-tag contains two 
immunoglobulin (IgG) binding domains of Staphylococcus aureus protein A (Prot A) and a 
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calmodulin binding peptide (CBP) separated by a tobacco etch virus (TEV) protease site 
(Kelly et al., 2007; Puig et al., 2001; Figure 5-41). The TAP-tag method allows 
purification of the protein of interest and associate proteins by fusion of the protein to the 
tag, expression of the tagged protein in the required cell line and purification of the protein 
or proteins in non-denaturing conditions. The Gunzl lab designed the PTP-tag by replacing 
the calmodulin binding peptide with the Protein C epitope (Prot C), see Figure 5-39. The 
PTP-tag contains the immunoglobulin (IgG) binding domain of Staphylococcus aureus 
protein A and the human Protein C separated by a tobacco etch virus (TEV) protease site 
(Schimanski et al., 2005a). 
 
Figure 5-41: Schematic diagram showing the TAP-tag and PTP-tag. 
The Protein A (Prot A) and calmodulin binding peptide (CBP) epitopes of the original TAP-tag are in light 
blue, the TEV protease site is black, and spacer sequences are grey. In the PTP-tag, the Protein C (Prot C) 
epitope is depicted in dark blue. Reprinted with permission from Elsevier: Schimanski et al. (2005b), 
Eukaryotic Cell 4, pp 1944.  
In consecutive steps, PTP-tagged protein purification is carried out as follows, see Figure 
5-42. Firstly, the tagged protein is bound to IgG beads or matrix via the Protein A epitope 
and multiple washes ensure that unbound proteins (C: contaminants) are removed, and the 
protein of interest and possible interactors remain. Next the protein or protein complexes 
are then released from the IgG and Protein A by cleavage with the TEV protease. These 
released proteins are then bound to anti-Protein C beads and washed again. The proteins 
were released from the beads using an EDTA buffer, and were eluted three times 
(Materials and Methods, Section 2.12 for the protocol). The eluate was then run on a 10 % 
SDS-PAGE gel and probed with anti-PAP anti-serum which detects the ProtA and anti-
ProtC anti-serum which detects the ProtC.  
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Figure 5-42: Overview of the PTP-purification strategy. 
In consecutive steps, PTP-tagged protein purification was performed as follows: In the first affinity column, 
the tagged protein is bound to IgG beads via the Protein A (ProtA) epitope. Washes ensure that contaminants 
(C) are removed. The protein(s) are then released from the IgG bead and Protein A by cleavage with the TEV 
protease (indicated by the scissors). In the second affinity column, the released protein(s) are then bound to 
anti-Protein C beads and washed again. The purified protein(s) are released from the beads using an EDTA 
buffer. Reprinted with permission from Elsevier: Piug et al. (2007), Methods 24, pp 219. 
5.7.2 Generation of the PTP-tagged RAD51 paralogue 
constructs 
5.7.2.1 Generation of the PTP tagged RAD51-5 construct 
To generate a C-terminal PTP-tagged RAD51-5 construct, 848 bp of the 3’ end of the 
RAD51-5 ORF was cloned into the pC-PTP-vector (Schimanski et al., 2005a). This 
fragment of RAD51-5 was PCR-amplified using the 51-5 Cterm PTP forward and reverse 
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primers (see Materials and Methods, Section 2.4.1, Table 2-1), which had the enzyme 
restriction sites ApaI and NotI on the forward and reverse primers respectively, to facilitate 
the cloning into the vector (see Figure 5-43). Once clones were confirmed and sequenced, 
the construct was linearised using a unique restriction enzyme site in the middle of the 
cloned fragment of RAD51-5, NsiI. This was then transformed into wildtype bloodstream 
stage Lister 427 T. brucei. Recombination of the construct should occur into the 
endogenous RAD51-5 locus. This resulted in the whole ORF becoming C terminally fused 
with the PTP ORF, as well as insertion of the resistance cassette for selection, in this case 
neomycin (Neo; see Figure 5-43). 
326 1174
Nsi I
Apa I Not I
pC-RAD51-5-PTP-Neo
Neo
Neo
Neo
Neo
Neo
 
Figure 5-43: Diagram showing design and use of the C-terminal PTP vector for RAD51-5 tagging at its 
endogeneous locus 
A fragment from 326 bp to 1174 bp of the RAD51-5 ORF was cloned into the pC-PTP-vector using ApaI and 
NotI restriction enzyme sites. This was then linearised using a NsiI site and transformed into wildtype T. 
brucei cells. Green arrow: selectable resistance cassette, (Neo; G418 resistance); Red arrow: targeted open 
reading frame, RAD51-5. Diagram adapted from Kelly et al., 2007. 
5.7.2.2 Confirmation of the PTP tagged RAD51-5 in T. brucei 
Once T. brucei RAD51-5 PTP transformants had been selected by G418 resistance at a 
concentration of 2.5 µl.ml-1, the genomic DNA was extracted and a PCR-amplification 
check was carried out to confirm that the construct had integrated into the RAD51-5 
endogenous locus. This was carried out using a forward primer which anneals with the 5’ 
end of the RAD51-5 ORF and a reverse primer which anneals in the middle of the PTP tag: 
named RAD51-5 For and PTP-Cterm Check Rev, respectively (see Materials and Methods, 
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Section 2.4.1, Table 2-1). The total length of PTP tag is 506 bp and the PTP-Cterm Check 
reverse primer anneals at position 222 bp from the 5’ end. Figure 5-42 shows the results of 
the PCR-amplification from two negative controls [genomic DNA extracted from wildtype 
untransformed cells (Figure 5-42, Lane 1), and pC-RAD51-5-PTP-Neo plasmid DNA 
(Figure 5-44, Lane 2)], and two transformed G418-resistant clones (Figure 5-44, Lane 3 
and 4). This figure confirmed that the PTP tag had integrated into the endogenous RAD51-
5 locus: the RAD51-5 ORF is 1174 bp in length, and the amount of the PTP tag ORF PCR-
amplified is 222 bp, so the total fragment size is 1396 bp, which is consistent with the size 
of the product observed.  
 
Figure 5-44: PCR-amplification to check PTP-tag integration into the RAD51-5 allele. 
PCR-amplification was carried out using a forward primer which bound to the 5’ end of the RAD51-5 ORF 
and a reverse primer which bound to the middle of the PTP tag, named RAD51-5 For and PTP-Cterm Check 
Rev primers respectively, to confirm that the PTP tag had integrated into the endogenous locus of RAD51-5. 
DNA extracted from two G418 resistant positive transformants was used as template for the PCR reaction 
(Lane 3 and 4). Genomic DNA extracted from wildtype untransformed cells (Lane 1), and plasmid DNA 
from the original construct: pC-RAD51-5-PTP-Neo (Lane 2) was used as negative controls. 
One of the clones analysed in Figure 5-44 (Lane 3) was chosen for further analysis. The 
cells were grown to a density of approximately 3 x 106 cells per ml, in 25 ml of HMI-9, 
lysed and the extracted proteins were separated on a 10 % SDS-PAGE gel. These proteins 
were then transferred to a nylon membrane and probed with anti-PAP antibody conjugated 
to HRP (Roche) at a dilution of 1:1000. The PTP-tag fused to RAD51-5 adds 19 kDa 
resulting in a total RAD51-PTP size of 61 kDa. Figure 5-45 shows the whole cell lysate 
probed with the anti-PAP antibody, revealing a band of the expected size. This confirms 
the PCR-amplification analysis and suggests that RAD51-5 has been successfully tagged 
with PTP. 
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Figure 5-45: Western analysis to confirm the integration of the PTP-tag into the endogenous RAD51-5 
locus. 
The transformed PTP-RAD51-5 cells were lysed and the extracted proteins separated on a 10 % SDS-PAGE 
gel. These proteins were then transferred to a nylon membrane and probed with anti-PAP antibody 
conjugated to HRP. The PTP tag fused to the RAD51-5 is 61 kDa in size, and can be seen below the 62 kDa 
marker band. 
5.7.2.3 Generation of the PTP-tagged RAD51-6 construct 
To overcome the lack of specificity of the anti-RAD51-6 anti-sera which could not be used 
for co-immunoprecipitation analysis (see Section 5.5.5), PTP-tagging of RAD51-6 was 
attempted. To generate an N-terminal PTP-tagged RAD51-6, the whole ORF of RAD51-6 
was cloned into the pN-PTP-vector. RAD51-6 was PCR-amplified using 51-6 Nterm PTP 
forward and reverse primers (see Materials and Methods, Section 2.4.1, Table 2-1). These 
primers had NotI and KpnI enzyme restriction sites, on the forward and reverse 
respectively, and were used to clone the fragment into the vector, see Figure 5-46. The 
fragment of RAD51-6 ORF cloned into the vector pN-PTP was from 4 bp to 1428 bp. This 
pN-PTP-RAD51-6-Puro construct was confirmed by sequencing and linearised using a 
unique restriction enzyme site in the middle of RAD51-6, BclI. The linearised construct 
was transformed into the heterozygous RAD51-6 mutant, which had one RAD51-6 allele 
disrupted with a blasticidin resistance cassette (see Chapter 3, Section 3.5.3). 
Recombination of the construct into the intact allele of RAD51-6 should result in the intact 
ORF becoming N-terminally tagged with PTP, with insertion via selection for the 
resistance cassette for puromycin, see Figure 5-46. 
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Bcl I
Not I Kpn I
pN-PTP-RAD51-6-Puro Puro
Puro
Puro
Puro
Puro
 
Figure 5-46: Diagram showing design and use of an N-terminal PTP vector for RAD51-6 tagging at its 
endogeneous locus. 
A fragment of RAD51-6 (from 4 bp to 1428 bp of the ORF) was cloned into the pN-PTP vector using NotI 
and KpnI restriction enzyme sites. This was then linearised using a BclI restriction site and transformed into 
T. brucei RAD51-6 +/- cells. Green arrow: selectable resistance cassette, puromycin (Puro); Red arrow: 
targeted open reading frame, RAD51-6. Diagram adapted from Kelly et al. (2007). 
5.7.2.4 Confirmation of PTP tagged RAD51-6 in T. brucei 
A selection of PTP-RAD51-6 clones that were resistant to puromycin were analysed to 
confirm integration of the PTP-tag. Genomic DNA was extracted from the clones and 
PCR-amplification was carried out. As a positive control, the whole ORF of RAD51-6 was 
PCR-amplified using the RECA2 StartORF-For and RECA2 EndORF-Rev (see Materials 
and Methods, Section 2.4.1, Table 2-1). Figure 5-47 shows the PCR products of one PTP-
RAD51-6 clone. Two fragments were obtained because the PTP-RAD51-6 construct was 
transformed into the RAD51-6 +/- cell line, which had one RAD51-6 allele disrupted with 
blasticidin resistance cassette (Chapter 3, Section 3.5.3). This resulted in a larger product 
as the resistance cassette added approximately 250 bps to the disrupted region (Figure 5-
47, Lane 1: 1685 bp fragment). The smaller fragment is the size of the intact RAD51-6 
allele (Figure 5-47, Lane 1: 1435 bp fragment). Using the same extracted genomic DNA 
and the PTP-Nterm check For and RECA2 EndORF-Rev primers, PCR-amplification was 
carried out to check if the PTP tag integrated into the RAD51-6 endogenous locus. Figure 
5-47, Lane 2 shows the fragment obtained, confirming that the RAD51-6-PTP-tag was 
present. 
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Figure 5-47: PCR-amplification to check PTP-tag integration into the RAD51-6 allele. 
The genomic DNA was extracted from one puromycin resistant clone and PCR-amplification analysis was 
carried out to confirm that the PTP-tag had integrated into the RAD51-6 allele. Lane 1 shows the PCR-
products obtained when using RECA2 StartORF-For and RECA2 EndORF-Rev primers. Lane 2 shows the 
PCR product when PCR-amplification was carried out using a forward primer which bound to the 5’ end of 
the PTP tag and a reverse primer which bound to the 3’ end of the ORF of RAD51-6.  
The protein extracts from this N-PTP-RAD51-6 clone and the C-RAD51-5-PTP clone (as a 
control) were separated on a 10 % SDS-PAGE gel and then transferred to a nylon 
membrane (Figure 5-48). The membrane was probed with anti-PAP antibody conjugated to 
HRP (Roche) at a dilution of 1:1000. The PTP tag fused to the N terminus of RAD51-6 
adds 19 kDa, resulting in a total PTP-RAD51-6 size of approximately 70 kDa. Figure 5-48 
shows this western blot where a band of the predicted size of PTP-RAD51-6 can be 
detected. Although there is non-specific binding at approximately 83 kDa in both the 
protein extracts from the N-PTP-RAD51-6 and C-RAD51-5-PTP clone, a band of the 
correct size of C-RAD51-5-PTP (~61 kDa), although faint, can be detected. This western 
blot also confirms the PCR-amplification result and shows that the PTP-RAD51-6 
predicted size of 69.4 kDa was present in protein extracts from the transformed clone. 
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Figure 5-48: Western analysis showing the PTP-tagging of RAD51-6 by probing the cell lysate with 
anti-PAP antibody. 
Western blot analysis was carried out to confirm that the PTP-tag fusion of RAD51-6 was correct. Lane 1 has 
the PTP-RAD51-6 cell extract and Lane 2 has the RAD51-5-PTP cell extract. Both extracts were separated 
on a 10 % SDS-PAGE gel and transferred to a nylon membrane. This was then probed with anti-PAP 
antibody conjugated with HRP (at a dilution of 1:1000). The bands at the predicted sizes of PTP-RAD51-6 of 
~ 70 kDa (Lane 1) and PTP-RAD51-5 of ~ 61 kDa (Lane 2) are indicated. 
5.7.3 Attempt to recover protein complexes by PTP 
purification 
Once PTP-tagging was confirmed, an attempt to purify RAD51-5-PTP was performed. 
Five litres of 3 x 106 cells per ml of RAD51-5-PTP cell culture were pelleted and the 
proteins were extracted as before for the co-IP analysis (see Section 5.6 and Materials and 
Methods, Section 2.6.2.2). The PTP-tagging purification of RAD51-5-PTP was then 
carried out, see Figure 5-40 which shows an overview of each step of the purification 
strategy. The IgG beads were equilibrated in the correct buffers and protease inhibitors 
were added (see Materials and Methods, Section 2.12 for details). A total of 4 ml of protein 
extract from the RAD51-5-PTP cells was added to the IgG beads (Invitrogen) and 
incubated at 4 oC for two hours. This allowed the RAD51-5-PTP protein (target protein) to 
bind to beads via the Protein A epitope (ProtA). After the incubation, the flow-through was 
collected and the column was washed, to ensure that all contaminants were removed. The 
RAD51-5-PTP and possible associated protein(s) remain bound to the IgG matrix. The 
RAD51-5-PTP was then released from the IgG beads and Protein A by TEV protease 
cleavage. To do this, 200 units of TEV protease were added to the beads and incubated 
overnight at 4 oC. After 16 hours, the flow-through containing RAD51-5-ProtC was 
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collected and then bound to anti-Protein C affinity matrix (Roche). This second affinity 
column was allowed to incubate at 4 oC for two hours, and then allowed to settle. The 
flow-through was collected. The matrix was washed before the proteins were released from 
the beads using an EDTA buffer. The RAD51-5-ProtC and any associated proteins were 
eluted.  
The flow-throughs, washes and elutant from the RAD51-5-PTP purification were 
electrophoresed on two 10 % SDS-PAGE gels (Figure 5-49, Lanes 1-9). On one gel, the 
proteins were stained with Coomassie blue (Figure 5-49A), and the other gel, the proteins 
were transferred to a nylon membrane. The Coomassie stained gel (Figure 5-49A) shows 
that the majority of proteins were in flow-through from the first IgG affinity column and 
that the following washes did not contain detectable amounts of protein. The western blot 
was first probed with anti-PAP-HRP anti-serum (at a dilution of 1:750) which detects the 
ProtA (Figure 5-49B). This blot showed that the original protein extract contained a band 
of the predicted size of RAD51-5-PTP (~ 61 kDa) (Figure 5-49B, Lane 1), while in the 
first flow-through this band was not detected (Figure 5-49B, Lane 2). The RAD51-5-PTP 
band was also absent in the following washes (Figure 5-49B, Lane 3-4). No other bands 
were detected in Lanes 5-9; this is expected as the TEV-protease cleavage results in the 
ProtA remaining bound to the IgG matrix in the column, while releasing the RAD51-5-
ProtC and any associated proteins (Figure 5-49B, Lane 5-9). This membrane was stripped 
and re-probed with anti-ProtC-peroxidase anti-serum (at a dilution of 1:3000; Roche) 
which detects the ProtC (Figure 5-49C). Unexpectedly, there was no detectable band of the 
correct size in the RAD51-5-PTP protein extract (~61 kDa), while there was considerable 
cross-contaminant bands in the extract and in the first flow-through (Figure 5-49C, Lane 1-
2). There was also no detectable RAD51-5-ProtC in the final eluate (Figure 5-49C, Lane 
9). The western blot shown in Figure 5-47C indicates that the anti-ProtC antibody is not 
specific and can not detect the RAD51-5-PTP protein. Due to time constraints, it was not 
possible to attempt to re-purify RAD51-5-PTP and PTP-RAD51-6. 
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Figure 5-49: Coomassie stain and western blot of the RAD51-5-PTP purification. 
Two 10 % SDS-PAGE gels were electrophoresed; each had the same solution loaded into the corresponding 
lanes as follows: Lane 1: RAD51-5-PTP protein extract. Lane 2: Flow-through from the first IgG affinity 
column. Lane 3: First wash of the IgG affinity column. Lane 4: Final wash of the IgG affinity column. Lane 
5: Flow-through after the TEV-protease cleavage. Lane 6: First wash of the anti-ProtC affinity column. Lane 
7: Third wash of the anti-ProtC affinity column. Lane 8: Final wash of the anti-ProtC affinity column. Lane 
9: The eluate. Figure 5-49A: shows the Coomassie stain of one of the gels. Figure 5-49B: shows the western 
blot of the transferred proteins probed with anti-PAP-HRP (at a dilution of 1:750). Figure 5-49C: The 
membrane was stripped and reprobed with anti-ProtC-peroxidase (at a dilution of 1:3000). 
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5.8 Possible co-expression of RAD51-3 and 
RAD51-4 
During the course of testing the specificity of the unpurified and affinity purified anti-sera, 
it was found that RAD51-4 was absent in the rad51-3 -/- mutant protein extracts. In 
contrast, RAD51-3 was present in the rad51-4 -/- mutant protein extracts. This experiment 
was repeated three times, and the results are shown in Figure 5-50. The wildtype, rad51-3 -
/- and rad51-4 -/- cell extracts were quantified using the Bradford method (Bio-Rad), and 
50 µg.ml-1 of each protein extract was separated on a 10 % SDS-PAGE gel. These proteins 
were transferred to a nylon membrane and probed with affinity purified anti-RAD51-4 
anti-serum at a dilution of 1:1000 (see Section 5.5.3). The RAD51-4 was detected with 
anti-rabbit anti-serum at a dilution of 1:5000 (Molecular Probes). The result of this analysis 
is shown in Figure 5-50A where the wildtype extract contains a distinct band of the 
predicted size of RAD51-4 (45.7 kDa) which was not detectable in the two homozygous 
mutant cell lines, rad51-3 -/- and rad51-4 -/-. This membrane was stripped by incubation 
with stripping buffer (Pierce) for 30 minutes, and washed twice in PBS-Tween20 for 30 
minutes. The blot was reprobed with affinity purified anti-RAD51-3 anti-sera at a dilution 
of 1:10 (see Section 5.5.2) and was detected using anti-sheep anti-serum at a dilution of 
1:5000 (Santa Cruz). Figure 5-50B shows that RAD51-3 is present in both the wildtype 
and rad51-4 -/- cell extracts, since there was a detectable band of the predicted size of the 
protein (54.5 kDa). As expected the RAD51-3 band was absent in the rad51-3 -/- protein 
extract (Figure 5-50B).  
 
Figure 5-50: Western analysis showing possible co-expression of RAD51-3 and RAD51-4. 
Western blot analysis was carried out to confirm the co-expression of RAD51-3 and RAD51-4. 50 µg.ml-1 of 
protein extract from wildtype, rad51-3 -/- and rad51-4 -/- cells were separated on a 10 % SDS-PAGE gel and 
transferred to a nylon membrane. Figure 5-50A: shows the membrane when probed with anti-RAD51-4 anti-
serum. This was stripped and reprobed. Figure 5-50B: shows the blot when probed with anti-RAD51-3 anti-
serum. The size markers, the predicted size of RAD51-4 (45.7 kDa) and RAD51-3 (54.5 kDa) are indicated. 
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There are two possible explanations for this result. First, is that RAD51-4 was not 
expressed in the rad51-3 -/- mutant cell line. The second is that RAD51-3 is required for 
the stabilisation of RAD51-4 in the cell. RT-PCR-amplification and Northern analysis can 
be used to determine whether RAD51-4 is transcribed in the rad51-3 -/- mutant cell line. 
This will not conclusively prove that RAD51-4 is translated and therefore not expressed. 
Another experiment to determine co-expression would be to analyse the RAD51-3 -/-/+ re-
expressor cell line for the reappearance of RAD51-4.  
5.9 Summary 
The results described in this chapter aim to identify the interactions between the T. brucei 
RAD51 paralogues. It has been shown that the mammalian Rad51 paralogues and yeast 
Rad51 paralogues complex with one another. The five mammalian Rad51 paralogues have 
been shown to form two distinct complexes, with one Rad51 paralogue, Rad51C in both 
complexes (Liu et al., 2002b; Masson et al., 2001b). The two yeast Rad51 paralogues have 
also been shown to interact with one another (Hays et al., 1995; Johnson & Symington, 
1995). Members of each mammalian and yeast complex, XRCC3-Rad51C and Rad55 
respectively, have been shown to interact with Rad51 (Hays et al., 1995; Liu et al., 2002b). 
As a consequence of these findings in other systems, it was predicted that one or more 
proteins from the T. brucei RAD51 family would interact with each other. Since the 
number of T. brucei RAD51 paralogues is similar to that of higher eukaryotes, there was 
also the potential for more than one complex of RAD51 paralogues. Three approaches 
were taken to examine if, or which, T. brucei RAD51 paralogues interact: yeast-two 
hybrid, co-immunoprecipitation, and epitope tagging of the RAD51 paralogues.  
Using both the yeast-two hybrid and co-immunoprecipitation methods, it has been shown 
that RAD51-3 and RAD51-4 interact with one another. These two methods provide strong 
evidence of an interaction between RAD51-3 and RAD51-4 in vivo. Yeast-two hybrid 
analysis has also shown that RAD51-3 and RAD51-6 interact. It is noteworthy that this 
interaction was weaker than the interaction seen between LexA-RAD51-3 and V5-NLS-
B42-RAD51-6. However, the reverse was not seen in the complimentary two-hybrid 
analysis where LexA-RAD51-6 and V5-NLS-B42-RAD51-3 fusions showed no 
interaction. This may be because the interaction is not as robust in this system. 
Nevertheless, substantial interaction between RAD51-3 and RAD51-6 was observed in 
comparison to the negative control. These results may indicate that, like the mammalian 
model, two distinct complexes are formed in T. brucei, with one RAD51 paralogue, 
RAD51-3, involved in both complexes. It may also be the case one complex is formed 
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involving all three proteins, RAD51-3-RAD51-4-RAD51-6. Further analysis is required to 
define whether or not the T. brucei RAD51 paralogues function as multiprotein complexes. 
It is widely accepted that Rad51 interacts with itself, forming a nucleoprotein filament on 
DNA (Benson et al., 1994). Yeast-two hybrid analysis also confirmed that the T. brucei 
RAD51 interacts with itself. In contrast, no other interactions were found between RAD51 
and any of the RAD51 paralogues using yeast-two hybrid analysis. It has been shown in 
Chapters 3 and 4 of this thesis (Sections 3.4.4, 3.7.4 and 4.5)  that RAD51 foci formation is 
decreased in the homozygous mutants of all the RAD51 paralogues: rad51-3 -/-, rad51-4 -
/-, rad51-5 -/-, and rad51-6 -/-. Therefore, it is unlikely that RAD51 does not interact with 
any of the RAD51 paralogues, though it is possible they influence RAD51 function 
through an unknown intermediate factor. It is conceivable that the RAD51 paralogues do 
interact with RAD51, even though the analyses used here failed to show interaction. It is 
possible, for instance, that such interactions are weak, or only occur in the context of 
damaged DNA. 
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Chapter 6. A luciferase assay to 
analyse homologous 
recombination in T. brucei 
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6.1 Introduction: Transformation efficiency to 
analyse homologous recombination rate  
To date, analysing the efficiency of homologous recombination (HR) in T. brucei has been 
performed primarily by a transformation efficiency assay by the McCulloch group. This 
method evaluates the ability of the parasite to undergo HR by measuring the rate of 
integration of a construct containing an antibiotic resistance marker flanked by sequences 
that target specific sites of the T. brucei genome. The advantage of this approach is that a 
defined set of targets can be analysed. In most cases, the resistance cassette is flanked with 
the intergenic processing flanks surrounding the α tubulin gene, which allows integration 
into the βα-tubulin array and expression of the drug resistance gene (Conway et al., 2002b; 
Hartley & McCulloch, 2008; McCulloch & Barry, 1999; Proudfoot & McCulloch, 2005a; 
Proudfoot & McCulloch, 2005b). This method has also been used to examine the 
transformation efficiency of different RAD51 paralogue mutant cells compared with 
wildtype cells (including in Chapter 3, Section 3.4.3, 3.7.3 and Chapter 4, Section 4.4 of 
this thesis). These studies demonstrate that integration of the drug resistance gene is under 
genetic control and consistent with the reaction being driven by HR. It has also been shown 
that the reaction efficiency is determined by extent of sequence homology between the 
construct and a single specified target sequence again consistent with it being driven by 
HR (Barnes & McCulloch, 2007; Bell & McCulloch, 2003).  
In this thesis, to measure the transformation efficiency, a linearised piece of DNA 
containing the ORF for phleomycin resistance (BLE), flanked with βα and αβ intergenic 
regions, was transformed into T. brucei cells by electroporation (see Materials and 
Methods, Section 2.8.3). If HR can occur, the targeting regions of the βα and αβ intergenic 
flanks enable the phleomycin resistance cassette to integrate and express from the βα-
tubulin array (see Figure 6-1), and as result, the cells become resistant to phleomycin. The 
tubulin genes are arranged as a tandem array of alternating α and β genes with a basic 
repeat length of ~3.7 kb. It is thought that this cluster has up to 19 αβ repeats in T. brucei 
strain 427 (Berriman et al., 2005; geneDB, 2009) and disruption of one α tubulin gene of 
the array does not appear to affect the growth rate or morphology of the cells. It has also 
been shown that the construct is very predominantly integrated by HR (Barnes & 
McCulloch, 2007). 
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Figure 6-1: Transformation efficiency assay 
A linearised piece of DNA containing an antibiotic resistance gene ORF, in this case encoding phleomycin 
resistance (BLE) flanked by βα and αβ intergenic regions, is transformed into T. brucei cells. If homologous 
recombination can occur, the flanks allow the resistance cassette to integrate into the βα tubulin array, 
replacing an alpha (α) tubulin ORF (blue box). This allows expression of the phleomycin resistance gene 
(BLE).  
Despite the validity of this approach, it measures transformation rather than directly 
measuring intra-chromosomal or inter-chromosomal recombination, and may be prone to 
experimental fluctuation. Transformation rate may be affected by many factors including 
DNA concentration, transformation conditions (for example: fluctuations in delivering 
voltage during electroporation) and the growth of the cells (for example: mutants in HR 
also have an increase in population doubling time). It has been shown that T. brucei 
recombination efficiency is dependent on the similarity of the sequence of the targeting 
regions (Barnes & McCulloch, 2007). In addition, this method uses a relatively non-
physiological substrate; the construct is a small, linear, non-replicative, non-transcribed 
piece of DNA that is not coated with chromatin and must pass through the cell and nuclear 
membrane to be recombined. The fact that the construct is linear causes this to be an 
artificial means of testing recombination, as the molecule ends may be viewed as double 
strand breaks (DSB) which may not always be the lesion that induces recombination. The 
antibiotic selection may also influence the number of transformants recovered. In separate 
experiments in this thesis, for instance, transformation efficiency was approximately 4 fold 
higher for the wildtype cells analysed in Chapter 3 (Section 3.4.3 and Section 3.7.3) 
compared to the same cell line analysed in Chapter 4 (Section 4.4).  
An alternative system has been developed to measure recombination in T. brucei by Horn 
and colleagues. This system uses controlled expression of a nuclease, I-SceI (Glover et al., 
2007). I-SceI is a rare cutting endonuclease and, when expressed in vivo, a DSB will result 
at the I-SceI site. After induction of the expression of I-SceI and DSB formation, the cells 
are allowed to recover, and are measured. The mapping of the survivors provides 
information regarding the rate and pathway of recombination. Again, however, this cannot 
analyse the natural rates of HR, or other recombination pathways in T. brucei, as it relies 
on a specific DSB initiation.  The objective of this chapter of the thesis was to develop an 
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alternative assay to test for HR rates and pathways in T. brucei, one which is more relevant 
physiologically and adaptable for different purposes. 
6.2 Principles of marker constructs to measure 
homologous recombination 
One method of analysing the rate of HR in a non-selective assay system was described by 
Swoboda et al. (1994). The system enabled visualisation of intrachromosomal HR events 
throughout the whole life-cycle of Arabidopsis thaliana by histochemical staining of the 
whole plant. The system used a disrupted β-glucuronidase (uidA) gene as a genomic 
recombination substrate. Two β-glucuronidase gene fragments sharing a region of 
sequence homology were integrated into the A. thaliana genome. The homologous regions 
were positioned in the same orientation to one another as direct repeats (see Figure 6-2A: 
Schuermann et al., 2005) and were separated by a hygromycin phosphotransferase 
resistance marker. If a recombination event occurred, the two gene fragments would form a 
functional β-glucuronidase ORF by recombining the homologous regions of the gene 
fragments (Swoboda et al., 1994). This assay system, called the GUS assay, allowed 
quantitative and precise localisation of the recombination event by showing functional β-
glucuronidase with addition of its substrate, 5-bromo-4-chloro-3-indoly glucuronide (X-
Glu) (Swoboda et al., 1994).  
This system was modified to detect any HR events in living tissues of A. thaliana (Fritsch 
et al., 2004) by using the firefly luciferase gene (LUC) as the reporter instead of the β-
glucuronidase gene. This system contained two fragments of the luciferase gene and, like 
the GUS assay, each fragment had homologous overlapping regions, see Figure 6-2B. 
Although Figure 6-2B uses the GUS assay to represent the system, the principle was the 
same for the LUC assay. The two homologous fragments were positioned as inverted 
repeats relative to one another. If HR occurred, the result would be a functional luciferase 
gene. To detect recombinants, the plants were sprayed with luciferin, and bioluminescence 
was observed (Fritsch et al., 2004).  
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Figure 6-2: Intra-chromosomal homologous recombination reporter constructs with direct and 
indirect repeats. 
Both constructs consist of two inactive fragments of a reporter gene, the β-glucuronidase gene. The gene 
fragments are GU’ and U’S, which share the homologous sequence, U’. During homologous recombination a 
strand exchange event can occur, which results in the production of the functional reporter gene, GUS. 
Figure 6-2A: shows the recombination event (indicated by the red X) required when the homologous regions 
are orientated as direct repeats to one another, resulting in the deletion of the sequence between the two 
fragments. Figure 6-2B: shows the recombination event required when the homologous regions are 
orientated as indirect repeats, resulting in the conservation of the intervening sequence. Reprinted with 
permission from Elsevier: Schuermann et al. (2005), Trends in Genetics 21, pp 176. 
In mammalian cells, similar constructs have been used to assay for HR. Pierce et al. (1999) 
used two modified non-functional GFP genes: one had an I-SceI endonuclease site and two 
in-frame stop codons within the ORF and the other GFP was truncated at the 5’ end. The 
GFP genes were oriented as direct repeats and were separated with a puromycin N-
acetyltransferase gene. I-SceI when expressed in vivo, caused a DSB at the I-SceI site 
(Pierce et al., 1999). The authors showed by flow cytometry that expression of I-SceI in 
wildtype transfected cell lines produced fluorescence (Pierce et al., 1999). Therefore, the 
DSB was repaired by HR between the two non-functional GFP genes, resulting in a 
functional GFP gene. It was also shown in this study that a Rad51 paralogue mutant, xrcc3 
-/-, did not produced fluorescence compared with the wildtype cells and the authors 
concluded that xrcc3 -/- mutant cells were defective in HR (Pierce et al., 1999).  
In other experiments using mammalian cells, disrupted resistance cassettes have been used 
instead of bioluminescent or fluorescent markers. The puromycin N-acetyltransferase and 
neomycin phosphotransferase genes have been used by Johnson et al. (1999) and Lio et al. 
(2004) respectively. Both studies used two non-functional resistance genes; one was 
disrupted by addition of an I-SceI site and the other was truncated. Expressing the I-SceI 
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endonuclease in the cells resulted in a DSB in the integrated construct and repair produced 
a functional resistance gene. The viable cells resistant to the drug were therefore able to 
undergo HR of the two non-functional drug resistance genes (Johnson et al., 1999; Lio et 
al., 2004). These studies showed that two of the mammalian Rad51 paralogues, XRCC2 
and Rad51C, promote the repair of the DSB by HR (Johnson et al., 1999; Lio et al., 2004).  
6.3 Generation of a positive control expressing 
luciferase 
Before generating the constructs to assay for recombination, it was necessary to confirm 
that the firefly luciferase gene expressed in T. brucei cells can result in the production of 
measurable bioluminescence similar to the observations by Wang and colleagues (Sommer 
et al., 1992). To this end, a positive control construct was generated. This construct was 
required to allow integration of the luciferase ORF into a transcribed region of the T. 
brucei genome, in particular wildtype bloodstream stage cells Lister strain 427. This 
construct contained the ORF of luciferase, and blasticidin S deaminase (BSD) flanked by 
the βα tubulin and actin intergenic regions (βα IR and Act IR). To generate this positive 
control construct, the βα IR, BSD, Act IR were cloned into the TOPO vector 2.1, as used in 
Chapter 3, Section 3.2.2. Briefly, blasticidin (400 bp) and the intergenic processing flanks 
(βα IR (240 bp) and Act IR (400 bp)) were PCR-amplified from the plasmid pCP101 
(Proudfoot & McCulloch, 2005a) using the primers: Tubulin For and Actin Rev (see 
Materials and Methods, Section 2.4.1, Table 2-1). The resulting PCR product of 
approximately 1040 bp was cloned into the TOPO 2.1 vector (Invitrogen, see Materials 
and Methods, Section 2.4.7), resulting in the plasmid TOPO-βα IR-BSD-Act IR. The 
luciferase ORF and αβ IR were then cloned into the TOPO-βα IR-BSD-Act IR vector. To 
this end, the firefly luciferase ORF was obtained from the pGL3-Basic vector (Promega) 
and, using XhoI and XbaI sites, the luciferase ORF was digested out of pGL3. The αβ IR 
region was then PCR-amplified from genomic DNA from wildtype T. brucei cells, using 
the AB forward and AB reverse primers, which had XbaI and ApaI restriction sites (see 
Materials and Methods, Section 2.4.1, Table 2-1). Using a three way ligation, the luciferase 
ORF and αβ IR were cloned into TOPO-βα IR-BSD-Act IR using the XhoI and ApaI 
restriction sites, with the XbaI site in between the luciferase ORF and αβ IR fragments. The 
resulting construct is as follows: TOPO-βα IR-BSD-Act IR-LUC-αβ IR. Once confirmed 
by DNA sequenced, the construct was then linearised using SacI and ApaI restriction sites 
and transformed into wildtype T. brucei cells (see Materials and Methods, Section 2.1.2). 
Integration of the construct should occur using the targeting regions (βα IR and αβ IR) 
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recombining it into the βα-tubulin array with the replacement of one α-tubulin gene (Figure 
6-3). 
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Figure 6-3: The positive control construct allowing luciferase expression from the βα-tubulin array. 
The luciferase open reading frame (ORF) and αβ-tubulin intergenic region (αβ-IR) were cloned with the 
blasticidin resistance cassette (BSD) and intergenic processing flanks, βα-tubulin intergenic region (βα IR) 
and actin intergenic region (Act IR). This construct was digested and linearised using restriction enzymes 
SacI and ApaI and integrated into the βα-tubulin array. 
Once electroporated, transformants were selected for by growth in media containing 2.0 
µg.ml-1 of blastidicin (Calbiochem; see Materials and Methods, Section 2.1.2). Five clones 
(A-E) were then selected to assay for luciferase activity (see Materials and Methods, 
Section 2.13). To do this, the cell density of each was counted, and using a 96 well plate, 
the five transformants were serial diluted from a density of 1 x 107 cells in PBS to final 
densities of 2 x 106 to 1.56 x 104 cells in a total volume of 200 µl. To each well, 20 µl of 1 
mM of d-luciferin/PBS (Promega) was then added, and incubated at 37 oC for 30 minutes. 
After this, the plate was removed from the incubator and left at room temperature for 15 
minutes. Bioluminescence was then read using a 404 nm filter (Envision). Figure 6-4 
compares the bioluminescence emitted from wildtype, non-transformed cells and the five 
blasticidin resistant transformants.  
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Figure 6-4: Bioluminescence production in T. brucei bloodstream stage cells. 
The cells from wildtype and five blasticidin resistance transformants (A-E) were serially diluted from 1 x 107 
cells to 7.8 x 104 cells per ml in a final volume of 200 µl, to assay for luciferase activity. The total number of 
cells analysed are indicated in the box on the right. This was carried out with the addition of the luciferase 
substrate, d-luciferin, and bioluminescence was measured in relative light units. 
Bioluminescence generated by luciferase was measured in an enzymatic reaction where d-
luciferin is converted to oxyluciferin and light (see review: Viviani, 2002). All five 
transformants produced bioluminescence in the presence of substrate, whereas no such 
reaction was detected with the non-transformed wildtype cells. This shows that as few as 
2.5 x 105 cells expressing luciferase can be detected by light emission (blue points in 
Figure 6-2), since this was clearly higher than the background readings for the wildtype 
cells. This suggests that T. brucei strain 427 is able to express luciferase from the βα-
tubulin array and that such expression can be detected at low densities. This assay also 
confirmed that d-luciferin is not toxic to the cells as recovery of all five transformants was 
possible. 
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6.4 A direct repeat luciferase construct to assay 
homologous recombination 
6.4.1 Generation of the luciferase construct 
Since the positive control construct, where the luciferase ORF was expressed from the βα-
tubulin array, showed that bioluminescence could be detected in bloodstream form cells, a 
luciferase reporter construct to assay for HR was generated. The first reporter construct 
contained two inactive fragments of the luciferase reporter gene (see Figure 6-5E). As for 
similar assays in other cells (see Section 6.2), these fragments contained homologous 
sequence (shaded area in Figure 6-5E) at their 3’ and 5’ ends, and were cloned in the same 
orientation to one another as direct repeats. The LUC gene fragments were separated by an 
antibiotic resistance cassette, phleomycin (BLE).  
This construct was generated in three parts (Figure 6-5). The first part consisted of cloning 
the βα and αβ tubulin intergenic regions into pBluescript. The fragment of the βα 
intergenic region was PCR-amplified using primers BA IR For and BA IR Rev, and the αβ 
intergenic region was PCR-amplified using primers AB IR For and AB IR Rev (see 
Materials and Methods, Section 2.4.1, Table 2-1). These fragments were cloned separately 
into TOPO vector 2.1 (Invitrogen) and sequenced. Both βα and αβ intergenic regions were 
then digested out of the TOPO vector using SacI and EcoRV, and EcoRV and KpnI, 
respectively, then cloned together into pBluescript. To do this, a three way ligation 
between these two fragments and SacI and KpnI digested pBluescript was performed, 
which resulted in the reconstitution of an EcoRV site between the two fragments. The 
resulting construct was named pBluescript-βα IR: EcoRV: αβ IR (see Figure 6-5A).  
The second stage required another pBluescript plasmid into which the actin and calmodulin 
intergenic regions were cloned. The actin intergenic region was PCR-amplified using the 
primers Actin For and Rev, and the calmodulin intergenic region was PCR-amplified using 
the primers Calmodulin For and Rev (see Materials and Methods, Section 2.4.1, Table 2-
1). Again these fragments were cloned separately into the TOPO vector 2.1 (Invitrogen) 
and then digested out of TOPO using XhoI and EcoRV for the actin intergenic region, and 
EcoRV and XbaI for the calmodulin intergenic region. The fragments were then cloned, 
using a three way ligation, into pBluescript pre-cut with XhoI and XbaI. As a result, an 
EcoRV restriction enzyme site was generated between the two fragments, and the construct 
was named pBluescript-Act IR: EcoRV: Cal IR, see Figure 6-5B. Next, the phleomycin 
resistance ORF (BLE) was PCR-amplified using the primers Bleo For and Bleo Rev, and 
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cloned into the pBluescript-Act IR: EcoRV: Cal IR construct. The BLE ORF was cloned 
between the actin and calmodulin intergenic processing regions using the EcoRV site. The 
resulting construct pBluescript-Act IR: BLE: Cal IR (see Figure 6-5C) was sequenced. 
Finally, the phleomycin resistance cassette comprising the BLE ORF, Act IR and Cal IR 
processing flanks was digested out of pBluescript-Act IR: BLE: Cal IR using the XhoI and 
XbaI restriction sites and cloned into EcoRV-digested pBluescript-βα IR: EcoRV: αβ IR, 
with the removal of the EcoRV restriction enzyme site between the βα:αβ intergenic 
regions. The resulting construct was pBluescript-βα IR-Act IR-BLE-Cal IR-αβ IR (see 
Figure 6-5D). 
The third part of the generation of the LUC construct involved the cloning of the two 
putatively inactive fragments of the luciferase gene, which contained overlapping 
homologous sequence. The fragments were cloned into pBluescript-βα IR-Act IR-BLE-Cal 
IR-αβ IR. The start of the luciferase ORF was PCR-amplified using the primers Start Luc 
For and Rev which amplified 1064 bp of the 5’ end of the gene (‘LUCIFE’ in Figure 6-
5E). The end of the luciferase ORF was PCR-amplified using the primers End Luc For and 
Rev which amplified 925 bp of the 3’ end of the gene (‘FERASE’ in Figure 6-5E). 336 bp 
is shared in the two fragments (‘FE’ in Figure 6-5E). The 5’ end of the luciferase gene was 
cloned using the StuI restriction site of the pBluescript-βα IR-Act IR-BLE-Cal IR-αβ IR 
between the βα IR and Actin IR, and the orientation was confirmed. Then the 3’ end of the 
luciferase gene was cloned using the PstI and SacII restriction sites with the loss of the 
XbaI site (indicated in red in Figure 6-5E). The resulting construct was pBluescript-βα IR-
LUCIFE-Act IR-BLE-Cal IR-FERASE-αβ IR (see Figure 6-5E). 
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Figure 6-5: Generation of a direct repeat luciferase construct to assay homologous recombination. 
The diagram shows the cloning strategy for the luciferase construct. Figure 6-5A: The βα and αβ tubulin 
intergenic regions (βα IR and αβ IR) were the cloned into pBluescript. Figure 6-5B: The actin IR (Act IR) 
and calmodulin IR (Cal IR) intergenic regions were cloned into a second Bluescript vector, Figure 6-5C: 
shows the integration of phleomycin resistant cassette (BLE) between the two actin IR and calmodulin IR. 
Figure 6-5D: shows the integration of the phleomycin resistance cassette and processing flanks, actin IR and 
calmodulin IR, in between the βα IR and αβ IR, resulting in pBluescript-βα IR-Act IR-BLE- Cal IR-αβ IR. 
Figure 6-5E: The two luciferase fragments (5’ end: LUCIFE; and 3’ end: FERASE) have homologous 
sequence (shaded area; FE), were cloned into pBluescript-βα IR-Act IR-BLE-Cal IR-αβ IR. The restriction 
sites are shown and XbaI in red indicates that this site has been removed during the cloning process. 
6.4.2 Transformation of the construct into T. brucei cells 
The plasmid was linearised using SacI and KpnI restriction enzymes and the DNA was 
transformed into wildtype T. brucei bloodstream stage Lister strain 427 cells. The βα and 
αβ intergenic sequences allowed integration into the βα-tubulin array, replacing the α 
tubulin gene (Figure 6-6). The actin and calmodulin intergenic regions provide the 
processing flanks for expression of the phleomycin resistance gene. Transformants were 
selected with 1.0 µg.ml-1 of phleomycin. The two luciferase fragments are oriented in 
direct repeat and share of 336 bp of homologous sequence (shaded area in Figure 6-6). 
Previous work has shown that this is a sufficient length of sequence for HR to occur 
(Barnes & McCulloch, 2007). Once transformed, passage of the transformants in medium 
containing phleomycin ensures the fragments of the luciferase gene will not recombined, 
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as recombination within the luciferase gene fragments would result in the loss of the 
phleomycin resistance gene (see Figure 6-2A).  
L     U     C     I     F     E F     E     R    A    S    Eβα IR αβ IR
1 1064 728 1740
α β αβα αβ IRαβ IR βα IR βα IR
BSDAct IR Cal IR
 
Figure 6-6: Integration of the luciferase construct into the βα tubulin array. 
The construct should integrate into the βα-tubulin array by homologous recombination on the βα and αβ 
tubulin intergenic region (βα IR / αβ IR), replacing an alpha (α) tubulin gene. The actin IR (Act IR) and 
calmodulin IR (Cal IR) processing flanks surround the phleomycin resistant ORF (BLE) which allows 
selection for transformants. The two luciferase fragments (LUCIFE and FERASE) share 336 bp of 
homologous sequences (shaded; FE). 
6.4.3 Assaying for homologous recombination using the 
luciferase construct with homologous regions as 
direct repeats 
Two phleomycin resistant transformants (1 and 2) were analysed. For each clone, two 
passages were performed; one remained on the phleomycin selection and the other without 
selection. Removal of the phleomycin selection should allow recombination of the 
homologous ends of luciferase to occur, generating a functional luciferase gene whose 
gene product could be detected by bioluminescence.  
Initial experiments tested whether the potential recombination events could be detected by 
PCR-amplification with primers that anneal to sequences within the boundaries of the 
integrated construct: Recombine Check For and Rev (see Materials and Methods, Section 
2.4.1, Table 2-1). By analysing the sizes of the PCR-amplified, it could be ascertained 
whether or not HR had occurred (Figure 6-7). The primer Recombine Check For anneals 
upstream of the homologous sequence at position 644 bp of the LUC ORF and the primer 
Recombine Rev Check anneals downstream of the homologous sequence at 1120 bp. For 
the positive control, genomic DNA from clone A (see Section 6.3, Figure 6-4), which had 
the intact luciferase ORF integrated into the βα tubulin array, was used as a template 
(Figure 6-7A and Figure 6-7D, Lane 1). The primer annealing sites are 476 bp apart in the 
intact luciferase ORF. Two clones (1 and 2) transformed with the βα IR-LUCIFE-Act IR-
BLE-Cal IR-FERASE-αβ IR construct were continually passaged on phleomycin. Genomic 
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DNA from them was used as template and the resulting PCR products are shown in lanes 
2, and 3 (Figure 6-7D). As recombination of the luciferase homologous sequence was 
prevented by phleomycin retention, the primer binding sites were further apart compared to 
the positive control (Figure 6-7B), generating a product of approximately 1980 bp. One 
clone transformed with the construct βα IR-LUCIFE-Act IR-BLE-Cal IR-FERASE-αβ IR 
was taken off phleomycin selection (Clone 1), and passaged for three months without the 
drug. After this period, genomic DNA was extracted from approximately 5 x 106 cells and 
PCR was performed using the same Recombine Check For and Rev. If recombination of 
the luciferase fragments occurred in this clone, the PCR product obtained would be the 
same size as that amplified from the positive control (Figure 6-7C). However, the PCR 
product obtained was ~ 2.0 kb, the same as the clones passaged on phleomycin (Figure 6-
7D, Lane 4), and no PCR product was observed at 476 bp. Therefore no recombination was 
detected. 
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Figure 6-7: Analysing recombination of the luciferase homologous sequence by PCR-amplification. 
The Recombine Check For and Rev approximate primer binding sites are indicated by the red arrows on the 
different genomic DNA templates: Figure 6-7A: The positive control, where the luciferase ORF is intact and 
integrated into the βα tubulin array. Figure 6-7B: The βα IR-LUCIFE-Act IR-BLE-Cal IR-FERASE-αβ 
construct where recombination was not allowed to take place, due to continuous selection of phleomycin. 
Figure 6-7C: The expected product, if recombination occurred between the homologous sequences of the 
luciferase fragments (FE; shaded area) after removal of selection. Figure 6-7D: The gel shows the PCR 
amplification products using the Recombine Check For and Rev primers and using genomic DNA from; 
Lane 1: luciferase positive control clone A, Lane 2 and Lane 3: clones 1 and 2 passaged on phleomycin, 
Lane 4: clone 1 passaged in HMI-9 without phleomycin for three months.  
The lack of detectable recombination could be due to the low amount of DNA amplified in 
this reaction, or because the spontaneous rate of recombination is too low, or due to the 
constructs inability to be recombined. To begin to address this, the two clones (1 and 2) 
were treated with a DNA damaging agent, to increase the probability of a DSB occurring. 
These two clones contained the original construct βα IR-LUCIFE-Act IR-BLE-Cal IR-
FERASE-αβ IR and were passaged in medium lacking phleomycin for at least three 
months. A total of 1 x108 cells from each clone were then treated with MMS at a 
concentration of 0.0004 % for 72 hours, genomic DNA was extracted and the PCR was 
performed again using the Recombine Check For and Rev primers. Again, this test did not 
reveal any recombination events, since the resulting PCR products obtained were 
approximately 2.0 kb is size (Figure 6-8). If recombination had occurred, a 476 bp PCR 
fragment of the size in the positive control (Figure 6-7A, Lane1) would have been 
detected, but was not visible, despite overloading the gel. 
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Figure 6-8: Analysing recombination of the luciferase homologous sequence by PCR-amplification 
after treatment with 0.0004 % MMS. 
Clone 1 and 2, which had been passaged on non-selective media for three months, were treated with 0.0004 
% MMS for 72 hours. Genomic DNA was extracted from approximately 1 x 108 cells, and PCR analysis was 
performed using the Recombine Check For and Rev primers. 
The above result suggests that MMS-induced DNA damage does not increase the rate of 
HR in this assay, such that functional LUC expression is detectable. This was analysed as 
before, see Materials and Methods, Section 2.13. A total of 1 x 107 cells were analysed and 
no detectable absorbance was measured (data not shown). It may still be the case that the 
assay is not sensitive enough. As a result, a large number of cells or large number of clonal 
populations would be required to detect LUC+ recombinants. It is also possible that more 
DNA damage is required, or that a different type of DNA damage may be needed. One 
possible solution could be the addition of an I-SceI endonuclease site to the construct, 
which would produce a DSB in the sequence between the two homologous regions when 
the nuclease is expressed in vivo (Pierce et al., 1999). This would then induce DNA repair 
and increase the rate for HR within the assay system. Indeed, the work of Glover et al. 
(2008) suggests that the available I-SceI induction system induces DSBs in nearly 100 % 
of cells. 
Another explanation is that the construct design is flawed, and is unable to undergo HR 
repair to lead to a functional LUC gene. The studies where the homologous regions in the 
gene fragments are in the same orientation with one another as direct repeat, used 1.6-3.7 
kb sequence separating the gene fragments (Johnson et al., 1999; Pierce et al., 1999; 
Swoboda et al., 1994). In the construct described here (Section 6.4.1) only ~1.1 kb of 
sequence separated the luciferase gene fragments. It is therefore possible that this sequence 
length is not sufficient to allow the DNA to ‘loop back’ for a recombination event to occur. 
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To attempt to test this, a variant of the LUC construct was generated (see Section 6.5.1 
below) were the LUC fragments are orientated as inverted repeats, as it may considered 
that less DNA looping is required to allow base-pairing during strand exchange. 
6.5 An inverted repeat luciferase construct to 
assay homologous recombination 
6.5.1 Generation of a luciferase construct with inverted 
homologous ends 
An alternative reporter construct was generated containing two inactive fragments of the 
luciferase reporter gene with homologous sequences orientated as inverted repeats relative 
to one another. In this case, these gene fragments were separated by the blasticidin 
antibiotic resistance cassette (BSD). This construct results in the homologous regions being 
in the same orientation when the construct forms a loop to allow recombination of the two 
homologous regions (see Figure 6-2B), which theoretically requires less intervening 
sequence between the LUC gene fragments. 
This construct was generated by modifying the pBluescript:βα-LUCIFE-actin-BLE-
calmodulin-FERASE-αβ made previously (see Section 6.4.3). Firstly, the phleomycin 
(BLE) resistance ORF was replaced with the blasticidin S deaminase (BSD) resistance 
ORF. This was done by digesting the BLE ORF out of the construct with flanking EcoRV 
restriction sites (Figure 6-5E), and replacing it with PCR-amplified BSD ORF. The primers 
BSD For and Rev were used for this, which had an EcoRV restriction enzyme site added 
(see Materials and Methods, Section 2.4.1, Table 2-1). The resulting construct checked by 
sequencing and was named pBluescript:βα-LUCIFE-actin-BSD-calmodulin-FERASE-αβ.  
In the next step, the 3’ end of the luciferase gene (‘FERASE’; in Figure 6-6) was removed 
by digestion with SacII and PstI. This was replaced with an inverted 3’ end of the 
luciferase gene, which had been PCR-amplified using the “End LUC New For” primer 
with a SacII restriction site and “End LUC New Rev” primer with a PstI restriction site 
(See Materials and Methods, Section 2.4.1, Table 2-1). This PCR product was cloned using 
the SacII and PstI generating the construct shown in Figure 6-9.  
The primer “End LUC New Rev” additionally had the target sequence of I-SceI nuclease 
incorporated meaning that the inducible I-SceI machinery designed by Glover et al. (2007), 
could be used to induce a DSB, forcing a recombination event to occur. The construct was 
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sequenced to confirm the LUC fragment orientation, sequence and that the I-SceI target site 
was present. Due to time constraints, this construct was not integrated or tested. 
L     U     C     I     F     E
F     E     R    A    S    E
βα IR αβ IRBSDAct IR Cal IR
α β αβα αβ IRαβ IR βα IR βα IR
PstI I-Sce
I SacI
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Figure 6-9: Luciferase construct and integration into the βα tubulin array. 
Two fragments of the luciferase gene were separated by an antibiotic resistance cassette for blasticidin 
(BSD), which was flanked by actin (Act IR) and calmodulin (Cal IR) intergenic regions. The 5’ end of the 
luciferase gene is indicated by LUCIFE and the 3’ of the gene is indicated by FERASE. The two luciferase 
fragments have homologous sequence (Shaded area: FE) and are orientated as inverted repeats. 
In order to test the role of the I-SceI DSB induction, it will be necessary to integrate the I-
SceI regulatory machinery into LUC assay-containing cells. The pHD1313 construct 
provides integration of the tetracycline inducible system, while the pRP-Sce construct 
provides the inducible I-SceI enzyme expression (Alibu et al., 2005; Glover et al., 2007). 
Once the luciferase construct is integrated into the βα tubulin array (Figure 6-9), the 
linearised pHD1313 and pRP-Sce can then be transformed into the same cell line (Alibu et 
al., 2005; Glover et al., 2007). Again, due to time constraints, this was not carried out to 
completion. 
6.6 Summary 
The aim of this chapter was to design a construct which will allow in vivo recombination 
events to be directly measureable and quantifiable in T. brucei. An assay system similar to 
ones described above (Section 6-2), will allow HR to be analysed in a non-selective way.  
This chapter represents the first steps in developing a novel assay for HR in T. brucei. 
Although it has left more unanswered questions than complete results, some positive data 
has been provided. Firstly, two luciferase-based reporter systems similar to the ones 
described in Section 6-2 are valid and have been generated for other model organisms. The 
direct repeat variant has been transformed, but appears not to spontaneously yield 
detectable LUC+ recombinants. It has also been possible to express firefly luciferase in T. 
brucei wildtype bloodstream stage cells from the βα-tubulin array, and using the substrate 
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d-luciferin, bioluminescence can be detected from a density of 2.5 x 105 cells (see Figure 
6-4). It has also shown that d-luciferin used in these experiments is non-toxic to T. brucei 
bloodstream stage strain 427, and that the cells can be recovered after washing with PBS 
and treatment with d-luciferin, and potentially could be sorted by fluorescence activated 
cell sorting (FACS).  
Future experiments to develop this approach have been outlined, and can include the 
introduction of the I-SceI machinery designed by Glover et al. (2007) into the cells that 
have the βα-LUCIFE-actin-BSD-calmodulin-I-SceI-ESAREF-αβ integrated into the αβ 
tubulin array. The transformation of pHD1313 and pRP-Sce should allow the induction of 
a DSB within the construct, using the I-SceI site engineered between the calmodulin and 3’ 
end fragment of LUC. Prior to this, it would be advantageous to transform the inverted 
repeat LUC construct into wildtype cells and ask if it spontaneously yield LUC+ 
recombinants. 
If the assay can be developed to detect recombination, a number of important experiments 
can be addressed. If the assay is successful, it could be envisaged that other experiments 
can also be carried out to test whether or not HR is affected by, for example, a mutation in 
a DNA damage repair gene. DNA damage can be easily measured in different populations 
of varying sizes. This assay has great potential, and can be adapted to measure the effect of 
a number of different variables; for example, the length of homologous sequence required 
for recombination, the extent of sequence identity needed, whether the genomic location 
influence recombination, or whether specific chemicals or stresses induce recombination. It 
could also be adapted to provide a screen for T. brucei genes that act in HR. The assay 
could be used to ask whether life cycle variation influences HR rate.  
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Chapter 7. Discussion 
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7.1 Introduction 
The aim of this project was to analyse the functions of the T. brucei RAD51 paralogues, 
RAD51-4 and RAD51-6, and to examine how all four RAD51 paralogues interact in the 
parasite. RAD51-4 and RAD51-6 were hypothesised to have roles in homologous 
recombination (HR) and DNA repair, since the previously analysed RAD51 paralogues, 
RAD51-3 and RAD51-5, were shown to function in these pathways (Proudfoot & 
McCulloch, 2005a). Both rad51-3 -/- and rad51-5 -/- mutants display sensitivity to the 
DNA alkylating agent, MMS, defects in HR, slow growth rates relative to the wildtype 
cells, and reduction in the extent of RAD51 foci formation (Proudfoot & McCulloch, 
2005a). Surprisingly, RAD51-3 but not RAD51-5 had a detectable role in antigenic 
variation, with the VSG switching frequency of rad51-3 -/- mutants reduced compared 
with the wildtype and RAD51-3 +/- cells while rad51-5 -/- mutants had no significant 
reduction in VSG switching frequencies (Proudfoot & McCulloch, 2005a).  
To analyse the functions of RAD51-4 and RAD51-6, homozygous mutants were generated 
in the T. brucei bloodstream stage using the Lister 427 transgenic strain 3174.2 
(McCulloch et al., 1997; McCulloch & Barry, 1999; Rudenko et al., 1996). The 
phenotypes of these cell lines were investigated. To determine if the four RAD51 
paralogues interacted with each other or with RAD51, yeast two-hybrid analysis, co-
immunoprecipitation assays and PTP-tagging of the RAD51 paralogues were performed. 
The findings of these experimental approaches are discussed here. The thesis also began to 
develop a novel luciferase assay to measure the rate of T. brucei HR. This is still in the 
early stages and will not be discussed here (see Chapter 6, Section 6.6 for discussion). 
7.2 Phylogeny of the T. brucei RAD51 paralogues 
7.2.1 Identification of the T. brucei RAD51 paralogues 
One of the aims of the study of RAD51-3 and RAD51-5 by Proudfoot & McCulloch 
(2005a) was to attempt to define RAD51-independent recombination pathways in T. 
brucei. T. brucei rad51 -/- mutant cell lines showed that DNA repair, HR and antigenic 
variation are significantly reduced compared to the wildtype, indicating an important role 
for RAD51-mediated HR in these processes (Conway et al., 2002b; McCulloch & Barry, 
1999). Nevertheless, none of these processes were obliterated in the rad51 -/- mutant cells 
(Conway et al., 2002b; McCulloch & Barry, 1999), leading to the conclusion that alternate 
pathways, independent of RAD51 operate. In the absence of RAD51, recombination still 
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occurs by HR, though MMEJ reactions have also been revealed (Burton et al., 2007; 
Conway et al., 2002b; Glover et al., 2008). However, the factors that catalyse either of 
these processes in T. brucei are unknown. To this end, Proudfoot & McCulloch (2005a) 
performed BLAST search analysis of the T. brucei genome with the amino acid sequence 
of S. cerevisiae Rad51, T. brucei RAD51 and E. coli RecA polypeptides. From this 
analysis five RAD51-related genes were identified (Proudfoot, PhD thesis). Searches using 
the amino acid sequence of T. brucei RAD51 revealed three distantly related, highly 
divergent proteins, named at the time RAD57, DMC1B and RECA2; these correspond to 
the current nomenclature of RAD51-3, RAD51-4 and RAD51-6 respectively. This search 
also revealed a gene encoding a protein more highly related to RAD51, which was shown 
to be an ortholog of DMC1 in other eukaryotes (Bishop et al., 1992; Proudfoot & 
McCulloch, 2005b). Finally, another distantly related RAD51-like protein encoded in the 
T. brucei genome named RECA, corresponding to RAD51-5, was identified with a BLAST 
search using E. coli RecA amino acid sequence (Proudfoot, PhD thesis, 2005). Though the 
four distantly related RAD51-like proteins appear to be RAD51 paralogues (see below), a 
motivation for this work was that it was conceivable that the RAD51-like genes found in T. 
brucei may retain strand exchange activity. It should be noted that such a property has not 
been tested to date for any of the T. brucei RAD51 paralogues, and cannot be concluded 
from sequence homology.  
An alignment of the amino acid sequences of the T. brucei RAD51, DMC1, and the 
RAD51 paralogues was performed (Proudfoot & McCulloch, 2005a). Figure 7-1 shows 
this alignment and highlights the considerable conservation of the two putative 
recombinases, RAD51 and the meiosis-specific DMC1, compared with the greater 
divergence of the RAD51 paralogues. In the core of the sequence of RAD51 and DMC1 
lies the putative nucleotide/ATP-binding domains: the Walker A and Walker B motifs 
(Walker et al., 1982). The Walker A and B motifs appear highly conserved in all four T. 
brucei paralogues, with the exception of a serine (S) residue to aspartic acid (D) mutation 
in the B motif of RAD51-4 (D277), suggesting they may be able to bind/hydrolyse ATP. 
However, any such activity and its influence on their functions can only be tested by 
mutagenesis or characterising the purified proteins, neither of which has been done to date. 
The rest of the sequence alignment suggests that sequence outwith the Walker A and B 
boxes appears to be less conserved between the putative recombinases and the RAD51 
paralogues, in particular in motifs that are conserved between T. brucei RAD51 and 
DMC1, which are found in other species. One of these motifs is a helix-hairpin-helix (H-h-
H) motif, which is a non-sequence specific DNA binding site (Shao & Grishin, 2000). 
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Another is a putative polymerization motif (PM), which is thought to be important in the 
assembly of the Rad51 nucleoprotein filament on the DNA strand (Shin et al., 2003).  
The Walker A motif binds ATP and the Walker B motif hydrolyses the ATP which 
releases the chemical energy, driving the strand exchange reaction (Story et al., 1993). The 
roles if any, of these highly conserved motifs appear to vary in different eukaryotic Rad51 
paralogues (Johnson & Symington, 1995; O'Regan et al., 2001; Wiese et al., 2002). The 
nucleotide binding and ATP-hydrolysis functions may also have important roles in the 
formation of mammalian Rad51 paralogue complexes, since it was found that mutation of a 
highly conserved lysine residue (K113) in the Walker A motif of XRCC3 was required for 
Rad51C-XRCC3 (CX3) complex formation (Yamada et al., 2004). While it was observed 
that a functional Walker B motif of Rad51D was required for interaction of Rad51D with 
XRCC2 and Rad51C (Wiese et al., 2006). The complexes Rad51B-Rad51C and Rad51D-
XRCC2 have also been shown to bind to ssDNA and dsDNA, as well as having DNA-
stimulated ATPase activity (Braybrooke et al., 2003; Lio et al., 2003; Shim et al., 2004; 
Sigurdsson et al., 2001). The CX3 complex was found to bind to ssDNA (Kurumizaka et 
al., 2001) as well as to Holliday junctions (Liu et al., 2004; Liu et al., 2007). It was 
observed that purified RAD51D possesses DNA-stimulated ATPase activity and binds to 
ssDNA but not dsDNA (Braybrooke et al., 2000). 
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TbrRAD51    1 -----MNTRTKNKKRTKEVIEDEVHDIDDTAFDDAAVDAVNDNTQEMQQQVGDAAGGPSFRVLQIMENYGVASADIKKLMEC---GFLTVESVAYAPKKSILAVKGISEAKAEKIMAECC 
TbrDMC1A    1 ----MQHVGTRSGK---------------SEAKDAAVSTDNSTHEDAAHTIMEIDR---------LTEQGVAAADVAKLRQA---GIFTVTGIHMQCRKDLVLIKGLSDAKVDKIIEAAR 
TbrRAD57    1 ----------------------------------MSVEQCSSLTPSLKAKLQNAGFLWLRDLCRCAQGGVETTFNVGKFLDD---SHLNAAAKRLQQNCSQLTHTEAIETARVVLPSAVC 
TbrDMC1B    1 MDALWPVAHDYANSNSDDDDDEGDDFVNLAQKPVVDLSDSDELTTQEADPLQMERVQVMLKKLEGLPGYGNGTRLENVLLQP---PCDVSQMLDASLDDVELLYRHISHTIVNSPDSTLL 
TbrRECA2    1 --MASVNAPTTLTSELFHALPCLRENPTDSVLTAALLQYCQDEDLVSAADLLLRLMVDQPHVQRRMTRSVENTHRHVPLPQPGDLQNFTDKVLEALCDRHVSQLSENSGAAGRSVRARGS 
TbrRECA     1 -----------------------------------------------------------------------------------------------------------------------M 
 
 
TbrRAD51  113 KLTPMGFTRATVFQEQRKE-------------------TIMVTTGSREVDKLLG------------GGIEVGSITELFGEFRTGKTQLCHTLCVTCQLPLS---------------QGGG 
TbrDMC1A   90 KLSDCGFSVGTAYLQQRGR-------------------VTRVTTGSTALDQLLG------------GGIESMSITEAFGEFRTGKTQIAHTLCVTCQLPIS---------------MGGG 
TbrRAD57   84 RTPAIRTLRELLDAEATKG-------------------IENVTTLCRSLDILLG------------GGLQVGTLTEICGPPGVGKTQLSMQLAVNCVLPKE---------------LGGL 
TbrDMC1B  118 PISVEDQLSSSCFG--------------------------VISTGHKCLDDVLA------------GGVKCGLVTEITGASGTGKTALALNLAGRAATLAR---------------EGRG 
TbrRECA2  119 GFSSVSVSVSDMLATAAAWGNDSVKLEGLAPLQPTNRKVHFFPTGCSLVDRLLAGTPSNATGGALEGGFCAGLLTEVHGEAGSGKTQLVLQCLFQCVARQQCALYAVNHLPELLISSGDG 
TbrRECA     2 SVCPPPWTGMTAEEISQRLALLTSQTILQHDLNRRFTQHAVFSTGSEELDRLLPD-----------GGMTCGTVLEVFGPPSGGKSRLVRR-------MIS---SFAAQGALEWTTRGVD 
 
 
TbrRAD51  187 EGMALYIDTEGTFRPERLVAVAERYS---------------------------------------------------------------------------LDPEAVLENVACARAYNTD 
TbrDMC1A  164 NGKAIYVDTEATFRPERIKPIAERFG---------------------------------------------------------------------------LDVEAVLGNILVARAYTHE 
TbrRAD57  158 QGGCLFIDTEGSFLPERFREIASAAVGHVREIVLQREKEGLGAGNVGVTNEENGVRQASFLNGAMNEVTAEQTCTTSSVESRKRGRVEAAVPPPLGAIVGSFTVDYILQRTQYVRVLDVV 
TbrDMC1B  185 NGKYHTLWISSNQHPFSTRATAGYLRSTLGTYRGDN-----------------------------------------------------NGSNAAEPDRFGGDAETALQQLAIVTIPTLG 
TbrRECA2  239 VGDNTFIDSLRGFATEKVAALYIVSEGVPASRLG-----------------------------PLATGALHRAKAMVLSAASRQPSIDVELLKARLDEFVTERTVVAGVGIRPVDGVGAL 
TbrRECA   101 VGICDGSPSKGLEVQQECLRARAEECCRPREWCVFYVLSDPSSLNPRHLREELEKALQRAMLCDVHCEG------------------EIERLLDDIIGRVQVVNFATLNDLLNFFRFLYH 
 
 
TbrRAD51  232 HQQQLLLQASATMAEHR-VAIIVVDSATALYR-----TDYNGRGELAARQMHLGKFLR-------------------------------SLRNLANEYNVAVVVTNQVVANVDGAAPTFQ 
TbrDMC1A  209 HQMHLLSMVAAKMVEDQ-FSLLVVDSVTALFR-----VDFSGRGELAERQQKLAKMLS-------------------------------NMIKLAEEYNVAVYITNQVVADPGGAS-MFV 
TbrRAD57  278 SLMALLNGLPAYIASHPGIRMVIIDSIAFPFRSLLQLNVNSNSGGVTESHGAVGKSVAGVDDSTGMNSGIPTSRQLGWQRARLLFRCGQLLQDHARELNLCIVVSNQMATRMGDIRGVDG 
TbrDMC1B  252 QLLEHMPVLRENIMLNDGVRLVVVDDFSAMVRR----TFTGMDGEVIERHNAVAALMN-------------------------------AMKSVAQDLRVAVVIITQSEVDLGHAFLYAV 
TbrRECA2  330 LRLLSDGTLSSAFSSLGNTGVVVVDSIADVVA-------GGSSGEEMNRWEISTTVASVGS----------------------------LLKSFAVKEGAAVVVTNQVRTSLSVSGEGMI 
TbrRECA   203 EEYPSSMH----HANQR-RALVVIDSVARLWD-----HPTCGATK-HARHWAAAELVR------------ELRNVIMLGNGWRGEYCGNIDSHHLDTEAGNVFCSVQAANA--------- 
 
 
TbrRAD51  315 ADS---------KKPIGGHIMAHASTTRLSLR-----------KGRGE------------------------------------QRIIKVYDSPCLAESEAIFGIYENGVGDVRD----- 
TbrDMC1A  291 ADP---------KKPIGGHILAHASTTRLSLR-----------KGRGD------------------------------------QRVCKIYDSPSLPEVECVFSISEQGIVDARE----- 
TbrRAD57  398 GFRT--------LVPALGDSWAYALSTRLLLTHQHDVLHHNEIEKRGEKCHDNMVFVMPSGQDSTTSCNDSDGGSGSKRLHAAQHRVARLVKSPAQPQGQCCFSISHRGVRDVFRPTL-- 
TbrDMC1B  337 NTRLRLSRCLLQPNDAAADVAGNVRLAHLLELVKSCMASDCKFECKFEG--------------------------------FYLGSVHLLTEGAVALRDVDFYGVDPFGYAVVPTFVHC- 
TbrRECA2  415 RRHT--------PVPALGMQWAVAPHVRVNLR---------RPQNTANAS----------------------------------RRQFTIICGPAHQPAYCSYLICNEGICNDE------ 
TbrRECA   291 ------------GTSVGGSVAVVLVNGCTNTRYCHTVVGPLGVPLWLAAAADIRLFIEPTSTSGDYPPTTGEDD----------GMLCTHQYGAAKHVLAVRVAKGSGSSVPRVGNIFLP 
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Figure 7-1: An alignment of T. brucei RAD51, DMC1 and the RAD51 paralogues. 
A comparison of the amino acid sequences of RAD51, DMC1 and the four RAD51 paralogues (RAD51-3, 
RAD51-4, RAD51-5, RAD51-6) was performed using Clustal W. Residues at a particular position with ≥ 30 
% sequence identity are in black and the conserved residues are in grey between the RAD51, DMC1 and the 
RAD51 paralogues. The conserved Walker A and B motifs are indicated. The helix-hairpin-helix (H-h-H), 
putative polymerization motif (PM) and structurally conserved residues (brown circles) in RAD51 and 
DMC1 are indicated. Reprinted with the permission from Oxford Journals, Proudfoot & McCulloch, 2005a. 
Proudfoot & McCulloch (2005a) attempted to assign functions to the T. brucei RAD51 
paralogues by phylogenetic analysis and amino acid sequence comparison with the 
relatively well-studied mammalian Rad51 paralogues. Table 7-1 shows the sequence 
homology of the T. brucei RAD51 paralogues compared with the H. sapiens Rad51 
paralogues, and with T. brucei RAD51, as well as the homology between the H. sapiens 
Rad51 and H. sapiens Rad51 paralogues. These data reinforce the view that while the 
recombinase, Rad51, is highly conserved with 60 % identity (70.8 % similarity) between T. 
brucei RAD51 and H. sapiens Rad51, the Rad51 paralogues have very low levels of 
sequence identity and similarity (ranging from 8.0 – 22.8 %, and 15.9 - 33.0 %,  
respectively) (Proudfoot, PhD thesis, 2005; Proudfoot & McCulloch., 2005a). 
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Table 7-1: The percentage of amino acid sequence identities and similarities when the T. brucei RAD51 
paralogues are compared with T. brucei RAD51 and H. sapiens Rad51 and Rad51 paralogues. 
The sequence identities (large font) and similarities (small font) are shown when the amino acid sequence of 
the T. brucei RAD51 paralogues (RAD51-3, RAD51-4, RAD51-5, RAD51-6) were compared with the H. 
sapiens Rad51 paralogues (XRCC2, XRCC3, Rad51B, Rad51C and Rad51D) using AlignX. Each of the H. 
sapiens and T. brucei RAD51 paralogues were also compared with the RAD51 amino acid sequence of that 
species (yellow shaded boxes). Adapted from Proudfoot, PhD thesis (2005) and Proudfoot & McCulloch 
(2005a). 
H. sapiens T. brucei 
RAD51Rad51 XRCC2 XRCC3 Rad51B Rad51C Rad51D
T.
 
br
u
ce
i 
RAD51 60.1 14.3 20.3 20.2 19.5 16.2 100
70.8 21.7 32 33.6 33.3 25.5 100
RAD51-3 17.7 12.4 16.3 17 22.8 10.8 17
27.6 19.4 27.8 26.4 33 20.3 25.9
RAD51-4 15.5 10.9 17.4 15.8 15.7 16.4 15.6
29.4 18.9 28.9 28.1 25.9 27.5 29.1
RAD51-5 11.3 13.5 11.8 12.1 12.2 13.5 10.8
22.8 23 21.1 23.7 24.3 22.7 25.2
RAD51-6 16.8 8 17 14.9 15.6 11.7 15.9
23.7 15.9 26.4 25.1 27 20.1 26.3
H. sapiens 
Rad51
100 16.1 21 24.7 22.2 15.8
100 24.9 33.6 37.1 33.1 27
 
These data reveal the difficulty in attempting to assign orthologues between the 
mammalian Rad51 paralogues and the T. brucei RAD51 paralogues, meaning that 
assigning function thorough sequence analyses is difficult, and could even be impossible, 
due to the high diversity of the proteins. This underlines the fact that biochemical analysis 
including the interaction studies (see below), are needed to assign function to the T. brucei 
proteins, which may then clarify their relationship with the Rad51 paralogues from other 
organisms.   
7.2.2 Varied number of Rad51 paralogues in different 
species 
The recombinases, RecA, Rad51 and RadA have been highly conserved during evolution 
of the eubacteria, eukaryotes and archaea, respectively. Rad51 has been identified in plants 
such as Arabidopsis thaliana (Doutriaux et al., 1998), Oryza sativa (Ishibashi et al., 2006),  
fungi such as Saccharomyces cerevisiae (Ogawa et al., 1993), Ustilago maydis (Bennett & 
Holloman, 2001), Coprinus cinercus (Stassen et al., 1997), nematodes such as 
Caenorhabditis elegans (Takanami et al., 1998), parasitic protozoans including Leishmania 
major (McKean et al., 2001), Plasmodium falciparum (Bhattacharyya & Kumar, 2003), 
and Trypanosoma brucei brucei (McCulloch & Barry, 1999), and higher eukaryotes such 
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as Mus musculus (Cartwright et al., 1998) and Homo sapiens (Benson et al., 1994). Dmc1 
also appears to be highly conserved, though it is restricted to eukaryotes (Bishop et al., 
1992; Doutriaux et al., 1998).  
In contrast, comparisons of Rad51 paralogues across the eukaryotic kingdom suggest these 
proteins are highly variable in sequence and also in number. Most multi-cellular organisms 
appear to have many Rad51 paralogues; for example, H. sapiens and A. thaliana each have 
five Rad51 paralogues (Bleuyard et al., 2005; Masson et al., 2001b), and Drosophila 
melanogaster has four (Abdu et al., 2003). Caenorhabditis elegans appears to be an 
exception with only one Rad51 paralogue (Boulton et al., 2002; Ward et al., 2007). The 
budding yeast S. cerevisiae has two, the fission yeast S. pombe has four (Khasanov et al., 
2004; Lovett & Mortimer, 1987; Martin  et al., 2006; Tsutsui et al., 2001) and U. maydis 
has one (Kmiec et al., 1994; Rubin et al., 1994).  Beyond the eukaryotes, RADB in 
archaean species Haloferax volcanii has been shown to possess Rad51 paralogue like 
functions (Guy et al., 2006). It is noteworthy, however, in eubacteria that no RecA 
paralogues have been found. Given that the activity of Rad51, when compared with RecA 
in vitro, is considerably reduced as discussed in Chapter 1 (Section 1.6.1) (Benson et al., 
1994; Conway et al., 2004), it is conceivable that a more complex Rad51 pathway exists 
with the need for co-factors, such as the Rad51 paralogues.  
If all these proteins are true Rad51 paralogues i.e. derived from Rad51 by gene duplication 
within the genome with the development of different functions to that of Rad51, it remains 
unclear why there is such a varied number. It may be the case that not all the Rad51 
paralogues have been identified for those species with small numbers because of narrow 
searches or incomplete genome sequence.  One finding which does not support this theory 
was first noted by Proudfoot (PhD thesis, 2005). It was observed that in T. brucei and T. 
cruzi four RAD51 paralogues could be identified by BLAST searches, whereas the highly 
related Kinetoplastida Leishmania major only has three RAD51 paralogues (Proudfoot, 
PhD Thesis). Table 7-2A shows an amino acid sequence comparison between the T. brucei 
and T. cruzi RAD51 paralogues, while Table 7-2B shows the same comparison between 
the T. brucei and L. major RAD51 paralogue amino acid sequences. It is noteworthy that 
the RAD51 paralogues are not found adjacent to each other, but are in disparate loci, 
suggesting they arose a long time ago.  
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Table 7-2: The percentage of amino acid sequence identities when the T. brucei RAD51 paralogues 
were compared with the predicted T. cruzi and L. major RAD51 paralogues. 
The sequence identities are indicated as a percentage when the amino acid sequence of the T. brucei RAD51 
paralogues (RAD51-3, RAD51-4, RAD51-5, RAD51-6) were compared to the predicted T. cruzi (A) and L. 
major RAD51 paralogues (B). The highest sequence identity for each comparison is indicated by yellow 
shading, and the predicted T. cruzi and L. major RAD51 paralogues were named accordingly. Adapted from 
Proudfoot, PhD thesis and Proudfoot & McCulloch., (2005a). 
A T. cruzi
RAD51 RAD51-3 RAD51-4 RAD51-5 RAD51-6
T.
 
br
u
ce
i 
RAD51 79.9 18.1 17.1 12.8 16.7
RAD51-3 16.1 49.8 14.6 12.5 12.7
RAD51-4 14.6 14.3 39.9 15.6 13.3
RAD51-5 11.4 12.4 12.4 34.8 13.8
RAD51-6 15.3 16.4 13.8 17.1 39.2
B L. major
RAD51 RAD51-3 RAD51-4 RAD51-5 RAD51-6
T.
 
br
u
ce
i 
RAD51 77.5 9.6 15.6 - 10
RAD51-3 16.3 23.9 13.2 - 11.4
RAD51-4 15.5 12.7 18 - 12.6
RAD51-5 9.8 7.6 12.9 - 8.7
RAD51-6 17.2 15.1 13.8 - 21.9
 
Since the study by Proudfoot & McCulloch (2005a) many protozoan genomes have been 
sequenced, and since these represent much of the diversity in eukaryotes, it provides an 
opportunity to review and update the picture of the RAD51 paralogues. Other genomes 
such as those of Giardia lamblia (Aurrecoechea et al., 2009; Morrison et al., 2007), 
Trichomonas vaginalis  (Aurrecoechea et al., 2009; Carlton et al., 2007), Entamoeba 
histolytica (Loftus et al., 2005), Dictyostelium discoideum (Eichinger et al., 2005), 
Leishmania (Peacock et al., 2007), Trypanosoma vivax (Sanger Institute, unpublished), 
Trypanosoma congolense (Sanger Institute, unpublished) and Encephalitozoon cuniculi 
(Gill & Fast, 2007; Katinka et al., 2001) have been sequenced. The genome sequences of 
Apicomplexans such as Crytosporidium parvum (Abrahamsen et al., 2004), Toxoplasma 
gondii  (Gajria et al., 2008), Theileria annulata (Pain et al., 2005), and the Ciliophoran 
Tetrahymena thermophila (Eisen et al., 2006) have also been completed. Based on this, 
BLAST searches with TbRAD51 and TbRAD51-3 were performed, then manually 
checked for Walker A and B boxes, as well as RecA-like signatures. This was done by 
BLASTing the NCBI database and identifying conserved RecA domains and hits to 
RecA/Rad51 (this was completed by McCulloch, 2009). The observed hits are detailed in 
Table 7-3. These data confirm that the Rad51 paralogues are highly variable in number 
throughout the eukaryotic kingdom. However, it is noteworthy that the Euglenozoa 
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especially the Trypanosoma have a large number of RAD51 paralogues, since most single 
celled eukaryotes have only 1-2 paralogues.  
Table 7-3: RAD51 paralogue gene numbers found in eukaryotic organisms. 
The table shows the status of the genome project for a range of different eukaryotes. It indicates the presence 
(+) or absence (-) of RAD51, DMC1, as well as the number of RAD51 paralogues and RecA-like genes. The 
RecA-like proteins are thought to act in DNA repair and HR of mitochondrial/chloroplast DNA (Cerutti et 
al., 1992; Hasegawa et al., 2004). (* Further discussion see text; This table was provided by Dr Richard 
McCulloch)  
Taxon Organism Status of genome project RAD51 DMC1
RAD51 
paralogue RecA
Parabasala T. vaginalis 7X coverage + + 2 -
Diplomonadida G. intestinalis 11X coverage - 2 - -
Euglenozoa
T. brucei Complete + + 4 -
T. vivax 5X coverage + + 4 -
T. congolense 1X coverage + + 4 -
T. cruzi Complete + + 4 -
L. major Complete + + 3* -
L. braziliensis Complete + + 3* -
L. infantum Complete + + 3* -
Apicomplexa
C. parvum Complete + + 2 -
T. annulatum Complete + + 1 -
P. falciparum Complete + + 1 -
T. gondii 10X coverage + + 1 -
Ciliophora T. thermophila Complete + + 1 -
Viridiplantae O. sativa Complete + + 5 3A. thaliana Complete + + 5 3
Entamoebidae E. histolytica Complete + + 1 -
Mycetozoa D. discoideum Complete + - 5 1
Microsporidia E. cuniculi Complete + - 1 -
Fungi
S. pombe Complete + + 4 -
S. cerevisiae Complete + + 2 -
U. maydis Complete + - 1 -
Metazoa
C. elegans Complete + - 1 -
D. melanogaster Complete + - 4 -
H. sapiens Complete + + 5 -
G. gallus Complete + + 5 -
 
This analysis confirms previous studies and shows that four RAD51 paralogues are present 
in the Trypanosoma species (T. brucei, T. vivax, T. congolense and T. cruzi) and that three 
RAD51 paralogues are found in the Leishmania species (L. major, L. braziliensis, and L. 
infantum; Table 7-3). This result has lead to a number of possible interpretations. The first 
is that all four RAD51 paralogues arose in the Kinetoplastidae by gene duplication before 
the evolutionary split between the Trypanosoma species and Leishmania, and 
undetermined differences in the biology of Leishmania species meant that RAD51-5 was 
no longer needed, whereas RAD51-5 remained important in function to the Trypanosoma 
species. The second is that RAD51-5 arose by a further gene duplication in T. brucei, T. 
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vivax, T. congolense and T. cruzi after the evolutionary split of the four Trypanosoma 
species from Leishmania. The third reason is that RAD51-5 was not identified in the L. 
major genome because of very low sequence identity with RAD51, and a gene encoding a 
RAD51-5-like protein is, in fact, present.  
The completion of the genome sequence since the work of Proudfoot & McCulloch 
(2005a), and the sequencing of further Leishmania species genomes, means that this can 
now be answered. As a result, we believe that the first hypothesis is correct, and that 
Leishmania has lost RAD51-5. A Leishmania “RAD51-5-like” gene was identified by 
looking for orthologues of the surrounding genes of T. brucei RAD51-5. Figure 7-2 shows 
a genome synteny diagram of the two regions around the genomic location of T. brucei 
RAD51-5 and the predicted location of L. major “RAD51-5”. From Figure 7-2, it is clear 
that the surrounding genes are highly conserved showing 32-68 % sequence identity. In 
contrast, a putative gene containing some homology (13.8 % identity) to T. brucei RAD51-
5 is present, and is also conserved in the other two Leishmania species (L. braziliensis, and 
L. infantum; Figure 7-3).  
RAD51-5
Hypothetical
Hypothetical
Map  kinase, predicted
1110017C15Rik protein
GH10149p (Fragment)
Cysteine conjugate beta-lyase, predicted
Cysteine conjugate beta-lyase, probable
ppg3, possible
Map kinase, probable
Hypothetical conserved
Hypothetical
L. major
Chr. 33  26395 bp
T. brucei
Chr. X  21167 bp
50.3
64.1
31.7
46.4
71.2
78.0
13.8
23.8
13.2
19.3
68.0
78.8
 
Figure 7-2: Synteny diagram between the orthologues of the surrounding genes of T. brucei RAD51-5 
and L. major hypothetical protein. 
The sequence identities (large font) and similarities (small font) are shown when the amino acid sequences of 
the surrounding proteins of T. brucei RAD51-5 were compared with the L. major hypothetical protein. 
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It is very questionable that the gene in this location of the Leishmania chromosome is a 
RAD51 paralogue. The only homology is within the Walker B box motif, and the 
Leishmania “RAD51-5?” proteins do not possess a recognisable Walker A box, nor do 
they have RecA-RAD51-like sequence homology in the region around the Walker A box 
which is a characteristic of a RAD51 paralogue. Such is the dissimilarity in these 
Leishmania “RAD51-5?” genes, that none were identified as orthologues in the genome 
annotations, in contrast to all surrounding genes. It appears that at one time, a RecA-like 
gene was present but has diverged to have other functions; of course, this would need to be 
tested experimentally. This appears compatible with the suggestion that the generation of 
RAD51 paralogues in the Kinetoplastida was an ancient event, and loss of RAD51-5 is 
more recent. 
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LmaRAD51-5?    1 ------------------------------------------------------------ 
LifRAD51-5     1 ------------------------------------------------------------ 
LbrRAD51-5?    1 MQSTTASWETMSDSAARARVLRLRQSATPLQDVYGAFSPWQHLSTSLPGLDSLLSVAGVC 
TbrRAD51-5     1 ------------------------------------------------------------ 
TcrRAD51-5     1 ------------------------------------------------------------ 
 
 
LmaRAD51-5?    1 -------------------------------------------------MTMYRQWYHDE 
LifRAD51-5     1 -------------------------------------------------MTMCRQWYHDE 
LbrRAD51-5?   61 EGVSGSDDRSGVESTIGGLPVGGLHELYGPPLSGKSWLLRRVGAAYVRRMTAYRQWYHDE 
TbrRAD51-5     1 ------------------------------------------------MSVCPPPWTGMT 
TcrRAD51-5     1 ------------------------------------------------MAVMPPPWEALT 
 
 
LmaRAD51-5?   12 LERVSKWAVETPRSTRTYDDEAQANKDDEGLCGEGEVADTWADSAGASPVTAMEEWDLYV 
LifRAD51-5    12 LELASKWAVETPRSTHTYDDEAHAKKDDEGLCSEGEVADTWADSTGASPVTAMEEWDLYV 
LbrRAD51-5?  121 LERVSKRAVEATLFTRKTDNEARAAKDDEDVDSEAEDAHICANSANPSPITAMEEWDLYV 
TbrRAD51-5    13 AEEISQRLALLTSQTILQHDLNRRFTQHAVFSTGSEELDRLLPDGGMTCGTVLEVFG--- 
TcrRAD51-5    13 AEDVSRRLAALAASASSVLEVGRCFSREAVFSTGSAAIDRLLPDGGVACGTVLEIFG--- 
 
 
LmaRAD51-5?   72 CLVSGAGAGSATHQLTAPPPSPSLLSPDVRSWVEELVAPFDSSSTLDRQGEAFVTGPAHW 
LifRAD51-5    72 CLVSGAGASSTTHQLTAAPPSPSLLSPDVRSWVEELVAPFDSSSTLDRQGEAFVTGPAHY 
LbrRAD51-5?  181 CLVRGAGADSKTHGLTASPPSPSLLSPDVRSWLKELVAPFDSSSTLDRQVESIVTGPVHG 
TbrRAD51-5    70 ------------------PP-----SGGKSRLVRRMISSFAAQGALEWTTRG-VDVGICD 
TcrRAD51-5    70 ------------------PP-----AAGKSHLVQQMVAAFAARGSVQWTAAKRSRTAVGG 
 
 
LmaRAD51-5?  132 HASTHRRQQQRDYAEQHIHFRVVHSPNELLAFLEHLGSNAALAPSAGAAFADAAPSIVPP 
LifRAD51-5   132 HASEHRRQQQRDYAEQHIHFCVVRSPNELLAFLEHLSGDAALAPSAGTTFADAAPSIVPP 
LbrRAD51-5?  241 YSSSH-QQQHRDYAEQHIHFRVVHSPNELLAFLECLGGGAASVPSTSTVFTNTTYSAAPP 
TbrRAD51-5   106 GSPSKGLEVQQECLRARAEEC-CRPRE--WCVFYVLSDPSSLNPRHLREELEKALQRAML 
TcrRAD51-5   107 NSVDRQQQQQQQQPHEEVEESKCGPCD--WSVFLLVSDPSSVSPQHIHELLKKALASATA 
 
 
LmaRAD51-5?  192 VPLVASQQQPSSLQLSRSSSTTTARGQKRRRSPRTAVSSSSSVSPSCGKLPQRTWRLQRQ 
LifRAD51-5   192 APLVASQQQPSSLQLSCGSSATTARGQKRRRSPRTAVSSSSSVSPFRGNFPQRTWRLQRQ 
LbrRAD51-5?  300 VPRVALQQQLLPSQLARGSLTTAMRGQKQHRSPGTTMPSSPSFPLACGSLPQCTWRLQRQ 
TbrRAD51-5   163 CDVHCEG------EIERLLDDIIGRVQVVNFATLNDLLNFFRFLYHEEYPSSMHHANQRR 
TcrRAD51-5   165 NSVQCDG------DADSLPSVMLKKIKFVPFKSPNDLLVFFRFLSRVEYFESCHHANRRR 
 
 
LmaRAD51-5?  252 RLLLLDGLDALWLHPSLGNHCATHTGQWFAEELHRRLRAVLLPRLSYAASNSAVVTPSYA 
LifRAD51-5   252 RLLLLDGLDALWLHPSLGNHCATHTGQWFAEELHRRLRAVVLPRLSYAASNSAVLTPSYA 
LbrRAD51-5?  360 RLLLLDGLDALWLHPSLGNHSATHTGQWFAEELHRQLRTVLLPRLGYAASDSTLLTAPSS 
TbrRAD51-5   217 ALVVIDSVARLWDHPTCG--ATKHARHWAAAELVRELRNVIMLGNGWRGEYCGNIDSHHL 
TcrRAD51-5   219 VLVVVDNVARLWEHPTCG--ATNHARHWMAAALVREVRNAILIGNGWRDVGSGEVEKRER 
 
 
LmaRAD51-5?  312 TAAASPTSPYPHHTLYSTVVFTNGCNGSSRGILNPQQLEARLAGPVGGAEGWTATLPRPS 
LifRAD51-5   312 TAAASPTSSHPYHTLYSTVVFTNGCNGSSRGILNPQQLEARLAGPVGGAKGWMATLPRPS 
LbrRAD51-5?  420 TAAAAPMSPHPQHVLYSTVVFTNGCHGSSRGFLTAQQLEARLAGPAGGVEGWAATLPRPS 
TbrRAD51-5   275 DTEAGNVFCS-----VQAANAGTSVGGSVAVVLVNGCTNTRYCHTVVG------PLGVP- 
TcrRAD51-5   277 HHHAHDASVS-----GQEISV-DCRGGSVAVVFVNGCTSVYHRKLATERTLPSKPLGVP- 
 
 
LmaRAD51-5?  372 GNAVWCRAADTRCLVEPAHPGLVSLPTPSSSYVHPARVSHGPGAMRQSCRGMTKAVGPSN 
LifRAD51-5   372 GNAVWCRAADTRCLVEPAHPGLVSLPTPSSSYVCSARVSHGPGAMRQSSRGMAKTFGPSN 
LbrRAD51-5?  480 GNAAWCRAVDTRCLIEPAHLGLVSILTPSFSYVRPAMAPHESSAVYQNGRRITGTFRQST 
TbrRAD51-5   323 --LWLAAAADIRLFIEPTST--------SGDYPPTTGEDDDGMLCTHQYGAAKHVLA--- 
TcrRAD51-5   330 --VWLAAAADVRLFVEPLCN--------ADWFLQHDRSSGDVCGTQQSEHAARATMR--- 
 
 
LmaRAD51-5?  432 ANSRESLVTVVKGGSCVAATWVLRDVTGGEQET 
LifRAD51-5   432 TNSLESLVTVVKGGSRVAATWLLRDVAGGAQES 
LbrRAD51-5?  540 ANYLESLVTVVKGGSRVAATWVLRNAADGEQEA 
TbrRAD51-5   370 -------VRVAKGSGSSVPRVGNIFLP------ 
TcrRAD51-5   377 -------VRLVKGGRTVGGEVTAV--------- 
 
A
B
?
?
?
?
?
?
?
?
?
?
 
Figure 7-3: An alignment of T. brucei and T. cruzi RAD51-5 with the predicted “RAD51-5”amino acid 
sequence of L. major, L. braziliensis, and L. infantum. 
Leishmania proteins were identified by looking for orthologues of the surrounding genes of T. brucei 
RAD51-5. The alignment shows a comparison of the amino acid sequences of these genes and T. brucei and 
T. cruzi RAD51-5. This was performed using Clustal W. Residues with ≥ 30 % sequence identity are in black 
and the conserved residues are in grey. The conserved Walker A and B motifs, RecA- RAD51-like sequence 
homology upstream of the Walker A motif (dashed line) and structurally conserved residues (brown circles) 
of T. brucei and T. cruzi RAD51-5 are indicated. 
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Phylogenetic studies on a large number of Rad51-like genes, including eubacterial, 
eukaryotic and archaean RAD51 homologues, orthologues and paralogues, has suggested 
that the Rad51/Dmc1/RadA group and the Rad51 paralogue group were likely to have been 
generated by gene duplication that predated the divergence of archaea and eukaryotes (Lin 
et al., 2006). In this scenario, one copy of the Rad51/Dmc1/RadA group is retained in most 
species, reflecting its central function. Subsequent gene duplication events are then 
hypothesised to have occurred early in eukaryotic evolution and generated six major Rad51 
paralogues which are retained in animals and plants: RadB, Rad51C, XRCC3, Rad51B, 
Rad51D, and XRCC2 (Lin et al., 2006). It is postulated that the evolution of these multiple 
Rad51 paralogues in eukaryotes was driven by the necessity to maintain the fidelity of the 
genome, increasing the ability to repair damaged DNA and allowing genetic diversity 
without detriment to the cell. It maybe also be the case that the many Rad51 paralogues 
have evolved to support the Rad51 filament and to aid the function of the other paralogue 
complexes. It also appears that this diversification occurred in the archaea, as the 
eukaryotic RAD51 paralogues may have evolved from, or be related to RadB (Lin et al., 
2006). 
One difficulty with the work of Lin et al. (2006) is that the phylogenetic analysis 
concentrated on Rad51 paralogues in vertebrates and plants excluding yeast, Drosophila, 
C. elegans, which the authors acknowledge show less clear orthology, but suggest have 
abbreviated Rad51 paralogue number due to gene loss. A phylogenetic tree incorporating 
sequences from these and protozoan organisms is shown in Figure 7-4 and their accession 
numbers are listed in Appendix 4, Table 15 and 16 (sequence alignment in ClustalX; tree 
drawn in Treeview; McCulloch, 2009). In this analysis, the close phylogenetic grouping of 
RAD51, DMC1, RecA, RadA and RadB proteins is retained, but the Rad51 paralogues 
display much greater sequence diversity. Some of the orthology detailed by Lin et al. 
(2006) can be seen by the grouping of HsaRAD51C with AthRAD51C (purple asterisks in 
Figure 7-4), and HsaXRCC3 with AthXRCC3 and potentially SceRad57 (blue asterisks in 
Figure 7-4). Some groups are much less clear, for example it is not obvious from Figure 7-
4 that SceRad55 and AthXrcc2 are related to HsXrcc2 (red asterisks in Figure 7-4) as 
stated by Lin et al. (2006). Indeed, the level of likelihood of such a tree being accurate 
when grouping the Rad51 paralogue sequences is very low, as the bootstrap values were 
typically <50 % (not shown).  
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Figure 7-4: A phylogenetic tree of the Rad51 related proteins. 
Diagram comparing the amino acid sequences of the Rad51 related proteins from prokaryotic and eukaryotic 
species. Rad51, Dmc1, RecA, RadA and RadB groups are highly reproducible with bootstrap values of >90 
% (data not shown) and these groups are highlighted by brackets. This Figure was provided by Dr Richard 
McCulloch, 2009. 
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In light of these phylogenetic studies, defining the orthology and potential functions of the 
T. brucei proteins, RAD51-3, RAD51-4, RAD51-5, and RAD51-6, is problematic. It is 
unclear if these proteins arose from a very ancient gene duplication. Therefore should these 
genes be called RAD51-like genes instead of RAD51 paralogues? Nonetheless, many of 
these proteins have clear roles in HR and DNA repair, and all of the T. brucei proteins act 
in these processes (see below). Indeed, similar phenotypes have also been described for the 
mutants of T. brucei RAD51 paralogues when compared with the mammalian paralogues 
(discussed in Chapter 4; see below). Nevertheless, the amino acid sequences of the T. 
brucei proteins appear to have the highly conserved Walker A and Walker B motifs of 
RAD51 (see Figure 7-1) which are found in other species of Rad51 paralogues therefore 
defining them as RAD51 paralogues may be correct. Functional characterisation is 
required to determine the extent of the RAD51 paralogue orthology, and thereby clarify the 
evolutionary history of these genes. 
7.3 Roles of the T. brucei RAD51 paralogues  
7.3.1 DNA repair and homologous recombination in T. 
brucei RAD51 paralogue mutants  
The phenotypic analyses described for the rad51-4 -/- and rad51-6 -/- mutant cell lines in 
Chapter 3 indicates that RAD51-4 and RAD51-6 have a role in DNA repair and HR in T. 
brucei, as both mutant cell lines exhibit increased sensitivity to DNA damage, defects in 
HR-driven integration of plasmid constructs and reduced ability to produce RAD51 foci 
(see below). This analysis in conjunction with previous work on RAD51-3 and RAD51-5 
(Proudfoot & McCulloch, 2005a) confirm that four RAD51 paralogues are present in T. 
brucei. It also indicates that perhaps there are multiple pathways of HR in T. brucei, where 
RAD51 and the RAD51 paralogues play central roles (Barnes & McCulloch, 2007; Bell & 
McCulloch, 2003; Bell et al., 2004; Conway et al., 2002a; Conway et al., 2002b; Hartley 
& McCulloch, 2008; McCulloch et al., 1997; McCulloch & Barry, 1999; Proudfoot, 2005; 
Proudfoot & McCulloch, 2005b). The in vitro growth rates, as measured by population 
doubling rates of rad51-4 -/- and rad51-6 -/- mutants were significantly different from 
those of wildtype and heterozygote mutant cell lines. A similar growth defect was also 
seen for the rad51-3 -/- and rad51-5 -/- mutant cell lines (Chapter 4, Section 4.2; Proudfoot 
& McCulloch, 2005a). Although the cause of the increase in population doubling rate is 
unknown, it is probably due to increased cell death similar to that observed in the 
mammalian Rad51 paralogue mutant cell lines (Takata et al., 2000; Takata et al., 2001). 
Sensitivity to genotoxic agents was also significantly increased in the rad51-4 -/- and 
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rad51-6 -/- mutant cell lines, indicating that treatment with DNA damaging agents is more 
detrimental to the mutants compared with the wildtype. Again, this finding is comparable 
with phenotypes seen in rad51-3 -/- and rad51-5 -/- mutants (Proudfoot & McCulloch, 
2005a). It is notable, however, that the rad51-4 -/- mutant cell lines were less sensitive to 
phleomycin compared with the other three RAD51 paralogue mutants (see Chapter 4, 
Section 4.3). The reason for this increased resistance is unknown, but it may imply that the 
role of RAD51-4 in the DNA repair pathway is not as crucial as the roles of other RAD51 
paralogues. The transformation efficiencies of rad51-4 -/- and rad51-6 -/- mutants were 
each significantly reduced compared with the wildtype and corresponding heterozygous 
mutant cell lines, indicating that a lack of either RAD51-4 or RAD51-6 affects HR. These 
phenotypes are again comparable with HR rates in rad51-3 -/- and rad51-5 -/- mutants 
(Proudfoot & McCulloch, 2005a).  
This analysis completes the work started by Proudfoot & McCulloch (2005a), and suggests 
that all four RAD51 paralogue mutants have comparatively equivalent phenotypes, with 
two interesting exceptions. Firstly, the number of RAD51 foci formed in response to 
phleomycin. The resistance to phleomycin of the rad51-4 -/- mutants compared to the other 
RAD51 paralogue mutants appears to be comparable with RAD51 foci formation in 
response to DNA-damage by phleomycin (Chapter 3, Section 3.4.4; Chapter 4, Section 
4.5). Secondly, VSG switching frequency of the rad51-5 -/- mutant cell line was not 
significantly different from the wildtype and RAD51-5 +/- cell lines (Proudfoot & 
McCulloch, 2005a). 
7.3.2 RAD51 foci formation in T. brucei RAD51 paralogue 
mutants 
In mammalian cells, it has been observed that in response to DNA damage, the percentage 
of cells with detectable Rad51 foci increases in a time- and dose- dependent manner (Haaf 
et al., 1995; Raderschall et al., 1999). It was confirmed that the Rad51 relocalisation 
occurred at the site of DNA damage and was associated with the ssDNA that could result 
from a strand break (Raderschall et al., 1999; Tashiro et al., 2000). It has also been 
observed that Rad51 relocalises on the chromosomes of meiotic cells (Haaf et al., 1995; 
Plug et al., 1996; Scully et al., 1997). T. brucei RAD51 relocalisation to distinct sub-
nuclear foci in response to DNA damage is also observed (Glover et al., 2008; Hartley & 
McCulloch, 2008; Proudfoot & McCulloch, 2005a). These studies confirm that Rad51 
participates in nuclear processes which control chromosomal recombination and genome 
integrity. 
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RAD51 relocalisation into foci occurs at a reduced level in the four T. brucei RAD51 
paralogue mutants compared with the wildtype (Chapter 4, Section 4.5). This was also 
found to be the case in rad51 paralogue mutant chicken DT40 cell lines (Takata et al., 
2000; Takata et al., 2001). It is possible that this residual RAD51 localisation in the 
individual RAD51 paralogue mutants is catalysed by other factors. One possibility is that 
other RAD51 paralogues might act, though this must be interpreted in the context of 
whether the other proteins’ expression is compromised in such mutants, and whether or not 
they act in stable complexes (see below). Alternatively, different proteins may be involved; 
one strong candidate is BRCA2. brca2 -/- mutant cell lines were also shown to have a 
reduced capability for RAD51 foci formation, suggesting that BRCA2 also has a function 
in RAD51 relocalisation (Hartley & McCulloch, 2008). It is unclear, however, if this is a 
complementary or distinct role. It has also been suggested that residual RAD51 foci 
formation may be due to a higher number of spontaneous DSBs in the mutants’ genomes 
compared with wildtype cells. Repair of such spontaneous breaks may occur by RAD51 
foci formation independent of the RAD51 paralogues. Whether the RAD51 paralogues 
protect against gross chromosomal rearrangements, indicative of spontaneous breaks, has 
not been analysed. Spontaneous chromosomal aberrations have been described in T. brucei 
brca2 -/- and chicken rad51 paralogue mutant cell lines, and could support this theory 
(Hartley & McCulloch, 2008; Takata et al., 2001).  
A small number (approximately 1-3 %) of non-treated T. brucei wildtype and RAD51 
paralogue mutant cells contain observable RAD51 foci, though the reason for this is 
unknown (data not shown; Hartley & McCulloch, 2008; Proudfoot & McCulloch, 2005). 
These foci may be indicative of endogenous DNA damage repair sites, stalled replication 
forks or they may represent RAD51 storage sites. Rad51 foci have also been detected in 
around 9-13 % of non-irradiated irs1 (xrcc2 mutant) and irs1SF (xrcc3 mutant) hamster 
cells and a comparable portion of non-irradiated wildtype hamster cells (Tarsounas et al., 
2004a). These authors suggest that the requirement for the mammalian Rad51 paralogues, 
XRCC2 and XRCC3, is by-passed when the Rad51 foci are associated with S-phase 
replication (Tarsounas et al., 2004a). However, such a cell cycle stage specificity has not 
yet been examined in T. brucei mutant cell lines. 
Surprisingly, rad51-4 -/- mutant cell lines were more resistant to one DNA damaging 
agent, phleomycin, compared with rad51 -/- and the other RAD51 paralogue mutants. This 
result may indicate that RAD51-4 has a less important role in the DNA repair pathway 
than the other proteins. One possibly, for instance, is that RAD51-4 acts as a non-essential 
co-factor for the other RAD51 paralogues, such as providing stabilisation of RAD51-3 
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(discussed in Section 7.4 below). This reduced phleomycin sensitivity is mirrored in the 
finding that the rad51-4 -/- mutants show an increased ability to undergo RAD51 
relocalisation to foci when the cells were treated with 1.0 µg.ml-1 phleomycin compared 
with the other RAD51 paralogue mutant cell lines (treated with the same concentration of 
drug). When each mutant cell line was treated with 1.0 µg.ml-1 phleomycin for 18 hours, 
72.7 % of wildtype cells had observable RAD51 foci, compared with 11 % of rad51-3 -/-, 
17 % of rad51-5 -/-, and 15.3 % of rad51-6 -/-, while in contrast, 52.7 % of rad51-4 -/- 
mutant cells had observable foci. To ensure that these results were not due to a lack of 
RAD51 expression in the RAD51 paralogue mutants, western blot analysis showed that 
each of the RAD51 paralogue mutant cell lines were expressing RAD51 (see Chapter 4, 
Section 4.5), confirming that the reduction of RAD51 foci was due to a defect in the 
mutant cells ability to relocalise the protein. It was also shown that rad51-/- mutants 
treated with phleomycin unsurprisingly did not produce any RAD51 foci, because RAD51 
is absent in these cells. 
7.3.3 VSG switching observed in the RAD51 paralogue 
mutants  
The rad51 and RAD51 paralogue homozygous mutants were all generated in the T. brucei 
strain 3174.2, which allowed the VSG switching frequencies and mechanisms to be 
analysed (McCulloch et al., 1997; McCulloch & Barry, 1999). Previously, it was found 
that, despite RAD51-3 and RAD51-5 having very similar roles in DNA repair, HR and 
RAD51 localisation, only the rad51-3 -/- mutant cells were defective in VSG switching 
(Proudfoot & McCulloch, 2005). This indicated that, similar to RAD51, RAD51-3 
contributes to T. brucei antigenic variation, during which HR is critical (McCulloch & 
Barry, 1999; McCulloch & Barry, 1999). To further examine the role of the RAD51 
paralogues in T. brucei antigenic variation, VSG switching frequencies of the rad51-4 -/- 
and rad51-6 -/- mutant cell lines were quantified.  
The rad51-4 -/- mutant cells (X-/-, Y-/-) had VSG switching frequencies of 4.06 (+/- 1.57) 
and 5.64 (+/- 1.8) switched variants per 107 cells per generation, respectively. The rad51-6 
-/- mutant cells (X-/-, Y-/-) had VSG switching frequencies of 2.7 (+/- 1.5) and 4.9 (+/- 
3.2) switched variants per 107 cells per generation, respectively. The average VSG 
switching frequency of the RAD51-4 and RAD51-6 heterozygote mutant cell lines was 12.6 
switched variants per 107 cells per generation, which was ~50 % higher than wildtype cells, 
which had a frequency of 8.36 switched variants per 107 cells per generation (See Chapter 
3, Section 3.4.6 and Section 3.7.5). The reason for this apparent increase in VSG switching 
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frequency of the heterozygote mutants compared with the wildtype cells is unknown. 
However, the VSG switching frequency of the wildtype strain 3174.2 has been shown by 
others to range from ~2-14 switched variants per 107 cells per generation in different 
experiments (Conway et al., 2002a; Hartley & McCulloch, 2008; McCulloch et al., 1997; 
McCulloch & Barry, 1999; Proudfoot & McCulloch, 2005a; Proudfoot & McCulloch, 
2005b). The differences of the VSG switching frequency observed between the wildtype 
and heterozygote cell lines may therefore reflect the considerable variation in the VSG 
switching process, or in this assay. Irrespective of this, the analysis showed that the rad51-
4 -/- and rad51-6 -/- mutants had an impaired ability to undergo VSG switching, as the 
frequencies with which switching variants arose in the homozygous cells were 
significantly lower than that of the heterozygous cell lines from which they were derived. 
Compiling all of the available VSG switching data generated by this assay suggests that 
each of the RAD51 paralogue mutants have, to some extent, an impaired ability to undergo 
antigenic variation compared with wildtype cells, as the average VSG switching 
frequencies for wildtype was 7.18 (+/- 1.32), rad51 -/- was 0.44 (+/- 0.33), rad51-3 -/- was 
1.07 (+/-0.69), rad51-4 -/- was 4.85 (+/- 1.55), rad51-5 -/- was 4.47 (+/-3.17) and rad51-6 
-/- was 3.79 (+/-2.05)  switched variants per 107 cells per generation (Chapter 4, Section 
4.6). These data suggest that rad51 -/- and rad51-3 -/- mutants have a lower mean VSG 
switching frequency compared with the three other RAD51 homozygous mutants (rad51-4 
-/-, rad51-5 -/- and rad51-6 -/-), implying that RAD51 and RAD51-3 are central to VSG 
switching while the other paralogues may have only secondary roles. For RAD51-5, it was 
concluded that it does not have a role in VSG switching (Proudfoot & McCulloch, 2005a). 
Similarly to RAD51-5, MRE11 was shown not to affect VSG switching, even though it has 
clear roles in DNA repair and HR (Bell & McCulloch, 2003). The authors suggested that 
MRE11 and RAD51-5 may act in early or later stages of HR, which may be circumvented 
in the VSG switching event, although we still have no insight into the mechanism.  
Hartley & McCulloch (2008) also suggested that general DNA repair and HR have 
different requirements to the T. brucei antigenic variation pathway during their study on 
the BRCA2 gene. The human ortholog of T. brucei’s BRCA2 was shown to interact with 
Rad51 via non-identical BRC repeats (Lo et al., 2003; Pellegrini et al., 2002). T. brucei 
BRCA2 has an unusually large set of BRC repeats compared with other eukaryotes, 
containing 14 identical BRC repeats and one non-identical, C terminal repeat (Hartley & 
McCulloch, 2008). Phenotypic analyses showed that T. brucei brca2 -/- mutant cell lines 
are defective in DNA repair, HR and antigenic variation (Hartley & McCulloch, 2008). A 
truncated BRCA2 was generated in T. brucei cells by deleting the 14 identical repeats but 
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retained the divergent BRC repeat (Hartley & McCulloch, 2008). The cell line expressing 
this truncated BRCA2 polypeptide was impaired in DNA repair, HR and RAD51 foci 
formation (Hartley & McCulloch, 2008). However, these defects in the repair pathways 
were not reflected in the VSG switching rate (Hartley & McCulloch, 2008), which was 
comparable to the wildtype. These data imply that the one non-identical BRC repeat alone 
is unable to act with RAD51 in the DNA repair pathways of T. brucei, and an undefined 
number of distinct BRC repeats are needed for a fully functional BRCA2. On the other 
hand, loss of the 14 identical BRC repeats in the BRCA2 truncated cell line did not affect 
VSG switching (Hartley & McCulloch, 2008), implying that the interaction between 
RAD51 and the BRC repeats of BRCA2 is not required for antigenic variation. As brca2 -
/- mutant cells are defective in VSG switching, BRCA2’s role in antigenic variation may 
be independent of RAD51 interaction. Alternatively, the HR pathway directed by RAD51 
for VSG switching is distinct in its requirements compared with those for general repair. 
For example, the length of sequence homology needed might be quite different.  
Taken as a whole, these data suggest that VSG switching is mediated by a number of the T. 
brucei DNA repair proteins, including full length BRCA2, RAD51 and at least some of the 
RAD51 paralogues, (RAD51-3, RAD51-4, RAD51-6; Proudfoot & McCulloch, 2005a; see 
Chapter 4, Section 4.6), although it is unclear how central the role for RAD51-4 and 
RAD51-6 are in the process. In contrast, other proteins that act in HR and DNA repair, 
such as RAD51-5 and MRE11, either do not have a role in antigenic variation or contribute 
indirectly meaning that no affect on VSG switching can be detected by the available assay 
(Bell & McCulloch, 2003; Proudfoot & McCulloch, 2005a). Nonetheless, it appears that T. 
brucei utilises multiple pathways of HR and it remains to be seen how many of these 
HR/DNA repair reactions contribute to VSG switching (Conway et al., 2002b; McCulloch 
& Barry, 1999). As yet, all of the factors involved in each pathway are unknown. 
7.4 Interactions between the RAD51 paralogues 
Results of the phenotypic analyses of each of the four T. brucei RAD51 paralogue mutants 
are highly similar with the two exceptions of less sensitivity to phleomycin in rad51-4 -/- 
and a putative role for RAD51-3 in VSG switching. This may suggest either that these 
paralogues are involved at separate steps in a HR pathway, or are part of a protein 
complex, or complexes, involved in the pathway. There are many lines of evidence in other 
eukaryotes to support the hypothesis that the Rad51 paralogues act as part of multi-protein 
complexes. Studies with the S. cerevisiae Rad55 and Rad57 paralogues confirmed that 
both contribute as a complex to the formation of the Rad51 nucleoprotein filament in the 
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DNA repair pathway (see Figure 1-13). For example, it has been shown that the two 
paralogues interact with one another, and that Rad55 interacts with Rad51 (Hays et al., 
1995). Another study showed that the Rad55-Rad57 heterodimer functions with RPA 
(DNA binding protein) to promote Rad51 pairing on ssDNA in the early step of strand 
exchange (Sung, 1997). Finally, the sensitivity of rad55 or rad57 mutants to ionizing 
radiation was partially suppressed by the overexpression of RAD51 (Johnson & 
Symington, 1995). Double mutants of rad55 and rad57 show similar and often equivalent 
phenotypes to that of the single rad55 or rad57 mutants, indicating an epistatic relationship 
between the two genes (Johnson & Symington, 1995).  
Studies with the five mammalian Rad51 paralogues confirm formation of multi-protein 
complexes, some involving Rad51, but here these appear to have roles in many steps of the 
Rad51-dependent DNA repair pathway. Two main studies suggested that the mammalian 
Rad51 paralogues form two distinct complexes, Rad51B-Rad51C-Rad51D-XRCC2 
(BCDX2) and Rad51C-XRCC3 (CX3; see Figure 1-14), with the transient binding of 
Rad51 (Liu et al., 2002b; Masson et al., 2001b). Biochemical analyses of purified protein 
complexes have shown that both BCDX2 and CX3 complexes bind to ssDNA and cause 
DNA aggregation (Masson et al., 2001a; Masson et al., 2001b). As a result it was proposed 
that the two complexes have similar roles to that of the S. cerevisiae heterodimer complex 
Rad55/Rad57, acting in the early stages of strand exchange through their ssDNA-binding 
properties (Masson et al., 2001a; Masson et al., 2001b), perhaps stabilising the 
nucleoprotein filament. Interestingly, the competitive effect of RPA against Rad51 binding 
to ssDNA was shown to be alleviated by the Rad51B-Rad51C sub-complex (Sigurdsson et 
al., 2001), and this complex was also shown to interact weakly with Rad51 (Lio et al., 
2003). The BCDX2 complex also binds to nicked duplex DNA, which perhaps implies a 
role in the repair of DNA (Masson et al., 2001b). Analysis of purified Rad51D showed the 
protein has DNA binding and ATP-hydrolytic properties (Braybrooke et al., 2000), and 
further studies indicated that Rad51D is associated with telomeres independent of the other 
two complex proteins, XRCC2 and Rad51C (Tarsounas et al., 2004b). From this it was 
proposed that Rad51D has telomere protective activities, perhaps preventing telomeric 
attrition and fusion (Tarsounas et al., 2004b). Finally, it has been proposed that Holliday 
junction resolvase activity is associated with the CX3 complex and that Rad51C is 
localised as foci in the late stages of meiotic recombination, during prophase I: pachytene 
and diplotene, in mouse spermatocytes (Liu et al., 2007). This localisation is distinct from 
the Rad51 localisation, which is mainly observed as foci in the early stages of prophase I: 
leptotene and zygotene (Liu et al., 2007). This finding, which suggests a post-synaptic role 
for CX3, appears to contradict the study of Takata et al. (2001), where Rad51 foci 
Rachel Dobson, 2009   Chapter 7, 250 
formation was shown to be affected by rad51C and xrcc3 mutation which would imply a 
function at the early step of HR. However, Liu et al. (2007) noted their data cannot rule out 
the possibility of CX3 having dual roles in the early and late stages of HR, or possibly 
having distinct functions in mitotic and meiotic recombination.  
In summary, despite the lack of clarity in the precise roles for the yeast and mammalian 
RAD51 paralogues in HR, there is considerable evidence for stable complexes and in 
mammals, potentially multiple distinct complexes. This project sought to ascertain whether 
this was also true in T. brucei, which is highly diverged from yeast and mammals. Like the 
yeast and mammalian Rad51 paralogues, T. brucei paralogue self-interactions were not 
observed by yeast-two hybrid analysis. In contrast, T. brucei RAD51 was found to interact 
with itself. It seems likely that this is consistent with functional and bioinformatic 
prediction. RAD51 (and DMC1) act through the formation of a nucleoprotein filament, 
mediated by a polymerisation motif (Shin et al., 2003). This motif is not recognisable in 
any T. brucei RAD51 paralogues, and has not been noted in any Rad51 paralogues from 
other organisms. It appears, therefore, that the paralogues interact in discrete complexes. 
The study of the T. brucei RAD51 paralogues indicated that the proteins do interact with 
one another: RAD51-3 and RAD51-4 interaction was confirmed by the yeast two-hybrid 
system, while RAD51-3 and RAD51-6 were also shown to interact, though somewhat 
more weakly than RAD51-3 and RAD51-4. It should be noted, that the strength of the 
observed interaction in the yeast two-hybrid system may not relate to true physiological 
and biochemical interaction. The relative stability of the interactions in vitro does not 
always correlate with their stability in vivo. For example, the yeast two-hybrid interaction 
between Rad55 and Rad51 is slightly stronger than that of Rad55 and Rad57 (Hays et al., 
1995; Johnson & Symington, 1995). However, experiments such as co-
immunoprecipitation suggest the opposite occurs in vivo, with a very stable interaction 
between Rad55 and Rad57 (Sung, 1997). Nevertheless, the interaction between RAD51-3 
and RAD51-4 was confirmed by co-immunoprecipitation from T. brucei cell extracts. 
Yeast two-hybrid analysis could not be carried out using RAD51-4 as the bait protein due 
to auto-induction by RAD51-4. As mentioned above, RAD51-3 and RAD51-6 were shown 
to interact, although the opposite was not the case and no interaction was observed 
between LexA-RAD51-6 and V5-NLS-B42-RAD51-3. It may be the case that this 
interaction is direction dependent in yeast two-hybrid analysis. There was no observable 
interaction between RAD51-5 and any other RAD51 paralogue in yeast two-hybrid 
analysis. The lack of specificity of the anti-RAD51-5 and anti-RAD51-6 anti-sera and 
preliminary PTP tagging purification of these proteins did not yield any information. 
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Interestingly, analysis of protein expression levels showed that in T. brucei rad51-3 -/- 
mutants, RAD51-4 was undetectable. In contrast, RAD51-3 was readily detectable in 
rad51-4 -/- protein extracts. This appears to suggest that the stability of RAD51-4 is 
dependent on the presence of RAD51-3, but not the reverse. A similar finding was shown 
in human cell lines: when Rad51C was depleted in HeLa cells by RNA interference, the 
level of XRCC3 protein was reduced, suggesting that XRCC3 is dependent on Rad51C for 
its stability (Lio et al., 2004). In contrast, other known interactors of Rad51C, (XRCC2 and 
Rad51D), were not affected in the Rad51C depleted cells (Lio et al., 2004). Both Rad51B 
and Rad51 protein levels appeared to partly reduce for day two following transfection with 
Rad51C siRNA, but recovered thereafter the 48 hours (Lio et al., 2004). The explanation 
for these findings appears to lie in the existence of stable protein-protein interaction, and 
presumably in the absence of a binding partner, the remaining protein is targeted for 
destruction, either because it folds incorrectly or is trafficked aberrantly (Lehninger et al., 
1993). If we assume that the mammalian and T. brucei RAD51 paralogues have similar 
functions, we could postulate that T. brucei RAD51-3 and mammalian Rad51C have 
equivalent roles, stabilising RAD51-4 and XRCC3, respectively. In this context, it is 
interesting to note that rad51-3 -/- mutant cell lines produced less DNA damage-induced 
RAD51 foci than rad51-4 -/- mutant cell lines (discussed above, Section 7.3.2). Also, 
rad51-3 -/- mutant cell lines have greater defects in HR and VSG switching, perhaps 
indicating that rad51-3 -/- mutant cells are more compromised than the rad51-4 -/- mutant 
cells (see Chapter 4). These differences in phenotype may simply be the result of rad51-3 -
/- mutant cell lines also lacking functional RAD51-4 (and potentially the other paralogues). 
One way of improving the understanding of the epistatic relationship of the two proteins 
would be to generate rad51-3 -/- rad51-4 -/- double mutants and compare the phenotype to 
the single mutants. If growth rate, HR, DNA damage sensitivity of the double mutants are 
comparable to those observed in the single rad51-3 -/- mutant, it would demonstrate that 
RAD51-3 is epistatic to RAD51-4. As discussed above, rad51-3 -/- mutants produced less 
phleomycin induced RAD51 foci compared with the rad51-4 -/- mutants: 11 % of the 
rad51-3 -/- mutant cells were RAD51 foci positive compared with 52.7 % of the rad51-4 -
/- mutant cells (Chapter 4, Section 4.5). If we postulate that T. brucei RAD51-3/RAD51-4 
and mammalian Rad51C/XRCC3 have equivalent roles respectively, it is striking that the 
pattern of RAD51 foci observed for the T. brucei RAD51 paralogue mutants is similar to 
that of the mammalian mutant cells. After 8 hours of gamma radiation, 8 % of chicken 
DT40 rad51c mutant cells had Rad51 foci, whereas approximately double that number (16 
%) had Rad51 foci in the xrcc3 mutants (Takata et al., 2001). These data are consistent 
with the hypothesis that rad51c mutant cells are somewhat more compromised than the 
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xrcc3 mutants (Takata et al., 2001), and therefore Rad51C has a more fundamental role in 
DNA repair and HR. 
There is strong evidence that RAD51-3 and RAD51-4 interact (described as 3-4), and that 
RAD51-3 and RAD51-6 interact (described as 3-6) (see Figure 7-5). In contrast, we have 
no evidence, at least to date, that RAD51-5 interacts with the other paralogues. On the 
basis of these data, three possible models for interaction between the T. brucei RAD51 
paralogues can be proposed. One is that 3-4 and 3-6 interactions form a component within 
a multi-protein complex (see Figure 7-5A). This could either be a linear complex with 
RAD51-3 at the centre or a more circular complex if 4-6 were found to interact. The other 
model is that 3-4 and 3-6 are two distinct heterodimeric complexes, independent of one 
another, perhaps similar to the mammalian BCDX2 and CX3 sub-complexes (see Figure 7-
5B). It is also possible that both these models are correct (Figure 7-5), and the formation of 
a larger multiprotein complex can occur containing 4-3-6, while the two smaller sub-
complexes 3-4, 3-6 can form and function independently. As discussed above, mammalian 
Rad51C was also found to be part of a larger multi-protein group (BCDX2), eventhough 
Rad51C interacts in two functional sub-complexes; Rad51B-Rad51C was shown to 
overcome the inhibitory affect of RPA and XRCC3-Rad51C was found to have resolvase 
activity. Although it is easy to see why multiple individual interactions occur 
simultaneously, the true function of this large complex of mammalian Rad51 paralogues 
(BCDX2) is unknown. The main and most plausible reason for the complex function is 
stability, as the complex was soluble in vitro while individual proteins were insoluble 
(Masson et al., 2001b). in vitro assays have shown that BCDX2 binds to ssDNA, has ATP 
hydrolysis activity and stimulates Rad51 binding to DNA, but as yet the function of this 
multi-protein complex in vivo has not been determined. 
Irrespective of which model is true for these three T. brucei RAD51 paralogues, the 
interaction, if any, between them and RAD51 and RAD51-5 is still unclear. It may be the 
case that RAD51 interaction is transient as observed in S. cerevisiae (Sung, 1997) and in 
mammalian cells (Sigurdsson et al., 2001). It is also plausible that any interaction with 
Rad51 is DNA damage mediated, and to date no experiments have tested this. Yeast two-
hybrid analysis failed to find evidence that RAD51-5 interacts with any of the other 
RAD51 paralogues, whereas there is a clear indication that the protein has a role in DNA 
repair, RAD51 foci formation and HR (Proudfoot & McCulloch, 2005a), confirming its 
definition as a RAD51 paralogue. It is intriguing that RAD51-5 was not identified in 
Leishmania, indicating perhaps that RAD51-5 has a specialised role in T. brucei and T. 
cruzi, which is not required in the closely related parasite.  
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Figure 7-5: Models of the T. brucei RAD51 paralogue interactions. 
Two models for interaction of the four T. brucei RAD51 paralogues, RAD51-3 (3), RAD51-4 (4), RAD51-5 
(5), and RAD51-6 (6) predicted from the interaction analyses data. Figure 7-5A: shows a multi-protein 
complex formed by RAD51-3, RAD51-4 and RAD51-6. Figure 7-5B: shows two sub-complexes formed by 
all the T. brucei RAD51 paralogues. It has not been elucidated yet where RAD51 (51) fits into this model. 
Rachel Dobson, 2009   Chapter 7, 254 
7.5 Future goals 
The results described in this thesis confirm the hypothesis that T. brucei possesses four 
RAD51 paralogues, and shows that each have roles in the HR and DNA repair pathways of 
the parasite. However, their precise roles in these pathways are still unknown. Analysis of 
cell cycle changes in rad51 -/- and the RAD51 paralogue homozygous mutants would 
determine if the slow growth phenotype is due to a cell cycle defect. Also analysis of 
cloning survival of the rad51 -/- and the RAD51 paralogue homozygous mutants would 
determine if slow growth was due to cell death.  
Biochemical analyses of individual, purified RAD51 paralogues, as well complexes of two 
or three paralogues, will lead the way to a better understanding of the function of the 
proteins in the T. brucei HR pathway. Understanding their function in the pathway may 
also help to define the paralogues of other systems. Phylogenetic analysis of this set of 
proteins has proved difficult, and assigning orthology with other eukaryotes appears to be 
impossible due to the sequence divergence. Biochemical analyses such as DNA binding 
properties, HJ resolvase activity and DNA strand exchange ability, would help define the 
proteins in relation to the mammalian paralogues.  
Analysis of the RAD51 paralogue interactions has left a number of unanswered questions. 
As discussed above, it is still unknown whether these proteins act in one large complex or 
multiple smaller complexes. Yeast two-hybrid analysis of RAD51-5 and RAD51-6 did not 
show interaction with any other RAD51 paralogue. Also, the purified anti-RAD51-5 and 
anti-RAD51-6 anti-sera did not bind specifically to the RAD51-5 and RAD51-6 proteins. 
As a result attempts to purify the PTP-tagged RAD51-5 and RAD51-6 were performed. 
Future experiments such as tagging the endogenous RAD51 and RAD51 paralogues in 
procyclic cell lines may yield more conclusive results. PTP tagging has been perfected in 
these cells. Using procyclic cells will also provide a large amount of extracted protein to 
improve success of the assay. As a result, this will allow mass spectrometry analysis of the 
precipitated proteins and will provide a comprehensive representation of what is 
interacting in vivo. Also tagging RAD51-4 and RAD51-6 with different tags such as HA or 
Myc tag would enable sub-cellular localisation of these proteins in the presence of DNA-
damage. 
One interesting finding, the co-stabilisation of RAD51-3 and RAD51-4, requires further 
study and confirmation. Analysing the presence of RAD51-4 by western blot in the re-
expressor of RAD51-3 in the rad51-3 -/- mutant will confirm co-stabilisation of the two 
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proteins. Also analysing the presence of RAD51-3 in the re-expressor of RAD51-4 in the 
rad51-4 -/- mutant will also confirm co-stabilisation. Epistatic analysis of not only these 
two genes but also RAD51 and the other RAD51 paralogues, would indicate whether or 
not they act on the same or multiple pathways. Double knockout analysis, as well as 
overexpression studies, would lead to a better understanding of their interactions and 
functions within the cell. 
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Appendices 
Appendix 1: RAD51-4 ORF 
DNA sequence (in black) and translated amino acid sequence (in blue) for RAD51-4. The 
positions of the primer binding sites are marked by coloured arrows. 
                    N Term For 
                    REX For 
                Start ORF For 
  M   D   A   L   W   P   V   A   H   D   Y   A   N   S   N   S 
1 ATG GAT GCA CTC TGG CCA GTG GCA CAT GAC TAT GCA AAC AGC AAC TCT 
 TAC CTA CGT GAG ACC GGT CAC CGT GTA CTG ATA CGT TTG TCG TTG AGA 
 
 
  D   D   D   D   D   E   G   D   D   F   V   N   L   A   Q   K 
49 GAT GAT GAT GAT GAT GAG GGG GAT GAC TTC GTC AAC TTG GCA CAG AAG 
 CTA CTA CTA CTA CTA CTC CCC CTA CTG AAG CAG TTG AAC CGT GTC TTC 
 
 
  P   V   V   D   L   S   D   S   D   E   L   T   T   Q   E   A 
97 CCT GTA GTA GAT CTT AGT GAT TCT GAT GAA CTT ACC ACA CAA GAA GCA 
 GGA CAT CAT CTA GAA TCA CTA AGA CTA CTT GAA TGG TGT GTT CTT CGT 
 
 
  D   P   L   Q   M   E   R   V   Q   V   M   L   K   K   L   E 
145 GAT CCA CTC CAA ATG GAG CGT GTT CAA GTT ATG CTG AAG AAG TTG GAG 
 CTA GGT GAG GTT TAC CTC GCA CAA GTT CAA TAC GAC TTC TTC AAC CTC 
 
 
  G   L   P   G   Y   G   N   G   T   R   L   E   N   V   L   L 
193 GGC CTT CCA GGT TAT GGG AAC GGC ACG CGT CTT GAA AAC GTG CTA CTG 
 CCG GAA GGT CCA ATA CCC TTG CCG TGC GCA GAA CTT TTG CAC GAT GAC 
 
 
  Q   P   P   C   D   V   S   Q   M   L   D   A   S   L   D   D 
241 CAA CCC CCT TGC GAT GTT TCA CAG ATG CTA GAC GCC TCG CTG GAT GAT 
 GTT GGG GGA ACG CTA CAA AGT GTC TAC GAT CTG CGG AGC GAC CTA CTA 
                                                      Start ORF Rev 
                C Term For 
  V   E   L   L   Y   R   H   I   S   H   T   I   V   N   S   P 
289 GTG GAG CTT CTC TAC AGA CAC ATA AGC CAC ACC ATC GTT AAC TCT CCC 
 CAC CTC GAA GAG ATG TCT GTG TAT TCG GTG TGG TAG CAA TTG AGA GGG 
 
 
  D   S   T   L   L   P   I   S   V   E   D   Q   L   S   S   S 
337 GAT TCC ACG CTT CTT CCC ATT TCC GTT GAA GAC CAA CTC TCC TCC AGT 
 CTA AGG TGC GAA GAA GGG TAA AGG CAA CTT CTG GTT GAG AGG AGG TCA 
 
 
  C   F   G   V   I   S   T   G   H   K   C   L   D   D   V   L 
385 TGT TTT GGG GTG ATA TCC ACT GGC CAT AAG TGT CTA GAT GAT GTG CTT 
 ACA AAA CCC CAC TAT AGG TGA CCG GTA TTC ACA GAT CTA CTA CAC GAA 
 
 
  A   G   G   V   K   C   G   L   V   T   E   I   T   G   A   S 
433 GCT GGC GGC GTG AAG TGT GGC TTA GTC ACG GAG ATT ACC GGG GCA AGT 
 CGA CCG CCG CAC TTC ACA CCG AAT CAG TGC CTC TAA TGG CCC CGT TCA 
                  N Term Rev 
 
  G   T   G   K   T   A   L   A   L   N   L   A   G   R   A   A 
481 GGC ACG GGT AAG ACA GCC CTG GCG CTC AAT CTC GCT GGG CGT GCG GCA 
 CCG TGC CCA TTC TGT CGG GAC CGC GAG TTA GAG CGA CCC GCA CGC CGT 
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  T   L   A   R   E   G   R   G   N   G   K   Y   H   T   L   W 
529 ACT CTG GCA AGA GAA GGC AGG GGT AAT GGA AAG TAT CAT ACA CTT TGG 
 TGA GAC CGT TCT CTT CCG TCC CCA TTA CCT TTC ATA GTA TGT GAA ACC 
 
 
  I   S   S   N   Q   H   P   F   S   T   R   A   T   A   G   Y 
577 ATC AGC AGC AAT CAG CAT CCA TTT TCA ACC AGA GCC ACC GCC GGT TAC 
 TAG TCG TCG TTA GTC GTA GGT AAA AGT TGG TCT CGG TGG CGG CCA ATG 
 
 
  L   R   S   T   L   G   T   Y   R   G   D   N   N   G   S   N 
625 CTA CGG TCT ACA CTT GGT ACA TAT AGA GGT GAC AAC AAT GGA AGC AAT 
 GAT GCC AGA TGT GAA CCA TGT ATA TCT CCA CTG TTG TTA CCT TCG TTA 
 
 
  A   A   E   P   D   R   F   G   G   D   A   E   T   A   L   Q 
673 GCT GCT GAA CCC GAC AGG TTT GGC GGA GAT GCA GAA ACT GCG CTA CAA 
 CGA CGA CTT GGG CTG TCC AAA CCG CCT CTA CGT CTT TGA CGC GAT GTT 
 
 
  Q   L   A   I   V   T   I   P   T   L   G   Q   L   L   E   H 
721 CAG TTG GCA ATA GTA ACA ATC CCA ACG CTC GGG CAG CTT CTG GAG CAT 
 GTC AAC CGT TAT CAT TGT TAG GGT TGC GAG CCC GTC GAA GAC CTC GTA 
 
 
  M   P   V   L   R   E   N   I   M   L   N   D   G   V   R   L 
769 ATG CCT GTT CTC CGT GAG AAT ATT ATG CTG AAT GAC GGC GTA CGC CTC 
 TAC GGA CAA GAG GCA CTC TTA TAA TAC GAC TTA CTG CCG CAT GCG GAG 
 
 
  V   V   V   D   D   F   S   A   M   V   R   R   T   F   T   G 
817 GTG GTG GTG GAT GAT TTT AGC GCC ATG GTA CGT CGG ACC TTT ACT GGT 
 CAC CAC CAC CTA CTA AAA TCG CGG TAC CAT GCA GCC TGG AAA TGA CCA 
 
                              End ORF For 
  M   D   G   E   V   I   E   R   H   N   A   V   A   A   L   M 
865 ATG GAT GGG GAG GTA ATT GAA CGG CAC AAC GCC GTT GCA GCG CTT ATG 
 TAC CTA CCC CTC CAT TAA CTT GCC GTG TTG CGG CAA CGT CGC GAA TAC 
 
 
  N   A   M   K   S   V   A   Q   D   L   R   V   A   V   V   I 
913 AAC GCA ATG AAG AGC GTT GCG CAG GAC CTT CGC GTG GCT GTT GTG ATA 
 TTG CGT TAC TTC TCG CAA CGC GTC CTG GAA GCG CAC CGA CAA CAC TAT 
 
 
  I   T   Q   S   E   V   D   L   G   H   A   F   L   Y   A   V 
961 ATT ACG CAA TCG GAA GTG GAT CTT GGT CAC GCT TTC TTG TAC GCA GTA 
 TAA TGC GTT AGC CTT CAC CTA GAA CCA GTG CGA AAG AAC ATG CGT CAT 
 
 
  N   T   R   L   R   L   S   R   C   L   L   Q   P   N   D   A 
1009 AAC ACT CGC TTG CGT TTG TCG AGA TGC TTG CTG CAA CCA AAT GAC GCA 
 TTG TGA GCG AAC GCA AAC AGC TCT ACG AAC GAC GTT GGT TTA CTG CGT 
 
 
  A   A   D   V   A   G   N   V   R   L   A   H   L   L   E   L 
1057 GCA GCA GAT GTG GCA GGT AAT GTA CGC TTG GCT CAC CTG CTG GAA CTA 
 CGT CGT CTA CAC CGT CCA TTA CAT GCG AAC CGA GTG GAC GAC CTT GAT 
 
 
  V   K   S   C   M   A   S   D   C   K   F   E   C   K   F   E 
1105 GTG AAG AGT TGC ATG GCT TCG GAC TGC AAA TTT GAG TGC AAA TTT GAG 
 CAC TTC TCA ACG TAC CGA AGC CTG ACG TTT AAA CTC ACG TTT AAA CTC 
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  G   F   Y   L   G   S   V   H   L   L   T   E   G   A   V   A 
1153 GGG TTT TAT TTA GGT TCT GTA CAC CTC TTA ACA GAG GGG GCA GTG GCA 
 CCC AAA ATA AAT CCA AGA CAT GTG GAG AAT TGT CTC CCC CGT CAC CGT 
 
 
  L   R   D   V   D   F   Y   G   V   D   P   F   G   Y   A   V 
1201 CTG AGG GAT GTT GAT TTT TAC GGT GTG GAC CCA TTC GGT TAC GCT GTG 
 GAC TCC CTA CAA CTA AAA ATG CCA CAC CTG GGT AAG CCA ATG CGA CAC 
 
 
  V   P   T   F   V   H   C   * 
1249 GTG CCA ACA TTT GTT CAC TGC TAG 
 CAC GGT TGT AAA CAA GTG ACG ATC 
                                                                End ORF Rev 
                                                                               REX Rev 
                                                               C Term Rev 
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Appendix 2: RAD51-6 ORF 
DNA sequence (in black) and translated amino acid sequence (in blue) for RAD51-4. The 
positions of the primer binding sites are marked by coloured arrows. 
 
                     REX For 
                  Start ORF For 
  M   A   S   V   N   A   P   T   T   L   T   S   E   L   F   H 
1 ATG GCT AGC GTG AAT GCT CCC ACA ACT CTC ACC AGT GAG CTC TTC CAT 
 TAC CGA TCG CAC TTA CGA GGG TGT TGA GAG TGG TCA CTC GAG AAG GTA 
 
 
  A   L   P   C   L   R   E   N   P   T   D   S   V   L   T   A 
49 GCG CTT CCA TGC CTG CGG GAG AAT CCA ACC GAT AGT GTG CTC ACC GCC 
 CGC GAA GGT ACG GAC GCC CTC TTA GGT TGG CTA TCA CAC GAG TGG CGG 
 
 
  A   L   L   Q   Y   C   Q   D   E   D   L   V   S   A   A   D 
97 GCA CTG CTG CAA TAT TGT CAG GAT GAA GAT CTG GTA TCC GCT GCA GAT 
 CGT GAC GAC GTT ATA ACA GTC CTA CTT CTA GAC CAT AGG CGA CGT CTA 
 
 
  L   L   L   R   L   M   V   D   Q   P   H   V   Q   R   R   M 
145 TTA CTA CTG CGG TTG ATG GTG GAT CAA CCT CAT GTG CAG CGG CGT ATG 
 AAT GAT GAC GCC AAC TAC CAC CTA GTT GGA GTA CAC GTC GCC GCA TAC 
 
 
  T   R   S   V   E   N   T   H   R   H   V   P   L   P   Q   P 
193 ACA CGT TCT GTC GAG AAT ACA CAT CGA CAT GTG CCG TTG CCT CAA CCT 
 TGT GCA AGA CAG CTC TTA TGT GTA GCT GTA CAC GGC AAC GGA GTT GGA 
 
                                                        
  G   D   L   Q   N   F   T   D   K   V   L   E   A   L   C   D 
241 GGA GAT TTG CAG AAC TTC ACA GAT AAG GTG CTA GAA GCG CTA TGC GAT 
 CCT CTA AAC GTC TTG AAG TGT CTA TTC CAC GAT CTT CGC GAT ACG CTA 
                                                         Start ORF Rev 
 
  R   H   V   S   Q   L   S   E   N   S   G   A   A   G   R   S 
289 CGA CAT GTG TCA CAA CTA TCT GAA AAC TCA GGT GCT GCT GGG AGG AGT 
 GCT GTA CAC AGT GTT GAT AGA CTT TTG AGT CCA CGA CGA CCC TCC TCA 
 
 
  V   R   A   R   G   S   G   F   S   S   V   S   V   S   V   S 
337 GTG AGG GCT CGC GGT AGC GGT TTT TCT TCG GTA TCA GTG AGT GTG TCG 
 CAC TCC CGA GCG CCA TCG CCA AAA AGA AGC CAT AGT CAC TCA CAC AGC 
 
 
  D   M   L   A   T   A   A   A   W   G   N   D   S   V   K   L 
385 GAC ATG CTG GCA ACT GCA GCT GCA TGG GGA AAT GAT TCC GTG AAA TTG 
 CTG TAC GAC CGT TGA CGT CGA CGT ACC CCT TTA CTA AGG CAC TTT AAC 
 
 
  E   G   L   A   P   L   Q   P   T   N   R   K   V   H   F   F 
433 GAG GGG CTG GCA CCT TTG CAG CCA ACT AAC CGG AAA GTT CAC TTC TTC 
 CTC CCC GAC CGT GGA AAC GTC GGT TGA TTG GCC TTT CAA GTG AAG AAG 
 
 
  P   T   G   C   S   L   V   D   R   L   L   A   G   T   P   S 
481 CCA ACA GGC TGC TCA CTG GTG GAC CGC CTG CTC GCA GGA ACC CCG TCA 
 GGT TGT CCG ACG AGT GAC CAC CTG GCG GAC GAG CGT CCT TGG GGC AGT 
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  N   A   T   G   G   A   L   E   G   G   F   C   A   G   L   L 
529 AAT GCC ACG GGT GGT GCT CTT GAA GGC GGG TTT TGC GCT GGA CTT CTC 
 TTA CGG TGC CCA CCA CGA GAA CTT CCG CCC AAA ACG CGA CCT GAA GAG 
 
 
  T   E   V   H   G   E   A   G   S   G   K   T   Q   L   V   L 
577 ACG GAG GTG CAT GGT GAA GCA GGA AGC GGA AAG ACA CAA CTT GTA TTA 
 TGC CTC CAC GTA CCA CTT CGT CCT TCG CCT TTC TGT GTT GAA CAT AAT 
 
 
  Q   C   L   F   Q   C   V   A   R   Q   Q   C   A   L   Y   A 
625 CAG TGC TTA TTC CAA TGC GTT GCT AGG CAA CAG TGT GCT CTG TAT GCT 
 GTC ACG AAT AAG GTT ACG CAA CGA TCC GTT GTC ACA CGA GAC ATA CGA 
 
 
  V   N   H   L   P   E   L   L   I   S   S   G   D   G   V   G 
673 GTG AAT CAC TTA CCC GAG CTG TTG ATC AGC TCA GGC GAT GGT GTT GGT 
 CAC TTA GTG AAT GGG CTC GAC AAC TAG TCG AGT CCG CTA CCA CAA CCA 
 
 
  D   N   T   F   I   D   S   L   R   G   F   A   T   E   K   V 
721 GAC AAC ACG TTT ATT GAT AGT TTG CGT GGC TTT GCA ACT GAA AAG GTG 
 CTG TTG TGC AAA TAA CTA TCA AAC GCA CCG AAA CGT TGA CTT TTC CAC 
 
 
  A   A   L   Y   I   V   S   E   G   V   P   A   S   R   L   G 
769 GCG GCT CTT TAT ATT GTG TCT GAG GGC GTT CCT GCC AGC CGA CTT GGG 
 CGC CGA GAA ATA TAA CAC AGA CTC CCG CAA GGA CGG TCG GCT GAA CCC 
 
 
  P   L   A   T   G   A   L   H   R   A   K   A   M   V   L   S 
817 CCA CTC GCA ACA GGG GCG CTT CAT AGA GCA AAA GCG ATG GTC CTT TCC 
 GGT GAG CGT TGT CCC CGC GAA GTA TCT CGT TTT CGC TAC CAG GAA AGG 
 
 
  A   A   S   R   Q   P   S   I   D   V   E   L   L   K   A   R 
865 GCG GCT TCC CGT CAA CCG TCT ATT GAC GTG GAG CTT TTG AAG GCT CGT 
 CGC CGA AGG GCA GTT GGC AGA TAA CTG CAC CTC GAA AAC TTC CGA GCA 
 
 
  L   D   E   F   V   T   E   R   T   V   V   A   G   V   G   I 
913 CTT GAT GAA TTC GTG ACG GAA CGA ACT GTC GTT GCC GGT GTG GGG ATT 
 GAA CTA CTT AAG CAC TGC CTT GCT TGA CAG CAA CGG CCA CAC CCC TAA 
 
 
  R   P   V   D   G   V   G   A   L   L   R   L   L   S   D   G 
961 CGA CCA GTT GAT GGA GTT GGG GCG TTG TTA CGA CTG CTA TCG GAT GGT 
 GCT GGT CAA CTA CCT CAA CCC CGC AAC AAT GCT GAC GAT AGC CTA CCA 
 
 
  T   L   S   S   A   F   S   S   L   G   N   T   G   V   V   V 
1009 ACG CTG TCT AGT GCC TTC TCA TCT TTA GGC AAT ACT GGG GTG GTG GTT 
 TGC GAC AGA TCA CGG AAG AGT AGA AAT CCG TTA TGA CCC CAC CAC CAA 
 
                                                 End ORF For 
  V   D   S   I   A   D   V   V   A   G   G   S   S   G   E   E 
1057 GTA GAT TCC ATT GCA GAT GTA GTG GCT GGT GGA TCT TCG GGC GAG GAG 
 CAT CTA AGG TAA CGT CTA CAT CAC CGA CCA CCT AGA AGC CCG CTC CTC 
 
 
  M   N   R   W   E   I   S   T   T   V   A   S   V   G   S   L 
1105 ATG AAC CGT TGG GAA ATT TCC ACT ACC GTA GCA TCT GTG GGG AGT TTG 
 TAC TTG GCA ACC CTT TAA AGG TGA TGG CAT CGT AGA CAC CCC TCA AAC 
 
 
 
 
261 
  L   K   S   F   A   V   K   E   G   A   A   V   V   V   T   N 
1153 TTG AAG TCA TTC GCA GTT AAG GAA GGG GCT GCC GTG GTA GTA ACG AAT 
 AAC TTC AGT AAG CGT CAA TTC CTT CCC CGA CGG CAC CAT CAT TGC TTA 
 
 
  Q   V   R   T   S   L   S   V   S   G   E   G   M   I   R   R 
1201 CAA GTT CGC ACG TCG CTA TCT GTT TCC GGT GAG GGG ATG ATA CGC CGC 
 GTT CAA GCG TGC AGC GAT AGA CAA AGG CCA CTC CCC TAC TAT GCG GCG 
 
 
  H   T   P   V   P   A   L   G   M   Q   W   A   V   A   P   H 
1249 CAC ACA CCA GTA CCC GCG TTG GGG ATG CAA TGG GCC GTT GCT CCT CAT 
 GTG TGT GGT CAT GGG CGC AAC CCC TAC GTT ACC CGG CAA CGA GGA GTA 
 
 
  V   R   V   N   L   R   R   P   Q   N   T   A   N   A   S   R 
1297 GTC CGT GTA AAT CTG CGG CGA CCG CAA AAT ACG GCA AAC GCA TCG CGT 
 CAG GCA CAT TTA GAC GCC GCT GGC GTT TTA TGC CGT TTG CGT AGC GCA 
 
 
  R   Q   F   T   I   I   C   G   P   A   H   Q   P   A   Y   C 
1345 CGG CAA TTC ACG ATA ATA TGC GGC CCT GCT CAC CAA CCC GCA TAT TGC 
 GCC GTT AAG TGC TAT TAT ACG CCG GGA CGA GTG GTT GGG CGT ATA ACG 
 
 
  S   Y   L   I   C   N   E   G   I   C   N   D   E   * 
1393 TCT TAT TTG ATT TGT AAC GAA GGT ATA TGC AAC GAC GAA TGA 
 AGA ATA AAC TAA ACA TTG CTT CCA TAT ACG TTG CTG CTT ACT 
                                                      End ORF Rev 
                                                                                                                                       REX Rev 
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Appendix 3: Student’s t-tests for the phenotypic analysis of the rad51-4 -/- 
and rad51-6-/- mutants 
Chapter 3 describes the phenotypic analysis of the rad51-4-/- and rad51-6 -/- mutants. To 
analysis the phenotype growth doubling times, clonal survival and IC50 values for DNA- 
damaging agents, transformation frequencies, and ability to form RAD51 foci were 
calculated. The means were calculated from three independent experiments for each assay. 
Unpaired, two-tailed Student’s t-tests were carried out to compare the mean results of all 
the assays. These were done for the cell lines against each other to determine if there was a 
significant difference. A significant difference between the results is shown by a p-value of 
p ≤ 0.05. Not significantly different results are shown as “-“. NA is not applicable. ND is 
not determinable. Each cell line is described: wildtype strain 3174.2 (wt), two independent 
RAD51-4/6 heterozygous mutants (X+/-, Y+/-), rad51-4/6 homozygous mutants (X-/-, Y-/-
) and re-expressor cell lines (X-/-/+, Y-/-/+) 
 
1. Statistical analysis of the doubling time of RAD51-4 mutants. 
NA-0.00040.0016---Y-/-/+
-NA0.00050.0018---X-/-/+
0.00040.0005NA-0.00570.00280.0012Y-/-
0.00160.0018-NA0.01240.00630.0041X-/-
--0.00570.0124NA--Y+/-
--0.00280.0063-NA-X+/-
--0.00120.0041--NAwt 
Y-/-/+X-/-/+Y-/-X-/-Y+/-X+/-wt 
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2.   Statistical analysis of the clonal survival of RAD51-4 mutants when treated with increasing 
concentrations of MMS (0.0001%, 0.0002%, 0.0003%, 0.0004%). 
NA------Y-/-/+
-NA-----X-/-/+
--NA----Y-/-
---NA---X-/-
----NA--Y+/-
-----NA-X+/-
------NAwt 
Y-/-/+X-/-/+Y-/-X-/-Y+/-X+/-wt 0.0001
 
NA-0.00630.0131---Y-/-/+
-NA0.00040.00270.0298--X-/-/+
0.00630.0004NA-0.00000.01300.0097Y-/-
0.01310.0027-NA0.00030.03220.0241X-/-
-0.02980.00000.0003NA--Y+/-
--0.01300.0322-NA-X+/-
--0.00970.0241--NAwt 
Y-/-/+X-/-/+Y-/-X-/-Y+/-X+/-wt 0.0002
 
NA-0.01700.0001---Y-/-/+
-NA0.00620.0005---X-/-/+
0.01700.0062NA-0.01640.02560.0420Y-/-
0.00010.0005-NA0.01190.01040.0349X-/-
--0.01640.0119NA--Y+/-
--0.02560.0104-NA-X+/-
--0.04200.0349--NAwt 
Y-/-/+X-/-/+Y-/-X-/-Y+/-X+/-wt 0.0003
 
NA-0.00960.0096---Y-/-/+
-NA0.00960.0096--0.0493X-/-/+
0.00960.0096NAND0.00310.03420.0165Y-/-
0.00960.0096NDNA0.00310.03420.0165X-/-
--0.00310.0031NA--Y+/-
--0.03420.0342-NA-X+/-
-0.04930.01650.0165--NAwt 
Y-/-/+X-/-/+Y-/-X-/-Y+/-X+/-wt 0.0004
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3. Statistical analysis of the clonal survival of RAD51-4 mutants when treated with increasing 
concentrations of phleomycin (0.025 µg.ml-1, 0.05 µg, .ml-1 0.075 µg.ml-1, 0.1 µg.ml-1). 
NAND---Y-/-
NDNA---X-/-
--NA--Y+/-
---NA-X+/-
----NAwt 
Y-/-X-/-Y+/-X+/-wt 0.1
 
NA-0.02620.02190.0306Y-/-
-NA0.03470.02850.0412X-/-
0.02620.0347NA--Y+/-
0.02190.0285-NA-X+/-
0.03060.0412--NAwt 
Y-/-X-/-Y+/-X+/-wt 0.025
 
NA-0.01330.00720.0132Y-/-
-NA0.01410.00760.0139X-/-
0.01330.0141NA--Y+/-
0.00720.0076-NA-X+/-
0.01320.0139--NAwt 
Y-/-X-/-Y+/-X+/-wt 0.05
 
NAND0.00110.01960.0290Y-/-
NDNA0.00110.01960.0290X-/-
0.00110.0011NA--Y+/-
0.01960.0196-NA-X+/-
0.02900.0290--NAwt 
Y-/-X-/-Y+/-X+/-wt 0.075
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4. Statistical analysis of the IC50 values for MMS of the RAD51-4 mutants. 
NA------Y-/-/+
-NA-----X-/-/+
--NA--0.02250.0387Y-/-
---NA0.04690.00630.0120X-/-
---0.0469NA--Y+/-
--0.02250.0063-NA-X+/-
--0.03870.0120--NA wt 
Y-/-/+X-/-/+Y-/-X-/-Y+/-X+/-wt
 
 
5.  Statistical analysis of the IC50 values for phleomycin of the RAD51-4 mutants. 
NA--0.02680.0499Y-/-
-NA-0.01230.0280X-/-
--NA--Y+/-
0.02680.0123-NA-X+/-
0.04990.0280--NAwt 
Y-/-X-/-Y+/-X+/-wt
 
6. Statistical analysis of the transformation efficiencies of the RAD51-4 mutants. 
NA-0.02070.00170.0047Y-/-
-NA0.03730.00310.0089X-/-
0.02070.0373NA--Y+/-
0.00170.0031-NA-X+/-
0.00470.0089--NAwt
Y-/-X-/-Y+/-X+/-wt
 
 
7. Statistical analysis of the VSG switching frequencies of the RAD51-4 mutants. 
wt X+/- Y+/- X-/- Y-/- X-/-/+
wt NA 0.0107 - 0.0285 - -
X+/- 0.0107 NA ND 0.0000 0.0001 -
Y+/- - ND NA 0.0002 0.0007 -
X-/- 0.0285 0.0000 0.0002 NA - 0.0286
Y-/- - 0.0001 0.0007 - NA -
X -/-/+ - - - 0.0286 - NA
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8. Statistical analysis of the doubling time of RAD51-6 mutants. 
NA-0.00060.0009---Y-/-/+
-NA0.00040.0006---X-/-/+
0.00060.0004NA-0.00050.00040.0004Y-/-
0.00090.0006-NA0.00080.00070.0007X-/-
--0.00050.0008NA--Y+/-
--0.00040.0007-NA-X+/-
--0.00040.0007--NAwt 
Y-/-/+X-/-/+Y-/-X-/-Y+/-X+/-wt 
 
9. Statistical analysis of the clonal survival of RAD51-6 mutants when treated with increasing 
concentrations of MMS (0.0001%, 0.0002%, 0.0003%, 0.0004%). 
NA-0.0127----Y-/-/+
-NA0.0081----X-/-/+
0.01270.0081NA-0.00600.01010.0149Y-/-
---NA0.0434--X-/-
--0.00600.0434NA--Y+/-
--0.0101--NA-X+/-
--0.0149---NAwt 
Y-/-/+X-/-/+Y-/-X-/-Y+/-X+/-wt 0.0001
 
NA-0.03140.0126---Y-/-/+
-NA0.00610.0012---X-/-/+
0.03140.0061NA-0.00130.00310.0132Y-/-
0.01260.0012-NA0.00000.00030.0043X-/-
--0.00130.0000NA--Y+/-
--0.00310.0003-NA-X+/-
--0.01320.0043--NAwt 
Y-/-/+X-/-/+Y-/-X-/-Y+/-X+/-wt 0.0002
 
NA-0.00920.0119---Y-/-/+
-NA0.00290.0034---X-/-/+
0.00920.0029NA-0.03590.00290.0046Y-/-
0.01190.0034-NA0.04030.00380.0062X-/-
--0.03590.0403NA--Y+/-
--0.00290.0038-NA-X+/-
--0.00460.0062--NAwt 
Y-/-/+X-/-/+Y-/-X-/-Y+/-X+/-wt 0.0003
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NA-0.03350.0335---Y-/-/+
-NA-----X-/-/+
0.0335-NAND---Y-/-
0.0335-NDNA---X-/-
----NA--Y+/-
-----NA-X+/-
------NAwt 
Y-/-/+X-/-/+Y-/-X-/-Y+/-X+/-wt 0.0004
 
10. Statistical analysis of the clonal survival of RAD51-6 mutants when treated with increasing 
concentrations of phleomycin (0.025 µg.ml-1, 0.05 µg.ml-1, 0.075 µg.ml-1, 0.1 µg.ml-1). 
NA-0.00000.00130.0003Y-/-
-NA0.00000.00100.0002X-/-
0.00000.0000NA--Y+/-
0.00130.0010-NA-X+/-
0.00030.0002--NAwt 
Y-/-X-/-Y+/-X+/-wt 0.025
 
NAND0.00310.00200.0036Y-/-
NDNA0.00310.00200.0036X-/-
0.00310.0031NA--Y+/-
0.00200.0020-NA-X+/-
0.00360.0036--NAwt 
Y-/-X-/-Y+/-X+/-wt 0.05
 
NAND---Y-/-
NDNA---X-/-
--NA--Y+/-
---NA-X+/-
----NAwt 
Y-/-X-/-Y+/-X+/-wt 0.075
 
NAND-ND-Y-/-
NDNA-ND-X-/-
--NA--Y+/-
NDND-NA-X+/-
----NAwt 
Y-/-X-/-Y+/-X+/-wt 0.1
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11.  Statistical analysis of the IC50 values for MMS of the RAD51-6 mutants. 
NA------Y-/-/+
-NA-----X-/-/+
--NA-0.00060.00070.0010Y-/-
---NA0.00310.00380.0048X-/-
--0.00060.0031NA--Y+/-
--0.00070.0038-NA-X+/-
--0.00100.0048--NAwt 
Y-/-/+X-/-/+Y-/-X-/-Y+/-X+/-wt
 
12.  Statistical analysis of the IC50 values for phleomycin of the RAD51-6 mutants. 
NA-0.00420.01750.0108Y-/-
-NA0.00220.01010.0060X-/-
0.00420.0022NA--Y+/-
0.01750.0101-NA-X+/-
0.01080.0060--NAwt 
Y-/-X-/-Y+/-X+/-wt
 
13. Statistical analysis of the transformation efficiencies of the RAD51-6 mutants. 
NA-0.03730.02650.0148Y-/-
-NA0.05020.03640.0220X-/-
0.03730.0502NA--Y+/-
0.02650.0364-NA-X+/-
0.01480.0220--NAwt
Y-/-X-/-Y+/-X+/-wt
 
14. Statistical analysis of the VSG switching frequencies of the RAD51-6 mutants 
NA-----X-/-/+
-NA-0.01810.0487-Y-/-
--NA0.00110.00540.0328X-/-
-0.01810.0011NA--Y+/-
-0.04870.0054-NA-X+/-
--0.0328--NAwt 
X-/-/+Y-/-X-/-Y+/-X+/-wt 
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Appendix 4: Accession numbers of the RAD51-related genes  
The accession numbers for the Rad51, RecA, RadA, RadB and RAD51-like genes used 
during the phylogenetic analysis are shown in Table 15 and 16. The sequences were 
obtained from Trypanosoma brucei (Tbr), Leishmania major (Lma), Trypanosoma cruzi 
(Tcr), Entamoeba histolytica (Ehi), Giardia lamblia (Gla), Dictyostelium discoideum 
(Ddi), Toxoplasma gondii (Tgo), Plasmodium falciparum (Pfa), Crytosporidium parvum 
(Cpa), Theileria annulata (Tan), Tetrahymena thermophila (Tth), Trichomonas vaginalis 
(Tva), Saccharomyces cerevisiae (Sce), Homo sapiens (Hsa), Arabidopsis thaliana (Ath), 
Schizosaccharomyces pombe (Spo), Drosophila melanogaster (Dme), Caenorhabditis 
elegans (Cel), Ustiligo maydis (Uma), Encephalitozoon cuniculi (Ecu), Oryza sativa (Osa), 
Escherichia coli (Eco), Campylobacter jejuni (Cje), Neisseria gonorrhoeae (Ngo), Bacillus 
subtilis (Bsu), Streptomyces lividans (Sli), Staphylococcus aureus (Sau), Pyrococcus 
furiosus (Pfu), Methanococcus jannaschii (Mja), Archaeoglobus fulgidus (Afu), 
Thermoplasma acidophilum (Tac). 
15. Accession numbers of the T. brucei RAD51, DMC1 and the RAD51paralogues. 
TbrRAD51 Tb11.01.0360
TbrDMC1 Tb09.211.1210
TbrRAD51-4 Tb11.02.4880
TbrRAD51-3 Tb11.02.0150
TbrRAD51-5 Tb10.389.1770
TbrRAD51-6 Tb927.3.5230
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16. Accession numbers of the RAD51-related genes 
Species Accession Number
LmaRAD51 AAC16334; LmjF28.0550
LmaDMC1 LmjF35.4890
LmaRAD51-3 LmjF33.2490
LmaRAD51-4 LmjF11.0230
LmaRAD51-6 LmjF29.0450
TcrRAD51 Tc00.1047053503801.30
TcrDMC1 Tc00.1047053506885.310
TcrRAD51-3 Tc00.1047053504153.220
TcrRAD51-4 Tc00.1047053503613.30
TcrRAD51-6 Tc00.1047053508075.20
TcrRAD51-5 Tc00.1047053510123.30
EhiRAD51 63.m00157
EhiDMC1 10.m00382
EhiRAD51-3 RAD51C; 59.m00167
GlaRAD51 XP_001709425; GL50803_13104
GlaDMC1b XP_001710001; GL50803_13346
DdiRAD51 DDB0168161; DDB0217219
DdiRAd51-3 RAD51c; DDB0186043
DdiRAd51-4 xrcc3; DDB0185591
DdiRAD51-6 DDB0169470; mitochondrial
DdiRAD51-7 DDB0188824
DdiRAD51-8 DDB0217538
TgoRAD51 ToxoDB:59.m03654
TgoDMC1 ToxoDB:35.m00010
TgoRAD51-3 645.m00312
PfaRAD51 PlasmoDB:PF11_0087
PfaDMC1 PlasmoDB:MAL8P1.76
PfaRAD51-3 PFD0935c
CpaRAD51 CryptoDB:cgd5_410
CpaDMC1 CryptoDB:cgd7_1690
CpaRAD51-3 cgd2_4070
CpaRAD51-4 cgd6_4800
TanRAD51 TA07350
TanDMC1 TA07075
TanRAD51-3 TA12290
TthRAD51 TTERM_00142330
TthDMC1 TTHERM_00459230
TthRAD51-3 TTHERM_01143840
TvaRAD51 TVAG_204070
TvaDMC1 TVAG_155030
TvaRAD51-3 TVAG_426330
TvaRAD51-4 TVAG_144570
SceRAD51 NP_011021
SceDMC1 NP_011106
SceRAD57 NP_010287
SceRAD55 NP_010361
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Species Accession Number
HsaRAD51 Q06609
HsaDMC1 Q14565
HsaXRCC2 O43543
HsaXRCC3 O43542
HsaRAD51B O15315
HsaRAD51D AAC39719
HsaRAD51C AAC39604
AthRAD51 NP_568402
AthDMC1 JC4092
AthRAD51C NP_566040
AthRAD51B NP_180423
AthRAD51D NP_172254
AthXRCC2 NP_201257
AthXRCC3 NP_851202
SpoRHP51 P36601
SpoDMC1 O42634
SpoRDH55 O14129
SpoRDH57 Q9UUL2
DmeRAD51 BAA04580
DmeSpnD NP_733200
DmeSpnB NP_476740
DmeRAD51C NP_610466
DmeRAD51D NP_573302
CelRAD51 O44246 O44246_CAEEL 
CelRfs-1 P34348 YK82_CAEEL
UmaRAD51 AAC61878
UmaREC2 A56244
EcuRAD51 Q8SQX0_ENCCU
EcuRAD51-2 Q8SW20_ENCCU
OsaDMC1A AAM76793
OsaDMC1B AAM76792
EcoRECA P03017
CjeRECA CAB73660
NgoRECA CAA35247
BsuRECA P16971
SliRECA P48294
SauRECA CAG40263
PfuRADA NP_579655
MjaRADA E64408
AfuRADA O29269 RADA_ARCFU
TacRADA Q9HJ68 RADA_THEAC
PfuRADB P81415 RADB_PYRFU
AfuRADB O28184 RADB_ARCFU
TacRADB Q9HJD3 RADB_THEAC
MjaRADB Q57702 RADB_METJA
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